FY 2011 BUDGET OVERVIEW: DEPARTMENT OF HEALTH AND HUMAN SERVICES

WITNESS

HON. KATHLEEN SEBELIUS, SECRETARY

OPENING STATEMENT BY CONGRESSMAN OBEY

Mr. OBEY. Well, good morning, Madam Secretary. Sorry to be late. I don't really have any good excuse. I just got involved in some things.

Secretary SEBELIUS. I don't think the chairman is ever late, sir.

Mr. OBEY. Well, I think so. I detest being late.

Anyway, let me welcome you here today. It is good to have you at a historic time, as you and your department begin to implement the health reform legislation we just passed. That debate has been going on a long time, and the Congress and the President have finally made some decisions. And, to me, the job at hand now is to try to implement it, make it work, see whether adjustments need to be made down the line, and make certain that it develops in a way which is beneficial to the American people.

In this subcommittee, we have been doing a number of things to make health care more accessible, more affordable, and more effective. In the Recovery Act, for instance, we accelerated those efforts. For example, we have been expanding education and training programs to address the shortage of nurses, primary care doctors, and other health professionals and to encourage more practitioners to go into primary care and to practice in places where they are most needed. As far as I am concerned, that means especially rural areas.

Our regular appropriation bills have increased funding for health professional programs by 35 percent over the past 4 years, and the Recovery Act included another $500,000,000 for that purpose.

Another focus has been on prevention. We have provided a billion dollars for prevention and wellness activities to jump-start new efforts in this area. I should add at this point that one of my special concerns is the area of hospital infections. It just seems to me that that has to be at the top of our list, in terms of priorities. We don't do people any favors if we give 30,000,000 people additional access to health care and then they wind up dying because of something that they caught in a hospital. That happens at a disgracefully high level lately, and I think we need to be very aggressive in doing something about it.

Our subcommittee has also emphasized medical research. That includes basic and applied research supported by the National Institutes of Health. It includes patient-centered health research to help practitioners decide which treatment works most effectively.
for their patients and thereby improves outcomes. The Recovery Act added $1,100,000,000 to support a major expansion of patient-centered research.

Yet another priority has been to encourage a more widespread use of information technology and electronic health records to reduce medical errors and to make health-care delivery more efficient. In the 21st century, piles of paper are not the way we ought to be managing records that are vital to patient care. And, as you know, the Recovery Act included $19,000,000,000 to launch a major push for adoption of those technologies.

Finally, we have the need to combat fraud and abuse in health programs. We increased discretionary funding for this purpose by 57 percent last year to support a wide range of activities, from reviewing Medicare claims to prevent improper payments to conducting criminal investigations. We held a separate hearing on that issue several weeks ago.

While these and other health-care priorities are at center stage, HHS also has many other responsibilities. Its human services programs help families with access to child care, help low-income people pay their winter heating bills, and assist older Americans through programs like Meals on Wheels, to give just a few examples. The need for these services has grown during the current recession, and we have given the Department resources to respond in both the Recovery Act and our regular appropriations bills.

The President’s budget request provides further increases in some high-priority areas, including biomedical research at NIH, child care, Head Start, mental health and substance abuse programs, and health fraud and abuse control.

On the other hand, I am not at all thrilled at the proposed 35 percent cut to LIHEAP, and I am also concerned that we are not yet well prepared to deal with public health emergencies like a flu pandemic or bioterrorism.

I should also mention again that the administration has put us in a box—not you, but, frankly, the White House has—by one aspect of their budget submission because they have left a very large hole to fill with respect to Pell grants. And if we are going to meet our obligations in that area, we need to have that problem addressed, or a lot of people’s priorities, including the administration’s, will suffer greatly.

So, with that, let me welcome you. I look forward to hearing from you. But first let me call on Mr. Tiahrt for whatever comments he might have.

Mr. TIAHRT. Thank you, Mr. Chairman.

As always, it is good to have Secretary Sebelius, the former Governor of Kansas, before the committee today. I have a great many questions for the Secretary, so, in the interest of time and the hope that we will get to at least two rounds of questions, I am going to be brief.

Like many Americans, I have some very serious concerns about the recently enacted government takeover of health care in this country, what many refer to as “Obama-care.” I have concerns about what it will do to the quality of care people in this country currently receive, what it will do to small businesses and the peo-
ple who work for them. And I have concerns about what it will do to our already-hemorrhaging Treasury.

The level of spending authorized under this new law is breathtaking, not to mention the audacity of the Federal Government under this new law telling individual American citizens what they must do in regard to health insurance. Many of us opposed the new law and have serious concerns about what it means both in terms of the cost as well as the role of the government in health-care decisions.

Over the last 2 years, the President has made a number of promises regarding this new health-care law. On June 15th, 2009, the President said, “If you like your doctor, you will be able to keep your doctor, period. If you like your health-care plan, you will be able to keep your health-care plan, period. No one will take it away, no matter what.” Well, with $130,000,000,000 in cuts to the Medicare Advantage plans, it sure seems like 11,000,000 seniors will be in jeopardy of losing their plan.

The President also said, on March 25th of this year, that if you already have insurance, this reform will make it more secure and more affordable. Apparently, that is true unless you are one of the millions of Americans who buy an individual policy that you like and want to keep.

I am also concerned about the pressure that the host of newly authorized programs will force on other important programs in this bill. There are at least $100,000,000,000 in specific authorizations that Congress will be expected to fund and countless billions in programs with wide, open-ended authorizations. We have no idea how high those costs will be.

I could go on, but the bottom line for me is: What was promised isn’t what was delivered. I look forward to the opportunity to ask a few questions.

And I thank the chairman and yield back.

Mr. OBEY. Mr. Lewis.

Mr. LEWIS. Mr. Chairman, I would prefer to wait and listen to the Secretary and then ask questions.

Mr. OBEY. All right. Thank you.

Ms. Secretary, please proceed.

SECRETARY SEBELIUS OPENING STATEMENT

Secretary Sebelius. Well, thank you, Mr. Chairman. It is good to be here in the subcommittee with you, with Congressman Tiahrt, and other members of the subcommittee.

I want to thank you, first, for inviting me here today to talk about the 2011 budget, and I look forward to the opportunity to respond to questions. But I want to spend just a couple of minutes framing the budget. I think advances the Department’s central goals: improving the health of all Americans; expanding access to high-quality health care; and providing children, families, and seniors with the critical health services that give them a chance to thrive.

To do that, we have tried to make prudent investments that actually echo the goals that the members of this subcommittee have championed for years: attacking health-care fraud with new tools and more resources; a new focus on preventing chronic disease and
promoting wellness; emphasizing a reduction in medical errors and improving the overall quality of care; and strengthening our public health system so that we will be better prepared for new threats that come at us.

At a time when so many American families are trying to balance their own household budgets, we think it is appropriate that we not let taxpayer dollars go to waste. So the budget reflects the difficult, time-consuming work we have done over the last year to try to eliminate waste and fraud and focus our resources so they can make the biggest impact on Americans’ lives.

Last month, you heard from our department’s Deputy Secretary, Bill Corr, about some of the expanded efforts to identify, prosecute, and prevent health-care fraud as part of the new partnership with the Justice Department known as HEAT. And this budget, Mr. Chairman, builds on that progress. It adds new fraud-fighting funds to help us expand proven strategies, like putting Medicare fraud strike forces in cities that we know are hubs for fraudulent activities, and invests in promising new approaches like the systems that will help us analyze claims for suspicious activity in real time. When the budget takes effect, it is going to be a lot harder for criminals to get rich stealing from seniors and from the health-care system. And, over time, we believe the anti-fraud efforts will pay for themselves many times over.

The budget also takes aim at medical errors. We know that the quality of health care in America varies widely, and, most tragically, in the case of tens of thousands of Americans who die every year from health-care associated infections, many of which are preventable. Chairman Obey, you have been a national leader for eliminating these unnecessary deaths, and our budget is aimed at helping to do that by doubling the size of the CDC National Healthcare Safety Network to 5,000 hospitals.

You also mentioned the need to be ready for immunizations, and I want to thank you for your support of the CDC Section 317 immunization program, which we have asked to receive additional funds to make sure that all Americans have access to vaccines that are the best protection against some of our most dangerous diseases.

Investments like these will help make sure that Americans get the best possible care when they are sick, but we also have to do a much better job keeping Americans healthy in the first place. So this budget builds on the Recovery Act’s significant investment in health information technology, which moves us closer to nationwide interoperability and helps providers make health IT part of their daily routine.

We try to build on the historic investment in prevention and wellness that Congress made last year in the Recovery Act with new efforts that will reduce the harmful effects of chronic disease in our cities and create a new health prevention corps and aim at preventing unintended pregnancies.

And because minorities and low-income Americans are likely to be sick and less likely to get the care they need, our fiscal year 2011 budget makes critical investments in areas like community health centers and HIV/AIDS prevention and treatment so we can
address the disparities that have plagued our health system and our country for far too long.

HHS has spent our Recovery Act funds responsibly, balancing the need for getting these dollars into the economy with assuring the proper stewardship of taxpayer dollars. By January 2010, HHS Recovery Act recipients reported having created at least 30,000 new jobs and saving millions of jobs. The April report period has not yet concluded, but we fully expect those numbers to rise. By the end of September, we fully expect to obligate the remaining $6,800,000,000 in Recovery Act discretionary dollars available for fiscal year 2010.

So these are just a few ways that our department will work to build a healthier America. At the same time, we will continue our work, which is already under way, to effectively implement many of the provisions in the historic health insurance reform legislation that Congress passed last month. The Affordable Care Act enshrines the principle that every American should have access to the health care they need. It also begins the transformation of our health-care system, with a wide range of new programs and incentives to promote the kind of coordinated, patient-centered, evidence-based care that has been shown to generate far better health outcomes.

These changes, along with the investments in our fiscal year 2011 budget, will mean that Americans getting access to care as part of the Affordable Care Act will be joining a health-care system that is more consumer-friendly, provides more security, and, more importantly, does a better job at keeping them healthy.

Those are the goals, but we cannot accomplish any of them alone. We rely on partners across the Federal Government and States and communities across the country. And no one has a more important role than those of you in the United States Congress.

So I want to thank you again for the opportunity to be here today, and I would be happy to respond to the questions.

[Prepared statement of Secretary Kathleen Sebelius follows:]
COMMITTEE ON APPROPRIATIONS

SUBCOMMITTEE ON LABOR, HEALTH AND HUMAN SERVICES, EDUCATION AND RELATED AGENCIES

10:00 a.m. – Wednesday, April 21, 2010

HEARING:
Secretary Kathleen Sebelius, Department of Health and Human Services
STATEMENT OF
KATHLEEN SEBELIUS
SECRETARY
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

ON

THE PRESIDENT'S FISCAL YEAR 2011 BUDGET

BEFORE THE
SUBCOMMITTEE ON LABOR, HEALTH AND HUMAN SERVICES,
EDUCATION, AND RELATED AGENCIES
COMMITTEE ON APPROPRIATIONS
UNITED STATES HOUSE OF REPRESENTATIVES

APRIL 21, 2010
Chairman Obey, Representative Tiahrt, and Members of the Subcommittee, thank you for the invitation to discuss the President’s Fiscal Year (FY) 2011 Budget for the Department of Health and Human Services (HHS).

In his State of the Union Address, President Obama laid out an aggressive agenda to create jobs, strengthen opportunity for working families, and lay a foundation for long-term growth. His FY 2011 Budget is the blueprint for putting that vision into action.

At HHS, we are supporting that agenda by working to keep Americans healthy, ensuring they get the health care they need, and providing essential human services for children, families, and seniors.

Our budget will make sure that the critical health and human services our Department offers to the American people are of the highest quality and are directly helping families stay healthy, safe, and secure—especially as we continue to climb out of a recession.

It promotes projects that will rebuild our economy by investing in the next generation of research and the advanced development of technology that will help us find cures for diseases, innovative new treatments, and new ways to keep Americans safe from a pandemic or a potential terrorist attack.

But this budget isn’t just about new programs or new priorities or new research. It is also about a new way of doing business with the taxpayers’ money. Where there is waste and fraud, we must root it out. Where there are loopholes, we must close them. And where we have opportunities to increase transparency, accountability, and program integrity, we must take them. These are top priorities of the President. They are top priorities of mine. And our budget reflects that they are top priorities for my Department.

The President’s FY 2011 Budget for HHS totals $911 billion in outlays. The Budget proposes $81 billion in discretionary budget authority for FY 2011, of which $74 billion is within the jurisdiction of the Labor, Health and Human Services, Education, and Related Agencies Subcommittee.

This budget is a major step toward a healthier, stronger America. And it compliments the historic health insurance reform legislation that many of you helped pass last month.

The Patient Protection and Affordable Care Act (Affordable Care Act) will give Americans with insurance a new level of security by creating common sense rules that require insurance companies to treat them fairly.

It will make insurance affordable for millions of Americans by creating a new insurance marketplace and providing tax credits for those who need additional help.

And it will start to bring down costs for families, businesses, and governments with the broadest health care cost-cutting package ever.
As one of the federal government agencies implementing this law, my department is already working with partners across the country to make sure we carry out this law responsibly and effectively.

Our guiding principle as we do so is putting Americans back in charge of their health care. We will provide information and education if it’s needed; set basic guidelines to help create competitive insurance markets; serve as an umpire to make sure insurance companies treat Americans fairly; and provide targeted resources to help empower consumers.

Investing in Prevention
Reducing the burden of chronic disease, collecting and using health data to inform decision-making and research, and building an interdisciplinary public health workforce are critical components to successful prevention efforts. In addition to what is in the President’s Budget, the Affordable Care Act provides a significant investment in prevention through the Prevention and Public Health Fund for HHS to further its prevention efforts. This investment will allow HHS to expand and sustain efforts in prevention, wellness, and public health programs authorized within the Public Health Service Act to improve the health of the nation and help restrain health care costs.

The FY 2011 Budget reflects the HHS commitment to prevention. The Budget includes $20 million for the Centers for Disease Control and Prevention (CDC) Big Cities Initiative to reduce the rates of morbidity and disability due to chronic disease in up to 10 of the largest U.S. cities. These cities will be able to incorporate the lessons learned from implementing evidence-based prevention and wellness strategies of the American Recovery and Reinvestment Act of 2009 (Recovery Act) Communities Putting Prevention to Work Initiative. This Recovery Act initiative is key to promoting wellness and preventing chronic disease, and we appreciate the support of Congress in making these funds available. In March, HHS awarded $373 million for the cornerstone of this initiative, funding communities to implement evidence-based strategies to address obesity, increase physical activity, improve nutrition, and decrease smoking. The Big Cities Initiative requested in FY 2011 will allow us to build on the success of the Recovery Act. I’d like to particularly thank Chairman Obey for his leadership in providing funds for the CDC Section 317 Immunization program to provide many of the vaccines public health departments provide to children and adults. The FY 2011 Budget includes $579 million, an increase of $17 million, for the Section 317 program to increase vaccination coverage and to support States in obtaining reimbursement of immunization services provided to children with private health insurance.

The Budget also includes $10 million at CDC for a new Health Prevention Corps, which will recruit, train, and assign a cadre of public health professionals in State and local health departments. This program will target disciplines with known shortages, such as epidemiology, environmental health, and laboratory science.

To support teen and unintended pregnancy prevention and care activities in the Office of Public Health and Science and CDC, the Budget provides $222 million in funds. Of this,
$125 million will be used for replicating programs that have proven effective through rigorous evaluation to reduce teenage pregnancy; research and demonstration grants to develop, replicate, refine and test additional models and innovative strategies; and training, evaluation, technical assistance, outreach, and additional program support activities. The request includes $4 million to carry out evaluations of teenage pregnancy prevention approaches, and another $4 million in Public Health Service (PHS) evaluation funds for this activity. This also includes $22 million for CDC to reduce the number of unintended pregnancies through science-based prevention approaches. In addition, the FY 2011 Adolescent Family Life (AFL) Budget includes $17 million to provide support for AFL Care demonstration grants and research programs. In an effort to ameliorate the negative effects of childbearing on teen parents, their infants, and their families, care grant community-based projects develop, test and evaluate interventions with pregnant and parenting teens, and focus on ways to build and strengthen families.

Behavioral health is essential to the wellbeing of all Americans. The Budget includes an additional $135 million within the Substance Abuse and Mental Health Services Administration (SAMHSA) and Health Resources and Services Administration (HRSA) for innovative approaches to prevent and treat substance abuse and mental illness. These efforts include increases of $35 million for community-based prevention, $25 million to expand behavioral health services at health centers, and $17 million associated with homelessness prevention. An increase of $13 million will expand the treatment capacity of drug courts, and $33 million will strengthen our capacity to deter new drug threats and assess our progress in reducing substance abuse.

Reducing Health Care Fraud
When American families are struggling to make every dollar count, we need to be just as vigilant about how their money is spent. That’s why the Obama Administration is cracking down on criminals who steal from taxpayers, endanger patients, and jeopardize the future of our health insurance programs. It is also why Deputy Secretary Bill Corr welcomed the opportunity to testify before this Subcommittee on Combating Health Care Fraud and Abuse in March. We look forward to continuing to work with you to strengthen our efforts to reduce health care fraud.

Last May, President Obama instructed Attorney General Holder and me to create a new Health Care Fraud Prevention and Enforcement Action Team, which we call “HEAT” for short. HEAT is an unprecedented partnership that brings together high-level leaders from both departments so that we can share information, spot trends, coordinate strategy, and develop new fraud prevention tools.

As part of this new partnership, we are developing tools that will allow us to identify criminal activity by analyzing suspicious patterns in claims data. Medicare claims data used to be scattered among several databases. If we wanted to find out how many claims had been made for a certain kind of wheelchair, we had to go look in several different places. This single, searchable database means that for the first time ever, we’ll have a complete picture of what kinds of claims are being filed across the country.
Our FY 2011 Budget includes $1.7 billion in funding to fight fraud, including $561 million in discretionary funds to strengthen Medicare and Medicaid program integrity activities, with a particular emphasis on fighting health care fraud in the field, increasing Medicare and Medicaid audits, and strengthening program oversight while reducing costs. We appreciate the Committee’s support of past requests for fraud prevention; and building on the successes we have been able to achieve with those funds, we are now seeking an additional $250 million over the FY 2010 level that we hope you can support.

This investment will better equip the Federal government to minimize inappropriate payments, pinpoint potential weaknesses in program integrity oversight, target emerging fraud schemes by provider and type of service, and establish safeguards to correct programmatic vulnerabilities. This multi-year discretionary investment will save $9.9 billion over 10 years.

The Budget also includes a set of new administrative and legislative program integrity proposals that will give HHS the necessary tools to fight fraud by enhancing provider enrollment scrutiny, increasing claims oversight, and improving Medicare’s data analysis capabilities, which will save approximately $14.7 billion over 10 years. Along with the $9.9 billion in savings from the discretionary investments, these new program authorities will save nearly $25 billion in Medicare and Medicaid over 10 years.

**Improving Quality of and Access to Health Care**

At HHS, we continue to find ways to better serve the American public, especially those citizens least able to help themselves. We are working to improve the quality of and access to health care for all Americans by supporting programs intended to enhance the health care workforce and the quality of health care information and treatments through the advancement of health information technology (IT) and the modernization of the health care system.

The Budget includes $3.6 billion for Centers for Medicare & Medicaid Services’ (CMS) Program Management. To strengthen the ability of CMS to meet current administrative workload demands resulting from recent legislative requirements and continued growth of the beneficiary population, the funding provides targeted investments to revamp IT systems and optimize staffing levels so that CMS can meet the future challenges of Medicare, Medicaid, and CHIP while being an active purchaser of high quality and efficient care.

For example, $110 million will support the first year of a comprehensive Health Care Data Improvement Initiative (HCDII) to transform CMS’s data environment from one focused primarily on claims processing to one also focused on state-of-the-art data analysis and information sharing. Without this funding CMS would not be able to transform Medicare and Medicaid into leaders in value-based purchasing and in data sources for privacy-protected patient-centered health research. This funding is imperative for CMS to meet the needs of future growth, financial accountability, and data content and availability. The HCDII is the cornerstone of a business strategy that will
optimize the delivery of efficient, high-quality health care services. CMS needs this
funding to strengthen disaster recovery and security operations to protect against loss of
data or services; to enable timely data sharing and analysis to fight fraud, waste, and
abuse; and to transform payment processes to support quality outcomes.

To strengthen and support our Nation’s health care workforce, the Budget includes
$1.1 billion within the Health Resources and Services Administration (HRSA) for a wide
range of health professions programs. This funding will enhance the capacity of nursing
schools, increase access to oral health care through dental workforce development grants,
target students from disadvantaged backgrounds, and place an increased emphasis on
ensuring that America’s senior population gets the care and treatment it needs.

The Budget includes an increase of $290 million to ensure better access to health centers
through further expansions of health center services and integration of behavioral health
into health centers’ primary care system. This funding builds on investments made under
the Recovery Act and will enable health centers to serve more than 20 million patients in
FY 2011, which is 3 million more patients than were served in FY 2008. The Affordable
Care Act provides $1 billion in FY 2011 to health centers to expand service capacity to
underserved and uninsured patients and increase the comprehensive, culturally
competent, quality primary health care services provided. In addition, the Affordable
Care Act investments in construction and renovation of health center sites will expand
health centers capacity to provide primary and preventive health services.

The Budget advances the President’s health IT initiative by accelerating health IT
adoption and electronic health records (EHR) utilization – essential tools for modernizing
the health care system. The Budget includes $78 million, an increase of $17 million, for
the Office of the National Coordinator for Health Information Technology (ONC) to
continue its current efforts as the Federal health IT leader and coordinator. During
FY 2011, HHS will also begin providing an estimated $25 billion over 10 years of
Recovery Act Medicare and Medicaid incentive payments primarily to physicians and
hospitals who demonstrate meaningful use of certified EHRs, which will improve the
reporting of clinical quality measures and promote health care quality, efficiency, and
patient safety.

The Budget supports HHS-wide patient-centered health research, including an additional
$261 million within the Agency for Healthcare Research and Quality (AHRQ) over
FY 2010. HHS also continues to invest the $1.1 billion provided by the Recovery Act to
improve health care quality by providing patients and physicians with state-of-the-art,
evidence-based information to enhance medical decision-making.

Promoting Public Health
Whether responding to pandemic flu or researching major diseases, HHS will continue its
unwavering commitment to keeping Americans healthy and safe.

The Budget includes over $3 billion, an increase of $70 million, for CDC and HRSA to
enhance HIV/AIDS prevention, care, and treatment. This increase includes $31 million
to support the National HIV/AIDS Strategy currently under development and for CDC to integrate surveillance and monitoring systems, address high-risk populations, and support HIV/AIDS coordination and service integration with Viral Hepatitis, STDs, and TB. The increase also includes $40 million for HRSA’s Ryan White program to expand access to care for underserved populations, provide life-saving drugs, and improve the quality of life for people living with HIV/AIDS.

To improve CDC’s ability to collect data on the health of the Nation for use by policy-makers and Federal, State, and local leaders, the Budget provides $162 million for Health Statistics, an increase of $23 million above FY 2010. This increase will ensure data availability on key national health indicators by supporting electronic birth and death records in States and enhancing national surveys. CDC will support 10 states that have not begun implementing electronic birth records and will work with States to gradually phase in electronic death records through a 50-50 match.

The Budget includes $222 million, an increase of $16 million, to address Autism Spectrum Disorders (ASD). Research at the National Institutes of Health (NIH) will pursue comprehensive and innovative approaches to defining the genetic and environmental factors that contribute to ASD, investigate epigenetic changes in the brain, and accelerate clinical trials of novel pharmacological and behavioral interventions. CDC will expand autism monitoring and surveillance and support an autism awareness campaign; and HRSA will increase resources to support children and families affected by ASD through screening programs and evidence-based interventions.

The FY 2011 Budget continues and builds on the important work of reducing healthcare-associated infections, such as by expanding CDC’s National Healthcare Safety Network from 2,500 to 3,000 hospitals. We appreciate the Chairman’s leadership in this area and we are committed to addressing this serious public health issue.

The Budget includes $352 million, an increase of $16 million, for CDC Global Health Programs to build global public health capacity by strengthening the global public health workforce; integrating maternal, newborn, and child health programs; and improving global access to clean water, sanitation, and hygiene. Specifically, CDC will expand existing programs and develop programs in new countries to provide workforce training in areas such as epidemiology and outbreak investigation, and to implement programs that distribute water quality interventions to create safe drinking water. In addition, CDC will integrate interventions, such as malaria control measures, expanded immunizations, and safe water treatment to reduce newborn, infant, and child mortality. Additionally, the Budget includes $6 million in the Office of Global Health Affairs to support global health policy leadership and coordination.

**Protecting Americans from Public Health Threats and Terrorism**

Continued investments in countermeasure development and pandemic preparedness will help ensure that HHS is ready to protect the American people in either natural or man-made public health emergencies. The Budget includes $476 million, an increase of
$136 million, for the Biomedical Advanced Research and Development Authority to sustain the support of next generation countermeasure development in high-priority areas by allowing the BioShield Special Reserve Fund to support both procurement activities and advanced research and development.

Reassortment of avian, swine, and human influenza viruses has led to the emergence of a new strain of H1N1 influenza A virus, 2009 H1N1 flu, that is transmissible among humans. On June 24, 2009, Congress appropriated $7.65 billion to HHS for pandemic influenza preparedness and response to 2009 H1N1 flu. HHS has allocated some of these resources to support States and hospitals, to invest in the H1N1 vaccine production, and to conduct domestic and international response activities. The Budget includes $302 million for ongoing pandemic influenza preparedness activities at CDC, NIH, Food and Drug Administration (FDA), and the Office of the Secretary for international activities, virus detection, communications, and research. In addition, the use of balances from the June 2009 funds will enable HHS to continue advanced development of cell-based and recombinant vaccines, antivirals, respirators, and other activities that will help ensure the Nation's preparedness for future pandemics. Previous appropriations for H5N1 allowed us to be better prepared for H1N1 than we ever would have been otherwise, and only by continued work on better vaccines, antivirals, and preparedness will we be ready for the next virus—which could well be a greater challenge than H1N1 has been.

**Improving the Wellbeing of Children, Seniors, and Households**

In addition to supporting efforts to increase our security in case of an emergency, the HHS Budget also seeks to increase economic security for families and open up doors of opportunity to those Americans who need it most.

The Budget provides critical support of the President’s Zero to Five Plan to enhance the quality of early care and education for our Nation’s children. The Budget lays the groundwork for a reauthorization of the Child Care and Development Block Grant and entitlement funding for child care, including a total of $6.6 billion for the Child Care and Development Fund, an increase of $800 million in the Child Care and Development Block Grant, and $800 million in the Child Care Entitlement.

The Administration’s principles for reform of the Child Care and Development Fund include establishing a high standard of quality across child care settings, expanding professional development opportunities for the child care workforce, and promoting coordination across the spectrum of early childhood education programs. The Administration looks forward to working with Congress to begin crafting a reauthorization proposal that will make needed reforms to ensure that children receive high quality care that meets the diverse needs of families and fosters healthy child development.

To enable families to better care for their aging relatives and support seniors trying to remain independent in their communities, the Budget provides $102.5 million for a new Caregiver Initiative at the Administration on Aging. This funding includes $50 million
for caregiver services, such as counseling, training, and respite care for the families of elderly individuals; $50 million for supportive services, such as transportation, homemaker assistance, adult day care, and personal care assistance for elderly individuals and their families; and $2.5 million for respite care for family members of people of all ages with special needs. This funding will support 755,000 caregivers with 12 million hours of respite care and more than 186,000 caregivers with counseling, peer support groups, and training.

Funding for the Head Start program, run by the Administration for Children and Families (ACF), will increase by $989 million to sustain and build on the historic expansion made possible by the Recovery Act. In FY 2011, Head Start will serve an estimated 971,000 children, an increase of approximately 66,500 children over FY 2008. Early Head Start will serve approximately 116,000 infants and toddlers, nearly twice as many as were served in FY 2008. The increase also includes $118 million to improve program quality, and the Administration plans to implement key provisions of the 2007 Head Start Act reauthorization related to grantee recompetition, program performance standards, and technical assistance that will improve the quality of services provided to Head Start children and families.

The Budget proposes a new way to fund the Low Income Home Energy Assistance Program to help low-income households heat and cool their homes. The request provides $3.3 billion in discretionary funding. The proposed new trigger would provide, under current estimates, $2 billion in mandatory funding. Energy prices are volatile, making it difficult to match funding to the needs of low-income families, so under this proposal, mandatory funds will be automatically released in response to quarterly spikes in energy prices or annual changes in the number of people living in poverty.

Investing in Scientific Research and Development
The investments that HHS is proposing in our human services budget will expand economic opportunity, but another critical way to grow and transform our economy is through a healthy investment in research that will not only save lives but also create jobs.

The Budget includes a program level of $32.2 billion for NIH, an increase of nearly $1 billion, to support innovative projects ranging from basic to clinical research, as well as including health services research. This effort will be guided by NIH’s five areas of exceptional research opportunities: supporting genomics and other high-throughput technologies; translating basic science into new and better treatments; reinvigorating the biomedical research community; using science to enable health care reform; and focusing on global health. The Administration’s interest in the high-priority areas of cancer and autism fits well into these five NIH theme areas. In FY 2011, NIH estimates it will support a total of 37,001 research project grants, including 9,052 new and competing awards.

Recovery Act
Since the Recovery Act was passed in February 2009, HHS has made great strides in improving access to health and social services, stimulating job creation, and investing in
the future of health care reform through advances in health IT, prevention, and scientific research. HHS Recovery Act funds have had an immediate impact on the lives of individuals and communities across the country affected by the economic crisis and the loss of jobs.

As of September 30, 2009, the $31.5 billion in Federal Payments to States helped maintain State Medicaid services to a growing number of beneficiaries and provided fiscal relief to States. NIH awarded $5 billion for biomedical research in over 12,000 grants. Area agencies on aging provided more than 350,000 seniors with over 6 million meals delivered at home and in community settings. Health Centers provided primary health care services to over one million new patients.

These programs and activities will continue in FY 2010, as more come on line. For example, 64,000 additional children and their families will participate in a Head Start or Early Head Start experience. HHS will be assisting States and communities to develop capacity, technical assistance and a trained workforce to support the rapid adoption of health IT by hospitals and clinicians. CDC will support community efforts to reduce the incidence of obesity and tobacco use. New research grants will be awarded to improve health outcomes by developing and disseminating evidence-based information to patients, clinicians, and other decision-makers about what interventions are most effective for patients under specific circumstances.

The Recovery Act provides HHS programs an estimated $141 billion for Fiscal Years 2009 – 2019. While most provisions in HHS programs involve rapid investments, the Recovery Act also includes longer term investments in health IT (primarily through Medicare and Medicaid). As a result, HHS plans to have outlays totaling $86 billion through FY 2010.

Conclusion
This testimony reflects just some of the ways that HHS programs improve the everyday lives of Americans. Under this budget, we will provide greater security for working families as we continue to recover from the worst recession in our generation. We will invest in research on breakthrough solutions for healthcare that will save money, improve the quality of care, and energize our economy. And we will push forward our goal of making government more open and accountable.

My department cannot accomplish any of these goals alone. It will require all of us to work together. And I am eager to work with you to advance the health, safety, and well-being of the American people. Thank you for this opportunity to speak with you today. I look forward to answering your questions.
SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
KATHLEEN SEBELIUS

Kathleen Sebelius was sworn in as the 21st Secretary of the Department of Health and Human Services (HHS) on April 28, 2009. As Secretary, she leads the principal agency charged with keeping Americans healthy, ensuring they get the health care they need, and providing children, families, and seniors with the essential human services they depend on. She also oversees one of the largest civilian departments in the federal government, with nearly 80,000 employees.

Since taking office, Secretary Sebelius has been a leader on some of the Obama administration’s top priorities. As the country’s highest-ranking health official, she has been a powerful voice for reforming our health insurance system. She has also been charged by the President with coordinating the response to the 2009 H1N1 flu virus. And under her leadership, HHS has provided a wide range of services from health care to child care to energy assistance to help families weather the worst economic crisis since the Great Depression.

Secretary Sebelius has answered President Obama’s call to form partnerships across government to improve the lives of Americans. She is the Co-Chair, with Secretary Vilsack, of the President’s Food Safety Working Group. With Attorney General Holder, she chairs the new Health Care Fraud Prevention and Action Team (HEAT). She has teamed up with Secretary Duncan improve early childhood education. As part of President Obama’s “Year of Community Living,” she is working with Housing and Urban Development Secretary Shaun Donovan to improve the lives of seniors and people with disabilities who wish to live at home.

Secretary Sebelius has been a leader on health care, family, and senior issues for over 20 years. As Governor of Kansas from 2003 to 2009, she fought to create jobs, improve access to affordable health care, and give every Kansas child a quality education. In 2005, Time Magazine recognized her achievements by naming her one of America’s Top Five Governors.

Before being elected Governor, she served from 1995 to 2003 as the first Democrat to be elected Kansas Insurance Commissioner. In that role, she was recognized as a strong advocate for consumers while streamlining the Department’s budget. For her efforts, Governing Magazine selected her as their Public Official of the Year for 2000. Prior to her service as Insurance Commissioner, she was a member of the Kansas House of Representatives from 1987 to 1995.

Secretary Sebelius is the first daughter of a governor to be elected governor in American history. She holds a Master of Public Administration degree from the University of Kansas and a Bachelor of Arts degree from Trinity Washington University. She is married to Gary Sebelius, a federal magistrate judge. They have two sons, Ned and John.
Mr. OBEY. Thank you.
Mr. Tiahrt.

HEALTH CARE REFORM

Mr. TIAHRT. Thank you, Mr. Chairman.
A while back, I found the comments made by our Speaker of the House, Ms. Pelosi, quite interesting. Specifically, she said on March 9th before the legislative conference of the National Association of Counties that—and I quote—“we have to pass the bill so that you can find out what is in it.” My preference is that the American people know what was in the bill before it is passed, but I suppose that is just a philosophical difference.

I was even more interested in a recent Rasmussen poll that shows that 56 percent of Americans believe that we should repeal Obama-care. In Kansas, it is over 70 percent, probably because four out of five jobs are small-business jobs, and there is a great deal of concern about what it will do to small employers. To be honest, I am not particularly surprised by that number, and I expect it will grow, since the American people are only now beginning to find out what has been done in the bill.

This bill is widely unpopular. What is the most difficult part for the administration to sell to the American people?

Secretary SEBELIUS. That is——

Mr. TIAHRT. Yeah, which part of this bill will be the most difficult to convince the American people that it is going to be good for them?

Secretary SEBELIUS. Well, Congressman, I think there has been an extraordinary amount of misinformation about what the law is and what it isn’t. And one of the jobs that we have, I think, moving forward and that I look forward to, frankly, is telling people what is in the bill.

For instance, for small-business owners, there is a lot of misinformation about mandates that currently are not part of the law, and were never part of the law. So any employer who has less than 50 employees has not only no mandate but may be eligible for tax breaks that begin this year at 35 percent, helping to secure employee coverage, and, eventually, in 2014, will have access to a new market.

You and I know in Kansas that small employers are often squeezed out of the marketplace, priced out of the marketplace, don’t have the leverage, whether they are a farm family or a small-business owner, that the large employers have. They don’t have negotiating power. And they will have——

COST OF INSURANCE PREMIUMS

Mr. TIAHRT. Bringing up the costs——

Secretary SEBELIUS [continuing]. Opportunity through a State-based exchange.

Mr. TIAHRT. I am sorry. I have limited time.

Because of the cost, there was an article in the New York Times that talks about the effects the new law will have on insurance premiums that are routinely paid by ordinary Kansans, as you mentioned. Specifically, the article focuses on mandates contained in
the new law that have been in place in New York, in Massachusetts, and a few other States.

The article concludes that people who buy their own insurance—and that includes the self-employed, people who work for small businesses, and early retirees, those who do not yet qualify for Social Security—will have to pay, on average, an additional $2,100 for their health insurance.

How does the administration justify forcing Americans who form the backbone of our economy, specifically those associated with small businesses, to pay an additional $2,100 for their insurance? Did we learn anything from Massachusetts, New York, and other States that have been doing some of these things that are contained in this new law, or is the New York Times wrong?

Secretary Sebelius. Well, I would suggest that the New York Times may be pricing a policy in Massachusetts but is not pricing what will eventually be a State-based exchange in Kansas.

The law is set up in a way that Kansas will have an opportunity, if they choose, to put together a State-based exchange to have the policies and programs be State-based. It doesn't import the mandates from Massachusetts and impose them on Kansas. It really is the law of the State of Kansas.

So I haven't read the article, but the State-based exchanges, I would suggest, will make it much more affordable for those in the individual market or the small-group market to have affordable care, because they currently don't have the bargaining power and they are squeezed out or priced out of the market.

Mr. Tiahrt. I will submit that article for the record, Mr. Chairman, if it is okay with you.

[The information follows:]
April 17, 2010

New York Offers Costly Lessons on Insurance

By ANEMONA HARTOCOLLIS

When her small executive search firm in New York City canceled its health insurance policy last year because of the recession and rising premiums, April Welles was able to buy her own plan and still be covered for her cancer and multiple sclerosis.

She was lucky to live in New York, one of the first states to require insurance companies to offer comprehensive coverage to all people regardless of pre-existing conditions. But Ms. Welles, 58, also pays dearly: Her premium is $17,876 a year.

“That’s a lot of groceries,” she said.

New York’s insurance system has been a working laboratory for the core provision of the new federal health care law — insurance even for those who are already sick and facing huge medical bills — and an expensive lesson in unplanned consequences. Premiums for individual and small group policies have risen so high that state officials and patients’ advocates say that New York’s extensive insurance safety net for people like Ms. Welles is falling apart.

The problem stems in part from the state’s high medical costs and in part from its stringent requirements for insurance companies in the individual and small group market. In 1993, motivated by stories of suffering AIDS patients, the state became one of the first to require insurers to extend individual or small group coverage to anyone with pre-existing illnesses.

New York also became one of the few states that require insurers within each region of the state to charge the same rates for the same benefits, regardless of whether people are old or young, male or female, smokers or nonsmokers, high risk or low risk.

Healthy people, in effect, began to subsidize people who needed more health care. The healthier customers soon discovered that the high premiums were not worth it and dropped out of the plans. The pool of insured people shrank to the point where many of them had high health care needs. Without healthier people to spread the risk, their premiums skyrocketed, a phenomenon known in the trade as the “adverse selection death spiral.”

“You have a mandate that’s accessible in theory, but not in practice, because it’s too expensive,” said Mark P. Scherzer, a consumer lawyer and counsel to New Yorkers for Accessible Health Coverage, an advocacy group. “What you get left clinging to the life raft is the population that tends to have pretty high health needs.”

Since 2001, the number of people who bought comprehensive individual policies through HMOs in New York has plummeted to about 31,000 from about 128,000, according to the State Insurance Department.

At the same time, New York has the highest average annual premiums for individual policies: $6,630 for single people and $13,296 for families in mid-2009, more than double the nationwide average, according to America’s Health Insurance Plans, an industry group.

Rates did not rise as high in small group plans, for businesses with up to 50 workers, because the companies had an incentive to provide insurance to keep employees happy, and so were able to keep healthier people in the plans, said Peter Newell, an analyst for the United Hospital Fund, a New York-based health care research organization.

While premiums for large group plans have risen, their risk pools tend to be large enough to avoid out-of-control rate hikes.

The new federal health care law tries to avoid the death spiral by requiring everyone to have insurance and penalizing those who do not, as well as offering subsidies to low-income customers. But analysts say that provision could prove meaningless if the government does not vigorously enforce the penalties, as insurance companies fear, or if too many people decide it is cheaper to pay the penalty and opt out.

Under the federal law, those who refuse coverage will have to pay an annual penalty of $695 per person, up to $2,085 per family, or 2.5 percent of their household income, whichever is greater. The penalty will be phased in from 2014 to 2016.

“In this new marketplace that we envision, this requirement that everybody be covered, that should draw better, healthier people into the insurance pool, which should bring down


4/20/2010
rates,” said Mark Hall, a professor of law and public health at Wake Forest University. But he added, “You have to sort of take a leap of faith that that’s going to happen.”

As part of the political bargain to get insurance companies to support insurance for all regardless of risk, called community rating, New York State deregulated the market, allowing insurers to charge as much as they wanted within certain profit margins. The state can require companies to retroactively refund overcharges to consumers, but it seldom does.

Now, Gov. David A. Paterson has proposed to reinstate prior approval by the state of rate increases for the small group and individual plans, as a way to reverse New York’s death spiral of healthy people fleeing the market. The change would affect about 3 million of the 10 million New Yorkers insured through private plans, according to the Insurance Department. Most of those are in small group plans, though the biggest beneficiaries might be those seeking individual coverage, where premiums are highest.

New York’s insurance companies are vigorously fighting prior approval. Mark L. Wagar, the president of Empire BlueCross BlueShield, said New York’s problem was not deregulation of rates, but the lack of an effective mandate for everyone to buy insurance. To illustrate, he offered a statistic on how many people in the 18-to-26 age group, who are largely healthy, have bought individual insurance coverage through his company: 88 people out of 6 million insured by his company statewide.

New York is “the bellwether,” Mr. Wagar said. “We have the federal health reform on steroids in terms of richness and strictness.”

The federal health care overhaul contains some protection for people who buy into the new insurance exchanges — organized marketplaces — created by the law. Beginning in 2014, states will be able to recommend that the Department of Health and Human Services ban companies from the exchanges if they impose rate increases the states consider unreasonable.

Mr. Wagar also said that New York’s medical costs, universally acknowledged as being among the highest in the country, were a factor in its high premiums. He noted that the state already regulated insurance company profit margins, allowing them to allocate no more than 25 cents of every dollar for profits and administration in small group plans and 20 cents for individual plans. The governor is proposing to lower both margins to 15 percent.

Troy Oechsner, deputy superintendent for health at the State Insurance Department, blamed the insurance companies for raising rates beyond what was necessary — by being off on their projections — thus accelerating the exodus of healthy people.
"What we saw them do is they really jacked up rates because they could," Mr. Oechsner said.

To a large extent, insurance companies police themselves, according to Mr. Oechsner. From 2000 to 2007, insurance plans reported that they exceeded state profit allowances just 3 percent of the time, resulting in about $48 million in refunds to policyholders, Mr. Oechsner said. Yet subsequent Insurance Department investigations found that insurers should have refunded three times as much.

The governor's budget projects that reinstating prior approval would help the state close its $9 billion deficit, saving taxpayers $70 million in the first year, and $150 million after that, by stemming the exodus of people from high-priced plans into state-subsidized plans.

An analysis of the governor's plan released recently by the Business Council of New York State, whose membership includes insurance companies, contested the governor's savings estimate, saying that it was "at best speculative," and that the savings would probably be nominal.

Mr. Hall, the Wake Forest professor, said that with the risk spread over a bigger pool of insured people under federal changes, insurers would be expected to reduce their prices, especially in New York. But Mr. Hall said that insurers might hesitate to do that until they were sure people were going to buy coverage, which could lead to a sort of mutual paralysis.

"You can literally think of people standing around a swimming pool, saying let's jump in at once," he said.

As for Ms. Welles, she is not sure how much longer she can keep paying rising rates.

"This is not something that will be sustainable for the rest of my life," she said. On the other hand, she added, "frankly, with the kind of cancer I have, I don't think I'll be paying this for too many years."
Mr. TIAHRT. While I am not a lawyer, I am aware——

Secretary SEBELIUS. I am not either.

Mr. TIAHRT [continuing]. That the Supreme Court has declared unconstitutional many Federal laws that contain individual mandates. However, the new health-care law contains a provision that appears to mandate that every individual in the United States must have some form of health-care insurance.

Regardless of the lessons we have learned in Massachusetts and New York with respect to individual mandates, what makes this administration think that it can constitutionally mandate that every American must buy health insurance?

And I ask specifically because there appears to be a fairly large segment of the American population that chooses, for one reason or another, not to buy health insurance even though they can afford it. This is a basic issue of liberty for me, not unlike deciding to purchase a house or rather to rent.

So what is it about the mandate that we think we can impose on the American people? And do you think it will survive a constitutional test?

Secretary SEBELIUS. Well, Congressman, I am also not a lawyer, but I have discussed the constitutional challenges with both our legal team and the legal team at the Justice Department, who feel that the Commerce Clause gives strong constitutional basis for the personal responsibility section of this bill.

As you know, when Governor Romney signed the Massachusetts law, he felt that a critical piece of expanding health coverage was personal responsibility, that those who could afford, actually, to purchase coverage would do so; and if they needed assistance, that the State, in that instance—and, in our instance, the Federal Government—would provide that assistance, and there would be a waiver for those who couldn’t afford it.

It is the framework that we used to put together the Affordable Care Act, and I think at least the lawyers will debate this in the courtroom, but I am convinced that it does stand on the strong constitutional grounds.

Mr. TIAHRT. Thank you, Mr. Chairman.

Mr. OBEY. Mrs. Lowey.

Mrs. LOWEY. Thank you, Mr. Chairman.

And welcome, Madam Secretary.

Throughout the health-care debate, one of my highest priorities was to enable the Federal Government to better track and prevent premium increases for consumers. One of the provisions in the new law involves medical loss ratio, requiring insurance to spend at least 80 percent of premiums on health-care services. This will a great benefit to those who cannot continue to pay skyrocketing premiums. The law includes a host of other cost-control measures, including allowing exchanges to bar access to insurers with unreasonable premium increases.

By the way, I found in my district—I had countless meetings with large employers, small employers, individuals, hospitals, doc-
tors, and I cannot tell you how many people talked about their rates being doubled in the last 5 years. So we have to do something about this in this bill.

And if you could share with us, how does the budget request enable HHS to police insurers and protect consumers from abusive practices? And, more generally, are there any changes to the budget request that are necessary now that health-care reform has been signed into law?

First, let's talk specifically about the medical loss ratio, and then whatever time is remaining, I would appreciate it.

Secretary Sebelius. Well, the medical loss ratio, Congresswoman, as you suggest, is part of the Affordable Care Act. I am a former insurance commissioner, and I am familiar with looking at the kind of data that is currently going to be requested. So we have already reached out to the National Association of Insurance Commissioners to, as suggested by the law, have them help to frame the definitions that are used as part of the formula for the loss ratio.

I have actually reached out, also, to my former colleagues, Governors across the country to remind them—and in some States there is the full range of rate review authority, and in other States they are really missing big pieces of it, like California and others who found themselves in a situation where they do not have prior approval of rate increases—to remind them that that may be a good thing to address in their legislative session.

So we are aggressively putting together the framework for a review of medical loss ratios and working in very close connection with the State insurance commissioners and the Governors to do just that.

I think that our budget, what we have done, Congresswoman, as part of the implementation of the Affordable Care Act is to stand up a new Office of Consumer Information and Insurance Oversight that is going to be charged with not only implementing the medical loss ratio standards but a whole host of the market conduct standards for insurance companies and working very closely with the State offices.

STATE INSURANCE COMMISSIONERS

Mrs. Lowey. Before we get to the next question, from your experience—and you interacted, I know, with other State commissioners before you took on these responsibilities—are there any States that are actually monitoring this issue effectively now? And I appreciate the fact that you said you had been meeting with the State commissioners of insurance. Are there any States that do it effectively?

Secretary Sebelius. I think there are. There are some models out there that we look at very closely.

Again, the State laws vary. So some States have what they call “prior approval.” Before a company can actually impose a rate increase, they have to submit actuarial data to the Department, have it reviewed, look at administrative costs, overhead costs, CEO salaries, and what portion of the premiums they are actually paying out in health benefits. Others have what they call “file and use,” where the company actually notices you that you have a rate in-
crease and just files it with the Department. And some don't even
have that. So there is a wide range of oversight.

We are very hopeful that we can—this isn't, as you know, a Fed-
eral takeover of anything. It really is a State-based insurance regu-
laratory system that stays a State-based insurance regulatory sys-

tem. But we are working very hard with the States to remind them
that this responsibility is theirs.

We have asked—I actually went to the health insurers and asked
that companies submit to our office at a minimum their actuarial
information of what their overhead costs are, and what their ben-
etit payouts are, so we can at least make it transparent to the
American public. So far, we haven't had a terribly robust response,
but I am hoping that we will.

Mrs. LOWEY. I look forward to your keeping us up to date on this.

Because, from my perspective and many of my colleagues', we were
moved to pass this legislation because, frankly, everybody, from
small business to large small business, was just getting rate in-
creases.

And my time is up. And I look forward to continuing to hear from
you and getting this information.

Thank you, Mr. Chairman.

Mr. OBEY. Mr. Lewis.

SINGLE-PAYOR SYSTEM

Mr. LEWIS. Thank you, Mr. Chairman.

Welcome, Madam Secretary. I don't envy you the challenge you
have before you. All of us face the same thing, but you are in a
very special hot seat.

In general, I would like to talk about medical errors a bit and
a bit about Medicare. But before getting to that, as we have gone
through this debate over the last year, it has become very apparent
to any observer who has looked closely that the key players on the
majority side—the President; the Speaker; the Speaker's closest ad-
visor, Mr. Miller of Oakland; indeed, Henry Waxman—have been
supportive of a single-payor system.

Now, I know that is not the bill that we produced, but it lays the
foundation for exchanges to become a lot more than State-based
but, rather, Federal-dominated. And it concerns me an awful lot
that we ignore that.

Would you respond to you and your office's view of a single-payor
system at the Federal level?

Secretary SEBELIUS. Certainly, Congressman. I would be glad to.

I think, from the outset of this discussion, there were certainly
those in the House and the Senate who favored a single-payor sys-

tem and felt that that was by far the preferable option. From the
beginning, the President made it very clear that he did not, in spite
of the fact that he had, in years in the legislature and even when
he came to the United States Senate, talked about that as an op-

tion that would be ideal. The more he looked at the situation, with
180,000,000 Americans having insurance coverage that was pref-
erable to them and that they liked, he felt that what we needed
to do was build on the current system. And that is really the struc-

ture that the bill took from the outset, in spite of, I think, the dis-
appointment of some in the caucuses who would have preferred to really dismantle the third-party-payor system.

So this really starts at the States. States put together exchanges either as a single State or in a multi-State area, if that is what they choose. We provide technical assistance to the States to do that. And even though the timetable for exchanges doesn’t begin until 2014, we intend, starting next year, to begin very robust discussions so that we don’t wait until the last minute and have States in a situation where they can’t do this.

We have already had lots of positive discussions, and States are very eager to do this. And I think it will very much be a State-based program. And particularly, Congressman, it is not to dismantle what is in place right now. It is really to replace the market for self-employed Americans, many of whom cannot find affordable coverage, don’t have any leverage, a lot of small-business owners who find themselves in the same situation.

MEDICAL ERROR RATES

Mr. Lewis. Madam Secretary, if I could take you to medical errors—

Secretary Sebelius. Yes. Yes.

Mr. Lewis [continuing]. You suggest that, within the Department, you want to at least model some evaluation of medical errors to see how we can improve on that pattern within the health-care delivery system. Might I suggest that one of the major Federal medical health-care delivery systems lies within our military. There is plenty of evidence that there is rampant across this system an error-based system of delivery.

I would suggest that you might start there and help us, with you, to evaluate what is going on in that medical health-care delivery system that supposedly is serving the most important servants we have in our society, the men and women who have fought for this country.

Huge problem there. I would be interested in your reaction.

Secretary Sebelius. I am sorry. I want to understand what you are saying, Congressman. We have begun, certainly, discussions with not only the VA but the Department of Defense on their system. But you are suggesting that there are rampant medical errors within the health-care system for—

Mr. Lewis. That is correct. There is evidence at the highest levels that system deliveries are, at best, producing an awful lot more errors than the norm. And we might start that examination right there.

Secretary Sebelius. Well, I think that is a good point, and I will follow up on that. Thank you.

MEDICARE ADVANTAGE

Mr. Lewis. One of the President’s major promises was that, if you like your health care, you can keep it. And yet, to pay for the new health-care plan, the law, it appears, would cut in a major way Medicare Advantage by more than $130,000,000,000. I have 50,000-plus seniors in my district who enjoy Medicare, and, indeed, they are concerned about what these proposed cuts might do to that service and existing delivery.
What can my seniors expect relative to implementing this program?

Secretary Sebelius. Well, I think that there is a provision, as you know, as part of the law that, over a decade, a portion of the overpayment to the Medicare Advantage plans will gradually be phased out. There are about 400 companies right now offering about 1,100 plans throughout the country. About 11,500,000 seniors taking advantage of those plans.

We have just actually put out the 2011 Medicare Advantage updates, which will have the same rate payments for 2011 as they did for 2010, and noticed plans across the country. There will be a robust array of choices for Medicare recipients, as there are right now.

I don't think there is any question that we are going to begin to pay more attention and collect more data, and the CMS, on medical outcomes, will be looking at not only the fee-for-service side of Medicare but also the Medicare Advantage side of Medicare to make sure that, if enhanced payments are going out the door, it is really for higher-quality health outcomes. And we know bundled care produces that, medical home models produce that. And there are a number of Medicare Advantage plans who are very eager to engage in that.

But I think that the misinformation to seniors about the fact that Medicare Advantage is somehow not going to be a choice is just wrong. We anticipate that there will be no shortage of choices of Medicare Advantage plans throughout the country.

Mr. Lewis. Thank you, Mr. Chairman.

I must say, Mr. Chairman, that what she just mentioned is a major stumbling block. But if I were going to point to the greatest stumbling block, it is when the average family, let's say 25 to 45, suddenly finds a mandate, with the IRS looking over their shoulder, that they must start putting money into a pool for some future service delivery.

Thank you.

Mr. Obey. Well, I would say the greatest stumbling block is when people with insurance have to pay $1,000 a year to subsidize people who don't have it because we didn't have, until now, a program like this.

Ms. Lee.

DIVERSITY IN HEALTH PROFESSIONALS

Ms. Lee. Thank you very much, Mr. Chairman.

Good to see you, Madam Secretary.

First of all, let me just thank you so much for your leadership in helping to move the historic health-care reform bill forward, for your steady leadership and your choice and your experience.

And also, for those of us who were adamant about a public option in terms of keeping costs down and holding the insurance companies accountable, we are counting on you to make sure that that happens, short of having a public option. And so, thank you very much for understanding how important that is.

Myself, Congressman Honda, Congresswoman Roybal-Allard, the Tri-Caucus was lockstep, very adamant, on addressing racial and health disparities as part of the health reform bill. And I would
like for you to elaborate on how this budget actually supports the
goal of diversity in the health professions through recruitment and
training; how you increase diversity at NIH institutions and re-
searchers, ensuring that the racial and ethnic minorities benefit
from any new, innovative health research at NIH; also, in terms of
the direct support for our Nation’s minority medical colleges, the
targeted support to help eliminate these disparities within commu-
nities where we see them the most.
And so, in this budget, I just want to see how you are shaping
this. I know that this year the Office of Minority Health, through
I think it is called the National Partnership for Action to End
Health Disparities, has produced a draft report, a national plan of
action on disparities. So I just want to get a sense of where you
are on that.
Secondly—and I will ask all my questions right away, and then
you can respond. Secondly, national AIDS strategy: Current budget
allocation? Who is going to lead the implementation of the national
AIDS strategy? And what part of the current budget allocation—
I think it is $70,000,000—that is going to HRSA and CDC will be
dedicated to the national HIV-AIDS strategy?
Thirdly, let me ask you about nursing, because I had a long con-
versation with the dean of the Samuel Merritt Nursing School in
Oakland, and she indicated that just in the Bay Area alone, 40 per-
cent of all new nursing graduates since October 2008 have yet to
find a job. Yet I thought there was a nurses shortage in our coun-
try.
I spend a lot of time, as I say to many, I spend a lot of time in
hospitals. My mother is 85 years old. My sister has multiple scle-
rosis. And these are very good nurses, but we are always being
treated by traveling nurses, nurses who have retired and who come
to the hospitals to work because, I am told, that there is a short-
age. And yet now the dean of the nursing school says nurses cannot
find a job.
So I would like to, kind of, get some sense of what you think is
going on out there and what we can do to ensure that qualified
nurses are being hired.
And if I have any more time, I will ask some more questions, but
.go on and respond to those.
Thank you again, Madam Secretary, and good to see you.
Secretary SEBELIUS. Well, thank you, Congresswoman. I will try
to hit the high points on the issues you raised.
First, health disparities is, I think, a glaring failure of the health
delivery system over years. And while our department I think has
done a fairly decent job documenting health disparities, there has
not been a very good strategy to actually reduce or eliminate health
disparities.
So the National Action Plan that you refer to is really the first
time since 1985 that there will be a secretarial-level plan address-
ing health disparities. And it is one that I take very seriously. It
is in draft form right now. We look forward to having a chance to
preview it with you and to work on it.
I don’t think there is any question that passage of the Affordable
Care Act is one of the most important steps we can make toward
closing the gap. Over and over again, it has been identified that the
lack of insurance, the lack of access to affordable health care is one of the underlying causes of health disparities. So a big step was made.

Our budget, actually, will build on that effort in a number of ways. Not only will the Office of Minority Health focus with a strategic roadmap on this National Plan—and we see it not only within our department, but an across-government-agency effort, where health is impacted by neighborhoods, by food availability, and by the air you breathe. There are a lot of things that actually add or subtract from people's health. So we see this as a government-wide effort.

We do have additional resources in the 2011 budget that look at recruitment of health providers from minority communities to make sure that we have not only people serving in underserved areas, but actually minority providers—nurses, doctors, health technicians, mental health professionals.

As you know, the Affordable Care Act also made the Center for Minority Health and Health Disparities into an Institute at the National Institutes of Health which raises it to a level where it will have serious strategic focus and attention. So there are a whole host of assets coming together in a way that really hasn't been organized in our department.

And, again, we look forward—I know this has been not only a cause that you have taken very seriously but your fellow Tri-Caucus members have been focused on for years, and I really look forward to working with you as we address these gaps and these underlying health causes.

I would suggest, also, that the increased footprint for the Community Health Centers, which actually started in the Recovery Act and are, again, targeted to the underserved areas, as well as the efforts in wellness and prevention grants, will also help to close this gap.

I can't respond very well to the nursing job shortage situation that you talked about because that is the first time I have ever heard of nurses not being snapped up immediately to be hired. I hear the other side of the story over and over again, that people need more nurses in the pipeline. And that is exactly what we have been doing, is trying to fill that workforce pipeline with more scholarships being paid off, more increases to the National Health Service Corps, more people in underserved areas. So I need to follow up on that.

And then, finally, in the AIDS area, there is a national AIDS plan that is currently being formulated. It is not finalized at this point. As you know, President Obama has identified the fact that, while we had a very robust international HIV-AIDS strategy, we had kind of lost the attention and focus at the national level.

We have already launched, under CDC, an outreach program on testing and particularly identified some of the most vulnerable communities that we are beginning to interact with, using social networking.

But we look forward to the strategic plan, which will be led by the White House Office of National AIDS Policy and others who are focused on AIDS. There is a new AIDS Council, which will have a
national and international focus. And we are going to be very intimately working with them.

Mr. Obey. Mr. Rehberg.

HIGH RISK POOLS

Mr. Rehberg. Thank you, Mr. Chairman.

Temporary high-risk pools in Montana—I understand you have been in contact with our auditor already about it. But I noticed in the appropriations $5,000,000,000 was taken out of the general fund to pay for the high-risk pools around the country, but CMS is suggesting that the money will run out in 2011 and 2012. And, of course, they don’t have to be in place until 2014.

Why the shortfall? Well, why the anticipated shortfall? And are there other areas that you see it is already coming in over-budget?

Secretary Sebelius. Congressman, we don’t know exactly how many people will be able to be enrolled in the high-risk pool. A lot of States offer high-risk pools right now. I think Montana—

Mr. Rehberg. Which is one of the reasons we wondered why we did this in the first place. If we already had the high-risk pool in place, why supplant it with something created by the Federal Government to do something that we already had in place?

Secretary Sebelius. Again, this is a totally voluntary program, first of all. Secondly, it won’t be created by the Federal Government. If Montana chooses to set up what is a parallel pool, the money that is allocated in the Affordable Care Act is to subsidize rates so——

Mr. Rehberg. The point is——

Secretary Sebelius [continuing]. They don’t rise above 100 percent in Montana.

Mr. Rehberg. Correct.

Secretary Sebelius. They are well over 100 percent of the market right now, and it makes it very unaffordable for lots of folks.

Mr. Rehberg. But my question is, you asked for $5,000,000,000, you got $5,000,000,000, and CMS is already anticipating it will not last through 2011 or 2012. And the high-risk pools are not to be in place by 2014. A shortage, a shortfall, an overexpenditure. How are you going to deal with it? Are you going to limit access?

Secretary Sebelius. Again, sir, this is not a Federal program. If Montana chooses to participate, they will have an allocated set of resources, which helps subsidize care for Montanans who currently are uninsured and uninsurable.

Mr. Rehberg. Madam Secretary, you——

Secretary Sebelius. If they choose not to participate, that is a choice that the State will make.

Mr. Rehberg. Let’s go back to the question. The question was, the legislation created high-risk pools, or the opportunity to create a high-risk pool——

Secretary Sebelius. That is correct.

Mr. Rehberg [continuing]. By 2014.

Secretary Sebelius. No, sir. Right now. This is the bridge strategy to a new market——

Mr. Rehberg. Correct.

Mr. Rehberg. That is correct. But, by 2014, an alternative structure needs to be in place.

Secretary Sebelius. The exchanges.

Mr. Rehberg. Correct. But if the exchanges are in place in 2014 but you are using Montana and the other States' temporary pool, and if you appropriated $5,000,000,000 and it is not going to make it to 2014, you are going to have to come back to this Appropriations Committee and ask for more money.

You have already anticipated that it is going to cost more than you told us it was going to, in asking that the legislation be passed in the first place.

Secretary Sebelius. Sir, currently, the Federal Government pays a fraction of a State's high-risk pool. It puts about $50,000,000 into an overall plan. This is an attempt to provide a safety-net coverage if the money actually is going to have a shortfall.

Mr. Rehberg. Madam Secretary, with all due respect, that doesn't answer the question of the shortfall. I understand the bridge. I understand that you are going to cooperate or participate or help the States. But you said it was going to cost $5,000,000,000, your anticipated expenditure, and it is not.

Secretary Sebelius. Well, we don't know what it is going to cost, and I would——

Mr. Rehberg. So you disagree with CMS?

Secretary Sebelius. We don't even know how many States want to participate in the program at this point. We put out a letter to Governors. I talked to my former colleagues yesterday. We will, by April 30th, have some idea. I mean, we really don't know, at this point, sir.

Mr. Rehberg. Okay.

The second line of questioning that I would like to go down the path—in the stimulus package, the law certainly says you can't lobby.

Secretary Sebelius. Correct.

Mr. Rehberg. You know, a bastion of information from CNN. State of New York, obesity, educate leaders and decision-makers about trans fat—this is a $3,000,000 grant award. Santa Clara, California, advocating for an increased statewide tobacco tax. The city of Chicago, tax increase at the city, county, and State levels. Iowa Department of Public Health, $3,300,000,000, inform local policymakers about evidence- and practice-based pricing.

That sounds like lobbying.

Secretary Sebelius. Congressman, I read the same information from the same news source. I can assure you that we will follow to the letter of the law the Federal law which prohibits Federal funds and has, not just in the Recovery Act but consistently, prohibited lobbying with Federal dollars. We will track that very carefully. We have already notified a whole host of folks that that is the law of the land. That was part of the grant application and will continue to be part of the monitoring.

Federal funds will not be used for lobbying.

Mr. Rehberg. Okay. Because those were all quotes from the grant application in the first place.
Secretary Sebelius. A lot of the applicants have a whole host of strategies that they employ, have employed historically, and will continue to employ. We are funding programs that are not lobbying programs. They are actual prevention——

Mr. Rehberg. But your oversight missed it in the initial grant application.

Secretary Sebelius. Pardon me?

Mr. Rehberg. Your oversight missed it in the initial grant application. The grant application had those exact quotes in it.

Secretary Sebelius. They have been notified that there is an absolute prohibition for using any Federal funding for lobbying. And we will follow up on that very carefully.

Mr. Rehberg. Thank you.

Thank you, Mr. Chairman.

Mr. Obey. Ms. Roybal-Allard.

Ms. Roybal-Allard. Welcome, Madam Secretary.

Prevention and Wellness Funding

Last year, the American Recovery and Reinvestment Act made $650,000,000 in prevention and wellness funding available for chronic disease prevention and management. And this year, when Congress passed the Affordable Care Act, it included a $15,000,000,000 Prevention and Public Health Fund, of which $500,000,000 is, I believe, available this year. And, as I understand it, these new funds are not restricted to chronic diseases but are meant to fund the entire spectrum of public health efforts.

I have been told that your office is currently working on a system to distribute the funds this year. However, there seems to be significant concern in the infectious disease community that, in an effort to obligate the $500,000,000 by September 30th of this year, the Department will fund only existing grant applications for the ARRA of chronic prevention grants and that infectious disease programs will once again receive no funding.

Can you please outline how you plan to allocate these funds and whether you will include new applications for prevention funds to target infectious diseases such as HIV-AIDS, viral hepatitis, sexually transmitted diseases, tuberculosis, many of which are at crisis levels in many communities? And what strategies is your department undertaking to address these infectious-disease disparities in our minority communities?

Secretary Sebelius. Congresswoman, I would suggest that, at this point, as you have identified, conversations are going on with Members of the House and the Senate about the strategies for allocating these funds. So no decisions have been made, at this point, about either using traditional applications or not. But we absolutely want that kind of input and, you know, look forward to working with you on a plan.

I think that the effort will be to actually build on—as you know, the investment in the ARRA funds was really a first-time-ever investment in wellness and prevention and strategically focused, at least in the community grant applications, on two underlying causes of chronic disease, which were tobacco cessation and obesity.

This is likely to be a broader area. There are lots of ideas and good strategies about how to use this. We are looking carefully at
the scientific data, at the evidence-based programs. I can guarantee you that what actually has been demonstrated to work will be one of the guiding lights.

But I would say that discussion is very much under way, and we would appreciate your input.

Ms. ROYBAL-ALLARD. So they are still open with regard to funding infectious disease?

Secretary SEBELIUS. Yes.

REDUCING CESAREAN BIRTHS

Ms. ROYBAL-ALLARD. Okay.

As you are aware, the United States spends more on maternity care than any other country in the world. However, we rank 41st in the world in maternal mortality and rank 30th in infant mortality.

While we know there is an extensive body of research regarding best evidenced-based practices in maternity care, our health-care providers seem not to be following that research. For example, despite Healthy People 2010 goals of reducing Cesarean births to 15 percent, the United States continues to have a 31.8 percent Cesarean section rate.

Given the risks that are associated with medically unnecessary Cesareans and the extraordinary costs associated with Cesarean births, is the administration doing anything to refine our care system to support the best and most cost-effective, evidence-based care to reduce the rate of C-sections?

Secretary SEBELIUS. Congresswoman, I am not sure I can speak with any specificity about what actions are currently being taken in dialogue with providers about the C-section rate beyond just publishing the data and highlighting the data.

I can tell you that our Office of Women’s Health is very focused on maternal and child health issues and, frankly, what are pretty dismal health results, as you suggest—high expenditure and not terrifically good results.

I, again, think that the Affordable Care Act makes a big step in the direction of getting affordable prenatal care to pregnant women. That will be a major step forward——

INCREASING BIRTHING CENTERS

Ms. ROYBAL-ALLARD. I am sorry to interrupt, because I see my time is up, but I did want to know whether or not, since the new law requires Medicare to cover care provided in all free-standing birth centers at a cost of $6,000 less, is there any consideration in the initiatives to increase the availability of licensed birthing centers across the country?

Mr. OBEY. Very brief answer.

Ms. ROYBAL-ALLARD. Is that being looked at?

Secretary SEBELIUS. I can’t answer that, but I will look into it.

[The information follows:]

INCREASING BIRTHING CENTERS

Thank you for your interest in the Medicaid program and the availability of licensed, free-standing birthing centers. As you know, section 2301 of the Patient Protection and Affordable Care Act of 2010 (the Affordable Care Act) requires the
States to cover services provided by freestanding birth centers as a mandatory service under Medicaid. Currently, we are focused on implementing and providing technical assistance to the States on this provision. We expect that States with licensed, freestanding birthing centers will build a foundation for expanding these services to the Medicaid population and that their experience will be instructive to other States considering expanding the availability of such centers.

Ms. ROYBAL-ALLARD. Okay. Thank you.
Mr. OBEY. Mr. Alexander.

FMAP FORMULA

Mr. ALEXANDER. Thank you, Mr. Chairman.

Madam Secretary, I have two questions. One is about FMAP. Congressman Cao and all of the Louisiana delegation, as cosponsors, are supporting a piece of legislation to address Medicaid reimbursements or Medicaid costs. Governor Jindal is supporting the legislation, as well as Secretary Levine from the Louisiana Department of Hospitals. They are in a legislative session today dealing with the shortfall there of a half a billion dollars.

My question is, what is being done to prevent States like Louisiana, who were unfairly, when you look at the FMAP formula—because we got a lot of money, as the State of Louisiana was recovering from the hurricanes. Louisiana was looked at as being a State that was financially better off than they really are.

So what are we doing to prevent Louisiana or any other State, like yours, that received financial help from appearing to be wealthier than they really are and, therefore, suffering because of the Medicaid?

Secretary SEBELIUS. Congressman, we have spent a good deal of time with not only your State health officials, your Medicaid director, the mayor-elect of New Orleans, and others, Senator Landrieu, on this situation. Frankly, one of the reasons I think that there is now a legislative discussion is because the law is pretty clear that we don’t have administrative flexibility to change the calendar years for which the income level is calculated; and that is really the situation, is when the count began what the income level is and how it was calculated. But we are working very closely with them, well aware of the anomaly that income appeared to go very high because half the population was, frankly, gone and not counted and probably inaccurately reflects what is the true medical count.

And if we can have a legislative fix, we will try to move it very, very quickly. But we have our hands tied in terms of what administratively we can do for this situation. But I think it is really worth looking at.

As you suggested, it is not only Louisiana but what happens post-disaster in an area where Federal funding may come in as an aid after the fact, but then the result is a calculation that isn’t a very accurate picture of what the financial wherewithal is.

HEALTH CARE FRAUD

Mr. ALEXANDER. Thank you.

Chairman Obey a little earlier said something about a meeting that we had a few weeks ago about fraud. During that meeting, we heard all kind of reports about the number of physicians and other health care providers that were using sometimes information ob-
tained from the inside to defraud the taxpayers. I asked the question about the number of individuals from the inside that might have been found doing something wrong.

Again, I am not pointing fingers, but I just find it almost impossible to believe that there are numbers of individuals on the outside committing fraud at the numbers that we are hearing about without getting some help from the inside.

When we talk about organized crime—and that term was mentioned—organized means at least two. You can’t have organized crime with one. So I asked the question. I have not gotten an answer. I have had staff members to try to find out if in fact there are any individuals on the inside of any of the departments at all levels who have been found guilty of helping those on the outside. Can’t get an answer. There is no answer or either they won’t give it to us.

Secretary Sebelius. Congressman, I can tell you I am not aware—and I will make sure we get this data and get it right back to you—I am not aware of if you are talking about State and Federal employees who have been charged and found guilty. I do know if “inside” means providers and not necessarily just doctors but so-called equipment providers and home health providers, there are dozens and dozens of insiders in that instance who have been charged and prosecuted, which is really the only way that we would be able to document if they have actually been found in some case. But I can get that information to you.

That is the kind of thing that I think the new fraud effort is attempting to crack down on, people who pretend to be providers, if you will, set up sham operations, bill. But they are not necessarily part of organized crime. They are just operating as insiders but really conducting fraudulent activities. But we will circle back right away and get you that information.

[The information follows:]

HEALTH CARE FRAUD

The HHS Office of Inspector General’s (OIG) Office of Investigations (OI) has one known case where an employee was complicit in a health care fraud scheme. In the Los Angeles Region, two Centers for Medicare & Medicaid contractors admitted to receiving money, $15,000 and $5,000 respectively, from an outside source to process provider applications. One individual received 3 years probation and was fined $1,000, while the other received 2 years probation and was fined $5,000.

Because many of the providers who had applications expedited are subjects of ongoing investigations, the total loss to the Medicare program has not been fully determined. However, it was determined that one provider involved in this scheme, caused a $3.2 million loss to the government. Additionally, it is believed that at least one entity bribing the employees in this case is connected to an organized criminal enterprise, and there may be additional employees identified in this scheme.

Instance of “insider” fraud within the Department or involving its employees are extremely rare, and when identified, are taken very seriously and investigated to the fullest extent by our law enforcement partners.

Mr. Alexander. Thank you.

Mr. Obey. Ms. McCollum.

MEDICARE REIMBURSEMENT

Ms. McCollum. Thank you, Mr. Chair.

To the gentleman’s question, I know the Department, unfortunately, I have to report, in Minnesota found two internal problems
with fraud. So you do do internal audits, and I am sad to report that there were people in Minnesota involved in it. I am happy that they got caught.

I would like first, though, however, to commend Chairman Obey for his ongoing instrumental leadership in fighting for the best value and quality in health care. That just leads to a lot of hearings that you have had before and the hearing we are having today.

I would like to congratulate you on the passage of the health reform bill. Your work and the work of the administration were key to ensuring that health care reform became a reality. I believe that the current Medicare payment system is deeply flawed and too many hospitals and providers shoulder the burden of unfair Medicare reimbursement for high-quality, low-cost care that they deliver, my State being one of them. I look forward to working with you as you convene the National Summit on Geographic Variation, Cost, Access, and Value in Health Care this year. And on this issue and the timing implications for some of the fact finding that you are looking at and for the implementation of change, I am going to submit some of those questions for the record.

HOSPITAL ACQUIRED INFECTIONS

Ms. McCollum. So I would like to spend my remaining time talking about hospital-acquired infections. We are here today to learn how to work more effectively with you to improve the quality of our health care system for all Americans. Hospital-acquired infections contributed to almost a hundred thousand deaths. In a recent report, HHS concluded that hospital infections merited urgent action. We know that hospital infections add $28 to $33 billion to our national health care costs. This is a serious public health care concern, because we are not only paying the cost, there are patients paying for these mistakes with their lives.

HHS has set out a goal to reduce hospital-acquired infections by 10 to 20 percent in 2 years, and 50 percent within 10. But we are far from reaching that goal. We know that most of these infections are preventable through low-cost techniques. There is a New York Times article that even talks about how we have had remarkable progress in reducing infection rates but how many of the hospitals have not yet worked to overcome these infection rates because they are in an entrenched medical culture which is not changing.

My State has worked to lower infections, and I know others are doing that as well. You have examples at your Department on how we can reduce infection rates. But the report also points out that infection rates have gone up 8 percent.

So here are my questions:
Is the 8 percent increase because of better reporting, whether it is voluntary or mandatory? Because you can’t address a problem until you know and you face the fact that the problem exists. What are some of the obstacles to addressing this issue? Does the agency need this committee or the policy committee to work more closely with you to address this public health care concern moving forward?

Secretary Sebelius. First of all, Congresswoman, I think your targeted concern is one that is a huge issue, and it is not only a
huge cost issue, it is a huge safety issue. I know the Chairman has been working with you and sort of focused like a laser beam on this. The notion that we have a hundred thousand deaths a year from what happens to people when they are in the hospital, not what brought them in the first place, is, frankly, totally unacceptable. And hundreds of thousands more in just high-cost, longer-care strategies and lingering diseases. So it is a very serious issue.

We know what works. It has been demonstrated and proven. It has never been taken to scale.

So I think a couple of things are happening simultaneously. First of all, the notion of increases, I would say, is a part of better reporting. It also is a snapshot of the past. We are hopeful that more hospitals are getting more encouraging signs. This focus by the Department, by this Committee, through the Recovery Act, through the Affordable Care Act, and through our budgets, I think is relatively recent.

Secondly, there is no question that it is a question of focus by hospitals. You have required as part of the Affordable Care Act that all hospitals now have to report, which is a big step forward, and that reporting will be much more transparent to consumers and others, which is, again, a big step forward.

Third, we are putting real resources both to States for more frequent inspections and to hospital systems to encourage the adoption of the strategies that we know work.

Fourth is the electronic medical records. I was in a hospital in Cincinnati 2 weeks ago, in Children's Hospital, which does some of the most complicated surgeries on infants and even prenatally that I have ever seen. They have embedded into their electronic records system the checklist that we know works to reduce hospital infections. They have gone a thousand days without any safety concern. It is a great example of what meaningful use in an electronic records system can do, which is embed the kind of safety checklist, make sure it is done time and time again. If you can do it in that type of environment, we can do it everywhere.

So I think there are some resources coming together, but I can tell you that it is something that we take very, very seriously. And I think it is not only huge costs, but we are killing people by our health care system.

Mr. Obey. Mr. Cole.

MEDICARE REIMBURSEMENT RATES

Mr. COLE. Thank you, Mr. Chairman.

Madam Secretary, thank you for being here today.

As I talk to hospitals in my district, and it is a pretty rural district, a lot of small town, lot of Medicare- and Medicaid-intensive facilities, most of them are expecting, and this is not through your actions or through the health care bill, the Medicare reimbursement rates are being cut. They are going down. They look on the Medicaid new population that they will be getting under the health care bill as largely a break-even deal for them. They are really not making money off of that. They are very worried about what is going to happen to the private provider part of reimbursement.

Because the point has been made here earlier, private insurance subsidizes the uninsured, but it also subsidizes Medicare and Medi-
care to a large degree, because those programs don't break even on costs. So they are looking at their future, and they are wondering where the dollars will come from for them to literally keep their doors open. And then the people in the larger cities wonder what happened to those smaller hospitals that closed and that popula-
tion base is moved into their facilities.

So I would like you to just walk through how you see hospital reimbursement rate developing over the course as you phase in the new health care bill.

Secretary Sebelius. Congressman, I think that is a great question. Whether it is in rural areas in your district or in a State like Kansas, or in urban areas, I think every hospital administrator who I have talked to in the last 10 years has seen their uncompensated care rate rise. So there is currently a population with no payment stream at all and then insufficient payment streams and then private-payer streams.

So I think one of the features of the Affordable Care Act is to actually have a payment stream arguably under every patient who comes through the door. It is one of the reasons that a lot of the hospital systems worked carefully with us on the framework of health reform.

I do think that there also is an effort where the kind of bundled care strategies—again, hospital providers are very eager to have a payment system which actually looks at ways that they can be more appropriately compensated for keeping people out of the hospital. Right now, the only way they actually get compensated is if somebody actually comes back into the hospital.

And the sorts of embedded directional changes in the delivery system for health homes and bundled care and accountable care organizations actually have, I think, some huge advantages for hospital systems to have a more appropriate reimbursement system and actually keep people healthier in the long term. I would say the third piece of the puzzle is a lot of hospitals right now, particularly through emergency rooms, are delivering care which could much more effectively be delivered in a primary care setting, in a community health center, in a variety of areas. They have begun to work on strategies to kind of triage that care so they don't have to have this robust sort of preventive care, and that I think is also part of the new structure.

Mr. Cole. A lot of, again, my facilities are concerned with, again, on the private end of it is where they make the money to, frankly, reinvest in technology and facilities. They don't make that off Medi-
care. They don't make it off Medicaid. So they are really worried, are we going to crowd out the private market here and they won't have the money they need to give patients the best service that they possibly can give.

Secretary Sebelius. Well, I think with the exchange opportunities, the private market, I would suggest, may be stronger. What is happening right now, and has happened over the last 5 years certainly, is more and more small employers have dropped their private coverage because they can't any longer pay the premium. A lot of individuals lost insurance when they lost their jobs, but I think the restabilization of a marketplace, of a private marketplace
with larger purchasing pools but then stabilizing that coverage that people have is actually going to be good news.

Mr. Cole. I hope so. I think that is a point worth making, though. Because a lot of my friends who favor the public option think, forget where the money comes from that actually allows health care to be delivered. It is very heavily from the private sector. You overpay, quite frankly, if you are on private insurance already. We know that problem was alluded to earlier. But that also supports Medicare, Medicaid, and, frankly, the new health care insurance bill as well. So I would be very careful about killing the goose that has actually provided the eggs for everybody else.

Secretary Sebelius. Well, as you may know, of the 32 million or so estimated new enrollees in a health insurance system, the majority of those individuals will be in the private market, will not be in the public market.

Mr. Cole. Thank you, Mr. Chairman.

Mr. Obey. Mr. Honda.

HEALTH INSURANCE COSTS

Mr. Honda. Thank you very much.

Welcome, Madam Secretary.

Just to pick up with your last comment, the additional 32 million that will be added to the population, would that tend to drive the costs down across the board in terms of insurance premiums if we have the other things in place like the antitrust provision and a public option?

Secretary Sebelius. Congressman, what I think is anticipated to cost less is—first of all, the market right now is pretty fragmented. So if you are an individual buying your own coverage, or a small business owner, one health incident, one cancer survivor, one heart attack puts you in a very expensive category. Pooling that risk into an exchange, a much bigger purchasing pool, I think helps balance the costs overall. I think it is one of the reasons that costs will come down. Hopefully, a number of the underlying features that actually lower the overall health care costs also are impactful in terms of the health insurance costs.

Mr. Honda. It seems to me that that is something that we can work towards and anticipate. We do know, though, if we don't do anything, we have 47 million people without insurance and the costs continue to rise. In the last 18 months, at least in California, the premiums have gone from 30 percent one year, 38 percent this past year, in terms of premiums increase, in light of the debate we had already. So I am not sure the word is arrogant, but it sure is pretty bold to do that while we are having a debate on the high cost of insurance.

I want to thank you for taking on this job. It is a massive job; and I think it is a very complicated, complex job that you have. But I am looking forward to working with you on this.

I would note that the State you do come from is a very active State and very vigorous folks. I was pleased to see that a Congressperson did vote for the bill.

I think that in my own district, District 15, which is Silicon Valley, which has probably the highest per capita post-graduate folks, probably the highest average income in this country, I had some-
thing like 70,000 folks who were uninsured. That is almost 10 percent of my population. It doesn’t mean that they were unemployed, but they were uninsured.

A fellow who ran against me for office when I first ran, a young man, a good friend of mine, said that in the current situation he would not be able to go into business for himself because his child has a pre-existing condition. My past opponent and friend said, go for it. It is important for our country.

What is important for our country also is that we know that we have a viral hepatitis issue in America and globally, and we know that more Americans have chronic viral hepatitis. There is more of an incidence of that than HIV/AIDS, and the disease is 100 times more infections than HIV. While I am grateful to the President for requesting an increase for the division in your 2011 appropriation budget, I am glad that Assistant Secretary Koh, with whom we had met, had begun two major interagency tasks forces on this issue. We are very appreciative of that activity.

PREVENTION AND PUBLIC HEALTH FUND

I am also aware that there is about $500 million for prevention and wellness funds that is made available through this bill. But there is nothing that says how it is going to be spent. Do you have any idea how your Department will be looking at that and how it will be spent?

Secretary Sebelius. Congressman, I think that we are still seeking guidance from Members in the House and the Senate about that 2010 appropriation for the prevention funds. We did invest in prevention in 2009 and 2010 as part of the Recovery Act, and we see this as an opportunity to amplify and maybe look in some other directions, but those conversations are under way, and we would appreciate your feedback.

Mr. Honda. We certainly will be willing to do that.

Mr. Obey. The gentleman’s time has expired.

Mr. Ryan.

PREVENTION AND MINDFULNESS

Mr. Ryan. Thank you, Mr. Chairman.

I want to personally thank you for all your leadership with regard to the health care reform efforts in trying to push it through. I think history will judge us well, bringing a level of social justice to this country that we haven’t seen.

One of the things I mentioned before when you were here that I have been dealing with and working with for the past few months and years is the issue of stress in our society. I think as we talk about health care reform and the technology and everything else that there is a growing body of evidence, not just in the area of health care, of mindfulness and contemplative practices and their benefits on reducing stress levels and allowing our body to heal itself.

So as we are moving 30 million more people into the system, there is inevitably going to be more costs, and I think we have dealt with that. And it will reduce costs, and I think we have dealt with that.
But we need to, I think, pursue—and Mr. Honda just mentioned prevention. I know there is going to be a panel to evaluate what preventive measures actually work. So if you can just talk about that.

But I would also like to encourage you that on that panel should be somebody who has been in the field, working in the field of mindfulness-based stress reduction. I think it is the most cost-effective way to drive down health care costs. It is about individual responsibility. It is about teaching people to manage their own health right in line with everything else we are talking about. So I want to encourage you to do that.

It is not just in the area of health. The Defense Department is now doing this for pre-deployment for soldiers who are going over, allowing them to—and hopefully prevent a lot of the post-traumatic stress that goes on when these kids go into battle. So I want to encourage you to do that.

If you can talk for just a second about the panel that is going to be created to evaluate adequate preventive measures in the health care reform bill.

Secretary Sebelius. First, Congressman, I am all for looking at any strategy we can find that is successfully reducing stress. I am at the front of that line. I would be grateful for that evidence. I think that whether it is in this instance or the framework for the services, with the exchanges or others, certainly we will put together a very broad-based group of experts and look at what the evidence says. And in this area I think there are a number of cost-effective sort of patient-centered strategies that really do work. And so I look forward to getting the information from you and making sure that is part of the discussion.

Mr. Ryan. I will get it to you.

I was at a conference this past week and there was someone from Ms. McCollum's district at the University of Minnesota. They are offering basically a stress reduction class for incoming freshman. There is a 50-person wait list. So this is something that is throughout our society. So I think your leadership on this could be critical.

PRIMARY CARE PHYSICIAN SHORTAGE

Another question I have, and it is something one of my colleagues mentioned, the shortage of nurses, is the issue with primary care physicians. If you can touch upon that and how we are going to try to bridge our way through that.

Secretary Sebelius. I think there is no question we need more health care providers altogether, but we also need more of the providers to choose primary care, gerontology, family practice. So a couple of strategies simultaneously. One is using more of our loan repayment and scholarship funds to attract people to those fields at the outset and pay off more of the debt for health care provider training in the areas that we see the biggest needs.

As you know, the Affordable Care Act had a feature which actually, again, moves primary care providers for a couple of years with 100 percent Federal funding from Medicaid rates to Medicare rates, which I think is, again, a big step forward to more adequately compensating the kind of work they are doing.
Mr. Ryan. How about the bridge between those kids that they are going into school now maybe and they are saying, yeah, it looks like primary care is going to be an opportunity for me. But in 2014 they will be just getting their bachelor’s degree or their BS degree and moving on.

Secretary Sebelius. We are changing the Medicare pay rates, also. I think payment of debt once you get your medical degree is also a pathway to a much more robust primary care system. That is what I hear from medical students all the time, that they are in a real financial box in terms of not being able to pay off their loans and being inadequately compensated once they become providers. So we are looking at both ends of that puzzle.

Mr. Ryan. So you think they will move over immediately.

Secretary Sebelius. I do. Actually, we have seen an increase already this year in primary care choices made by first-year residents. It is up about 20 percent.

Mr. Ryan. Great. Thank you.

Mr. Obey. Ms. DeLauro.

HEALTH REFORM COMPLIANCE AND ENFORCEMENT

Ms. DeLauro. Thank you, Mr. Chairman.

Welcome, Madam Secretary. Thank you for your efforts in helping us to pass what is historic legislation.

I know that your Department is working overtime to make sure that we begin the implementation of this legislation and that the people of this country can really experience the benefits as quickly as possible, whether they are small business owners or seniors or young adults or parents or people who have a pre-existing condition.

We have already seen a couple of instances where insurance companies seem to be changing their behavior in response to the bill. On the positive side, we have seen several companies who plan to move ahead of schedule to let adult children stay on their parents’ plan until age 26.

But there are instances in which we will need to watch insurance companies closely to make sure they are following the new rules that have been laid out. For example, some reports, including the Senate Commerce Committee, indicates that insurers may be manipulating their medical loss ratios, reclassifying certain expenses to make it look like they are spending at a higher percentage of the premium dollar on medical care in order to meet the standards in the law. The Affordable Care Act included rate review provisions, including grant funding to assist States carrying out rate reviews to stop insurance from hiking those premiums to unacceptable levels. This law now bans a host of insurance company abuses: rescissions, denials of coverage for pre-existing conditions, gender rating, and health status rating.

Let me just lay out the three pieces of this question, and I will let you go.

What resources and tools does HHS and the Department of Labor need for enforcement of health reform and holding insurance companies accountable?

With regard to medical loss ratio, how are you going to work with the National Association of Insurance Commissioners to en-
sure that terms like clinical services, activities to improve quality are defined appropriately, that do not include more routine activities that are more typically classified as administration expenses?

Today, in the New York Times, there is an article that says, Senate bill sets a plan to regulate premiums. The Federal Government could regulate rates in States where State officials do not have sufficient authority and capability to do so. Let me ask you to comment on that.

So if you could address those three pieces, I would appreciate it.

Secretary SEBELIUS. In terms of the resources and tools, Congresswoman, we are working very closely with both Labor and with Treasury that has a sort of piece of some of these puzzles on the initial regulations. That has gone pretty well. We have put together our Office on Consumer Information and Insurance Oversight. It is going to be led by a former insurance commissioner who also has worked in many States around the country on regulatory oversight.

We are working very, very closely with my former colleagues at the National Association of Insurance Commissioners because this has got to be, frankly, a State-led, on-the-ground program. They are the ones who have this ability and information.

I think there is a very robust discussion. They are in the midst of identifying the terminology and definition for the medical loss ratio. We are looking at some laws that are in place and work very well and what the actuaries can actually take a look at. So it is something we are going to take very seriously.

In terms of the rate review, the original Senate bill had a provision that Senator Feinstein was promulgating of a rate authority that would actually be the interim strategy between the time the bill passed this year and the time that the new exchanges were in place. That rate authority was not part of the reconciliation measure and I think would set up a framework where, absent State review authority, there would be a fallback review authority.

So I think that debate is likely to go on and may be an important piece of this puzzle, because, right now, unless a State changes the laws and takes on this responsibility, there really is not fallback, other than highlighting what rating is under way. But there is no rating authority right now with the Department of Health and Human Services, and we are encouraging States to do just that.

Ms. DeLAURO. I am really pleased to hear that.

As you know, I come from the State of Connecticut. We probably are the insurance capital of the country. Over and over again, as my other colleagues have experienced, the insurance companies, we have lived in their world a very long time. It is now time for them to live in our world.

Thank you, Mr. Chairman.

Mr. OBEY. Mr. Moran.

PREVENTION ISSUES

Mr. MORAN. Thank you very much, Mr. Chairman.

Let me join the chorus of gratitude for your leadership, Madam Secretary. But it does seem as though you are paddling upstream against the current. When you look at your budget, about 85 percent of it is really not under your control. It is reimbursement after
people have gotten sick, and it is to the elderly. Medicare and most of Medicaid is still nursing home care for seniors.

But something dramatic is happening in the health care of this current generation of young people that bodes ill for the future costs of care. Asthma rates have tripled in this past generation. One in every six American children now has a developmental disorder—attention deficit disorder, mental retardation, dyslexia. One in every 59 boys is diagnosed with autism today. After accidents, cancer is the leading cause of death among children. Primary brain cancer has gone up about 50 percent. Childhood obesity has quadrupled in the last 10 years. Diabetes is out of control, about 25 million people now. In fact, they now say one in two minority children will develop diabetes during their lifetime. That is unbelievable.

So it would seem that somehow we have got to get a handle on prevention. What is causing all this? Because it really is a dramatic change in the last generation. The First Lady's emphasis upon obesity, upon what people eat, is critically important. I would like to know how you are integrating that in terms of your program priorities.

It also may have something to do with the chemicals in the air we breathe or the water we drink or the food we eat. In fact, there was an analysis of umbilical cord blood in 2007 and 2008 that showed that the average infant had 232 industrial compounds present in the umbilical cord blood. So many people think there may be an endocrine-disrupting effect on health care that is contributing to this massive increase in certain diseases.

I ask you because you have responsibility for the National Institute of Environmental Health Sciences. I know they have some indication this may be what is behind these massive changes in childhood illnesses. I am wondering if you have any plans to enable them to take a more robust, aggressive approach in terms of the environment's effect as well as what you are doing in coordinating with the First Lady's initiative on obesity.

Secretary SEBELIUS. Thank you, Congressman.

The statistics you recite are alarming and, unfortunately, very real and ones that we have to take incredibly seriously. The shorthand is that we spend more, live sicker, and die younger than most developed countries; and there is something fundamentally wrong with that picture.

The First Lady's initiative, as you know, is not only focused on what you eat. That is a piece of the puzzle. But I think it is a strategy that really looks across the areas and understands that the health of kids is impacted by what they eat in and outside their houses, what goes on in school, how much exercise they get, whether there is a safe place to play and walk, a whole host of strategies that I think provide a template for the kind of thing that you are talking about.

I don't think there is any question that, first, reporting is better in this generation. Some of what you are talking about is probably highlighted by better monitoring, better reporting. But that doesn't nearly compensate for the incredible increases. Some of it is preventable in terms of what we are doing to ourselves, and some of it is likely to have environmental impact.
My Assistant Secretary for Health, Dr. Koh, has reengaged our Department in a very robust fashion in working with the Environmental Protection Agency and others in looking at the health impact of environmental issues. HHS had kind of withdrawn from that space for a while, and we are very much back at the table. So whether it is looking at carbon content or water-based diseases or air quality, which has a huge impact on asthma, there are huge health impacts from environmental issues. And I would suggest also that the Food and Drug Administration is taking very seriously a whole host of investigations in terms of chemical content, which may well impact people not in terms what they are eating, but the kind of cans, the bottling, a whole host of other areas.

Secretary Sebelius: Something that I think we are reengaging in a very active way and share your alarm and what the current health profile is for this country.

Mr. Moran. Thank you, Madam Secretary.

Mr. Obey. Madam Secretary, I have a number of questions that I would like you to answer for the record, one on health professions workforce, another on pandemic flu, a third on LIHEAP, one on health-care associated infections, oral health, health information technology, and several others.

HEALTH CARE REFORM

Mr. Obey. But let me ask a couple of questions about the bill that we just passed.

Mr. Tiahrt and I are friends, but we often disagree. We are not disagreeable friends, but we are disagreeing friends very often. But in light of his characterization of the health care bill as a government takeover, let me ask a few questions. Is the VA a government agency?

Secretary Sebelius. Yes, sir.

Mr. Obey. Is Medicare a government program?

Secretary Sebelius. Yes, sir.

Mr. Obey. Is Medicaid a government program?

Secretary Sebelius. Yes.

Mr. Obey. I thought so, too. Is this health care bill like Canada or Britain, or is it more based on a private-sector system?

Secretary Sebelius. The system is based on building out a private-sector strategy with new health exchanges.

Mr. Obey. Will the doctors under the system work for the government?

Secretary Sebelius. Not unless they do right now. Some do for the VA, as you know, and for the Department of Defense. But, no.

Mr. Obey. What about the nurses? Are we adding millions of nurses to the Federal payroll?

Secretary Sebelius. No, sir.

Mr. Obey. What are these things called insurance companies? Are they public entities or are they private?

Secretary Sebelius. Private-sector companies.

Mr. Obey. Are they usually profit-making private entities?

Secretary Sebelius. From everything I can tell, yes, sir.

Mr. Obey. I thought so, too.

What does the health reform bill do for the fiscal solvency of the Medicare program?
Secretary Sebelius. Well, the estimate that was made when the reconciliation bill was proposed was that it added a minimum of 10 years to the life of the Medicare trust fund.

Mr. Obey. What does it do to change the payment system from one based on frequency of procedures to one based on quality of medical outcomes?

Secretary Sebelius. Congressman, it sets a direction for Medicare to become, I would say, a quality-based purchaser as opposed to the current strategy of fee-for-service, which is more about content than about quality.

Mr. Obey. I agree with all of that.

Let me just tell you a story, because we have had such controversy and such points of disagreement about the details of this plan.

Between 1930 and 1938, a fellow by the name of Gerry Boileau represented my congressional district. He was the last of the LaFollette Progressive Republicans. When Fiorello LaGuardia became mayor of New York, he succeeded LaGuardia as the spokesman for the Progressive Republicans in the House; and then he was beaten in 1938.

My dad ran a supper club when I was much younger. Gerry came home and became a local judge. He came into our place one evening, and we started talking, and I finally asked him, Gerry, what beat you in 1938?

He said, senior citizens. He said, I was strongly for Social Security and in my district the seniors were against it.

I said, what on Earth are you talking about? How can seniors possibly be against Social Security? Not the seniors I know today. He said, in those days, it was different. He said, in those days, we had Social Security as one alternative, which is a contributory program. And then we had the Townsend plan, old Doc Townsend from California, who didn't want a contributory plan. He just wanted, I think, a hundred-dollar-a-month welfare payment to every senior. And he said, we all knew that couldn't survive very long because the country doesn't like welfare. So he said, I strongly supported Social Security. And old Doc Townsend came into my district and helped organize Townsend clubs; and he said, they beat me.

The point of the story is this: We look today, shortly after the health reform bill is passed, and we see all of these little fights that we had—regional, ideological, philosophical—but I think 20 or 25 years from now we are going to look back at the bill and say, what on Earth was that fight all about? How on Earth could we ever have functioned without this program? I think all of these little fights that were so important to people as we were going through them, none of them are going to be remembered. What will be remembered is that we finally put this country in the rank of civilized societies that do not require people with very little money to beg in order to get health care. That, to me, is basically the lesson of Gerry Boileau's story.

I mean, I lost a whole lot more fights than I won on the health reform bill. I favored public option. I have no objection to single payer. I, frankly, didn't care as long as we got two things, as long as we covered as many people as possible and as long as we
changed the rules of the game so that little people weren't squeezed by corporate giants called insurance companies. That is basically all I wanted. Everything else is candy.

I just want to thank you for the work that you did on this package and to thank everybody who voted for it and to thank those who opposed it and raised constructive questions along the way. Because, to me, regardless of all these little debates that we had, the obligation that all of us have now is to simply try to make it work and to think through whether there have to be adjustments down the line, make certain we have got plenty of oversight, and especially make certain we have got a huge expansion of our efforts to go after waste, fraud, and abuse. Because you have got lots of jerks in this society who will try to take advantage of this and rip off the taxpayer and rip off customers. If we believe in expanding these services, we just can't let that nonsense happen.

Secretary Sebelius. Well, I appreciate that, Mr. Chairman.

I spent Easter weekend with my father, who turned 89 on the 22nd of March. He served in the United States Congress on the Energy and Commerce Committee 45 years ago when Medicare was passed. He told me a number of stories about how ferocious that battle was, how ferociously a number of people opposed Medicare's passage, and how differently it looked then than it does now, where he is now a pleased beneficiary, and reminded me that over 45 years there have been changes, there have been a number of improvements, but the basic tenet that, once you turn 65 in this country, that you have health security, was a promise made then and a promise that we intend to keep now. It was interesting having his historic perspective on the beginning of this new chapter in American health security.

Mr. Obey. Thank you. I am going to have to go over to the House for action on a bill that is going to be pending shortly. And so if I have to leave before the hearing is done, it is nothing you said. I just have to get over there.

Secretary Sebelius. I am pleased to hear that.

Mr. Obey. I will ask Ms. DeLauro to take over if we are not done. Meanwhile, I would like to run a second round for about 3 minutes apiece.

Mr. Tiahrt.

UNFUNDED PROGRAMS IN HEALTH REFORM

Mr. Tiahrt. Thank you, Mr. Chairman. I want to remind you the hearing isn't done, so maybe there will be something come up that won't make you want to leave early.

One of the things that concerns me greatly is about the cost of this. Because, quite frankly, we have overspent this year by more than $800 billion this fiscal year. We know that there are at least 80 programs that are in the bill that require discretionary appropriations, and we have about $110 billion for these 80 programs. There are also 36 programs, at least—three dozen programs—that are open-ended.

I have asked the Congressional Budget Office to give us some estimate as to what they are going to cost. They don't sound like very cheap programs. Of the 36, community health insurance option, design and implementation of regional systems for emergency care,
trauma care centers and service availability, oral health care prevention activity, programs relating to congenital heart disease, multi-State qualified health plans, community-based collaborative care networks, to name a few.

So, in addition, it is my understanding the CBO has estimated that CMS and the IRS will need an additional $20 billion in order to set up the systems just to implement ObamaCare. So has your Department developed a cost estimate for all these new programs that are not in the President’s budget, and when will you be sending an addendum to the President’s budget for next year to cover these costs, and where will the money come from?

Secretary Sebelius. Well, Congressman, you have our 2011 budget presentations; and there is not an intent to send an addendum to the budget.

Mr. Tiahrt. How will you cover the cost of these programs that are not in the budget? It says in the law such sums as required. Where are such sums going to come from?

Secretary Sebelius. Well, my understanding is, the way that process works, if there isn’t authorization in the bill itself, this will be a discussion that you and your colleagues will have here in Congress.

Mr. Tiahrt. So we are going to have to come up for the funding for these programs?

Secretary Sebelius. If the priorities are to move ahead on those programs, I assume they will be funded. But you have our 2011 budget submission before you.

Mr. Tiahrt. So the 302(a) allocation that we have and the 302(b) allocation for your Department right now doesn’t have a request from the President for such sums as required on these 36 programs.

Secretary Sebelius. That is correct.

Mr. Tiahrt. So, Mr. Chairman, where are we going to get the money for these programs that we don’t have any budget for and we won’t have any allocation for?

I guess he is involved in another conversation.

My concern is that we don’t have the funding for this and we have no idea how much it is going to cost and, again, we don’t know where the money is coming from. China is not lending us money on long-term Treasury bills now. The Fed has loaned money to the United States. They already owe us—or we owe them $5.5 trillion as taxpayers. Where is the money going to come from?

Secretary Sebelius. Congressman, again, I think that the programs are likely not to exist unless they are funded by Congress. That is not currently part of the authorized bill. I think the very good news for the American public is that, unlike the last major health initiative move forward, the prescription drug benefit, this bill is paid for. It is paid for over time. In fact, the Congressional Budget Office has estimated an $100 billion decrease in the deficit in the first 10 years and closer to a trillion dollars decrease over the next 10 years. This is fully paid for over the life of the program.

Mr. Tiahrt. You can’t count Medicare dollars twice. We are taking money out of Medicare and adding them to the program that you are going to administer. Where is the money for the $500 billion for Medicare? There are a lot of programs, Mr. Chairman, that
don’t have funding. They are not in the President’s budget. We won’t get the allocation for them. I am just wondering how we are going to fund them.

Mr. OBEY. First of all, the gentleman’s time has expired.

But let me simply answer the gentleman’s question by saying there is a big difference between programs that are authorized and programs that are mandatory. These are not mandatory programs, to my understanding.

Mr. TIAHRT. Are we not going to fund the community health insurance option, the oral health care prevention activities?

Mr. OBEY. Given the fact that we have a good $17 billion hole in the budget on Pell Grants, I have no idea what we are going to be funding on anything.

Mr. TIAHRT. Thank you, Mr. Chairman.

Mr. OBEY. I don’t think anybody else does, either.

Who is next? Ms. Roybal-Allard.

UNDERAGE DRINKING

Ms. ROYBAL-ALLARD. Secretary Sebelius, Congresswoman DeLauro and I have been working together for over 10 years to reduce the dangerous incidence of underage drinking in this country, and we were very pleased that your administration recommended an increase to the STOP grants this year to enable more communities to address the critical problem. We have heard, however, that the HHS is looking to further expand its efforts in underage drinking prevention.

The questions that I have are, first of all, CDC and NIH are recognized leaders in developing evidence-based strategies on underage drinking. So what are you doing to ensure that the rest of HHS uses their guidance and guidelines in implementing programs directed at preventing and reducing underage drinking? How will you ensure that the State public health agencies with their own rich experience in tobacco control and other public health insurance are fully engaged in collaboration with State substance abuse agencies? And what will be the roles and resources available to the various HHS agencies to ensure that all of this happens?

Secretary SEBELIUS. Congresswoman, as you say, we do have a recommended budget increase for the STOP Act. I think that is a step of directing more resources.

We also have a talented new leader in the agency as my Assistant Secretary of Substance Abuse and Mental Health Services, Pam Hyde, who not only has run State systems but has worked in the private sector and run medical systems and is very tuned into this issue and is very much at the table looking at collaborative strategies.

So we have the Substance Abuse and Mental Health Services Administration at the table. We have our scientific-based evidence from CDC and the strategies that work on the ground, and we are working in collaboration with State and local partners to make sure what we know is effective actually is drilled down. So this is an effort.

One of the things that the President made clear to all of his Cabinet officers is that he wants us to leverage our assets not only
across departments but within our own agencies. So we have a number of cross-agency collaborations, and this is one of them.

SECTION 317 VACCINATION PROGRAM

Ms. ROYBAL-ALLARD. That is great to hear.

In fact, you mentioned in an earlier statement, the 317 vaccination program. This program historically has been used for vaccinating children. However, each year, hundreds of thousands of American adults are hospitalized and tens of thousands die from diseases that could have been prevented through vaccination.

It is estimated that the cost of the health burden to society from vaccination-preventable diseases is approximately $10 billion annually. How will HHS use existing funding streams to address the issue of increasing adolescent and adult vaccinations, and has the Department considered developing an adult immunization strategy? And, in particular, what could be done to increase vaccination rates among health care workers?

Mr. OBEY. If we could have a fairly short response, please.

Secretary SEBELIUS. We are working on this. I was just at the 44th annual vaccination week-long conference. We learned a lot of lessons from H1N1 that we intend to apply across the board, and one of them is how to deal more effectively with not only minority communities but with health care workers.

Ms. ROYBAL-ALLARD. Hopefully, we can follow up on this.

Mr. OBEY. Mr. Cole.

Mr. COLE. Thank you, Mr. Chairman.

I was listening to that wonderful story about Gerry Boileau. And I must say, the moral I drew was that progressive Republicans always get beat by liberal Democrats that say they love them. So it is kind of a warning story there for me.

On a more serious note, I share Mr. Tiahrt’s—-

Mr. OBEY. But he got beat by another Republican.

PROJECTED COVERAGE RATES

Mr. COLE [continuing]. I share Mr. Tiahrt’s concern about some of the financial bases of the bill, the one he particularly highlighted about the transfer of Medicare funds out for, really, a new entitlement program at a point when we have a baby-boom generation hitting Medicare age. I just don’t think it is going to hold.

Let me ask you about another part of it that concerns me greatly, Madam Secretary. Right now we assume that there is—and I think you said the majority of people moving into the system would be insured by private insurance. I am not 100 percent sure that is accurate, because the numbers I saw suggested about half were going to be, actually, Medicaid patients. So, at best, it is pretty close as to whether they are going to be purchasing insurance.

And, as I understand the bill, frankly, those younger people are going to have an option—well, it is, quote, “mandatory.” They can pay a penalty as opposed to just buy insurance. The penalty that I have seen is cheaper than the insurance. And I would suggest a lot of them are going to do what most people in their 20s and early 30s do, and that is take the cheaper road out. Whether that is wise or not is debatable, but I think that is true.
So how confident are you that the new people showing up to be insured, given the fact that many of them are Medicaid and given the fact that many of them have a way out when they are young and healthy, are actually going to provide the revenue stream that the bill envisions?

Secretary SEBELIUS. Well, Congressman, the experience in Massachusetts, which is one that we looked to—and there are other States who have—Wisconsin, again, has a pretty near-universal insurance avenue. But in Massachusetts, a fairly similar structure—an individual mandate with a relatively low penalty for failing to buy insurance, plus a hardship waiver—has produced 97, 98 percent insurance coverage.

The experience that they have found is that people really wanted insurance; they just felt that there were too many financial barriers or health barriers, frankly, to get into the marketplace.

So, at least in the instance that that fairly similar structure has been tried, there actually was a very robust take-up in spite of some skeptics who thought that people would opt out if they were younger and healthier.

PHYSICIAN-OWNED HOSPITALS

Mr. COLE. Let me ask you—my time is about to run out, and it is a totally unrelated question. But one of the provisions of the bill that really concerned me, the treatment of physician-owned hospitals—and I realize there is a philosophical divergence in Congress over that particular issue. In my State, they are some of the highest-performing hospitals that we have. By every rating they provide excellent care, and we have been very pleased with them.

What is the general attitude of the administration toward physician-owned hospitals, looking forward?

Secretary SEBELIUS. I can honestly tell you I haven’t ever been involved in a, sort of, philosophical discussion. There isn’t any directional discussion. I think it has more come from Congress, frankly, and the alarm in certain areas of the country of the proliferation to what some have seen as the disadvantage of community hospitals trying to run emergency rooms and contributing to graduate medical education and then being cherry-picked by provider-based hospitals.

But I don’t think the Department, itself, has a directional strategy. It really is looking at high-quality, cost-effective health-care delivery. And, as you say, some are in physician-owned hospitals and others are sometimes in community hospitals. But that is really our goal.

Mr. COLE. I would just say in closing on that, just so you know, in our State most of the physician-owned hospitals operate emergency rooms, they take Medicare patients. So they really stack up pretty favorably. And I would just commend you to consider that as one of the models, going forward. I am glad to hear that there is not an administration position per se.

Thank you.

Mr. OBNEY. Mr. Honda.

CHILDREN’S HEALTH TASK FORCE

Mr. HONDA. Thank you, Mr. Chairman.
The health reform issues are also going to be including our concerns of children's health issues. And children probably compromise 50 percent of our Medicaid rolls. Will there be any thought about establishing a children's health task force?

And leading up to that, my county of Santa Clara County recently has had the third-highest rate of TB in California, and it has really grown from almost an elimination of TB in our county to being third in the State of California.

Given that rise and given the work that you are going to be required to do, as far as travelling and everything else like that, I was just concerned that you had sufficient resources to be able to do the kind of travel and create the kind of presence that is going to be expected when you are going around the country to make the negotiations and be an advocate for this program.

Those two questions, if I could have a quick response.

Secretary Sebelius. Congressman, I think in terms of the travel and presence responsibility, cloning would come in very handy in this instance, because I do think there is a lot of confusion and concern and also a lot of eagerness about people wanting to know about the bill, how it is going to work, how it is going to be implemented. And I can assure you, I am going to do my best, as are lots of members of our department, to be out and about everywhere.

The Children's Health Insurance Program, which you all extended in 2009 prior to the passage of the Affordable Care Act, I think is a great focus on making sure that children have appropriate intensive care, particularly at the youngest ages. And we are undergoing a very aggressive outreach effort in conjunction with faith-based and neighborhood groups, with health-care providers, with State and local partners, to identify and enroll the approximately 5,000,000 children who are eligible but currently not enrolled. It continues to be a challenge.

The good news is, even last year in very difficult budget times, States and local governments signed up an additional 2,500,000 American children. We would like to see that continue to rise. And I think that, as you know, the SCHIP program continues during the life of the Affordable Care Act. And I think that is going to focus that kind of attention and services on the children's population and one that we take very seriously.

Mr. Obey. Mr. Ryan.

FORUM HEALTH BANKRUPTCY

Mr. Ryan. Thank you, Mr. Chairman.

Madam Secretary, you know Ohio well. I represent a district in Youngstown and Akron. And in the city of Youngstown, we have two health-care systems. One of them is Forum Health, which employs approximately 4,000 people in the region, and it is now trying to emerge from bankruptcy. Youngstown has about a 15 or 16 percent unemployment rate. The city of Warren has one very similar.

In adding 30,000,000 new people to the system and many in Ohio and western PA, I don't think now is a good time to see a hospital close down. And I was wondering if there is anything in your sights or from the administration that could help address this issue.
Secretary Sebelius. Well, my understanding is we solved one of the problems, in terms of a payment stream that will continue during the discussion, which I think is important. And, again, I think that the framework of having a payment system under the individuals who will seek hospital care in the future is a big step forward. And hospitals have really struggled.

I also think that there were huge improvements made in the bill over the course of the discussion dealing with disproportionate share allocation, where originally there was a thought that it could disappear entirely, and I think that was recalculated appropriately based on the fact that there are huge disparities in terms of the patient load that is likely to hit various hospitals.

But I think you are absolutely right that we need a robust health-care delivery system. And it is something that we are going to be working with local communities, looking at ways we can provide resources in this kind of bridge strategy to make sure they continue to provide services.

Mr. Ryan. Well, in the meantime, until 2014 when everyone comes in, I mean, hospitals like this could potentially close down. And I think in the Department of Agriculture there are some loan guarantees. And maybe we can come up with some ways to help these hospitals refinance. Because, you know, between now and then, a lot could happen, and the other hospital in town can’t handle the influx that they could potentially receive.

Secretary Sebelius. With the Community Development Block Grant money, I think which is in HUD, and some other funding streams, I think we have to be more creative about bringing other agencies in. HHS really doesn’t have either operational money or construction money, with regard to hospitals. But I think having that dialogue with my Cabinet colleagues is something that I am going to pursue, because it has come up in a number of areas, and it is a very critical piece of the health-care system. I think just like closing a school in a small town, you can’t close a hospital, or people won’t stay in the community.

Mr. Ryan. Right. So I look forward to working with you on that, because it is urban development, it is health, it is education, it is everything. So I appreciate that.

Mr. Obey. Ms. DeLauro.

FOOD SAFETY

Ms. DeLauro. Thank you, Mr. Chairman.

Madam Secretary, let me just ask a food safety question of you. The volume of FDA-regulated imports has increased substantially over the past decade. The statistics say that FDA recorded 8,200,000 imported food lines in 2007; fewer than 2,800,000 entry lines a decade earlier.

You have just over 1 percent of these lines that were physically examined and/or tested. It is often reported that, even with increased funding that the Congress has provided to the agency in these past 3 fiscal years, the FDA will still inspect less than 2 percent of import lines in 2011.

This is mainly because the FDA relies on a very weak border inspection system. I also might add that there are indications that
there potentially will be more inspectors but we could have fewer inspections.

Again, can you tell us how do you think the FDA can improve in this area? There is the FDA food safety bill pending before the Congress in the Senate. How can that help to change this equation? And how do we deal with improving the inspection ratios in the next 5 years?

Secretary SEBELIUS. Well, Congresswoman, first of all, thank you for your long-time leadership and expertise and interest in this area. And it is one that has changed dramatically over time. We no longer have an American-based food system, and I think that the regulatory framework is 20th-century at best and the system is global and increasingly global. Half our fruits and vegetables come from outside our borders; about two-thirds of the seafood comes from outside our borders, just to name a couple of products.

No question that the new framework passed by the House and pending in the Senate is a huge step forward and has a lot of the expertise of this committee’s stamp on it—not this committee, but your expertise as part of moving that ahead.

I do think that part of the strategy also is the FDA establishing a much more robust footprint in other parts of the world. So there are now four new offices in China, there are offices in Mexico, there are offices elsewhere, to not wait until products actually come across the borders, but look at the origins of those products.

Secondly, I think it is critical that we have a much more robust and a different relationship with the private sector. The food industry often takes the hit. At a time of a recall, they have enormous financial risk, but have been, I think, not as engaged and involved in self-reporting, identification, quick recalls. The FDA needs some additional subpoena power and automated recall power, but also engagement of the industry at a much earlier stage, which, again, is part of the framework moving forward.

Ms. DeLAURO. Mr. Chairman, just one final comment.

I just would say this to you, Madam Secretary. For years and years and years, the whole issue has been that trade in this area of food safety has trumped public health. I will be vigilant—I am hopeful, but vigilant that that will continue not to occur, that trade will get in the way of what we can do with regard to the public health as it regards food safety. Thank you.

Thank you, Mr. Chairman.

Mr. OBEY. Thank you.

Madam Secretary, thank you for being here. We kept you a few minutes over, but not much. Good luck to you.

Secretary SEBELIUS. I appreciate it. Thank you so much.
HEALTH PROFESSIONS WORKFORCE

Mr. Obey: While so many people struggle to find jobs in this tough economic time, the demand for highly trained health care professionals continues to grow. In fact, the health care sector added more than 600,000 jobs since December 2007. The Bureau of Labor Statistics predicts that more than half of the top 30 fastest-growing occupations through 2018 are related to health care.

Last year this subcommittee instructed your Department and the Labor Department to establish an interagency taskforce to work on health professions training issues. What is the status of this task force? Can you provide an update on its progress so far?

Secretary Sebelius: The interagency task group composed of staff from HRSA and the Department of Labor has been engaged in discussions regarding collaborative strategies since last fall. Key areas of attention are strengthening and expanding career ladder programs to allow individuals to enter and advance through the workforce as well as examining the potential for collaboration in area of workforce data activities. HRSA expects the report to be available within the next few months. The report will identify key areas of collaboration and outline a strategy to proceed forward aligning similar interests and activities.

Mr. Obey: In the Recovery Act, Congress provided $200 million to HHS for health professions training to give more Americans the opportunity to enter this growing industry. How have you used this funding?

Secretary Sebelius: The American Recovery and Reinvestment Act (ARRA) provides funding to support health professions training programs to address the health professions workforce shortage as well as improve workforce diversity, including:
- Training of underrepresented minority students, including recruitment and retention to increase diversity in the workforce and to increase access to healthcare to underserved populations;
- Training of the primary care medical and dental workforce to help address the primary care workforce shortage and to make primary healthcare services more available to the American public in all areas of the country;
- Training of the public health workforce and the training of preventive medicine residents to address the public health workforce shortage; and
- Education and training of nursing students and faculty as well as the provision of loan repayments and scholarships to address the nursing shortage and to increase the supply and diversity of the nursing workforce and to address the shortage of nursing faculty.

ARRA funding was also used to provide access to support the purchase of equipment to be used to expand the capacity and improve the quality of health professions training programs.

Mr. Obey: Future workforce shortages are predicted in almost every field in health care. Given those predictions, can you explain why the President's budget request provides no increase at all for most health professions training programs?
Secretary Sebelius: The FY 2011 President’s Budget provides a $169 million, a 
$27 million increase, for scholarships and loan repayments in the National Service Corps which 
will add 400 providers to the more than 8,100 that will be providing primary care services across 
the country. The Budget continues support for programs aimed at increasing the supply of health 
professionals focusing on primary care and public health and increasing the diversity of the 
workforce. The Budget also supports the provision of clinical training experiences in medically 
dereserved areas to increase the likelihood that providers will go on to practice in underserved 
areas. The President’s 2011 Budget requests increased funding for workforce information and 
analysis. These funds will be used to strengthen and expand the analytical efforts that inform 
program investments for the future.

ORAL HEALTH CARE

Mr. Obey: Oral health should be an inseparable component of general health and we need 
to do a better job of making that happen. Dental problems can cause severe physical suffering 
and disrupt a child's ability to learn. They can also be the first sign of other serious illnesses.

Statistics show that Americans do not have proper access to oral health care. For instance, 
tooth decay is the most common chronic childhood disease and yet almost one-fourth our children 
did not have a dental visit in the last year. The budget request includes an additional $25 million 
for service expansion grants for Health Centers. Can you tell me why oral health care was not 
included within this request?

Secretary Sebelius: The $25 million for behavioral health is an expanded initiative to 
address the behavioral health needs of health center patients, in particular focusing on the 
addiction service needs of patients. The President’s budget does include continued support for 
the Increase Demand for Service grants that included a significant expansion in oral health 
services. As of March 31, 2010, health centers reported having expanded oral health services to 
more than 300,000 additional patients, supporting more than 700,000 oral health visits and more 
than 500 additional oral health professionals.

Mr. Obey: Can you tell me why the request for the Maternal and Child Health Block 
Grant Program did not increase oral health grants when the request included an additional $1.4 
million for Special Projects of Regional and National Significance?

Secretary Sebelius: The President’s 2011 Budget request maintains funding for the oral 
health set-aside at the FY 2010 amount of funding. The increase in Special Projects of Regional 
and National Significance funds will support innovative projects to improve maternal and child 
health.

Mr. Obey: What steps have you taken to ensure that, at each agency within HHS, dentists 
are part of the leadership team that shapes public health policy? For example, the Agency for 
Health Research and Quality plays an important role in identifying and publishing best practices 
for medical treatment. Despite the importance of oral health, there are no dentists on the agency's 
National Advisory Council.
Secretary Sebelius: While currently there are not any dentists on AHRQ's National Advisory Council (NAC), the NAC has addressed the issues of improving access to and quality of dental care. Title IV of the Children's Health Insurance Program Reauthorization Act (CHIPRA; Public Law 111-3) called for the Secretary to identify an initial core set of children's health care quality measures to be posted for general comment by January 1, 2010. AHRQ, working in very close partnership with CMS, was responsible for identifying the initial core set of measures.

As part of their effort to use a transparent and evidence-based process for identifying initial measures, AHRQ asked its NAC to establish a time-limited Subcommittee (SNAC) to look at Children's Healthcare Quality Measures. The SNAC agreed to recommend to the NAC 25 measures for the initial core measure set, which included measures to improve quality of and access to dental care. When AHRQ makes its next public call for individuals interested in serving on the NAC, I will take into careful consideration those individuals who have backgrounds in dentistry and oral health.

SECTION 317 IMMUNIZATION PROGRAM

Mr. Obey: How many children, adolescents, and adults were served or are estimated to be served by the CDC Section 317 program in FY09, FY10, and FY11?

Secretary Sebelius: CDC has estimates for the number of children and adolescents served for all three fiscal years and for the percentage of vaccine purchase funds used to purchase adult vaccines in FY 2009. CDC does not have numbers of adults vaccinated or estimates for the percentage of vaccine purchase funds used to purchase adult vaccines in FY 2010 or FY 2011 until CDC can analyze provider orders for those fiscal years. Grantees prioritize their Section 317 funds to meet the needs of their priority populations, which includes children and adolescents, and vaccines are provided to adults as funding allows. Because provider priorities can change, relying on actual order information is a more accurate data source to use to estimate the number of adults vaccinated. Based on provider orders from FY 2009, approximately 12 percent of Section 317 vaccine purchase funds (approximately $31 million) were used to purchase adult vaccines.

<table>
<thead>
<tr>
<th>Number of Children Able to Be Fully Vaccinated¹</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2009</td>
<td>208,249</td>
</tr>
<tr>
<td>FY 2010</td>
<td>194,098</td>
</tr>
<tr>
<td>FY 2011</td>
<td>207,858</td>
</tr>
</tbody>
</table>

¹Provide all ACIP routinely-recommended vaccines for a child from birth through 18 years of age with the following vaccines: DTap, Hib, polio, MMR, hepatitis B, varicella, PCV, hepatitis A, Tdap, MCV, rotavirus, influenza, and HPV (females only). Adolescents served are included in the category of 0-18 year olds.

Mr. Obey: With the $4.8 million requested to conduct needs assessments and develop plans that will enable health departments to bill private insurance programs for immunization services provided to cover patients, how many States are estimated to be supported and at what estimated funding levels?
Secretary Sebelius: With the $4.8 million requested, CDC estimates that ten Section 317 grantees could be supported with an average award of $480,000 per grantee.

VECTOR-BORNE DISEASES

Mr. Obey: What is the rationale for eliminating the vector-borne diseases portfolio at CDC? Will the surveillance program, ArboNet, continue to operate in FY2011 and beyond despite this elimination?

Secretary Sebelius: The FY 2011 budget request does not include specific funding vector-borne activities, including West Nile Virus (WNV) surveillance. Several years of CDC funds have allowed states to develop and enhance their WNV activities. FY 2011 funds include $155.2 million for the emerging infectious disease budget line, an increase of $18.9 million above FY 2010. These Emerging Infectious disease funds can support vector-borne activities in FY 2011, including WNV if determined a priority by States and the CDC. Because the priority determination for these funds has not yet been made, the continuation of ArboNet is uncertain at this time.

Mr. Obey: If not, how will data be collected for vector-borne disease surveillance, such as for the following nationally notifiable diseases that use this surveillance system to detect disease: Dengue fever, West Nile virus, St. Louis encephalitis, Yellow Fever, Eastern equine encephalitis, Western equine encephalitis, California serogroup virus, Powassan virus, etc.? Plus there are other diseases for which CDC collects data using ArboNet, but are not considered nationally notifiable - how will data be collected for those diseases?

Secretary Sebelius: The States are required to report only human cases of dengue, yellow fever, West Nile, St. Louis encephalitis, western equine, LaCrosse, and Powassan viruses. These will continue to be reported to the National Electronic Disease Surveillance System (NEDSS). For diseases not considered nationally notifiable which CDC collects data using ArboNet, if CDC does not continue ArboNet, then CDC will not collect data on diseases that are not nationally notifiable.

HEALTHCARE-ASSOCIATED INFECTIONS (HAI’s)

Mr. Obey: People go to the hospital to get better. But according to CDC, 1.7 million Americans get sicker and nearly 100,000 die every year in health care facilities when they acquire a healthcare associated infection. I have made preventing and reducing healthcare-associated infections a major funding priority for this subcommittee. Since fiscal year 2009, we have invested $139 million into an aggressive campaign to eliminate these easily preventable infections. Funding has been provided for establishing a National Action Plan; supporting hospitals and States to fund prevention, research, and monitoring efforts; and launching a National Consumer Education Campaign.

I am pleased to see that your budget request includes $27 million for CDC’s National Healthcare Safety Network, which is a $12 million or 80 percent increase. This funding will support health care-associated infection and prevention activities in all 5,000 short stay and critical access hospitals. But in the last three years, the Committee’s investments have not
focused solely on CDC. Based on HHS’ own action plan to prevent healthcare-associated infections, increased resources have also been provided to the Office of the Secretary, the Agency for Healthcare Research and Quality (AHRQ), and the Centers for Medicare and Medicaid Services.

A report released just last week by AHRQ states that healthcare-associated infection rates are not declining and are, in fact, getting worse. So why hasn’t HHS prioritized additional resources in 2011, beyond the CDC increase, to address these preventable infections?

Secretary Sebelius: We appreciate your leadership and support in the Department’s efforts to reduce healthcare-associated infections. Both CDC and CMS are implementing programs for the one-time funds of $50 million provided to States under the Recovery Act for healthcare associated infections. With Recovery Act funds, CDC is supporting States in leveraging the National Healthcare Safety Network, and CMS is expanding State Survey Agency inspection capability of Ambulatory Surgery Centers nationwide. The FY 2011 Budget includes $79 million across AHRQ, CDC, and the Office of the Secretary, an increase of $12 million above FY 2010. This increase builds on CDC’s Recovery Act efforts to expand the National Healthcare Safety Network and continues the healthcare-associated infections activities of other agencies and offices.

Mr. Obey: What more needs to be done to eliminate these infections from occurring in U.S. healthcare facilities?

Secretary Sebelius: The HHS Action Plan to Prevention Healthcare-Associated Infections provides a vision for addressing these infections. Specifically, the plan identifies priority measures and five-year national prevention targets for assessing progress in healthcare-associated infections prevention and can be accessed at http://www.hhs.gov/ophs/initiatives/hai/infection.html.

BLOOD DISORDERS

Mr. Obey: Please tell the Committee how the current blood disorders portfolio at CDC will be impacted by the change requested in the FY 2011 budget request.

Secretary Sebelius: The FY 2011 President’s Budget requests $20 million for a program that realigns CDC’s Blood Disorders program to address the public health challenges associated with blood disorders and related secondary conditions. Rather than fund a disease-specific program for specific categories of blood disorders, the new program uses a comprehensive and coordinated agenda to prioritize population-based programs targeting the most prevalent blood disorders. This public health approach will impact as many as 4 million people suffering with a blood disorder in the United States versus approximately 20,000 under the current programmatic model. In FY 2011, CDC plans to focus on the following three areas of greatest burden and unmet need: deep vein thrombosis and pulmonary embolism, hemoglobinopathies (such as sickle cell disease and thalassemia), and bleeding disorders.

Mr. Obey: For example, the CDC budget justification indicates that CDC is proposing to shift the focus away from its traditional clinical orientation and towards a population-based public
health model. Does this mean that CDC's support for the 140 hemophilia treatment centers, 8 hemostasis and thrombosis centers, and 6 thalassemia centers will end in FY2010?

Secretary Sebelius: CDC anticipates increased program efficiencies by merging and re-designing data collection systems from those that focus on single disorders to a single system that collects data needed for monitoring health outcomes for multiple disease and disorders. CDC does not anticipate a discontinuation of funding in FY 2010; rather, these efficiencies will be achieved as grant awards expire over the next two years and new funding opportunities are developed. For instance, CDC has a long and robust history of partnership with a national network of 135 hemophilia treatment centers that has a documented history of improved health outcomes for hemophilia patients. CDC plans to continue this national network for the hemophilia population as well as those suffering from the most prevalent blood disorders.

INTEGRATION OF PUBLIC HEALTH SURVEILLANCE SYSTEMS

Mr. Obey: CDC and State and local public health departments have numerous surveillance systems in place to monitor infectious diseases. CDC has BioSense, the National Electronic Disease Surveillance System, Global Disease Detection centers, and disease-specific outbreak response networks, such as FoodNet, the Laboratory Response Network, the National Healthcare Safety Network, etc. Each State and some large cities also have their own surveillance systems in place. Do all of these systems feed into a larger national surveillance system?

Secretary Sebelius: Each of these systems, whether electronic or paper-based is part of a larger national surveillance enterprise that relies on trained and well qualified public health practitioners to integrate data from various systems. The larger enterprise is made up of Federal, State, and local public health agencies working with private providers to collect longitudinal data at both the clinical and population level. Each part contributes to a more comprehensive picture of the health status of the nation’s communities that can only be found in integrating biosurveillance information from numerous sources. This integrated information is the basis for enhanced decision making across the biosurveillance enterprise. This cannot be accomplished through a single technology solution. Rather, it can only be accomplished through integration of data from various sources by well qualified and trained public health professionals.

Mr. Obey: What is CDC doing to integrate these systems?

Secretary Sebelius: CDC is completing its organizational improvement efforts, which includes the creation of the Office of Surveillance, Epidemiology, and Laboratory Services (OSELS) to integrate information and data across CDC programs and with partners. Currently, CDC is cataloguing all the biosurveillance/surveillance systems, programs, tools, collaboratives, and registries at CDC. At the completion of the initial compilation of this catalogue, information about existing human health-related biosurveillance/surveillance assets will be more visible across disciplines and tiers of government which will foster improved programmatic decision-making and coordination of public health efforts. This will also give agency decision makers a better understanding of where gaps and redundancies are across the enterprise and will provide a roadmap for resource uses in the future.
Mr. Obey: What is CDC doing to standardize public health disease data collection across jurisdictions to facilitate better information sharing?

Secretary Sebelius: The Nationwide Health Information Network (NHIN) and the standards for biosurveillance published by the Health IT Standards Panel (HITSP) are expected to serve as the foundation for a nationwide health information exchange. Interconnected networks will share common services and adhere to standards and requirements to enable interoperability. The enriched data-sharing environment will allow both clinical and public health professionals automated processes for entering information, access to health information when they need it, automated analyses that support notifiable disease detection and outbreak cues, query abilities for additional investigation when warranted, and feedback loops to validate findings and enact countermeasures.

Mr. Obey: What specific gaps remain in coordinating public health surveillance and what steps are being taken to address these gaps?

Secretary Sebelius: The optimum surveillance approach for event detection varies by locality and is affected by such considerations as population density, healthcare provider density and distribution, geographic area under observation, nature of healthcare provision, availability of laboratories, endemic diseases, and other local factors. The National Biosurveillance Strategy for Human Health (Strategy) provides the foundation for a long-term effort to improve a nationwide capability to manage health-related data and information. The Strategy identifies six priority areas to address critical gaps and suggest opportunities for improvement. They are as follows: Electronic Health Information Exchange, Electronic Laboratory Information Exchange, Unstructured Data, Integrated Biosurveillance Information, Global Disease Detection and Collaboration, and Biosurveillance Workforce of the Future.

There are still some significant gaps from State to State in the capabilities of Electronic Laboratory Information Exchange. This is the ability to exchange electronic information from labs with public health epidemiologic programs. Laboratory reporting is required in all States for test results related to State reportable and nationally notifiable conditions. Thus, this information, when combined with other epidemiologic data, forms the basis for public health investigations. Additional examples in gaps for this and the other priority areas can be found in The Strategy: (http://www.cdc.gov/od/oc/surveillance/bc.html). CDC is working with Federal, State, local, tribal, and territorial partners to monitor and support the implementation of the Strategy.

BIOSENSE

Mr. Obey: CDC's BioSense program as it was initially designed was criticized for not sharing information at the State and local public health levels and for being solely data focused and not focused on public health outcomes. As the Committee understands it, CDC has revised the BioSense program to address some of the concerns. Please update the Committee on the status of the BioSense program. Is it now fully operational or are more changes envisioned?

Secretary Sebelius: BioSense is operational across the current participating healthcare facilities, health systems, and health department surveillance systems. However, because the BioSense Program is not yet fully integrated with State and local health department syndromic
surveillance programs, future changes are envisioned to correct this. These changes include efforts to ensure distribution of data to all levels of public health and to support State and local public health systems’ capacity development to ensure they are able to analyze and interpret the data for public health action. The BioSense program will use an approach that puts more emphasis on supporting and coordinating the ongoing development and use of automated surveillance systems in States and supports a more collaborative approach to the development and direction of BioSense.

Mr. Obey: Are there efforts within CDC to integrate other already existing CDC and State surveillance program data into BioSense?

Secretary Sebelius: BioSense is now being integrated into the operating picture at more state health departments since data are now available to both CDC and states. Furthermore, CDC is continuing to request input from partners to make BioSense a more user-friendly and meaningful system to those on the front lines of public health in State and local health departments. This input will be supplemented with the recommendations of a Technical Expert Panel (TEP), which will be constituted once the new BioSense design and prototype development solicitation is awarded. The solicitation is in progress. The TEP will assist in reviewing and making recommendations to further increase the utility of BioSense to the public health community at large and to the response community for situation awareness specifically. It is likely that BioSense program stakeholders will identify some existing CDC and State surveillance program data that should be integrated into BioSense to improve the utility of the data for population health assessment and improvement.

Mr. Obey: Currently, there are over 1,800 healthcare facilities reporting data – 573 hospitals and 1,239 DoD and VA facilities - along with some State-wide and health system-wide data feeds going into the BioSense system, but there remains geographic distribution issues. How many facilities, health systems, or public health departments and laboratories would be ideal to support the BioSense program?

Secretary Sebelius: There is no definitive number of facilities, systems, or public health departments and laboratories that would ideally support BioSense. The BioSense program intends to expand its coverage to provide more comprehensive surveillance of the U.S. population. Expansion will be guided by the information priorities and capabilities of State, local and Federal public health systems while maintaining information quality, timeliness, and utility to support population health assessment and improvement.

Mr. Obey: What is the strategy to recruit additional participants into the BioSense program and to address geographic disparities?

Secretary Sebelius: CDC will pursue a new BioSense system design and prototype development solicitation to transform a closed, rigid, proprietary network and system architecture to an open, distributed, collaborative one that is jointly governed by representatives of the entire public health community. CDC will also integrate State and local BioSense investments, where practical, with surveillance efforts funded under the current Public Health Emergency Preparedness (PHEP) and the Epidemiology and Laboratory Capacity (ELC) cooperative agreements. More emphasis will be placed on supporting and coordinating the ongoing
development of automated surveillance systems in States and implementing a more collaborative approach to how data are used and shared to support health improvement. Additionally, increased attention will be given to the potential value for providing surveillance data for a broader spectrum of public health programs.

FUTURE OF PUBLIC HEALTH AND COMMUNITY-BASED PREVENTION

Mr. Obey: The four leading causes of death are chronic conditions: heart disease, cancer, stroke, and chronic lower respiratory disease. These conditions account for 75 percent of U.S. health care costs. Everybody agrees that we need to do more to prevent these diseases rather than just treating people once they’re sick. Doing so both saves money and makes people healthier. Health reform will begin that process with a significant emphasis on coverage for preventive health services.

In addition to screening and tests done in medical settings, we know that there are also many evidence-based, proven interventions that are implemented in communities, schools, and worksites. The Department of HHS conducts or supports these community-based interventions with partnerships at the State and local levels. What is the Department's plan to review its public health programs to determine what changes in public health and community-based programs will be necessary over the next few years as health reform is implemented?

Secretary Sebelius: As part of the annual budget formulation process, HHS assesses its current investments to inform what programmatic and policy changes would achieve the greatest health impact. As the Administration formulates the FY 2012 budget, HHS will include within its assessment the impact health reform implementation has on its programs to inform what changes may be necessary over the next few years.

Mr. Obey: In Massachusetts, funding for public health has drastically decreased since the State implemented health reform legislation, on the theory that people who used to be uninsured and get their screenings and immunizations at the public health department would now be getting these services at the doctor’s office. Yet, it turned out that some people continued to go to the health department for basic screenings, immunizations, and health services.

What can we learn from the Massachusetts experience? Do you envision that public health will continue to play a role in providing access to health services or will the focus shift to community-based prevention and education efforts?

Secretary Sebelius: Currently, both public health efforts and community-based efforts are components for successfully preventing illness and disease. Both will continue to play a role in prevention.

SUICIDE RATE INCREASES

Mr. Obey: Although the CDC statistics for suicide rates are only available through 2006, there are many other indicators that suicide rates are increasing. Both the Department of Defense and the Department of Veterans Affairs have reported an increase in suicide rates, and the National Suicide Prevention Lifeline received 15 percent more calls in 2009. Suicide remains the
eleventh leading cause of death in the United States and among the top three causes in ages 15-24. What do you see as the key factors that may be causing the suicide rate to increase? What actions has the Department taken to increase prevention efforts?

Secretary Sebelius: The strongest risk factors for attempted suicide in adults are depression, alcohol abuse, cocaine use, and separation or divorce. The strongest risk factors for attempted suicide in youth are depression, alcohol (including binge drinking) and other substance use, and aggressive or disruptive behaviors. The major risk factors for completed suicide among people who abuse alcohol are: (1) current drinking, (2) major depression, (3) suicidal thoughts, (4) loss of support from family and friends, (5) living alone, and (6) unemployment. While economic circumstances themselves are generally regarded as insufficient to cause a suicide, unemployment is associated with depression, substance abuse, and marital turmoil, all of which are independently linked to suicide risk. People who have alcohol and substance use disorders have increased social and financial problems that may lead to high-risk behaviors that include self-harm. In addition, the economic downturn has led to significant cutbacks in State and local mental health services, reducing available help at the very time that need may be greatest. Thus, even as suicide prevention efforts in the United States have intensified for groups such as youth and veterans, the impact may be overshadowed in the general population by the impact of unemployment, home foreclosure, and cutbacks in mental health services.

The FY 2011 President’s Budget includes an increase of $6 million for activities to prevent suicide. This funding will expand the capacity of the National Suicide Prevention Lifeline, expand suicide prevention activities in American Indian and Alaska Native communities, and support youth suicide prevention efforts.

These proposed investments will build on ongoing suicide prevention efforts and collaborations. For example, the Substance Abuse and Mental Health Services Administration (SAMHSA) has developed a Treatment Improvement Protocol (TIP-50) that focuses on substance abuse prevention/risk assessment for substance abuse providers and has been widely disseminated. SAMHSA is also supporting the identification, development and dissemination of best practices in suicide prevention, focusing on risk and protective factors related to suicide – with particular attention to mental health and substance abuse issues affecting suicide risk. SAMHSA has also been working closely with the Veteran’s Administration and the Department of Defense on suicide prevention efforts across the lifespan. SAMHSA and the Veterans Administration collaborated in making the Veterans Hotline available to all callers to the National Suicide Prevention Lifeline and made a Veterans Chat service available. SAMHSA has also participated on the Department of Defense Task Force on Prevention of Suicide in the Armed Forces, and is providing support to military families.

Mr. Obey: Depression is a major indicator for suicidal behavior risk. What steps has the Department taken to ensure that depression and suicide risk are screened for?

Secretary Sebelius: Depression is a major indicator for suicide risk, and the Department continues to undertake efforts to screen for depression and suicide risk. For example, the Substance Abuse and Mental Health Services Administration (SAMHSA) has incorporated screening for depression and suicide risk into several of its programs, plans to incorporate such screening into additional programs, has introduced standards to assure that every caller to the
National Suicide Prevention Lifeline is screened for suicide risk, and supports the National Depression Screening Day. Similarly, the Health Resources and Services Administration (HRSA) is working to increase the capacity to its community health centers to respond to behavioral health needs such as depression and risk for suicide.

PROGRAM INTEGRITY - UPDATE ON PREVENTION AND SHARING

Mr. Obey: Earlier this year this subcommittee held a hearing on Combating Health Care Fraud and Abuse, an issue of joint concern. We have a joint obligation to meet the needs of the people who qualify for programs covered by Health and Human Services. In so doing, we have an obligation to assure taxpayers' funds are used effectively-and not wasted or lost to fraud, as you understand.

In the earlier hearing, HHS Deputy Secretary Bill Corr indicated that HHS was planning to take steps to increase the sharing of best practices, data, and information with the private sector to further leverage the industry-wide investments toward this effort. In addition, we had discussions on tension between "pay and chase" - that is, pay the bill first and then try to get the money back if the payment turns out to have been unwarranted and paying claims right the first time.

Please provide an update on what actions have occurred or have been planned since the last hearing to increase sharing with the private sector and within HHS to detect fraudulent and improper claims before they are paid?

Secretary Sebelius: This Administration is committed to combating waste, fraud and abuse and reducing the amount of improper payments in our Federal health care programs. HHS continues to explore ways to work with the private sector to fight health care fraud while balancing sensitivities about protecting personally identifiable information and the integrity of ongoing investigations and law enforcement activities. For example, OIG has increased outreach to and collaboration with the National Health Care Anti-fraud Association to work through these issues.

The Office of Inspector General also will conduct a compliance training program for health care providers, compliance professionals, and attorneys in a series of sessions across the country. The training will focus on methods to identify fraud risk areas and compliance best practices so providers can strengthen their own compliance efforts and more effectively identify and avoid illegal schemes that may be targeting their communities.

Furthermore, several new authorities within the Affordable Care Act will enable HHS and CMS to bring new tools to bear in addressing these problems. For example, CMS recently issued an interim final rule to implement Affordable Care Act provisions that require providers or suppliers submitting claims to Medicare or Medicaid to include a National Provider Identifier (NPI) on enrollment applications and claims in Medicare & Medicaid. It also required physicians and practitioners who order and refer certain items and services for Medicare beneficiaries to enroll in Medicare. Furthermore, it required providers, physicians, and other suppliers participating in the Medicare program to maintain and provide access to documentation, upon request when they refer or furnish covered items or services at high risk of waste and abuse –
including durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) and home health services.

HIGH RISK POOLS

Mr. Oney: The budget request does not provide funding for the High Risk Pools programs and notes the expectation of funding from another source. In FY 2010, this sub-committee provided $55 million of support to continue funding of risk pools. We understand that a significant amount of current funds may be available to support the FY 2011 requirement.

Please explain the plan, risk, and if other sources of funds are available in FY 2011 to support this program. Also, if the budget level of zero is supported, what is the potential impact in FY 2011 on the individuals being covered?

Secretary Sebelius: As you know, the Affordable Care Act provides $5 billion in Federal funds to support a temporary high risk pool program to provide coverage to people who are uninsured because of preexisting conditions. The establishment of these new high risk pools is one of our first tasks in implementing the Affordable Care Act and will help individuals who cannot get affordable health coverage through the private market obtain the coverage they need.

Regarding the existing State high risk pool programs, we recognize that funding is only available through FY 2010 and that the President’s FY 2011 budget did not request funding for FY 2011 because of ongoing health reform negotiations at the time. We understand how important Federal funding is for State high risk pools and we appreciate your interest in assuring that States have the funding they need to ensure coverage for this vulnerable population. I look forward to working in partnership with you and other members of Congress to ensure that vulnerable populations continue to receive access to insurance through high risk pools.

LIHEAP

Mr. Oney: The President's budget would cut the Low-Income Home Energy Assistance program, or LIHEAP, by 35 percent—from $5.1 billion in FY 2010 to $3.3 billion in FY 2011. That concerns me very much. Energy prices are not coming down, and with the recession, needs are up. This winter, the number of households seeking assistance with their heating bills reached record numbers for the third year in a row. About 8.8 million households are estimated to have gotten help from LIHEAP this winter, 1.2 million more than the winter before. In Wisconsin, applications were up 25 percent over last year. This is not the time to be cutting LIHEAP by a third.

I understand that the President's budget proposes authorizing legislation which would make additional funds available to LIHEAP on a mandatory basis, triggered by energy prices and incomes. However, there is no legislation moving to enact that proposal, and probably little chance of finding the offsets that would be required under pay-as-you-go rules to turn part of LIHEAP into an entitlement.

While theoretical discussions may be underway about the proper budgetary treatment for LIHEAP, this subcommittee has the concrete problem of finding funds to keep LIHEAP going for
next winter. Frankly, the Administration's budget leaves us in a lurch. Any thoughts on how we solve this problem? What do you think the impact would be if we reduced discretionary appropriations for LIHEAP to the amount recommended in the President's budget?

Secretary Sebelius: We believe that the inclusion of a mandatory funding trigger is the best way to fund LIHEAP because it will automatically provide additional funding in response to increases in need. Under current economic predictions, the trigger proposal would provide $2 billion in mandatory funds in FY 2011. Adding the $3.3 billion discretionary funding requested, a total of $5.3 billion is requested for LIHEAP in FY 2011, an increase of $200 million over the amount provided for FY 2010.

ADMINISTRATION ON AGING: SENIORS' NUTRITION AND MEALS ON WHEELS

Mr. Obey: I'm concerned about the President's budget for senior citizens' nutrition services through the Administration on Aging at HHS. In particular, I'm talking about the "meals on wheels" program that delivers meals to seniors who have trouble leaving home, and the related program that provides meals at senior citizens centers and similar locations.

These programs are important: more than 90 percent of people receiving meals on wheels say that service makes it possible for them to continue living in their homes, and more than a quarter of people receiving help from any of the seniors' nutrition programs say those programs provide the majority of their daily food. With the tough economic times, need for these programs are increasing. At the same time, funding from state and local governments and private contributions is decreasing. To help meet these challenges, the Recovery Act added $100 million for fiscal years 2009 and 2010.

The President's budget does propose an increase for senior's nutrition, but that increase is just 1 percent - not enough to make up for cost increases, declining contributions, and the end of the Recovery Act funding. According to the budget documents, the number of meals supported has been dropping for the past two years, and would decrease again by 14.7 million meals under the Administration's budget for FY 2011. Shouldn't we be worried about this trend?

Secretary Sebelius: As you note, the President's Budget requests an increase of $8 million for nutrition programs administered by the Administration on Aging. These programs have strong partnerships with State Tribal and local governments, philanthropic organizations, and private donors that contribute funds in greater proportions than is the case for other Older Americans Act programs.

HEALTH INFORMATION TECHNOLOGY

Mr. Obey: Health Information Technology is an important tool in our effort to improve health care delivery and reduce medical errors. The Recovery Act appropriated $2 billion for the Office of the National Coordinator to award grants that would help advance the adoption of electronic health records published.

But having an electronic health record is not enough; doctors need to use it to capture medical history, coordinate patient treatment, and ensure that the correct medications are ordered.
So, the Recovery Act also provided a financial incentive for providers who make meaningful use of electronic health records. A great deal has already been accomplished to ensure the smooth implementation of this incentive program. However, there are things that still need to happen if physicians and hospitals are to qualify for meaningful use payments in 2011. When can physicians and hospitals expect to begin receiving incentive payments? What do you see as the greatest challenge to this process?

Secretary Sebelius: Under the statute, Medicare and Medicaid incentive payments to eligible hospitals and professionals must begin in FY 2011 and CY 2011 respectively. We are currently finalizing the regulation, with the final publication expected during FY 2010 to meet the statutory deadline to make the first year’s incentive payments for meaningful use of certified electronic health record (EHR) technology as authorized by the HITECH Act.

States have already begun to receive federal matching funds for state planning activities necessary to implement (EHR) incentive payments under Medicaid. The HITECH Act provides for a 90 percent federal match for state planning activities to administer the incentive payments to Medicaid providers, to conduct adequate oversight of the program and pursue initiatives to encourage adoption of EHR technology to promote health care quality and the exchange of health care information.

The most significant challenges to this process will be ensuring that eligible providers and hospitals are in compliance with the “meaningful use” regulation. CMS is working closely with the HHS Office of the National Coordinator of Health Information Technology (ONC) on a number of health information technology initiatives authorized by the HITECH Act, including establishing 60 Regional Extension Centers (REC) across the country. These RECs will offer technical assistance, guidance, and information to support and accelerate health care providers’ efforts to become meaningful users of EHRs.

Mr. Obey: What concerns have hospitals and providers expressed about this program and the published rules and what actions has the Department taken to address these concerns?

Secretary Sebelius: The Department has undertaken numerous education and information events to educate physicians, hospitals, vendors and other interested parties about the HITECH proposed rule. These efforts include CMS’ second annual Multi-State Health IT Collaborative for E-Health Conference (held in February 2010), and ongoing stakeholder engagement through meetings and conference calls.

The biggest concern hospitals and providers have conveyed to CMS is meeting the requirements of demonstrating meaningful use of EHRs. CMS has been working with the HHS Office of the National Coordinator (ONC) to ensure aligned and consistent policies toward certified electronic health record (EHR) technology in order to reduce barriers to its adoption. Understanding the difficulties faced by providers in re-engineering their practice workflow to incorporate EHRs, CMS is determined not to set the meaningful use bar so high as to impede adoption while assuring that providers who receive incentive payments are adopting and using EHRs in a manner that improves the quality of care. CMS and ONC have been diligently working toward the President’s vision for health information technology as a core component of the U.S. health system, but we know this is an incremental process. As such, the Department is
committed to continue working with and listening to providers across the nation to encourage participation in the CMS EHR incentive payment programs.

PANDEMIC FLU

Mr. Obey: Since 2004, we have invested more than $13 billion to help the Nation get better prepared to deal with a flu pandemic, and to respond to the H1N1 flu outbreaks. One major element of preparedness is the ability to quickly produce and distribute safe and effective vaccine. As we have discussed time and time again in this subcommittee, flu vaccines in the U.S. are still produced using 1940s egg-based technology. The funding previously appropriated included seed money to modernize U.S. vaccine production, reduce the amount of time it takes to produce vaccine, and increase the number of domestic vaccine manufacturers. But that seed money rightfully shifted to respond to the H1N1 pandemic. How do we get the research and development efforts back on track to create a modern flu vaccine infrastructure in the U.S.?

Secretary Sebelius: The 2009 H1N1 pandemic clearly demonstrated the need to continue pandemic preparedness efforts, including building a modern influenza vaccine infrastructure in the Nation. Following a comprehensive review of H1N1, we will assess the next steps and report back to you.

Mr. Obey: Of the $7.7 billion appropriated in last year's emergency supplemental for pandemic flu, about $1.3 billion remains unallocated. Why hasn't this remaining funding been allocated? When will it be allocated and for what purposes?

Secretary Sebelius: HHS is in the process of evaluating pandemic influenza needs in light of lessons learned from 2009-H1N1 influenza response. Plans for pandemic influenza balances will be based on these lessons learned, as well as on the National Pandemic Influenza Plan, including increasing domestic vaccine production capacity, and advanced development of vaccines and antivirals.

Mr. Obey: I am also very disappointed that the FY 2011 budget proposes to fund $156 million for ongoing CDC flu activities, including the salaries of 170 CDC staff, with the 2009 emergency supplemental resources. Congress intended that funding be used for emergency response, development and purchase of vaccines, antivirals, medical supplies, and personal protective equipment, vaccine delivery, upgrading State and local public health capacity, and surveillance. What is the rationale for taking base salaries and expenses costs out of an agency's annual budget and funding it through an emergency supplemental? Won't this approach lead to a significant funding cliff in future years once the supplemental funding is exhausted?

Secretary Sebelius: Using existing pandemic influenza funding for CDC’s pandemic influenza activities in FY 2011 is fiscally responsible, since HHS does not need to request additional FY 2011 funding for this purpose. This transfer will also allow CDC to begin some pandemic preparedness activities sooner than FY 2011, since the supplemental funding can be used at any time. Pandemic influenza needs will be re-examined in a year to determine the appropriate source and level of funding for CDC in FY 2012.
WORLD TRADE CENTER TREATMENT AND SCREENING PROGRAM

Mrs. Lowey: The last administration was not always responsive to the medical needs of World Trade Center rescue and recovery workers. While there have been significant improvements over the last year, and I am pleased that the FY 2011 budget request includes $150 million for the program, I am still concerned that we are not doing enough to care for these people who have multiple, and often severe, medical problems. What is HHS doing to evaluate the long-term medical needs for these individuals?

Secretary Sebelius: CDC’s National Institute of Occupational Safety and Health supports the World Trade Center (WTC) Healthy Registry. This registry is the largest public health registry, which tracks the health of over 70,000 people directly exposed to the WTC disaster. The Registry collects data, analyses data, and distributes the findings to track the long-term physical and mental health effects of the WTC attacks.

Mrs. Lowey: How much would a comprehensive medical services program for these victims cost?

Secretary Sebelius: The WTC Program that CDC implements provides monitoring and treatment services for both responders and non-responders of the WTC attacks for conditions associated with exposure to smoke, dust, debris, and psychological trauma in the September 11, 2001 WTC attacks. To continue these services, the FY 2011 President’s Budget requests $150 million, which is +$79 million above FY 2010.

Mrs. Lowey: Could you provide a report outlining these long-term needs and the estimated cost of such a program?

Secretary Sebelius: In response to the FY 2010 House Appropriations Committee Report, CDC will continue providing quarterly reports requested on the WTC Program. These reports include information on the program’s budget request, obligations, number of people served, and on the prevalent health conditions impacting participants.

Mrs. Lowey: Is your Department planning to address this need, and will it be done through a more comprehensive contract for the national responders?

Secretary Sebelius: WTC National Responder Health Program (NRHP) provides monitoring and treatment to responders outside of the NYC-NJ metropolitan area. The NRHP contractor explains to members the covered health conditions, procedures, and medications offered under the WTC NRHP; guides them to available social service resources as needed (e.g., food, housing, non-covered medical expenses); assists with applying for Workers’ Compensation benefits, provides program information via letters and summaries of services provided; and makes efforts to locate enrolled responders that have been inactive or lost to the program. The WTC Responder Program in NYC, the Community Program, and the WTC Health Registry all conduct outreach activities and coordinate to refer enrollees with health conditions related to the WTC attacks to the appropriate WTC treatment programs and services.
CHILDHOOD OBESITY

Mrs. Lowey: As part of First Lady Michelle Obama's childhood obesity initiative, HHS will dedicate up to $20 million in Community Economic Development program funds to the Healthy Food Financing Initiative to award competitive grants to support projects that finance grocery stores, farmers markets, and other sources of fresh, nutritious food. How many grants does HHS plan on making with $20 million?

Secretary Sebelius: We estimate we will fund 25 grants.

Mrs. Lowey: How does the FY11 budget request help combat child obesity?

Secretary Sebelius: The FY 2011 President’s Budget supports child obesity-related activities across HHS agencies as part of the Department’s obesity related efforts. For instance, the budget includes $58 million, in CDC to fund 25 States to implement State-wide programs to prevent obesity through activities such as population-based interventions, evaluation, surveillance, policy and environmental change, and translation of research to practice. Of the $58 million, $20 million is for CDC’s new Big Cities Initiative, which will reduce rates of morbidity, disability, and premature mortality due to chronic diseases in up to ten of the largest U.S. cities. Activities for this new program will include obesity prevention activities for children through improved nutrition and increased physical activity. The Big Cities Initiative will incorporate lessons learned from the Recovery Act Communities Putting Prevention to Work Initiative, which implements evidence-based prevention and wellness strategies to address, in part, obesity.

In addition, the Budget includes $5 million in FDA, $784 million in NIH, and $26 million in AHRQ for obesity-related research that will inform obesity prevention and control efforts across all ages, including children. Finally, NIH, CDC, and the Robert Wood Johnson Foundation together launched the National Collaborative on Childhood Obesity Research in February 2009. In FY 2011, this collaborative will continue to focus on efforts that have the potential to benefit children, teens and their families, and the communities in which they live.

UNDERAGE DRINKING AND SUBSTANCE ABUSE

Mrs. Lowey: I am concerned that HHS is blending underage drinking and drug use with other adolescent mental health issues. Teenagers who use alcohol and other drugs do not necessarily have mental health issues, and I believe the best way to combat the problem is to implement alcohol- and drug-specific prevention strategies. What is HHS doing to ensure that programs to address underage drinking and youth substance abuse focus on strategies to decrease access and availability?

Secretary Sebelius: As you know, the Substance Abuse and Mental Health Services Administration (SAMHSA) funds 101 Sober Truth on Preventing Underage Drinking (STOP) grants, which support community coalitions to raise public awareness about underage drinking, to enhance prevention skills of community-based providers who serve youth and their families, and to provide support for alcohol-free activities and alternatives. Underage drinking prevention strategies focus on decreasing access and availability including reducing access to alcohol (e.g. merchant education, parent and third party access awareness); changing consequences (e.g.
individual and business rewards, revocation of licenses for non-compliance); and changing physical design (e.g. location of beer gardens at special events, decrease quantity of alcohol signage).

The majority of the 747 Drug Free Community Support grants (administered in collaboration with the Office of National Drug Control Policy), which serve all 50 states, include an underage drinking prevention focus. *The Surgeon General’s Call to Action* emphasizes that preventing underage drinking is a collective responsibility for all members of the community. The strategies implemented through these community grants to decrease access and availability are city curfews, school extracurricular activity policies, positive faith-based and community activities, business/workplace testing, and health care professional advisement.

SAMHSA also funds a number of underage drinking prevention websites to respond to public demand for information:

- Building Blocks for a Healthy Future is designed for the parents and educators of children aged 3 to 6. Access and availability are addressed indirectly with parents by focusing on parenting skills (e.g., role modeling around the use of alcohol and drugs, problem-solving, dealing with stress, and modeling positive traits and behaviors). For more information see [http://www.bblocks.samhsa.gov/](http://www.bblocks.samhsa.gov/)

- Too Smart to Start addresses the information needs of youth aged 11 to 18 and their parents, educators and communities. Tailored strategies for parents, educators, and communities to reduce youth access and alcohol availability are provided. For more information see [http://toosmarttostart.samhsa.gov/](http://toosmarttostart.samhsa.gov/)

- [www.stopalcoholabuse.gov](http://www.stopalcoholabuse.gov) is a Federal portal of resources related to underage alcohol use prevention and serves the needs of national prevention coalitions. How-to guides and public education resources regarding access and availability are available for parents, community/faith-based organizations, business, educators, youth, enforcement/adjudication, and prevention/treatment providers.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) also supports research on preventing underage drinking. Given that alcohol use is pervasive among adolescents and the association between early initiation and future alcohol problems, NIAAA is developing empirically-based guidelines and recommendations for screening children and adolescents to identify risk, especially in younger children, for alcohol use and alcohol use disorders.

NIAAA will also solicit studies that evaluate the use and effectiveness of the guidelines in various settings. In FY 2009, NIAAA solicited applications to study decision-making processes in adolescents as they relate to drinking behavior, and the role of neural circuitry development in adolescent decision-making and alcohol abuse and dependence. NIAAA is also planning a new research initiative on pharmacotherapy for adolescents and young adults with severe alcohol use disorders and major comorbidities, as well as behavioral interventions that target young individuals along the continuum of mild to severe alcohol-related behaviors.
GLOMERULAR DISEASES

Mrs. Lowey: Many glomerular diseases, such as focal segmental glomerulosclerosis (FSGS) cause severe damage to the filter mechanisms of the kidney and must often be treated by a kidney transplant: as of January of this year 759 of 4,123 FSGS patients awaiting kidney transplants had already received at least one transplant that failed. What progress is NIH making to ascertain the reasons for the resurgence of FSGS in some patients who have received kidney transplants?

Secretary Sebelius: The NIH has a robust and diverse portfolio of research into the causes of and treatments for FSGS and the problem of transplant failure in some patients. Basic science studies into the causes of transplant failure in FSGS patients include a collaborative set of studies between researchers at two academic institutions and scientists within the National Institute of Diabetes and Digestive and Kidney Diseases that is investigating a possible role for a recently-discovered protein—cardiotrophin-like cytokine 1 (CLC-1)—in the recurrence of FSGS. This protein may act as a "permeability factor" that allows protein to leak into the urine. This protein is found at high levels in the blood of some FSGS patients. Attempts to generate a mouse model in which this protein is expressed at high levels are underway. Another protein, called soluble urine plasminogen activator receptor, is also being studied as a possible cause of recurrent FSGS, at least in a subset of patients.

In the clinical research arena, NIDDK scientists are investigating whether variations in the MYH9 genetic locus—some of which are associated with increased risk of non-diabetic kidney disease such as FSGS—play a role in adverse outcomes following kidney transplantation. The NIDDK-supported FSGS Clinical Trial a collaborative network of U.S. research centers has now completed a test of the effectiveness of two different treatment regimens in children and young adults who have steroid-resistant FSGS of unknown origin (http://www.fsgsclinical.org). This is the largest randomized trial of FSGS ever conducted, and the results should be published soon. An ancillary study, the Novel Therapies for Resistant FSGS Clinical Trial (FONT), has successfully completed its first phase, testing the safety, tolerance, and pharmacokinetic profile of two novel therapies for FSGS that is not responsive to current treatment. The second phase will test these two therapies and a third agent, the milk sugar galactose, which has shown some promise as a therapy for recurrent FSGS following kidney transplantation.

HEALTH CARE REFORM AND PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE

Mrs. Lowey: The recently enacted health care reform legislation created a Patient-Centered Outcomes Research Institute, which will serve as a home for comparative effectiveness research (CER). During the reform debate, the clinical and translational research community voiced concern over potential conflicts of interest within the governance structure of this new Institute, as pharmaceutical and medical device industry stakeholders will have representation on its Board of Governors and advisory committees. Can you share your thoughts on this issue, and whether or not you share these concerns?

Secretary Sebelius: The Patient-Centered Outcomes Research provision of the Affordable Care Act requires that the Comptroller General appoint a Board of Governors to carry out the
duties of the Institute. As you point out, pharmaceutical and device manufacturers are to be represented on the Board. Additionally, the provision requires that members representing patients, physicians and providers, payers, and Federal and State governments also be represented to provide a broad range of perspectives and various areas of expertise. In an effort to ensure transparency of the Board's deliberations, meetings not concerned solely with personnel matters shall be advertised at least seven days in advance and open to the public. In addition, the GAO is required to review what the PCORI has accomplished not less frequently than every five years and report annually to the Congress on its activities.
COMMUNITY HEALTH CENTERS AND POST REFORM FUNDING

Mrs. Roybal-Allard: With the passage of health care reform and the addition of millions of newly insured people in the United States, many Americans who have gone without care will soon be seeking a health care home through which they can access care. Our nation's Community Health Centers already serve as a health care home for nearly 20 million patients, and with the implementation of the new Community Health Centers trust fund, they stand to double the number of patients they serve over the next five years.

I'd like to ask you two questions: First, can you speak to the critical role that you envision for health centers in meeting our nation's primary care needs in a reformed health system?

Secretary Sebelius: For more than 40 years, health centers have delivered comprehensive, high-quality primary health care to patients regardless of their ability to pay. During that time health centers have become an essential primary care provider for America's most vulnerable populations: the poor, uninsured, and homeless; minorities; migrant and seasonal farm workers; public housing residents; geographically isolated; and people with limited English proficiency. With a proven track record of success, health centers are a key component to health care reform.

The Affordable Care Act provides $11 billion in funding for the operation, expansion, and construction of health centers throughout the Nation. This increased funding will double the number of patients seen by health centers over the next 5 years, making primary health care available for an additional 20 million people.

Mrs. Roybal-Allard: Secondly, in order for the full $11 billion investment supported through health reform by Congress and the Administration in health centers to be realized, is it your opinion that this committee should provide no less than the existing level of discretionary funding for the program--currently equal to $2.19 billion?

Secretary Sebelius: The President’s FY 2011 budget includes an increase of approximately $290 million over the FY 2010 level of $2.19 billion. This increase will continue support for the American Recovery and Reinvestment Act investment in 127 Health Center New Access Points as well as the services initiated under the Increased Demand for Services (IDS) grants to health centers nationwide, providing care to approximately 2.85 million medically underserved people. This funding level will also support the development of approximately 25 new access points, increasing access to comprehensive primary health care services to an estimated 150,000 additional health center patients. Additionally, this level will support an estimated 125 service expansion grants to expand the integration of behavioral health into existing primary health care systems, enhancing the availability and quality of addiction care at existing health centers.

MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT

Mrs. Roybal-Allard: The United States spends more on maternity care than any other country in the world, however we rank 41st in the world in maternal mortality and 30th in infant mortality. Despite these dismal rankings funding for the Title V Maternal and Child Health Services Block Grant dropped from $731 million in FY 2003 to $662 million last year. Can you
discuss the Administration's plans to reinvigorate investments to improve maternity care? What coordination is there within your Department to develop strategies that will help improve our standing among these dismal rankings?

Secretary Sebelius: The mission of the Maternal and Child Health (MCH) Block Grant Program is to improve the health of all mothers, children, and their families. Specifically the program seeks to: (1) assure access to quality care, especially for those with low-incomes or limited availability of care; (2) reduce infant mortality; (3) provide and ensure access to comprehensive prenatal and postnatal care to women (especially low-income and at risk pregnant women); (4) increase the number of children receiving health assessments and follow-up diagnostic and treatment services; (5) provide and ensure access to preventive and child care services as well as rehabilitative services for certain children; (6) implement family-centered, community-based, systems of coordinated care for children with special healthcare needs (CSHCN); and (7) provide toll-free hotlines and assistance in applying for services to pregnant women with infants and children who are eligible for Title XIX (Medicaid).

A program assessment of the Title V MCH Block Grant in 2008 determined that the program has had a positive impact, with strong and effective collaborations established between Federal, State, local and private-sector entities concerned with MCH. To this end, the Title V program plays an important role in the delivery of appropriate and effective care for high-risk pregnant women and infants. The Title V MCH Block Grant monitors and works closely with States to decrease the national rate of maternal and infant deaths. It should be noted that one factor contributing to the increase in the reporting of maternal mortality rates is due to changes in the classification and measurement of maternal mortality since the introduction of the revised Birth Certificate in 2003. This increase will likely continue as additional States adopt the new Birth Certificate and its classification of maternal mortality. However, these reporting changes do not fully explain the lack of progress in this area. Other factors include the increasing age of mothers at delivery and the increased prevalence of risk conditions, such as obesity, hypertension and diabetes, in this population.

Efforts to reduce the overall infant mortality rate continue, with the rate having decreased from 9.2 per 1,000 live births in 1990 to 7.0 per 1,000 births in 2002. However since 2002, the rate has remained essentially unchanged, with a range between 7.7 per 1,000 live births and 6.9 per 1,000 live births. A subsequent analysis concluded that multiple factors are contributing to the recent lack of progress. These factors include, but are not limited to, an increase in the number of very small infants (less than 750 grams), the rise in multiple birth rates, and increases in maternal age at childbirth.

Prenatal care is one of the most important interventions for ensuring the health of pregnant women and their infants. Overall, the proportion of pregnant women entering prenatal care in the first trimester increased from 76 percent in 1990 to 84 percent in 2005. While there has been progress in the timely initiation of prenatal care for all population groups, the rate of increase has been slow in recent years. Given the increasing prevalence of diabetes, obesity and pregnancy-induced hypertension during pregnancy, there is a need for such risk factors to be monitored and for timely and appropriate prenatal care to be provided.
As part of their partnership and collaborative relationship with MCHB, State and jurisdictional MCH grantees participate in extensive planning, reporting and evaluation processes. Beginning with a comprehensive statewide needs assessment every five years, with the next Needs Assessment being submitted in 2010, States evaluate the needs of their MCH populations, assess State resources and capacity, identify priority needs, develop program plans to address identified needs and establish performance targets for measuring progress. Specifically related to prenatal care and maternal/infant mortality, two of the 18 National Performance Measures in the State Title V MCH Block Grant program address the percentage of women who smoke in the last three months of pregnancy and the percent of women born to pregnant women receiving prenatal care beginning in the first trimester. The six National Outcome Measures require States to report on their infant mortality rates, neonatal mortality rates, perinatal mortality rates and the ratio of the black infant mortality rate to the white infant mortality rate. These Performance and Outcome Measures and the effective collaborations established between Federal, State, local and private-sector entities are sentinel for progress.

The Maternal and Child Health Bureau (MCHB) works with the State MCH programs in continuing to build the data capacity to better understand the issues which impact maternal and infant mortality and to design interventions that can create positive change. Efforts have centered on the development of client-based data systems that more accurately capture the direct, enabling and population-based services provided. MCHB regularly provides technical support to the States around the priorities identified in their comprehensive five-year needs assessments and the areas of needed technical assistance outlined in their annual applications.

EXTENSIVELY DRUG RESISTANT TUBERCULOSIS

Mrs. Roybal-Allard: As you know Extensively Drug Resistant Tuberculosis (XDR-TB) is a very severe form of TB that is extremely difficult and costly to treat, costing as much $1 million per case, and is often fatal. This issue is of particular importance to border states, like California, which has a disproportionately high burden of TB.

DHHS is to be commended for its ongoing efforts to respond to drug-resistant strains of tuberculosis, including the partnership between National Institutes of Health and Centers for Disease Control and Prevention on the development of the Federal TB Task Force Action Plan on XDR-TB. However I am concerned that the FY11 budget request includes a decrease in funding for the CDC Division of Tuberculosis Elimination. What impact will these cuts have on the cooperative agreements that exist between states and jurisdictions such as California and Los Angeles?

Secretary Sebelius: State TB control programs are integral to the nation’s capability to eliminate TB. CDC provides leadership, advice, and assistance to these State programs and develops guidance and national policy for TB control. The FY 2011 Budget includes $143 million for TB, which is $1 million below FY 2010. This reduction is part of a CDC-wide effort to achieve efficiencies in travel and contracting and to maintain the programmatic impact of TB prevention. Consequently, these reductions will not have a negative impact on the cooperative agreements that exist between States and jurisdictions, such as California and Los Angeles. Rather, these savings will improve the effectiveness of this program and other CDC programs agency-wide. FY 2011 funds will sustain and enhance work to reduce incidence of TB among U.S.-born persons in the United States. CDC will also continue to provide domestic and
international leadership and assistance to prevent, control, and eliminate TB.

**CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

Mrs. Roybal-Allard: Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in America, afflicting an estimated 10-12 million Americans, with another 10-12 million undiagnosed cases. In last year's Committee report, the COC was asked to develop a national plan to respond to COPD. Additionally, several members of this Subcommittee wrote a letter to COC in support of this initiative. Can you tell me the status of the development of this plan?

Secretary Sebelius: CDC supports the initial assessment and planning for public health in this important area. CDC is interested in consulting with experts to develop a national roadmap to explore the public health issues related to COPD, which would include addressing the public health role in prevention, treatment, and management. This would include the examination of the best strategies to address surveillance of COPD.

**HHS RESPONSE TO VIRAL HEPATITIS**

Mrs. Roybal-Allard: A report released in January by the Institute of Medicine (IOM) cites the dearth of federal resources to address viral hepatitis. This is causing many Americans to go unaware that they are infected with hepatitis B or hepatitis C until their disease has progressed to significant liver damage or liver cancer. Close to one in thirty "Baby Boomers" is living with hepatitis B or C and hepatitis is the cause of health disparities for blacks, Hispanics, and Asian Americans. In addition, viral hepatitis is the most common cause of chronic liver disease and liver cancer. Each year mortality associated with viral hepatitis is equal to that from AIDS; Yet at CDC, Viral hepatitis prevention receives only about 2% of funding that HIV/AIDS prevention receives.

The IOM identified hepatitis as an underappreciated health threat reflected by studies which show that most persons living with hepatitis are unaware of their infection and cited the lack of national coordination as hampering efforts to prevent and control this disease. The IOM recommended increased commitments to surveillance, education, vaccination and screening, and health services to reduce viral hepatitis associated liver disease and cancer. How is HHS responding to this call for action by IOM? Specifically, how will HHS help Federally Qualified Health Centers to improve their ability to care for patients affected by viral hepatitis?

Secretary Sebelius: The Health Resources and Services Administration (HRSA) supports Federally Qualified Health Centers (FQHCs) services for viral hepatitis treatment and prevention in several ways. HRSA requires, as a condition of health center funding and the FQHC "Look-Alike" designation, the provision of diagnostic lab services, screenings for communicable diseases, and immunizations against vaccine-preventable diseases, including hepatitis B virus. They also require that grantees provide health education to patients and the general community, including patient education on diseases including viral hepatitis. They promote screening and treatment of viral hepatitis through a national cooperative agreement, which among other things includes raising awareness of viral hepatitis among health center providers and patients, and provides technical assistance on strategies to treat and prevent patients with viral hepatitis.
As part of this effort, HRSA recently met with the National Alliance of State and Territorial AIDS Directors and the Northeast Hepatitis Coordinators' Alliance to strategize on hepatitis prevention and treatment in FQHCs. In an effort to better monitor hepatitis incidence in health center patients, HRSA has also revised its grantee reporting mechanism to better track patient hepatitis rates. Within HRSA, the HIV/AIDS Bureau and the Bureau of Primary Health Care (BPHC) are collaborating on ways to increase screening and referral to treatment for FQHC patients who are infected with Hepatitis C and those who are dually infected with HIV and hepatitis. In addition to workgroups within the Department on Viral Hepatitis, within HRSA, BPHC is working with the Association of Asian Pacific Community Health Organizations and the White House Initiative on Asian American and Pacific Islanders to develop strategies for improving prevention and treatment of viral hepatitis among Asian and Pacific Islander Americans.

Mrs. Roybal-Allard: Given the high number of people in drug treatment who also have hepatitis B or C, how can HHS help to increase hepatitis testing and hepatitis A/B immunizations in drug treatment centers?

Secretary Sebelius: For the past several years, the Substance Abuse and Mental Health Services Administration (SAMHSA) has included a requirement that entities applying for Drug Courts and HIV Treatment and Outreach funding develop a relationship with local departments of health to ensure access and referral to sexually transmitted infections, hepatitis B and C, and TB testing. These linkages have been successful in facilitating screening, immunization, and treatment for viral hepatitis. The experience of these programs has been very positive, with patients accessing the screening and immunizations and ongoing treatment. SAMHSA is working with States, providers, and grantees to establish and maintain relationships with primary care settings and to effectively integrate substance abuse specialty care with general health care. These relationships will advance the identification and treatment opportunities for individuals living with viral hepatitis.

SAMHSA is also demonstrating the cost-effective delivery of enhanced health services to an ethnic minority population receiving interventions for opioid dependence within a treatment setting, which has the potential to increase recommended vaccination and hepatitis testing services. The program has established a shipping strategy for vaccine and test products to minimize onsite storage and waste problems while reaching the maximum number of patients that can benefit from hepatitis vaccination or testing services. It has also established the true cost of implementing this service, with improvement opportunities for achieving greater efficiency through a quality assurance/improvement program.

Mrs. Roybal-Allard: Why hasn’t HHS directed the CDC to implement a comprehensive screening program to identify the 78% (HCV) and 65% (HBV) of people that do not know their status?

Secretary Sebelius: The FY 2011 President’s Budget includes $21 million for Viral Hepatitis Prevention, which is +$2 million above FY 2010, to prevent disease and death from chronic hepatitis infections, such as Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV). To improve the screening and clinical management of persons with chronic HBV infection, CDC released new recommendations for chronic HBV screening that defined target populations for
screening, and the prevention and care services needed by persons found to be infected with HBV. Research is underway to identify and disseminate best practices to implement CDC HBV testing recommendations and counseling messages best suited for primary care and immigrant health settings. Research is also underway that will inform updates to CDC’s hepatitis C screening recommendations.

In addition, HHS has formed a workgroup with representatives across HHS offices and agencies to develop a coordinated departmental response to viral hepatitis. The workgroup will promote program action and investments that foster health system interventions to ensure Americans with chronic viral hepatitis become aware of their infection early and slow their progression to liver disease, cirrhosis, and cancer. CDC is playing a key role in the workgroup and the group’s findings and recommendations will be essential for planning and helpful in determining priorities for moving forward to meet the challenges that viral hepatitis presents to our Nation.

Mrs. Roybal-Allard: Where and how much funding to address chronic hepatitis has been allocated with the ARRA wellness and prevention funds?

Secretary Sebelius: Congress appropriated $1 billion in the FY 2009 Recovery Act for Prevention and Wellness. Specifically, $300 million was appropriated for CDC’s Section 317 Immunization Program, $50 million was appropriated for healthcare-associated infections, and $650 million was appropriated to implement evidence-based prevention and wellness strategies to address the rates of chronic disease. The program HHS is executing to implement evidence-based prevention and wellness strategies is the Communities Putting Prevention to Work Program, which addresses obesity and tobacco prevention. Thus, none of the funding directly addresses chronic hepatitis.

MENTAL HEALTH FUNDING REDUCTIONS

Mrs. Roybal-Allard: The current fiscal crisis in our states is having a very negative effect on our nation’s public mental health system. Specifically, the National Association of State Mental Health Program Directors (NASMHPD) released a survey in December showing that - for the last three fiscal years - state governments have been forced to cut mental health spending by a combined total of $1.8 billion. In many states, the fiscal crisis is so severe that proposals to cut mental health funding by as much as 30 to 40% across-the-board are receiving very serious attention.

My understanding is that states are being forced to close public psychiatric hospitals, reduce access to crisis centers, and cut funding for frontline Community Mental Health Centers. While these funding reductions unfold, more low income and recently uninsured people are seeking out services through the public mental health system. Does the President’s FY11 budget contain provisions that can help states avert drastic mental health funding reductions?

Secretary Sebelius: Yes, the FY 2011 President’s Budget includes an increase of $23 million for mental health programs administered by the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition, the Budget includes an increase of $25 million to expand behavioral health services in community health centers that receive funding from the
Health Resources and Services Administration (HRSA). The Budget also maintains funding for the Mental Health Block Grant, which is a stable funding source that gives States flexibility to address their emerging needs.

Mrs. Roybal-Allard: Do you think that reality justifies the continuation of the Mental Health and Substance Abuse Block Grants?

Secretary Sebelius: The Mental Health Block Grant (MHBG) is the largest source of Federal support for mental health services with the exception of the Medicaid program. States and territories use MHBG funds to support mental health services included in their comprehensive community-based mental health service systems plans that provide services to 6.3 million adults with serious mental illness and children with serious emotional disturbances every year. The MHBG funds many initiatives crucial to these individuals that are difficult or impossible to pay for through more traditional clinic-based payment systems such as Medicaid, private insurance plans, or the Veterans Administration.

Funding provided through the Substance Abuse Prevention and Treatment Block Grant supports eligible individuals with a substance use disorder who meet need criteria as established by each State (e.g. 200% of poverty). This funding stream serves as the foundation for substance abuse treatment and prevention services in the States. While health reform will expand access to these services, there will continue to be a need for continued support from SAMHSA.

Mrs. Roybal-Allard: What kind of Medicaid and state exchange enrollment efforts will HHS mount specifically targeting people with cognitive disabilities of all kinds (e.g., intellectual disabilities, Down syndrome, autism, mental illnesses, Alzheimer's disease) and individuals with low health literacy?

Secretary Sebelius: The Department is currently in the process of implementing several new Medicaid policies enacted by the Patient Protection and Affordable Care Act of 2010 (the Affordable Care Act) that specifically target individuals with cognitive disabilities. For example, the Affordable Care Act requires the Secretary to establish a 3-year demonstration project under which States may provide Medicaid payment to non-publicly owned and operated institutions for mental disease (IMDs) for purposes of treating Medicaid beneficiaries ages 21-64 who are experiencing a mental health emergency. The provision appropriates $75 million in FY2011, which will remain available for obligation through December 31, 2015.

Another Affordable Care Act provision that will benefit individuals with cognitive disabilities is a Medicaid State plan option to permit coverage of any medical or remedial service recommended to reduce physical or mental disability and restore functionality. The Affordable Care Act also provides several new improvements to Medicaid long term services and supports that we believe will also greatly benefit individuals with cognitive disabilities. Major provisions in the law we are implementing include:

- the Community First Choice Option to expand home and community-based attendant services and supports;
- a $3 billion grant program for states to shift Medicaid beneficiaries into home and community-based (HCBS) settings beginning October 1, 2011;
- an extension of the Money Follows the Person demonstration through FY 2016; and
- a new option in the Medicaid State plan under which States can pay providers or teams of health care professionals for furnishing health home services, including care management, transitional care, patient and family support, referrals to community and social support services, and use of health information technology, for care given to individuals with chronic conditions including persistent mental health conditions.

PREVENTION AND PUBLIC HEALTH FUND

Mrs. Roybal-Allard: The Prevention and Public Health Fund created through health reform provides us with an unprecedented opportunity to begin to transform our public health system to prioritize prevention programs and could also serve as a way to address health disparities. What is the Department's process for allocating this funding?

Secretary Sebelius: HHS is reviewing options for allocating funds in FY 2010 and FY 2011. The Prevention and Public Health Fund provides HHS an opportunity to expand and sustain an investment in prevention, wellness, and public health programs to improve the health of the nation and help restrain health care costs.

Mrs. Roybal-Allard: For FY 2010 and FY 2011 how are you prioritizing spending - is there an overall framework you are using to ensure that we are maximizing our use of this funding?

Secretary Sebelius: HHS is examining section 4002 of ACA, which establishes the Prevention and Public Health Fund, to inform its allocation of these funds. In FY 2010, HHS is prioritizing allocation options in which funds can be obligated by the end of the fiscal year.

Mrs. Roybal-Allard: Once the National Prevention Strategy has been announced, will the Strategy guide funding allocations from the Prevention and Public Health Fund?

Secretary Sebelius: Once drafted, the National Prevention and Health Promotion Strategy, required in section 4001 of ACA, will inform, along with other considerations, future HHS allocations for the Prevention and Public Health Fund.

Mrs. Roybal-Allard: As you know, the House bill included categories of funding, including community prevention, prevention and wellness research, and core public health. Is the Department using similar categories to ensure that we are making progress in enhancing community prevention, bolstering capacity at health departments, and enhancing prevention and public health research?

Secretary Sebelius: HHS is evaluating all options for allocating resources from the Prevention and Public Health Fund consistent with ACA’s use of the Fund for “prevention, wellness, and public health activities.” To the extent that the House bill’s Prevention and Wellness Trust would have authorized funds to be appropriated for “prevention, wellness, and public health activities” consistent with ACA, those activities would be an eligible option for HHS to consider. The community transformation grants authorized in health reform legislation are specifically designed to reduce chronic disease rates, prevent the development of secondary conditions, and address health disparities.
Mrs. Roybal-Allard: Do you envision that the Prevention and Public Health Fund will provide funding for community transformation grants in the coming years, and how will you assure that they are effectively used to address health disparities?

Secretary Sebelius: HHS is reviewing options for allocating funds in FY 2010 and FY 2011 and has not made decisions regarding an allocation for any fiscal year. HHS is evaluating options consistent with ACA’s use of the Fund, as stated in section 4002 of ACA, for “prevention, wellness, and public health activities.” The Prevention and Public Health Fund cites the Community Transformation Grant Program as an example of an eligible use of Fund resources. Thus, HHS will consider this program as one eligible for an allocation of Fund resources.

The authorization for the Community Transformation Grant Program, in section 4201 of ACA, provides that addressing health disparities is an authorized purpose for these grants. In addition, the authorization states that grantees must submit detailed plans to promote healthy living and reduce disparities.

**Obesity and Chronic Disease Prevention**

Mrs. Roybal-Allard: I'm very pleased to see that obesity prevention has been an important priority for this Administration and particularly the First Lady. Within the Department's budget, how can we continue to emphasize obesity prevention? Are there particular programs or accounts that you think are most important to advancing this goal?

Secretary Sebelius: The FY 2011 President’s Budget supports obesity-related activities across HHS agencies as part of the Department’s obesity-related efforts. For instance, the budget includes $58 million, in CDC to fund 25 States to implement State-wide programs to prevent obesity through activities such as population-based interventions, evaluation, surveillance, policy, and environmental change, and translation of research to practice. Of the $58 million, $20 million is for CDC’s new Big Cities Initiative, which will reduce rates of morbidity, disability, and premature mortality due to chronic diseases in up to ten of the largest U.S. cities.

In addition, the budget includes $5 million in FDA, $784 million in NIH, and $26 million in AHRQ for obesity-related research that will inform obesity prevention and control efforts across all ages, including children. NIH, CDC, and the Robert Wood Johnson Foundation together launched the National Collaborative on Childhood Obesity Research in February 2009. In FY 2011, this collaborative will continue to focus on efforts that have the potential to benefit children, teens and their families, and the communities in which they live. Finally, Healthy People, a set of health objectives for the nation to achieve over the next decade, is produced by HHS and is utilized by the Federal government to help develop programs and policies and establish priorities to improve the health of the population. Healthy People 2020, scheduled to launch later this year, includes many objectives related to obesity prevention and can be used to guide obesity efforts.

Mrs. Roybal-Allard: What can be done in the childcare environment and/or Head Start to help give kids a healthier start? Is there anything HHS can do to address obesity in the childcare setting, and how is that incorporated into the FY 2011 budget?
Secretary Sebelius: Child care, Head Start, and other early childhood settings can play a key role in obesity prevention efforts by promoting improved nutrition and increased physical activity for children. The Administration is committed to improving the quality of child care, including health and safety standards and improved monitoring to ensure that children are in safe environments. As part of our commitment we are looking at ways that we can work with States and grantees to promote expert-recommended standards related to nutrition and physical activity.

We are also developing technical assistance to promote effective practices in early learning settings, such as extending the Head Start’s I Am Moving, I Am Learning (IMIL) initiative to child care and other settings. IMIL is a proactive approach to childhood obesity that promotes healthy food choices and seeks to increase the amount and quality of physical activity that children receive. Head Start is planning to expand this initiative to grantees that have not yet participated and, where possible, will make the training available to child care agencies. The training will be revised to include children from birth to age five and include age appropriate physical development activities, structured and unstructured play with 30-60 minutes of moderate to vigorous physical activity, and teaching about making good nutrition choices. It is integrated throughout a program’s existing curriculum and, along with health, supports children’s progress in the social-emotional and cognitive domains of the Head Start Child Outcomes Framework.

In addition to these efforts in the classroom, it is essential to provide educational materials on nutrition and physical activity to parents and other caregivers of young children. The President’s FY 2011 budget request would provide a significant increase for the Child Care and Development Block Grant—making additional quality and technical assistance dollars available for these critical activities.

Mrs. Roybal-Allard: Has the Department begun implementation of the CHIPRA childhood obesity demonstration project that was authorized in CHIPRA and funded through health reform? How will the Department evaluate the demonstration project, and if successful, does the Department plan to expand it?

Secretary Sebelius: CDC, in collaboration with CMS, will implement the CHIPRA childhood obesity demonstration project funded in health reform. CDC and CMS are working on implementation plans, including the evaluation plans. Evaluation measures likely will correspond to the grantees’ activities, such as the health outcomes resulting from the grantee’s

ARRA PREVENTION AND WELLNESS FUNDING

Mrs. Roybal-Allard: What is the Department doing to ensure coordination between chronic disease prevention funding that is awarded through the ARRA Prevention and Wellness Initiative and the annualized chronic disease prevention programs at CDC supported through the discretionary appropriations process?

Secretary Sebelius: Congress appropriated $1 billion in the FY 2009 Recovery Act for Prevention and Wellness. Specifically, $300 million was appropriated for CDC’s Section 317 Immunization Program, $50 million was appropriated for healthcare-associated infections, and $650 million was appropriated to implement evidence-based prevention and wellness strategies to address the rates of chronic disease. The program HHS is executing to implement evidence-based
prevention and wellness strategies is the Communities Putting Prevention to Work Program, which addresses obesity and tobacco prevention. The Recovery Act provided the $1 billion as a one-time appropriation. Consequently, although the chronic disease funding requested in CDC in the FY 2011 President’s Budget does not overlap with the one-time funds Congress appropriated in the Recovery Act in FY 2009, HHS expects that any lessons learned from the Recovery Act will inform chronic disease programs supported by CDC’s annual appropriation.

Mrs. Roybal-Allard: How will lessons learned from the ARRA investment be incorporated into the existing CDC chronic disease prevention programs?

Secretary Sebelius: The Recovery Act Communities Putting Prevention to Work Program provides a platform for the wide-scale application of a focused set of evidence-based policy, environmental, and systems change strategies. CDC will incorporate lessons learned from this program in its chronic disease prevention programs, such as the Big Cities Initiative, for which the FY 2011 President’s Budget requests $20 million. Funded cities of the Big Cities Initiative will implement evidence-based programs to reduce the risk factors that lead to chronic disease and will incorporate lessons learned from the Recovery Act program.

HEALTH DISPARITIES

Mrs. Roybal-Allard: As you know, AHRQ recently released the National Healthcare Disparities Report, which found that disparities related to race, ethnicity, and socioeconomic status still pervade the American healthcare system. In African Americans communities, 48 percent of adults suffer from chronic disease, compared with 39 percent of the general population. Studies have found that forty-four percent of Hispanics receive obesity counseling, and were one-third times less likely to be counseled than whites. Less than one-third of low-income individuals receive diabetes care to prevent progression of the disease, while more than half of people with high incomes receive proper care. What particular programs in the HHS budget would you prioritize in order to address health disparities?

Secretary Sebelius: Health disparities faced by racial, ethnic, and underserved communities are the manifestation and interplay of complex factors and evidence suggests that solutions for reducing health disparities must address those complex factors. It will take many different programs, working in collaboration, to effectively address health disparities. In this regard there are a number of programs in the FY 2011 HHS request that are intended to collectively contribute to improved outcomes for racial, ethnic, and underserved communities.

These programs focus on ensuring access to quality, culturally competent, and patient-centered care; promoting prevention and wellness; increasing access to early learning programs and supporting healthy environments; promoting community empowerment and community-driven interventions; ensuring the collection, reporting, and access to data on all populations; increasing the supply, diversity, and cultural competence of the health-related workforce, particularly within underserved communities; supporting research that specifically adds to the knowledge base on health concerns faced by communities of color; and, increasing coordination and partnerships among organizations, within and outside of the Department, whose programs and activities address factors that influence outcomes for minority communities.
Mrs. Roybal-Allard: CDC’s REACH program focuses on eliminating health disparities. How do you assess that program, and do you think it should be expanded in the future?

Secretary Sebelius: The FY 2011 President’s Budget requests $39 million for REACH, $1 million below FY 2010 for CDC-wide contract and travel savings, and will support 50 communities. The REACH program supports communities to implement strategies and interventions to advance the reduction and elimination of racial and ethnic health disparities. The program has been successful in addressing health disparities. For instance, the Chicago Department of Public Health REACH program used a multi-faceted community approach to improve access to diabetes and cardiovascular care and services. The percentage of program participants with diabetes who received annual hemoglobin A1C tests increased from 21 to 96 percent, the percentage who received annual eye exams increased from 22 to 72 percent, and the percentage who received annual foot exams increased from 42 to 72 percent.

Mrs. Roybal-Allard: One factor that contributes to health disparities is lack of access to nutritious foods. As you know, the President’s budget has proposed a $400 million joint USDA-HHS-Treasury initiative to address the issue of food deserts. Can you tell me a little more about this initiative and the HHS piece of it?

Secretary Sebelius: Each of the three agencies supporting the Healthy Foods Financing Initiative brings with it a particular expertise and a set of resources that complement one another. HHS specializes in community-based efforts to improve the economic and physical health of people in distressed areas. We will dedicate up to $20 million in Community Economic Development program funds to the Healthy Food Financing Initiative. Through the Community Economic Development program, we will award competitive grants to Community Development Corporations to support projects that finance grocery stores, farmers markets, and other sources of fresh and nutritious food. Targeting financial assistance to food deserts will not only increase the supply of healthy foods and create new markets for farmers, but also create jobs and support broader development efforts to revitalize distressed communities. HHS has supported fresh food projects in the past, like the Plaza del Valle in Panorama City, CA, a family-oriented public market. This project facilitated the creation of 22 new businesses and the expansion of 28 businesses.

The Department of Agriculture specializes in improving access to healthy foods through nutrition assistance programs, creating business opportunities for America’s farmers, and promoting economic development in rural areas. USDA’s proposed funding level of $50 million will support more than $150 million in public and private investments in the form of loans, grants, promotion, and other programs that can provide financial and technical assistance to enhance access to healthy foods in under served communities, expand demand and retail outlets for farm products, and increase the availability of locally and regionally produced foods. USDA has a solid track record of supporting successful farmers markets, and has also invested in grocery stores and creating agricultural supply chains for them such as in the People’s Grocery project in Oakland, CA.

The Treasury Department will support private sector financing of healthy food options in distressed urban and rural communities. Through the New Markets Tax Credit (NMTC) and financial assistance to Treasury-certified community development financial institutions (CDFIs), Treasury has a proven track record in expanding access to nutritious foods by catalyzing private
sector investment. The Healthy Foods Financing Initiative builds on that track record, with $250 million in authority for the NMTC and $25 million for financial assistance to CDFIs devoted to helping finance healthy food options.

Mrs. Roybal-Allard: What are the most promising provisions in health reform to help address these disparities?

Secretary Sebelius: In addition to provisions that improve and expand access to quality, affordable, patient-centered health care, other important provisions include:

- Establishing a clear and definitive operational structure for coordinating and evaluating health disparities policies, programs, and activities within the Department of Health and Human Services and its partners. The Patient Protection and Affordable Care Act of 2010, reauthorizes the Federal Office of Minority Health, creates offices within the Agency for Healthcare Research and Quality, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Food and Drug Administration, Health Resources and Services Administration, and Substance Abuse and Mental Health Services Administration that will improve our policies and programs related to minority communities. The Act also elevates the National Center on Minority Health and Health Disparities to an Institute.

- Improving data collection and reporting requirements for federally conducted or supported health care and public health programs based on existing standards for race and ethnicity and that accounts for the needs of sub-populations.

- Enhancing education and training opportunities to increase the supply, diversity, and cultural competence of the health-related workforce. The Act will address the low numbers of health professionals from minority communities through additional scholarship and loan repayment opportunities for disadvantaged students who commit to work in medically underserved areas and who serve as faculty in participating institutions. It also expands the allowable uses of the nurse diversity program.

- Promoting positive health behaviors and collaborative community-based prevention efforts focused on the social determinants of health.

- Developing and expanding the medical home model for Medicare and Medicaid patients through the new Center for Medicare and Medicaid Innovations. Medical homes are associated with a reduction in health care disparities for adults and better access to prevention services.

- Grants to states, public health departments, clinics and hospitals to promote the use of community health workers in medically underserved areas.

- Reauthorization and expansion of programs to support the development, evaluation and dissemination of model curricula for cultural competency at health professions schools and in continuing education programs.
- Funding for a home visiting program to at risk families and young children, based on the Nurse-Family Partnership program. This nurse home visiting program improves the health, well-being and self-sufficiency of low income, minority, first time mothers and their children.

- Funding to establish more community health centers to provide comprehensive, affordable care to low income, racial and ethnic minority communities.

HEALTH REFORM IMPLEMENTATION

Mrs. Roybal-Allard: Health reform will provide greater access to coverage. But the increased coverage rates will also amplify the current primary care shortages. How will the Department work with health departments and providers to assist the newly insured in accessing care?

Secretary Sebelius: The Act includes several provisions to ensure access to health care for all Americans. Specifically, the Act invests in the National Health Service Corps, reauthorizes and improves scholarship and loan repayment programs, increases workforce diversity, develops workforce planning and analysis and incentivizes primary care and practice in underserved areas.

Mrs. Roybal-Allard: How will the Department ensure that as we address the primary care shortages, we are at the same time creating a culturally competent workforce?

Secretary Sebelius: We view having a diverse, culturally competent health professions workforce as integral to ensuring access to health care. We support grant programs that focus on supporting curricula and training that will prepare a workforce. Many of the health professions grant programs – ranging from primary care, nursing, public health and geriatrics – emphasize teaching cultural competence to new providers and as part of continuing education.

Mrs. Roybal-Allard: What initiatives does HHS have to increase the number of nurse practitioners, who are highly qualified primary care providers, in the health care workforce?

Secretary Sebelius: HHS has several programs whose goal is to increase the number of nurse practitioners qualified to provide primary care. These programs include Advanced Nursing Education, Advanced Education Nursing Traineeship and Nurse Faculty Loan Programs.

The Advanced Nursing Education Program provides infrastructure grants to schools of nursing to develop, implement and evaluate educational programs at the master’s, post master’s, and practice doctoral level to prepare primary care nurse practitioners. These grants provide financial support to the schools for faculty, faculty development for purposes of the project, teaching/learning resources, clinical site development for student primary care learning experiences, equipment and supplies, travel, and data collection. They prepare nurses for advanced practice across the life span and have linkages with federally funded community based primary care practice sites such as Federally Qualified Health Centers, Nurse Managed and Rural Health Centers.
The Advanced Education Nursing Traineeship program provides grants to schools for award to students who are enrolled in primary care nurse practitioner programs to cover the costs of tuition, fees, books, and reasonable living expenses. Many of the students who are recipients of the traineeships are preparing to be primary care nurse practitioners.

The Nurse Faculty Loan Program provides grants to schools to establish a discrete revolving loan program that provides loans for students enrolled in masters and doctoral programs. The student is able to qualify for cancellation of 85 percent of the loan in exchange for working as nurse faculty over a four year period. Many of the recipients of these loans are preparing to be faculty for primary care nurse practitioner program, enabling the programs to increase the capacity of trained primary care nurse practitioners.

The Nurse Education Practice and Quality Program provides grants to schools of nursing to establish or expand non-institutional nursing practice arrangements (NPAs), also known as nurse managed health centers (NMHCs). The NMHCs are innovative health care delivery systems that improve access to primary health care in medically underserved areas and provide nursing practice for nurse practitioners and structured clinical experiences undergraduate and graduate nursing students. The NMHCs are considered safety-net providers of care that are owned and operated by schools of nursing and their primary care nurse practitioners.

Mrs. Roybal-Allard: Additionally, will HHS be looking more closely at decreasing the barriers to nurse practitioner practice in Medicare and Medicaid?

Secretary Sebelius: Under current law, Medicare will pay for services furnished by nurse practitioners if the Medicare benefit permits them to bill for such services. Medicare rules require that the services provided must be medically necessary and within the scope of practice in the State in which the nurse practitioner practices. Medicare payment for such services is generally 85 percent of the physician fee schedule rate.

A provision in the Accountable Care Act encourages expanded access to primary care services by providing a 10 percent additional payment for primary care services furnished by certain practitioners for 5 years beginning in 2011. Nurse practitioners would be eligible to receive this bonus if primary care services account for at least 60 percent of their allowed charges. Also, under current law, nurse practitioners may participate in the Medicaid program. Reimbursement to Medicaid providers is administered by the States and reimbursement rates for nurse practitioners vary.

**PANDEMIC INFLUENZA**

Mrs. Roybal-Allard: As we have seen with H1N1, new strains of flu can quickly emerge and spread. It is essential that we are prepared. What is the status of HHS' development of a professional judgment budget for pandemic preparedness, beyond what is in the president's request for FY 2011? When will it be available?

Secretary Sebelius: HHS is in the process of evaluating pandemic influenza needs in light of lessons learned from 2009-H1N1 influenza response. In addition, HHS is conducting a review of the medical countermeasure development process, which includes pandemic influenza. This
review will include recommendations to help ensure the Nation's preparedness for future pandemics and other threats.

Mrs. Roybal-Allard: Has the Department begun to update the National Strategy for Pandemic Influenza or its implementation plan, or do you have plans to do so in the future?

Secretary Sebelius: HHS is currently conducting an After Action Review of the H1N1 pandemic response. Following completion of that review, HHS will update the National Strategy for Pandemic Influenza to reflect successes and lessons learned from H1N1.

Mrs. Roybal-Allard: It is our understanding that the department is preparing an after action report on the H1 N1 response. When will the findings from this report be available to the committee?

Secretary Sebelius: It is anticipated that results from the HHS After Action Review of the H1N1 pandemic response will be available in the fall of 2010.

Mrs. Roybal-Allard: How much supplemental funding remains unexpended? When will the Department update the Committee on its plans for the remainder of the funds?

Secretary Sebelius: As of March 2010, $3.6 billion of the $7.65 billion in FY 2009 supplemental funding remains unobligated. Original plans for this funding assumed that two doses of H1N1 vaccine would be needed in order to provide protection against the virus. Since the H1N1 vaccine is well-matched to the virus and highly immunogenic, less FY 2009 supplemental funding was needed to purchase doses for Americans than originally projected. HHS is in the process of revising plans for this funding in light of lessons learned from 2009-H1N1 influenza response and the medical countermeasure review that is currently underway.

Mrs. Roybal-Allard: As you know, the Department has awarded emergency funding to state and local health departments for pandemic preparedness. When these funds run out, do you have plans to provide ongoing funding for state and local pandemic preparedness activities? Do you believe this funding stream should be combined with the Public Health Emergency Preparedness funding?

Secretary Sebelius: Emergency pandemic influenza funding was provided to 62 grantees, including all 50 states, four cities, and eight territories, for pandemic preparedness and response during the H1N1 pandemic. These grantees are the same as those receiving annual Public Health Emergency Preparedness (PHEP) funding. The FY 2011 President’s Budget includes $715 million for PHEP cooperative agreements to support preparedness in public health departments nationwide, including pandemic preparedness.

Mrs. Roybal-Allard: Does the Department have plans to review and evaluate state pandemic influenza response capacity, in light of the H1 N1 outbreak?

Secretary Sebelius: Yes. Recipients of emergency pandemic influenza funding for pandemic preparedness and response during the H1N1 pandemic are required to submit an H1N1 After Action Report and Improvement Plan (AAR/IP) to CDC by July 31, 2010. The AAR/IPs
will identify important issues from the H1N1 pandemic that States plan to address as part of their own process improvement plans with respect to pandemic preparedness and response activities. In addition, Public Health Emergency Preparedness (PHEP) grantees, are required by the Pandemic and All-Hazards Preparedness Act (PAHPA) to submit a plan for responding to pandemic influenza each year. CDC will develop revised guidance for States to use as they update their plans based on lessons learned from the 2009 H1N1 pandemic.

Mrs. Roybal-Allard: How will the Department replenish supplies from the Strategic National Stockpile that have been used during the H1N1 outbreak?

Secretary Sebelius: The antiviral drugs dispensed from the Strategic National Stockpile (SNS) during the response to H1N1 were replenished in 2009. HHS is currently evaluating the need for acquisition of additional vaccines, personal protective equipment, drugs, devices, and medical equipment following the 2009 H1N1 pandemic.

NEWBORN SCREENING AND PRIMARY IMMUNE DEFICIENCY

Mrs. Roybal-Allard: As you know the Secretary’s Advisory Committee on Heritable Disorders in Children voted in January to recommend to you that a newly-developed test for the most severe forms of primary immune deficiencies be added to the core panel of conditions recommended to be tested by the states. Because this is the first new test recommended since the core panel was created, it generates important questions about implementation.

What plans does the Department have, for this test or for others that maybe approved in the future, to educate the public (particularly new parents) about newborn screening and the critical role it plays in early diagnosis, containing healthcare costs and vastly improving the quality of life for children and their families?

Secretary Sebelius: The Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (Committee) made recommendations to the Secretary on February 25, 2010 to lay the groundwork for an iterative implemental development of infrastructure needed for: 1) ongoing research, 2) evaluation, 3) surveillance, 4) education, and 5) training for screening for Severe Combined Immunodeficiencies (SCID) and related T-cell lymphocyte deficiencies. The Committee’s recommendations are currently under review.

The Health Resources and Services Administration has created a Clearinghouse for Newborn Screening Information (authorized under the Newborn Screening Saves Lives Act 2008) to establish and maintain a central clearinghouse of current educational and family support and services information, materials, resources, research, and data on newborn screening.
RACIAL AND ETHNIC HEALTH DISPARITIES

Ms. Lee: As Chair of the Congressional Black Caucus I have been working with my colleagues to address racial and ethnic health disparities as part of the health reform law. I’d like you to elaborate if you can on what the Department is currently doing and what new initiatives you will be undertaking to address this important issue. How does the FY 11 budget request support the goals of increasing diversity in the health professions through recruitment and training?

Secretary Sebelius: HRSA administers several health workforce programs with a primary focus of increasing the diversity of the health professions workforce. The Centers of Excellence (COE) Program funds grants to recruit, train, and retain underrepresented minority (URM) students and faculty at health professions schools. COEs carry out activities to improve information resources, clinical education, curricula and cultural competence as they relate to minority health issues and facilitate faculty and student research on health issues particularly affecting URM groups. In FY 2011, an estimated 17 grant awards will provide training to approximately 257 faculty and 2,000 students from URM backgrounds.

The Health Careers Opportunity Program (HCOP) funds health professions schools to provide students from disadvantaged backgrounds, including students from URM backgrounds, with the necessary skills to enter into and successfully complete a health professions education. In FY 2011, an estimated 33 awards will afford approximately 2,700 students the opportunity to be exposed to and pursue careers in the health professions.

The Nursing Workforce Diversity program provides support for infrastructure grants aimed at increasing nursing education opportunities for individuals who are from disadvantaged backgrounds (including racial and ethnic minorities underrepresented among registered nurses) by providing scholarships or stipends, pre-entry preparation and retention activities. The program targets minority and disadvantaged students in nursing schools, pre-nursing programs, and students in secondary schools. In FY 2011, the President’s Budget includes approximately 47 grants to support the training of approximately 8,600 minority students/participants.

The Scholarships for Disadvantaged Students program provides grants to eligible entities to provide scholarships to students from disadvantaged backgrounds, many of whom are URM students. This program tackles a major barrier for disadvantaged and minority students’ access to a health professions education because of high tuition costs. In FY 2011 an estimated 18,000 disadvantaged students, including 11,200 URM students will receive scholarship support.

Ms. Lee: How does the FY 11 budget request support the goal of increasing diversity in NIH institutions and researchers?

Secretary Sebelius: Promoting and increasing diversity of the NIH workforce, and particularly of tenured and tenure track scientists in NIH’s intramural research programs, is a priority for the agency. In particular, the NIH is placing special emphasis on recruiting and hiring all under-represented minority scientists in tenure and tenure track positions (Black, Hispanic and American Indian/Alaska Native). NIH has developed a plan to enhance diversity and promote the inclusion of under-represented scientists within these ranks.
Elements of this plan include: a) reaching a diverse pool of applicants by notifying the diversity specialists at Association of American Medical Colleges accredited medical schools, and program directors at NIGMS Minority Opportunities in Research Programs of all tenured and tenure track vacancies and soliciting their assistance in reaching prospective applicants; b) reaching a diverse pool of applicants by conducting targeted outreach to individuals as well as organizations known to have diverse individuals with the requisite skills; c) preparing NCMHD loan repayment recipients to compete for NIH tenured and tenure track positions by providing the Disparities Research Education Advancing our Mission intramural postdoctoral training program; and d) conducting focus groups to learn about any barriers that may inhibit the employment and retention of diverse groups, and developing strategies to remove any identified barriers.

In addition, for the entire NIH workforce, not just the intramural research programs, there is strategy to recruit and retain Hispanic employees. Elements include: a) targeting outreach to the University of Texas, Texas A&M University, the University of New Mexico, and the University of Puerto Rico; b) NIH institutes participating in conferences which target Hispanic audiences; and c) NIH conducting focus groups to learn more about the workforce’s perceptions of the reasons for the limited numbers of Hispanics in the workforce.

Similarly, for all positions at NIH, there is a plan to recruit individuals with targeted disabilities. Elements include: a) the Disability Program Manager providing training sessions on special hiring authorities, reasonable accommodations, and the Americans with Disabilities Act Amendments to educate managers and supervisors; and b) NIH conducting focus groups to learn more about the workforce’s perceptions of the reasons for the limited numbers of individuals with targeted disabilities in the workforce.

Ms. Lee: How does the FY 11 budget request support the goal of ensuring racial and ethnic minorities benefit from new and innovative health research at the NIH?

Secretary Sebelius: Over the years, NIH research has helped to enhance our understanding of the complexity of health disparities. Most of our research efforts have been focused primarily on the biological pathway of health disparities through the study of diseases and conditions that disproportionately affect health disparity populations such as heart disease, diabetes, obesity, stroke, cancer, HIV/AIDS and infant mortality.

We have witnessed growing research interest and attention to minority health and health disparities since the establishment of the National Center on Minority Health and Health Disparities, now the National Institute on Minority Health and Health Disparities, which has been leading NIH efforts to address minority health and health disparities and to coordinate NIH research activities conducted and supported by ICs in these areas.

In recent years, the scientific knowledge base about health disparities has increased, and research findings point to social, economic, behavioral, and access to care factors as some of the significant contributors to health disparities, leading to increased research focus at NIH in these non-biological areas, as well as on poor and rural populations who also experience disparities in health.
NIH is engaging communities in its research activities as equal partners; multidisciplinary and specialized Centers of Excellence on health disparities are being supported around the country; and research capacity building to facilitate the conduct of scientific research, training, and career development is taking place at institutions around the country due to NIH funding. Innovative outreach, information dissemination and research translation activities are being funded in communities nationwide. The NIH Health Disparities Strategic Plan and Budget provides a roadmap for how the NIH will approach the improvement of health and elimination of health disparities among the nation's most vulnerable populations.

Ms. Lee: How does the FY11 budget request provide direct support for the nation's minority medical colleges and institutions?

Secretary Sebelius: The Department of Health and Human Services supports many programs that assist Historically Black Colleges and Universities, Tribal Colleges and Universities, Historically Black Medical Schools, and other institutions. For example, the FY 2011 request for the Office of Minority Health includes support for Central State University, Stone Child College, Tennessee State University, Morehouse College, and other institutions. The Office of Minority Health also provides support in collaboration with the National Institute on Minority Health and Health Disparities, to Charles Drew University of Medicine and Science, Meharry Medical College, and Morehouse School of Medicine.

Ms. Lee: How does the FY11 budget request provide targeted support to help reduce and eliminate these disparities while addressing communities with the greatest need?

Secretary Sebelius: The Office of Minority Health supports a number of programs that focus on communities of greatest need. For example, the Bilingual/Bicultural Demonstration Program, Curbing HIV/AIDS Transmission Among High Risk Minority Youth and Adolescents by Utilizing a Peer-to-Peer Outreach Model and New Application Technologies (CHAT), Youth Empowerment Program (YEP), Partnerships Active in Communities to Achieve Health Equity (PACT), and Linkage to Life Program (L2L) focus on targeted, hard-to-reach, high risk populations.

Ms. Lee: I understand that earlier this year the Office of Minority Health, through its National Partnership for Action to End Health Disparities, has produced a draft "National Plan for Action" on disparities. What resources will HHS be devoting to implementing the plan—particularly in circumstances where OMH/HHS may have little direct control over implementation without additional budgetary incentives?

Secretary Sebelius: We appreciate your interest and support for the National Plan for Action. In the Department's FY10 appropriation, members shared their concerns regarding racial and ethnic disparities in this country and the need for a national strategy that would be developed and implemented with partners to effectively and cohesively address this national problem. The National Plan for Action responds to the Congressional language and advances a coordinated approach. The Department is mindful of the importance of implementing incentives to ensure all sectors address actions that are part of their respective responsibilities and is assessing opportunities as part of the rollout of the National Plan for Action in the near future. The implementation of the National Plan for Action will be accomplished in phases. Funds for initial
implementation phase of the National Plan for Action are included in the FY 2011 request for the Office of Minority Health. These implementation activities will address the following:

- Supporting the information, capacity building, and technical assistance needs of stakeholders within the public and private sectors who are preparing to undertake strategies of the National Plan for Action that correlate with their work.

- Ensuring that Federal programs that address the social determinants of health and that can contribute to achieving health equity are coordinated and incorporate appropriate strategies of the National Plan for Action into their supported activities.

- Completing implementation of Health Equity Boards that will coordinate activities across sectors and organizations.

- Contributing to completion of data collection and reporting requirements mandated by the Patient Protection and Affordable Care Act and that also serves as a key strategy for eliminating health disparities under the National Plan for Action.

NATIONAL AIDS STRATEGY

Ms. Lee: I'm pleased that the Administration is moving forward in developing a truly comprehensive and collaborative National AIDS Strategy to guide our response to this epidemic. I'm worried however that the funding allocated to implementation of the strategy within your department for the coming fiscal year will be inadequate to truly meet the needs that have been identified.

What part of the current budget allocation - including the proposed $70 million increase in new funding at HRSA and CDC - will go towards implementation of the National AIDS Strategy? Do you need a separate increase in funding to address some of the coordination and implementation issues that will inevitably arise in moving forward with the Strategy?

Secretary Sebelius: The final National HIV/AIDS Strategy is still under development and is expected to be completed this summer in time for the FY 2011 Budget. All of the Department's $17.6 billion requested to be devoted to HIV/AIDS in the FY 2011 Budget are expected to play a part in implementing the National AIDS Strategy.

Ms. Lee: Who will ultimately lead implementation of the National AIDS Strategy? Will this continue to be an initiative within the White House - and who within HHS will be the point person for ensuring that Agencies within the Department are following through on their responsibilities?

Secretary Sebelius: The final National HIV/AIDS Strategy is still under development and is expected to be completed this summer. Consequently, decisions about organizational leads both across the Federal government and within the Department have not yet been finalized.
HHS'S ROLE IN THE PRESIDENT’S GLOBAL INITIATIVE

Ms. Lee: In April of 2009, the President announced a 6 year - $63 billion initiative to strengthen and improve the work of US global health programs in developing countries including to better integrate and coordinate US programs, encourage country ownership - including through building health systems and strengthening health capacity - encourage a women's centered approach to health, and to generally improve the effectiveness of these programs.

Although it was only launched last year - the FY11 Budget technically represents the 3rd year of funding for this initiative. Given the inherent expertise of HHS and specifically CDC in building and supporting public health systems - and the clear intent of the Administration in scaling up funding for global health programs it's a little perplexing why the budget includes so little funding for HHS to help carry out the Global Health Initiative. Indeed the Secretary's testimony only notes a $16 million increase for CDC's global health programs.

What exactly is HHS's role in implementing the global health initiative? Why is HHS's budget for global health not increasing commensurate to the role that CDC currently plays in our global health programs? How much funding does HHS/CDC receive each year in transfer authority from the State Department/USAID? Wouldn't these funds be better utilized and spent if they were provided directly to HHS/CDC in the President's budget?

Secretary Sebelius: All of NIH's $3.2 billion HIV/AIDS research portfolio and the $300 million requested in the NIH budget for use by the Global Fund to Fight HIV/AIDS, Tuberculosis, and Malaria, as well as CDC's $118 million Global AIDS Program and its $9 million Global Malaria Program are counted by the Administration as components of the President's $9.6 billion Global Health Initiative (GHI) in FY 2011.

In addition to these resources from its own budget, CDC administers through interagency agreements about $1.4 billion a year of USAID's PEPFAR funds. These funds are used to strengthen the capacity of PEPFAR countries to carry out laboratory, epidemiology, surveillance, and public health evaluation and workforce activities, which are essential components for strong sustainable public health systems. CDC strives to ensure that all of the funds it administers are spent well, regardless of whether the source is direct appropriations or interagency agreements. We are also working with the State Department and USAID to improve the coordination and efficiency of its joint arrangements.

HEALTH WORKFORCE ISSUES AND HEALTH REFORM

Ms. Lee: By all accounts the nation is already facing a huge workforce shortage just to meet the current demand for health services. Whether it's in the number of skilled nurses, physician's assistants, or doctor's we have a clear need for smart, educated, and highly skilled health professionals in this country. The fact is that our current education and clinical training system does not produce enough health professionals to meet the current demand for skilled labor - and as a result our nation is forced to recruit health professionals from abroad to help fill the gap.
At the same time - and because of the current economic downturn I’m hearing reports that graduating health professionals are finding it difficult to get a job even in the midst of a health workforce shortage.

I spoke recently to a dean of one of the nursing schools in my district - at the Samuel Merritt School of Nursing in Oakland - and she indicated that just in the Bay Area alone 40 percent of all new nursing graduates since November 2008 have yet to find a job. Normally every nursing school graduate in the Bay Area would find a job within 6 months. It’s not because their skills aren’t needed, it’s because hospitals and clinics can’t afford to bring on new staff while dealing with massive budget cuts at the local and state level they are instituting hiring freezes. In some cases hospitals are cutting back hours for existing staff due to a drop in demand for health services as people lose their job and their coverage.

What are we doing to ensure that we don’t lose the current crop of graduating nurses and other health professionals to other fields due to the economic downturn? Can we provide any immediate incentives to employers to ensure that they don’t turn away qualified job applicants in the middle of a workforce shortage?

Secretary Sebelius: According to the Department of Labor, the health sector is among the fastest growing sectors in the economy. Pursuing a health professions education in virtually any discipline is likely to provide a stable career with opportunities for advancement in the long run. While regional issues and the current economy may prevent some individuals from finding employment immediately upon graduation, it is expected that more jobs will become available as the economy improves.

In addition, individuals who are willing to relocate can also increase their opportunities for employment. HRSA does not have legislative authority to provide employers with incentives to hire new graduates. Using Recovery Act funding, HHS supported 427 nurses in obtaining loan repayment and scholarship support. Loan Repayment support places nurses into underserved areas and scholarship support also places nurses into underserved areas as well as provides funding so that nurses can complete their education. Recovery Act funding also supported 1,200 nursing students to receive loans so that they could complete their education.

Ms. Lee: It’s both a positive and a negative then that the new health reform law - while broadening access to health insurance for an additional 30 million people - will also require us to educate, train, and recruit a whole new generation of public health professionals to help provide health care to these new patients. Frankly its one of the reasons why I believe that health reform - in addition to improving health outcomes - will also help stimulate our economy and create millions of new jobs in the United States. At the same time I’m worried that we are already far behind in training new health professionals, and we’ve got to play alot of catch up if we are going to truly meet the demand for more skilled labor.

How will the Department’s FY11 budget help address the current health workforce shortage including for doctors and nurses - and what are we doing to put the nation on a path to graduating more health professionals over the next five years to take advantage of the new jobs that will be waiting in 2014 and beyond?
Secretary Sebelius: The FY 2011 President’s Budget provides continued support for programs that address workforce shortages. To expand the nation’s capacity to train more health professionals, the Health Resources and Services Administration (HRSA) takes deliberate steps to address shortages in faculty and clinical training sites, two key limitations on the number of health professionals trained. HRSA’s training programs support the development of faculty in primary care, geriatrics, and nursing, as well as supporting a diverse faculty through the Centers of Excellence Program.

HRSA also funds programs that help health professions students find clinical training experiences in underserved areas. Through the Recovery Act, HRSA will fund approximately $50 million in grants for equipment to directly support training. It is expected that this equipment will not only improve the quality of training, but in many cases expand the capacity of training programs. HRSA also invests in several programs that work to increase interest in health professions and support individuals from disadvantaged backgrounds who hope to pursue health professions education.

Ms. Lee: I’m also concerned that in seeking to meet the demand for new health professionals we will be forced to rely even more on other countries to fill these jobs - including in some cases recruiting foreign trained health professionals from countries who are experiencing their own health worker shortage.

Is the Department taking any steps to help mitigate or reduce the prevalence of “brain drain” in developing countries where we might be recruiting these health professionals from? Is your Department aware of and active in any voluntary efforts to encourage responsible recruitment practices and reduce the impact of our need to import labor to the US?

Secretary Sebelius: In 2003, in response to the Department of Agriculture’s announcement that it would no longer accept applications for J-1 Visa waivers for physicians, the Department of Health and Human Services reversed its long-standing refusal to request waivers for clinical care in underserved areas. In the first year the HHS J-1 Visa Waiver activity processed 43 applications with no restrictions on the type of outpatient facility or Health Professional Shortage Area (HPSA) score. For the last several years, applications have been limited to those J-1 physicians who will work in a HRSA grant-supported health center, a certified rural health clinic, or a 638-Compacted tribal facility in a HPSA with a score of seven or higher. From 2007 through 2009, with these guidelines in place, the HHS J-1 Visa waiver activity has processed roughly 10 waiver applications per year.

MULTIPLE SCLEROSIS AND SUPPORT FOR ADULT DAY PROGRAMS

Ms. Lee: As you may know, multiple sclerosis is a chronic unpredictable disease of the central nervous system. It’s thought to be an auto-immune disorder where the immune system incorrectly attacks healthy nerve fibers of the central nervous system, interfering with transmission of nerve signals throughout the body. It can actually be diagnosed among relatively young people and as a result can lead to chronic unpredictable disability throughout life.

One of the interventions identified by the MS community that could be really helpful to people living with the disease is support for adult day programs. Unfortunately most of these
programs are geared toward an elderly adult population and in some cases may not be the best fit for people living with MS who have different needs.

I’d like to get your thoughts on the possibility of the department collecting some best practice information on ongoing adult day programs that serve a younger disabled population, so we can better standardize and replicate these sorts of services across the country. Can resources we provide the FY11 budget of the Administration on Aging help to do some of this work?

Secretary Sebelius: The Administration on Aging currently has two efforts to provide adult day care programs and other services to younger disabled individuals. The first is the Veterans Directed Home and Community Based Services Program, which is designed to serve veterans of any age who are at risk of admission to a nursing home by providing them the opportunity to self-direct their care and access services to help them remain in the community. The second is the Lifespan Respite Care program, which supports the delivery of planned and emergency respite services while also providing for the recruitment and training of respite workers and caregiver training and empowerment. Our FY 2011 budget request proposes doubling this program from $2.5 million to $5 million. We expect these efforts to generate knowledge regarding best practices related to serving younger adults in adult day care settings.

ADMINISTRATIVE COSTS OF IMPLEMENTING HEALTH REFORM

Ms. Lee: The new health reform law requires the development, implementation and enforcement of a range of new regulations and programs to ensure that our constituents are able to utilize the benefits of health reform - ranging from ensuring that insurance companies can no longer discriminate based on pre-existing conditions, to greatly expanding support for community health centers and workforce training programs, to establishing health insurance exchanges similar to what Members of Congress can access. Clearly HHS will play a huge role in setting up this new system.

To what extent was the FY 2011 Budget prepared with the understanding of the administrative burdens that HHS will likely face in the coming year? Has your department conducting an initial needs assessment to anticipate what the real administrative costs of implementing health reform will be in 2011 - including in terms of how many new full time employees the Department will need to hire? Can you provide the subcommittee with more details on the administrative burdens that we will be expected to help fund over the next year?

Secretary Sebelius: The FY 2011 Budget was developed while the legislation was still being negotiated and the final policies and funding levels included in the bill had not yet been determined, so it does not include the final needs of implementing the health reform legislation. ACA included $1 billion for implementation costs, and HHS is assessing the scope of work required and is determining the most appropriate steps to take as we begin to implement the provisions of the Act. We do not know the full resource needs yet, but we will be closely monitoring agency needs throughout the implementation process. HHS is strongly committed to the successful implementation of health reform. Health reform implementation is one of the highest domestic priorities of the Administration and we will work with you to ensure that we get it right.
Ms. Lee: Do you need any additional resources now to help implement the portions of the law that take effect immediately?

Secretary Sebelius: Since the Affordable Care Act includes $1 billion for a Health Insurance Reform Implementation Fund; HHS is using those resources to implement immediate provisions.

INFERTILITY

Ms. Lee: Secretary Sebelius, last year the Committee requested that the CDC report on the development of a national public health plan for the prevention, detection and management of infertility. I understand that the plan is not completed yet. Can you share with the Committee what the status is of the report?

Secretary Sebelius: CDC is drafting this report, and HHS expects to transmit it to the Committee very soon.

Ms. Lee: In the report language to last year's appropriations bill, the Committee included funding within Safe Motherhood/Infant Health for the development of a national public plan for the prevention, detection and management of infertility. This plan is critical to the efforts of the more than 2 million women who battle this medical condition in the U.S. Can you tell me what the Department's priorities are regarding this infertility plan?

Secretary Sebelius: CDC's report addressed above will include information on the priorities for this plan, such as how to reduce the burden of infertility.

TEEN PREGNANCY PREVENTION PROGRAM

Ms. Lee: The $114.5 million teen pregnancy prevention initiative signed into law in December 2009 and championed by this Committee—marks an important victory for evidence-based policymaking and it could hardly be getting off the ground at a better time. However, unintended teen pregnancy is not the only negative sexual health outcome facing America's young people. One young person every hour is infected with HIV and young people ages 15-25 contract about half of the 19 million sexually transmitted diseases (STDs) annually, even though they make up only one-quarter of the sexually active population. By focusing the funding only on teen pregnancy prevention, and not including the equally important health issues of STDs and HIV, it seems that an opportunity has been missed to provide true, comprehensive sex education that promotes healthy behaviors and relationships for all young people, including lesbian, gay, bisexual, and transgender youth. So many negative health outcomes are inter-related and educators on the ground know that they best serve young people when they address the inter-related health needs of young people.

Is the administration open to making this a comprehensive prevention initiative that addresses the inter-related health needs of adolescents, including unintended pregnancy, STD, and HIV prevention?
Secretary Sebelius: The Department conducted a comprehensive review of the evidence base relating to teen pregnancy prevention and related risk behaviors through a contract with Mathematica Policy Research. This review defined the criteria for the quality of an evaluation study and the strength of evidence for a particular intervention. Based on these criteria, the Department has defined a set of rigorous standards an evaluation must meet in order for a program to be considered effective and therefore eligible for funding as an evidence-based program. As the review of the over 1,000 potentially relevant studies revealed, 28 programs met the evaluation criteria, reflecting a range of program models and target populations. And the results of this review of the evidence-base also support the inter-related health needs of adolescents. Of those 28 programs, 20 had evidence of impacts on sexual activity (for example, sexual initiation, number of partners, or frequency of sexual activity), 9 on contraceptive use, 4 on STIs, and 5 on pregnancy or births.

I have made reducing teen and unintended pregnancies one of my areas for key interagency collaborations at HHS and identified the set of strategies indicated below to reduce teen and unintended pregnancy. As you will note, these strategies include related risk behaviors, which include those contributing to STIs. In working to implement these strategies, HHS will draw upon both the public health and human services expertise in the Department, including the Administration for Children and Families (ACF), the Office of the Assistant Secretary for Planning and Evaluation, the Centers for Disease Control and Prevention, the Health Resources and Services Administration (HRSA), the National Institutes of Health (NIH), the newly created Office of Adolescent Health (OAH) and the Office of Population Affairs (OPA) within the Office of Public Health and Science. The strategies include the following:

- **Invest in Evidence-Based Teen Pregnancy Reduction Strategies** -- HHS will employ a comprehensive, evidence-based approach to reducing teen pregnancy. Under the newly funded Teen Pregnancy Prevention Program, HHS will fund the replication of models that have been rigorously evaluated and shown to be effective at reducing teen pregnancy or other behavioral risk factors as well as research and demonstration projects designed to test innovative strategies to prevent teen pregnancy. By conducting high-quality evaluations of both types of approaches -- those replicating evidence-based models and innovative strategies -- this initiative will expand the evidence base and uncover new ways to address this issue. Additional funding made available under the Affordable Care Act will provide formula grants to states to fund evidence based models and test new strategies as well. ACF, ASPE, CDC, OAH, and OPA will each play a critical role in these efforts.

- **Target Populations at Highest Risk for Teen Pregnancy** -- HHS efforts will focus on demographic groups that have the highest teen pregnancy rates, including Hispanic, African-American, and American Indian youth, and target services to high-risk, vulnerable and culturally under-represented youth populations, including youth in foster care, runaway and homeless youth, youth with HIV/AIDS, youth living in areas with high teen birth rates, delinquent youth, and youth who are disconnected from usual service delivery systems.

- **Increase Access to Clinical Services** -- HHS will ensure access to a broad range of family planning and related preventive health services, including patient education and
counseling; sexually transmitted infection (STI) and human immunodeficiency virus (HIV) prevention education, testing, and referral. Services can be provided through community health centers, Title X family planning clinics, and public programs. HHS-funded health services under the Title X family planning program will encourage family participation in the decision of minors to seek family planning services and provide counseling to minors on ways to resist attempts to coerce them into engaging in sexual activity.

Ms. Lee: In light of the evidence and recognizing that most young people are at risk of both unintended pregnancy and STIs, would the administration support the committee directing the Office of Adolescent Health to prioritize funds to those programs that are more comprehensive in scope in so far as they encourage abstinence and also encourage young people to always use condoms or other contraceptives when they are sexually active?

Secretary Sebelius: I believe it is important for communities to be able to choose evidence-based models that work for their specific needs. Under a contract with HHS, Mathematica Policy Research (MPR) conducted an independent, systematic review of the evidence base. This review defined the criteria for the quality of an evaluation study and the strength of evidence for a particular program or intervention. Based on these criteria, the Department has defined a set of rigorous standards an evaluation must meet in order for a program to be considered effective. As the review of the over 1,000 potentially relevant studies revealed, 28 programs met the evaluation criteria, reflecting a range of program models and target populations. Of those programs, 20 had evidence of impacts on sexual activity (for example, sexual initiation, number of partners, or frequency of sexual activity), 9 on contraceptive use, 4 on STIs, and 5 on pregnancy or births.

Applicants were requested to review the list of evidence-based curriculum and youth development programs which the Department identified as having met these standards. A summary listing of these interventions was published in Appendix A of the FOA. Program models listed in Appendix A are eligible for replication under the teen pregnancy prevention funding announcement issued by OAH on April 2, 2010. Applicants that wish to replicate a program that is not on the list in Appendix A, may apply to do so, but a set of stringent criteria must be met.

Based on the initial receipt of Letters of Intent for the replication grants, we strongly believe that communities have options for choosing models that will work for them. We expect additional communities will combine models or otherwise modify them to meet their needs and apply as demonstration projects under the second funding announcement issued by OAH on April 9, 2010. As demonstration projects are implemented over the coming years, we believe that additional models and approaches will be added to the evidence base, giving communities additional choices to address the specific, unmet needs in their communities.

Ms. Lee: What is your plan for hiring a permanent director of the Office of Adolescent Health and by when do you hope to have a permanent director in place? What are your goals for the Office of Adolescent Health beyond this new prevention initiative and what role do you see sexual health playing in these efforts?
Secretary Sebelius: The Office of Public Health and Science (OPHS) has initiated a competitive process for hiring a permanent director for the Office of Adolescent Health. OPHS anticipates that we will have a permanent director in place before the end of FY 2010.

I have made reducing teen and unintended pregnancies one of my areas for key interagency collaborations at HHS. We expect this to be one of several areas on which the Office of Adolescent Health will focus as it grows to full operational status. The OAH is leading an internal Adolescent Health work group that is currently developing recommendations in several areas. We are also exploring ways to tap the youth of America for their input on OAH, and HHS-wide, adolescent health issues. We expect additional strategies will focus on implementing the Patient Protection and Affordable Care Act, especially enrollment of eligible adolescents in Medicaid and CHIP, preventing and addressing mental disorders and promoting mental wellness among adolescents. OAH will also play a key role in continuing efforts to support pregnant and parenting adolescents through the implementation and administration of the new Pregnancy Assistance Fund and coordination with existing Title XX Adolescent Family Life Care grants, as well as with the Department of Education.

TITLE X- FAMILY PLANNING PROGRAMS

Ms. Lee: Title X family planning providers are often the sole preventive/primary care providers for low-income women and men. In a report released last year by the National Academy of Sciences Institute of Medicine, family planning was described as "one of the most significant public health achievements of the 20th century." The report goes on to say, "The Title X federal family planning program provides these critical services to those who have the most difficulty obtaining them," but it also cites the program's chronic underfunding, which prevents providers from meeting the current demands of operating a comprehensive family planning program. Would you agree that Title X funding should be expanded to meet the current needs of a comprehensive Title X family planning program?

Secretary Sebelius: Yes, I agree that funding for the Title X family planning program should be expanded. Toward this end, the FY 2011 President’s Budget requests an additional $10 million to support family planning services. Title X-funded family planning centers provide services to more than 5 million individuals annually, 70% of whom have family incomes at or below the Federal poverty level (FPL), meaning that services are provided to clients at no charge.

HIV TESTING INITIATIVE

Ms. Lee: Secretary Sebelius, I was pleased to see that CDC is planning on expanding its enhanced HIV testing initiative into additional jurisdictions and targeting additional populations, I think this will do a great deal to help identify those infected and get them into treatment as quickly as possible. Can you explain the planned reduction in funding for HIV testing at a time when CDC seems poised to expand this critical program?

Secretary Sebelius: The FY 2011 Budget requests $64 million for HIV testing, which is approximately $2 million below FY 2010. This reduction is part of a CDC-wide effort to achieve efficiencies in travel and contracting and to maintain the programmatic impact of HIV testing.
NATIONAL PUBLIC HEALTH PLAN ON INFERTILITY

Mr. Honda: Secretary Sebelius, last year the Committee requested that the CDC report on the development of a national public health plan for the prevention, detection and management of infertility. I understand the plan is not completed yet. Can you share with the Committee what the status is of the report?

Secretary Sebelius: CDC is drafting this report, and HHS expects to transmit it to the Committee very soon. In the report language to last year's appropriations bill, the Committee included funding within Safe Motherhood/Infant Health for the development of a national public plan for the prevention, detection and management of infertility. This plan is critical to the efforts of the more than 2 million women who battle this medical condition in the US.

Mr. Honda: Can you tell me what the Department's priorities are regarding this infertility plan?

Secretary Sebelius: CDC is drafting this report, and HHS expects to transmit it to the Committee very soon. The final report will include information on the priorities for this plan, such as how to reduce the burden of infertility.
MARCH 20TH LETTER TO THE MEMBERS OF THE QUALITY CARE COALITION

Ms. McCollum: On March 20, 2010, the Secretary of Health and Human Services sent a letter to the Members of the Quality Care Coalition with a commitment and plan to address the current geographic variation in Medicare reimbursement and advance health care quality and value to bend the cost curve that meets the goals outlined in Section 1157 and 1158 of the Affordable Health Care for America Act (H.R. 3962), which passed on November 7, 2009.

Your commitments to execute studies at the Institute of Medicine to improve geographic adjustment factors and implement the findings, and to make recommendations on changing the payment system to reward value and quality are critically important to bending the cost curve. In addition, I also look forward to working with you as you convene a National Summit on Geographic Variation, Cost, Access, and Value in health care this year. Could you inform the Committee as to the status of the efforts and the timeline outlined in your March 20th letter?

Secretary Sebelius: I am deeply committed to developing and implementing policies that advance health care quality and value, reduce unnecessary utilization, address geographic variation in reimbursement rates, and bend the cost-growth curve. The Department continues to take a number of steps to address these challenges.

In the March 20, 2010 letter, I committed to commissioning two studies on Medicare's geographic payment adjustments for hospitals and physicians and geographic variations in the volume and intensity of Medicare services. I am pleased that Department staff are making progress on contract language to direct the Institute of Medicine’s work. Second, planning has begun to convene a National Summit on Geographic Variation, Cost, Access, and Value in Health Care later this year to further examine these issues and consider ways to adjust our payment systems so they better account for geographic variation, while maintaining access and quality of care in all areas. Finally, once both the studies and the summit are done, I am confident that the results will be considered by both the new Center for Medicare and Medicaid Innovation and the Independent Payment Advisory Board.
MINDFULNESS-BASED STRESS REDUCTION

Mr. Ryan: Mindfulness-based stress reduction (MBSR) is the most commonly used meditation-based intervention in medical settings in the U.S. There is a growing body of scientific literature that has examined the impact of MBSR on pain, brain function, immune function, and on the symptoms and underlying biological mediators of some diseases, such as cardiovascular disease, psoriasis, and cancer. However, the extent to which MBSR might affect health care utilization has never been systematically studied. Even modest reductions in health care utilization could translate into significant dollar savings cumulatively throughout the nation and may have implications for health care policy. The Committee urges AHRQ to support research to determine whether MBSR impacts health care utilization.

Madam Secretary, the above report language was included in the FY2010 Labor-HHS Appropriations Report. What is HHS/AHRQ's plan for following through on the Committee's recommendation?

Secretary Sebelius: AHRQ aims to improve the quality, safety, efficiency, and effectiveness of the delivery of evidence-based preventive services, chronic care management in ambulatory care settings, and inpatient care. The relationship among psychological well-being, physical health, and the impact of stress reduction interventions on health care utilization are within AHRQ's Prevention/Care Management Portfolio's scope and interest. AHRQ would be interested in receiving, reviewing, and potentially funding grant applications for research projects that focus on the impact of mindfulness-basses stress reduction on health care utilization. AHRQ would also consider funding conferences that address this important topic.

ELECTRONIC HEALTH RECORDS (EHR)

Mr. Ryan: A significant amount of private and federal dollars has been spent over the years to address the need to establish nationwide electronic health records. According to the Office of the National Coordinator for Health Information Technology the reason behind the Health Information Technology movement is:

"To improve health care quality, prevent medical errors, increase the efficiency of care provision and reduce unnecessary health care costs, increase administrative efficiencies, decrease paperwork, expand access to affordable care, and improve population health."

To realize the full potential of the billions of dollars we have already spent on establishing EHRs, we need to make health information accessible and easy to review in a secured fashion to allow physicians and researchers to study the comparative effectiveness of treatments not just in their own health systems, but in patient settings throughout the nation. In mid-March I met with a company in Northeast Ohio, Explorys, which is creating a unique grid of medical data gleaned from millions of EHRs from the leading hospital systems across the country. This unique data grid will serve as a clearinghouse for anonymous health data across patient populations, with Defense-grade privacy protections in accordance with the HIPPA law, allowing researchers to conduct real-time comparative effectiveness analyses with a Google-like search engine and build cohorts to improve treatment outcomes while saving millions of dollars. This seems to me to be the vital next step in our HIT efforts.
With that in mind: What programs or projects are being funded in this current budget request to enable this kind of nationwide comparative effectiveness research and to expand the secondary use of health data from the EHRs we have implemented? Also, do any of these efforts involve public-private collaborations to accelerate this kind of system, taking all our work with HIT and EHRs to the next level and improving the quality of health care?

Secretary Sebelius: We agree that electronic health records (EHRs) hold great potential for facilitating the study of the effectiveness of different medical treatments. In FY 2010, HHS plans to spend $25 million appropriated under the Recovery Act to fund EHR-driven distributed research networks that link clinical and administrative data to allow for the investigation of the effectiveness of different medications, treatments, and strategies to improve health outcomes. The ability to analyze clinical data from EHR systems will allow research to occur on large numbers of patients in a variety of different health care settings and will increase the likelihood of being able to answer critical questions about the treatments for rarer conditions and for patients not currently included in clinical studies. This will certainly involve public-private partnerships and will lead to innovation in both the public and private sectors on the use and protection of clinical data from EHR systems.

In addition, the FY 2011 Budget includes $286 million within AHRQ to build on Recovery Act investments in comparative effectiveness research. Research funded in FY 2011 will include identification of new and emerging issues; evidence synthesis, gap identification, and generation; translation and dissemination of findings, training and career development; and stakeholder engagement. The Department, in close coordination with the individual operating divisions and the ONC, are making and proposing further investments in the HIT infrastructure needed to make our health care system a "learning health care system."

ACCOUNTABLE CARE ORGANIZATIONS

Mr. Ryan: With healthcare reform now law, the Obama Administration committed to create Accountable Care Organizations across the country to make healthcare providers more accountable and efficient through value-based purchasing, and improve quality and patient safety, including reducing preventable readmissions. Given that 80 percent of children with chronic illness become adults with chronic illness, it would benefit us not just to focus on improving adult care but also pediatric care.

Since pediatric care deals with Medicaid, and since Medicaid is administered by the states, we already have some accountable care models in place for Medicaid. The National Association for Children's Hospitals said that one of the best models in America is located in your (and my) home state of Ohio. Nationwide Children's Hospital has a partnership with the state in which they are paid a capitated model right now to manage a Medicaid population of 280,000 children, which is by far the largest in America. The Hospital has high immunization rates, a fully integrated IT system with telemedicine, and has done groundbreaking work on both childhood obesity and prematurity. When are you looking to launch the pilot programs to formally create pediatric Accountable Care Organizations?
Secretary Sebelius: Section 2706 of the Patient Protection and Affordable Care Act of 2010 establishes a pediatric accountable care organization (ACO) demonstration in the Medicaid and CHIP programs. Under this section, the demonstration is set to start on January 1, 2012; however, Congress has not yet appropriated the funds needed to begin implementation.

Mr. Ryan: How do hospitals apply to become an Accountable Care Organization?

Secretary Sebelius: Once funds are appropriated the Secretary will provide guidance and will solicit states for participation in the Medicaid and CHIP demonstration. Under the Affordable Care Act, a pediatric hospital that would like to apply to become an Accountable Care Organization (ACO) under the Medicaid and CHIP pediatric ACO demonstration may apply directly to the state. Medicaid and CHIP pediatric medical providers are recognized as an ACO for purposes of receiving incentive payments in the same manner an ACO would be recognized and eligible to receive payment as an ACO under Medicare (see section 3022 of the Affordable Care Act). Under section 2706 of the Affordable Care Act, in consultation with the Department, the state must establish an annual minimal level of savings under Medicaid and CHIP that an ACO must meet in order to be eligible for an incentive payment. Further, the State must be participating in the demonstration under an agreement with the Department and an ACO must enter into an agreement with the State for a period of not less than 3 years.

LIHEAP

Mr. Ryan: I'm concerned about the agency's request for the LIHEAP program. While I believe the Administration deserves credit for what is, historically speaking, a high request for LIHEAP, $3.3 billion is significantly below the enacted levels for the past two fiscal years. I believe it equates to about a 45 percent cut to the block grant Ohio receives to implement the program. And it goes without saying that LIHEAP is a critical, life-saving safety net for my low-income constituents in northeastern Ohio. Such a dramatic decrease is concerning to me, especially now, with unemployment at a high level.

As I mentioned, the Administration's should be applauded for submitting a budget proposal for LIHEAP that is high by historic standards. But it is far below the level of funding that Congress has appropriated for the past two years; and in my view, far below the demonstrated need on the ground in Ohio and elsewhere.

Secretary Sebelius: The Administration proposes a mandatory funding trigger for LIHEAP which will automatically provide additional funding in response to increased need. Under current economic predictions, the trigger proposal would provide $2 billion in mandatory funds in FY 2011. Adding the $3.3 billion discretionary funding request, a total of $5.3 billion is requested for LIHEAP in FY 2011, an increase of $200 million over the amount provided for FY 2010.

NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY (NIOSH)

Mr. Ryan: The NIOSH mining program has developed many solutions to mining safety and health problems; and one of the critical areas of their work addresses the prevention of dust
and gas explosions in mines. However, this work was seriously interrupted two years with the loss of the Lake Lynn Experimental Mine 50 miles southeast of Pittsburgh, PA, which I understand is still unresolved. Two years ago, there was a roof failure at that experimental mine and subsequently, NIOSH, has been trying to get the approval of CDC to rehabilitate the facility so that they can continue to conduct tests. CDC has not given NIOSH the authority or the funds to rehabilitate the facility.

Is the Department of Health and Human Services prepared to do whatever it takes to support critical mining safety research at NIOSH including making a commitment to restore NIOSH’s ability to conduct explosion testing in the next 9-12 months?

Secretary Sebelius: Yes, the Department of Health and Human Services recognizes that this critical capability must be restored as quickly as possible to allow continuation of critical research in explosion prevention. CDC is currently implementing an acquisition plan to obtain a long-term lease or purchase agreement, the first step before CDC can restore the Experimental Mine. Reconstruction of an entrance to the mine will be required before underground research can continue. At this time, CDC does not have the authority to make improvements to the mine under the current lease agreement.

TITLE X FAMILY PLANNING:

Mr. Ryan: A 2009 Guttmacher article noted that in after Massachusetts reformed its health care system, “access problems presenting themselves in the state indicate that even after health care reform, [community-based family planning centers] will continue to be needed as a critical source of high quality, low-cost primary and preventive reproductive health care. At the same time, the Massachusetts example suggests that national health care reform opens the possibility for family planning providers to formalize and be compensated for another vital but under-recognized function they have long played—acting as an entry point to care for clients who may have had little or no other interaction with the health care system.”

Do you agree that as we move towards implementation of health care reform and the coverage of approximately 30 million more people, it is important to provide increased resources to support the public health safety net, including the Title X program that provides quality care for millions of low income and underserved people?

Secretary Sebelius: I agree that we need to continue to support the public health safety net, including the Title X family planning program. As one example of such support, in an area that you have expressed interest in, the FY 2011 President’s Budget requests an additional $10 million to support family planning services.

Mr. Ryan: Title X family planning providers are often the sole preventive/primary care providers for low-income women and men. In a report released last year by the National Academy of Sciences Institute of Medicine, family planning was described as "one of the most significant public health achievements of the 20th century. The report goes on to say, "The Title X federal family planning program provides these critical services to those who have the most difficulty obtaining them," but it also cites the program's chronic underfunding, which prevents
providers from meeting the current demands of operating a comprehensive family planning program. Would you agree that Title X funding should be expanded to meet the current needs of a comprehensive Title X family planning program?

Secretary Sebelius: Currently, Title X-funded family planning centers provide services to more than 5 million individuals annually, 70% of whom have family incomes at or below 100% of the Federal poverty level (FPL), meaning that services are provided to clients at no charge. Title X providers are required to maximize resources available to provide family planning services through billing third parties that are authorized or legally obligated to pay for services. However, providers are stressed with the high number of clients for whom there is no third party reimbursement source. The Title X Program has an important role to play in preventing teen and unintended pregnancy, since clients are predominately young. According to the 2008 Family Planning Annual Report, prepared by RTI International for HHS’ Office of Family Planning, 24 percent of Title X clients were under age 20 and 51 percent were between the ages of 20 and 29.

An expansion in Title X funding will enable the Title X Program to serve additional clients in need of services, and will expand the availability of a broad range of contraceptive methods, as well as enable a more comprehensive set of services, including but not limited to: pre-conception and inter-conception care, HIV and STI/STD testing, cervical and breast cancer screening, and counseling and education on a number of preventive health measures, including nutrition and obesity prevention, smoking cessation, and prevention of intimate partner violence.

VECTER-BORNE DISEASES

Mr. Ryan: Secretary Sebelius, your budget proposes elimination of funding for vector-borne diseases, which includes all federal funding for West Nile Virus surveillance. The Ohio Department of Health tells me they rely on these funds—a little more than $250,000 annually—to monitor viruses carried by mosquitoes, as well as to provide supplies to local health departments, lab tests, and education and awareness efforts. Do you believe it’s wise to cut these funds when new viruses are emerging around the world, like Chikungunya virus, Japanese encephalitis and Rift Valley fever?

Secretary Sebelius: Although the FY 2011 budget request does not include specific funding for vector-borne activities, including West Nile Virus (WNV) surveillance, the budget request includes $155.2 million for the emerging infectious disease budget line, which is an increase of $18.9 million above FY 2010. These emerging infectious disease funds can support vector-borne activities in FY 2011, including WNV, if determined a priority by States and the CDC. Moreover, several years of CDC funds have allowed States to develop and enhance their WNV activities.

FEDERAL MEDICAL ASSISTANCE PERCENTAGES (FMAP):

Mr. Ryan: Madam Secretary, as you know, the House has twice acted on the Administration’s request to extend the ARRA Enhanced FMAP (EFMAP) by 6 months. According to many economists and independent experts, if EFMAP is not quickly extended, the result will be added uncertainty in the economy, weaker consumer confidence, further job loss, and ultimately a slower economic recovery.
Although my home state is in the middle of a two-year balanced budget, twenty-two states, whose legislative sessions will conclude at the end of April, are proposing deeper cuts and higher tax cuts than would be necessary if EFMAP were extended. First, if EFMAP is not quickly extended, what do you believe will be the impact on the economy and the national unemployment rate?

Secretary Sebelius: Given the continuing fiscal pressures States are facing, the Administration believes it is important to provide States with additional relief as the economy moves to recovery, and in keeping with our FY 2011 budget request, we hope Congress will include this necessary help for States in legislation this year. Because of this financial crisis, many States are eliminating jobs and contemplating severe cuts to critical services that struggling families rely upon. We believe this six-month extension of the increased EFMAP will ease burdens on States trying to recover and rebuild with fewer resources, provide economic stabilization for the States, and strengthen a critical safety net for children and families.

Mr. Ryan: Second, what will the impact be on state Medicaid programs and health care providers if EFMAP is allowed to expire?

Secretary Sebelius: The increased EFMAP has been critical in protecting Medicaid beneficiaries and providing additional fiscal relief to States. Medicaid is, by definition, a countercyclical program -- more people become eligible for Medicaid during a recession but the same economic conditions that give rise to more need also result in lower State tax revenues to finance the program. Although the economy is beginning to improve, States are continuing to experience significant budget problems.

We know this additional funding has helped protect existing coverage for millions of children, parents, and pregnant women and are concerned about the impact on vulnerable populations if the increased EFMAP expires in December 2010.
COMPARATIVE EFFECTIVENESS RESEARCH

Mr. Tiahrt: I have repeatedly expressed concerns with the comparative effectiveness research that was included in the so-called stimulus bill last year. After reading the Department's generic implementation plan that was submitted last year, nothing has changed my mind. My specific concern is that funding can be used to conduct research that will be used to justify rationing care. In my view, the only reason to do this research is to deny coverage of a procedure, a medical device or a drug because some bureaucrat out there thinks there's a cheaper alternative. Clinical comparative effectiveness research that will inform patients and doctors what procedures or treatments work best for them is important information to have and we should do it. But we need look no further than Canada, Great Britain or Australia to see how cost decisions have had a negative impact on availability of quality health care.

In Britain, the agency that determines what procedures and treatments will be financed by the National Health Service has tried repeatedly to stop breast cancer patients from receiving a powerful drug called Herceptin; it has tried to deny a drug to Alzheimer's patients; and it stopped MS patients from receiving medicine called Beta Interferon because it was too expensive. A recent study of Australia's cost-effectiveness policy found that if that same policy were implemented in the US, "millions of patients nationwide would face significant new barriers to obtaining medicines that they currently receive to treat serious and life-threatening diseases." The reality is that we all have different physiologies - a drug that works well for one person may not work well for another. This is the basis for the notion of personalized medicine, where doctors can take into account each patient's unique physiology to tailor treatments that will work best for them. Quite frankly, the only way I see cost-effectiveness research coming out in the end is socialized medicine, not personalized medicine.

How much of the $400 million in comparative effectiveness research that was provided to the Office of the Secretary in the American Recovery and Reinvestment Act is being used to support research that focuses on cost-effectiveness? Please provide a list of all grantees conducting cost-effectiveness research and the amount of the award. Are there plans to use a portion of those unspent funds to support cost-effectiveness research? The stimulus bill contains non-binding language that says these funds are not intended to be used as the basis of coverage decisions. If HHS decides to follow that language, what is the expected end use of cost-effectiveness research?

Secretary Sebelius: The American Recovery and Reinvestment Act (ARRA) Office of the Secretary comparative effectiveness research (CER) funds required two reports to Congress: one from the Federal Coordinating Council for Comparative Effectiveness Research (FCC-CER) and one from the Institute of Medicine. In keeping with the recommendations made by these groups in their reports, the funds are targeted toward building an infrastructure to conduct CER and to specifically enhance the research infrastructure to address the needs of priority and under-studied populations, including racial and ethnic minorities, children and the elderly, rural and inner city populations, and patients who have multiple chronic conditions and/or have suffered disproportionately from a particular condition. Additionally, it is anticipated that the infrastructure investments will assist in understanding the individual needs of patients and their caregivers. The emphasis of these investments is on the effectiveness and comparative effectiveness of clinical and health strategies with an overarching goal to learn what works best in
what patients and in what settings of care. None of the $400 million in OS CER ARRA funds is targeted to cost-effectiveness research.

LIHEAP

Mr. Tiahrt: Under the existing LIHEAP authorizing statute families are eligible for federal assistance if their income is at or below 60 percent of state median income (SMI). However, a couple of years ago this committee included a provision that permits states to provide LIHEAP benefits to families who earn as much as 75 percent of SMI.

Some have argued that all the provision did was provide states with additional flexibility for administering these funds. While that may not seem like a big deal, it causes me serious concern - specifically because what the provision does is water down assistance to the poorest of the poor in favor of providing federal subsidies to middle and upper middle class Americans who do not need the help.

For example, according to data provided by ACF, the State of California served less than 5 percent of its eligible population under the 60 percent formula. Yet, the Congress continues to grant states with the authority to increase their eligibility requirements to 75 percent of SMI despite the fact that some states are barely serving the eligible population at the 60 percent threshold. In some states, 75 percent of SMI would exceed $93,000 per year under that formula.

Please provide a list all states that have expanded LIHEAP benefits to greater than 60 percent of SMI, including the new cap those states have adopted and the maximum income level that would qualify a family for benefits in those states.

Secretary Sebelius: At this time, we know of only two States (Maine and Delaware) that have plans to use the new cap of 75 percent of State median income in their programs for FY 2010. The maximum income level would vary by household size. Using a household size of 4, the maximum income level would be $50,211 for Maine and $59,782 for Delaware. We will have actual data once States complete the LIHEAP Grantee Survey later this year.

Mr. Tiahrt: Has HHS conducted an analysis of the impact that increasing eligibility to 75 percent of SMI has had on truly low-income families?

Secretary Sebelius: ACF has not conducted this type of analysis. To date, we know of only two States that have chosen to increase eligibility. More complete data will be available later this year.

Mr. Tiahrt: I was alarmed to learn that LIHEAP has an improper payment rate around nine percent, and that LIHEAP payments were provided to 11,000 people who are deceased. Please outline the steps the Department is taking to correct this situation.

Secretary Sebelius: HHS has no tolerance for fraud or improper payments in the programs we administer. We have undertaken a number of initiatives to ensure program integrity across the board. The improper payment rate quoted is incorrect. We would note that GAO found that nine percent of the cases they reviewed contained invalid or incomplete information to confirm
applicant identity. A third of those cases lacked SSNs, which is not surprising since our previous guidance to States was that they could not request them.

To address these kinds of concerns, as a first step, are taking a number of actions to correct this situation. We are issuing guidance strongly encouraging States (who administer this program) to require LIHEAP applicants to provide Social Security Numbers for all members of their households as a condition for receiving benefits. States will be able to use this information to confirm the identity of all household members, confirm income reported for the household, and check that all of the household members listed in the application reside in the household. We also are requiring States to describe their systems for ensuring LIHEAP program integrity and will be working with States to improve these systems.

RECOVERY ACT JOBS SAVED AND CREATED

Mr. Tiahrt: We've heard a lot about "jobs saved," which pre-supposes a host of things that ought not to be taken as a given. For example, on December 15, 2009 the vice president sent a memo related to clean energy that says "a project that employs one person for two years would count as creating two jobs." Has HHS employed this methodology in its calculation of jobs created or saved?

Secretary Sebelius: The Department of Health and Human Services follows OMB's Dec 18, 2010 guidance [http://www.whitehouse.gov/omb/recovery_default.cfm] in calculating the number of jobs created or saved through Recovery Act funds. Accordingly, the number of jobs saved or created is reported specific to the quarterly reporting period and is not cumulative. Per OMB guidance, HHS recipients calculate job estimate totals by dividing the hours worked in the reporting period by the hours in a full-time schedule in that quarter. The Dec 18 guidance also "defines jobs created or retained as those funded in the quarter by the Recovery Act." The "full-time equivalents" (FTE) are adjusted to count only the portion corresponding to the share of the job funded by Recovery Act dollars. Also following OMB guidance, the number of jobs created and the number of jobs saved are reported as one number: the number of jobs created or saved.

Mr. Tiahrt: Please provide, as of April 21, 2010 the amount of the nearly $22 billion of discretionary funds provided to HHS by the American Recovery and Reinvestment Act that has been spent (outlayed) to stimulate the economy.

Secretary Sebelius: The HHS Financial and Activity Report for the week ending April 16, 2010, is the most recent data that would have been available as of April 21, 2010. As of April 16, HHS has outlaid $3.8 billion and obligated $15.6 billion of the $22.3 billion in discretionary Recovery Act funds available through FY 2010. Taking into account mandatory spending programs as well, HHS has outlaid in total $59.8 billion, or 59 percent of the available funds, and obligated $85.2 billion, or 84 percent of the available funds.

Mr. Tiahrt: How many jobs were "saved" as a result of that spending?

Secretary Sebelius: Recipients do not report jobs saved or created separately, but as one number, per OMB guidance. As of the May 3 HHS analyses of the April 2010 recipient reports, HHS recipients reported creating or retaining 44,265 jobs with Recovery Act funds. Recipients
reported creating or retaining 31,247 jobs in January and 20,000 jobs in October. These numbers are only for the stated reporting periods and are not cumulative (see Dec. 18, 2009, OMB guidance).

Mr. Tiahrt: In February the administration developed a new method of counting the number of jobs created or saved as a result of the "stimulus" bill, which is to count as a job saved any job that was in any way supported by "stimulus" funding - regardless of whether or not the job was in jeopardy. There have been news reports that indicate some Head Start centers gave raises to existing employees whose jobs were not in jeopardy and called those jobs saved. Are those numbers reflected in the Department's estimates of jobs "saved?"

Secretary Sebelius: OMB explained in its Dec. 18, 2009, guidance that it changed the way recipients should calculate saved or retained jobs so that they would "no longer be required to make a subjective judgment on whether jobs were created or retained as a result of the Recovery Act." Instead, recipients will more easily and objectively report on jobs funded with Recovery Act dollars. This update aligns with GAO's recommendation to "[make] more explicit that 'jobs created or retained' are to be reported as hours worked and paid for with Recovery Act funds.'"

In addition, OMB stated that COLA payments or retention bonuses are to be excluded from the calculation of jobs created or saved. Head Start recipients were instructed to exclude them from their jobs calculations. For additional information, see http://www.whitehouse.gov/omb/recovery_faq/

Mr. Tiahrt: Please provide a list of the number of jobs created and the number of jobs saved, by program, as a direct result of spending in the American Recovery and Reinvestment Act.

Secretary Sebelius: According to a preliminary analysis of the April Recovery Act recipient reports, recipients reported the following number of jobs funded by the recovery Act for the second quarter of FY 2010 by HHS Operating Division:

<table>
<thead>
<tr>
<th>Operating Division</th>
<th>Number of Jobs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administration for Children &amp; Families</td>
<td>17,794</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>17,224</td>
</tr>
<tr>
<td>Health Resources and Services Admin.</td>
<td>7,511</td>
</tr>
<tr>
<td>Centers for Disease Control &amp; Prevention</td>
<td>534</td>
</tr>
<tr>
<td>Administration on Aging</td>
<td>515</td>
</tr>
<tr>
<td>Indian Health Service</td>
<td>448</td>
</tr>
<tr>
<td>Program Support Center</td>
<td>87</td>
</tr>
<tr>
<td>Office of the National Coordinator for Health Information Technology</td>
<td>83</td>
</tr>
<tr>
<td>Centers for Medicare &amp; Medicaid Services</td>
<td>36</td>
</tr>
<tr>
<td>Agency for Healthcare Research and Quality</td>
<td>33</td>
</tr>
<tr>
<td><strong>Total Number of Jobs by OPDIV</strong></td>
<td><strong>44,265</strong></td>
</tr>
</tbody>
</table>
MEDICARE ADVANTAGE

Mr. Tiahrt: In order to finance the health reform bill Medicare Advantage is being cut by more than $130 billion. My understanding is that many seniors - about 11 million of them - choose Medicare Advantage plans because they offer more extensive coverage than the Medicare fee-for-service program. My concern goes to the oft-repeated promise that if people like the insurance plan they have now, they can keep it. But the reality is that cuts to Medicare Advantage are going to force one of two things - either a reduction in available services, the very services that caused seniors to choose Medicare Advantage in the first place, or higher premiums for people with fixed incomes.

What can seniors who chose Medicare Advantage over Medicare expect as a result of this cut? Has the administration given any consideration to the fact that more than 20 percent of seniors choose to participate in Medicare Advantage - and seem to be largely satisfied with their plans?

Secretary Sebelius: Medicare Advantage (MA) is the part of the Medicare program that allows beneficiaries to receive services via private insurance plans. Historically, private plans that participated in MA received significant taxpayer subsidies from the federal government, receiving payments on average 14 percent more than traditional Medicare.

The Administration recognizes that many MA beneficiaries are satisfied with their current coverage and will not implement any changes that result in a reduction in quality of care that these beneficiaries receive. However, the Administration is also required to implement the changes to the law that Congress passed in the Affordable Care Act. The Administration’s proposed strategy of a phased-in implementation of the modified MA benchmarks will soften the impact for beneficiaries residing in areas where the payment reductions would result in a significant reduction of extra benefits over a short period of time.

The Administration is also looking at the benefits that will accrue to MA plans under the Affordable Care Act. These benefits include additional incentive payments to high quality plans operating in areas where fee-for-service costs are low and increased beneficiary rebate percentages that reward enrollees who select high-quality and high-efficiency plans. Additionally, the Affordable Care Act includes new beneficiary protections that will improve access to important services for all Medicare beneficiaries such as chemotherapy administrative services, renal dialysis, and skilled nursing care.

BIODEFENSE RESEARCH

Mr. Tiahrt: Last year Congress transferred $304 million from the BioShield Special Reserve Fund (SRF) to the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. Does NIAID intend to issue a Request for Applications to ensure that the SRF funding that was transferred will be used for research related to biodefense, the purpose for which Congress originally provided the funding?

Secretary Sebelius: In the Consolidated Appropriations Act of 2010 (P.L. 111-117), $304 million was transferred from the Project BioShield Special Reserve Fund (SRF) to the
NIH, the lead Institute of NIH for biodefense research, as an offset for other new budget
authority. The total combined appropriation for NIH in FY 2010 is over $4.8 billion, of which
NIH estimates it will spend nearly $1.7 billion, including the transferred funds, for research on
biodefense and other emerging infectious diseases. One of the new activities to be supported in
FY 2010 will be projects solicited under a Broad Agency Announcement (BAA) entitled,
“Development of Technologies to Facilitate the Use of, and Response to, Biodefense Vaccines.”
Other new activities to be supported in FY 2010 include research and development of broad
spectrum antibiotics and filovirus vaccines.

MEDICALLY UNDERSERVED AREAS (MUA)

Mr. Tiahrt: As a representative of Kansas, I am very concerned that a significant number
of the Medically Underserved Areas (MUA) in the states which comprise the Midwest Census
Region continues to lack necessary access to community or migrant health center services. A
2008 GAO report found that sixty percent of the Medically Underserved Areas in the Midwest
Census Region states are without a federally supported health center site. These states had the
highest percentage of MUA's without a health center site in the United States according to the
GAO report. The underserved areas within the states of Ohio, Minnesota, Wisconsin, Kansas,
Indiana, Missouri, North Dakota, Michigan, Nebraska, South Dakota, Illinois, and Iowa need new
and expanded access points to health services.

Secretary Sebelius: The President's Budget includes additional funding to support the
development of approximately 25 new access points, increasing access to comprehensive primary
health care services to an estimated 150,000 additional health center patients living in medically
underserved areas.

Mr. Tiahrt: As the former governor of Kansas, Madame Secretary, you understand the
unique needs of the Midwest MUA's. What is the Department doing to make sure the needs of
medically underserved are met?

Secretary Sebelius: We are working to ensure that all of our health center grantees are
identifying and addressing the existing primary health care needs in their service areas and
throughout their target populations. Additionally, we are analyzing our methods of awarding new
grant funding so that our competitive processes are equitable across all regions of the nation,
including the Midwest region.

Mr. Tiahrt: Have you directed HRSA to identify new access point, service expansion,
health center capital and expanded medical capacity proposals from these states?

Secretary Sebelius: HRSA is working to ensure that all opportunities for competitive
grant funding equitably consider and address the needs of the medically underserved populations
of the nation, including those in the Midwest states.

QUESTIONS FROM TOWN HALL MEETINGS

Mr. Tiahrt: Over the past year, I have held several town halls across the State of Kansas,and met with hundreds of providers. I have heard many concerns about the health care reform
legislation, but the greatest is the frustration that Kansans have with the administration’s refusal to listen to them or even to answer their questions. Therefore, Madame Secretary, I ask that you answer these questions our fellow Kansans asked me to ask you:

"Why in the world would President Obama not post the healthcare changes and laws online?" - Shirley Ann (who would like to see a comprehensive list of all the changes in plain English).

Secretary Sebelius: The law, as well as documents describing the provisions of the bill and their effects, is available online at www.healthreform.gov.

Mr. Tiahrt: "How will we stop insurance premiums from being higher based on your credit report?" – Denice

Secretary Sebelius: In 2014, the Affordable Care Act will prohibit insurance companies from denying any individual coverage because of a pre-existing condition, excluding coverage of that condition, or charging more because of health status or gender. Individuals purchasing coverage through State exchanges can only have their premiums vary by a certain set of factors such as age and family size, not credit scores.

Mr. Tiahrt: "When can we expect a tort and litigation cap as part of the reform?" – Gary

Secretary Sebelius: The bill establishes a demonstration grant program for states to develop, implement, and evaluate alternatives to current tort litigation that 1) allow for the resolution of disputes over injuries allegedly caused by health care providers or health care organizations; and 2) promote a reduction of health care errors.

There is no need to federally override what is already working for states. The bill takes a better approach by giving states the resources they need to test out their reforms, measure the results, and build on what works. In fact, some of the biggest proponents of one of the more aggressive tort reform ideas – health courts – have called for grants to states as a first step.

Mr. Tiahrt: "What is the plan for healthcare for rural areas? Does reform address this disparity?" – Sandra

Secretary Sebelius: The legislation helps ensure access to quality, affordable health care in rural areas. The legislation creates state-based health insurance Exchanges to provide the same private insurance choices that the President and members of Congress will have. In addition, each exchange will include at least two multi-state plans to foster competition and increase consumer choice. Seed money is included to create non-profit health plans, like co-ops, to increase choice. The legislation provides for the development of standardized, easy-to-compare information through the Exchanges on different health insurance plans offered in their geographic area so that they can easily compare prices and health plans and decide which quality affordable option is right for them and their families. This will particularly benefit the one-third of farmers who purchase health insurance directly from an insurance company – more than three times the national average.
The new law invests in the health care workforce to ensure that people in rural areas have access to doctors, nurses, and high quality health care. Beginning next year, the Act will provide funding for the National Health Service Corps for scholarships and loan repayment for primary care practitioners, including doctors and nurses, who work in areas with a shortage of health professionals. The legislation provides more resources to medical schools to train physicians to work in rural and underserved areas, and establishes a loan repayment program for pediatric specialists who agree to practice in medically underserved areas such as a rural regions. These provisions will help rural Americans who do not have access to primary care.

Finally, the legislation ensures that hospitals and other providers in rural and remote communities receive the reimbursement they need to offer quality care to patients and keep their doors open.

Mr. Tiahrt: "If Sec. Sebelius is going to eliminate $90 billion from pharmaceutical companies, how can she expect people to keep their jobs and the companies to stay solvent?" – Mike

Secretary Sebelius: Health insurance reform will create jobs, vastly improve labor markets and the efficiency of American businesses, and encourage entrepreneurship and small business creation.

The delivery system reforms and revenue provisions in the bill provide incentives and create new measures to contain health care spending, allowing employers to hire more workers rather than spending money on rising health insurance premiums. The President’s Council of Economic Advisers (CEA) estimated that by simply slowing the growth of health care costs by 1.0 percent per year, the number of jobs could rise by more than 300,000 by lowering the unemployment rate that is consistent with steady inflation. By slowing the growth of health care costs, health reform will improve our economic security as individuals and our competitiveness as a nation. For pharmaceutical companies specifically, this is a minimal contribution when considering the increased customer base they will experience as 32 million more individuals become insured.
ANTHRAX VACCINE STOCKPILE NEEDS AND ACQUISITION CONTRACT PLANS

Mr. Rehberg: Madame Secretary, it is my understanding that the Department has a requirement and need to contract for additional doses of the FDA licensed anthrax vaccine because the number of the doses in the Strategic National Stockpile currently are well below the total needed to meet the Department's 75 million anthrax vaccine dose requirement and the shelf-life dates for using the earlier stockpiled anthrax vaccine doses have expired and others will continue to expire.

It is also my understanding that with the termination of an earlier contract and delays in the development of new experimental anthrax vaccines, HHS now estimates that it will take at least 8 years before potential development and FDA licensure of new anthrax vaccines.

Given many government and other experts are saying that the number one WMD threat is anthrax and there is a continuing need for protecting 151 responders and citizens from another potential anthrax attack with both vaccines and drugs, what are your plans and timing for contracting for additional doses of the current FDA licensed vaccine to replenish the stockpile and move toward meeting the 75 million dose stockpile requirement?

Secretary Sebelius: CDC is committed to support the research, development, and procurement of the countermeasures contained in the Strategic National Stockpile, including those for Anthrax. CDC has made tremendous progress in stockpiling antibiotics and other countermeasures for use in a public health emergency. CDC currently has a contract in place for procurement of additional FDA licensed anthrax vaccine in order to move toward meeting the 75 million dose stockpile requirement and is receiving the full production capacity of this vaccine. CDC is currently receiving shipments of the anthrax vaccine every four to eight weeks.

Mr. Rehberg: Given the delays and uncertainties with the development, procurement, manufacture and availability associated with vaccines in general and most recently for the pandemic vaccine, would it not be prudent now for the Department to enter into negotiations as early as possible for procurement of a multi-year supply of the anthrax vaccine for the stockpile to assure that we are better prepared to respond to an anthrax attack or multiple attacks?

Secretary Sebelius: CDC currently has a contract, with a multi-year contracting mechanism to ensure preparedness, in place with Emergent for procurement of additional 14.5 million doses of FDA licensed anthrax vaccine in order to move toward meeting the 75 million dose stockpile requirement, and is receiving the full production capacity of this vaccine.

COMPARATIVE EFFECTIVENESS RESEARCH

Mr. Rehberg: Madam Secretary, AHRQ has issued a solicitation for a vendor to undertake a so-called "academic detailing" program, under which the vendor will meet with doctors to "present information on comparative effectiveness" with "the intent of changing behavior in clinical practice." This raises a number of questions I'd like to have answered.

This solicitation is being conducted with stimulus bill funds. In the recently passed health care bill, there are specific standards applied to dissemination of government-funded comparative
effectiveness research by AHRQ. These standards, for example, ensure that differences in patient needs are recognized, and that communication does not take the form of policy requirements or treatment recommendations. Will AHRQ be adhering to these specific standards, or will it be disregarding them because this is being funded with stimulus money, even though Congress has since adopted specific policy about dissemination of comparative effectiveness information in a comprehensive health care law?

Secretary Sebelius: At this time, no contract solicitation on the academic detailing has been issued. AHRQ has announced the availability of the solicitation and expects to release it on or about May 14, 2010. Accordingly, the sensitivities related to the integrity of a competitive procurement apply here. In general, AHRQ's plans for dissemination of research findings on the effectiveness of different medical options are consistent with the tenets laid out in the recently passed health care reform legislation. AHRQ recognizes the importance of individual differences and the flexibility that must be considered when assessing evidence of the effectiveness of different treatment interventions. AHRQ will not be developing treatment recommendations or policy recommendations but will make the evidence available to health care decision makers, including patients and their caregivers for, their use in health care decisions.

Mr. Rehberg: The solicitation states that the program intends to "change behavior in clinical practice". That sounds to me like a government agency telling doctors what care they should deliver to patients. Please explain exactly what the government contractor will be advising physicians to do. For example, will it be to prescribe a particular medicine or treatment rather than an alternative that the physician may determine superior for his or her patient?

Secretary Sebelius: Studies have shown that it can take up to 17 years for evidence about treatment effectiveness to make its way into clinical practice. This effort will support the dissemination of research findings to clinicians so that they can make informed decisions on different treatment options for their patients. It will not mandate any treatment option but will provide unbiased and methodologically strong evidence to help health care decision makers.

Mr. Rehberg: Detailing is extensively regulated by the Food and Drug Administration. For example, FDA has strict requirements on the type of information on safety and comparative claims that manufacturers' representatives can make. The purpose of these requirements is to ensure that information provided to physicians is accurate and reliable and consistent with safe, high quality patient care. Will the government's academic detailing program adhere to these same standards?

Secretary Sebelius: The solicitation will clearly specify that communication to clinicians will be consistent with FDA policies. HHS will not be promoting a specific drug in a proprietary way but will be providing research evidence on an array of treatment alternatives. In many instances, options for treatment may include a medication, a medical procedure, or specific health behaviors such as exercise, or even what is sometimes called 'watchful waiting'. This is in contrast to traditional pharmaceutical detailing that promotes a particular product. HHS takes very seriously the importance of objective unbiased dissemination of research results.

Mr. Rehberg: The solicitation states that the vendor will conduct follow-up activities and document successful implementation. Please explain specifically what that means. Does it mean...
that doctors will be reported to HHS based on whether or not they follow the government
detailers’ recommendations? Will physicians’ treatment patterns be tracked by HHS to determine
whether they are following the detailing recommendations? Will there be any database or other
tracking of whether particular, identifiable physicians or physician practices adhere to the
detailing program’s views or choose to treat patients differently than specified by the detailing
program?

Secretary Sebelius: There has been no solicitation released. In general, HHS simply
wishes to assess the successfulness and impact on clinical decision making of the dissemination
of CER findings. It is solely intended as a measure of whether or not this method of
dissemination is successful in meeting the needs of health care decision makers.

Mr. Rehberg: What standards will apply to the information disseminated by government
detailers? What will be the process for reviewing the detailing information; will there be an
opportunity for public comment on this information? Will you work with me on defining an
appropriate role of the Institute in overseeing these activities?

Secretary Sebelius: All of the research findings disseminated will have undergone
extensive public and private peer review. No preliminary or draft results will be disseminated in
this activity and only final public and peer reviewed results will be disseminated.

Mr. Rehberg: The new health care bill gives government many new powers in relation to
doctors. In this environment, it is very important to protect the physician’s ability to use his or her
best professional judgment about how to treat his or her patients. With all the power that the
government has over doctors, what assurances will be provided to physicians that they will not be
penalized or subject to retaliation if they treat a patient differently than the government detailing
program wants them to treat their patients? With all the powers that government will have over
doctors, when a government-funded contractor comes into a doctor’s office and “recommends” to
the doctor how he or she should treat a patient, it seems to me that this could easily and
appropriately be perceived by the doctor as more than a mere suggestion.

Secretary Sebelius: Research findings are intended to provide physicians with tools, not
“rules”. This activity in no way is meant to undermine the autonomy of physicians but is
intended to assist them by providing the best available unbiased evidence on different treatment
options. Each patient is an individual and this activity is not meant to replace clinical judgment
but is intended to aid the clinician by providing timely evidence on available treatments.

Mr. Rehberg: What conflict of interest standards will apply to the vendor? And on what
basis will the vendor be paid?

Secretary Sebelius: This competitive contract will be very explicit about conflict of
interest and its avoidance. The contractor will be reimbursed according to established Federal
government procurement standards.

Mr. Rehberg: Currently, about 75% of all prescriptions are filled with generics and that
percentage is projected to rise in coming years as major brand drugs go off patent. And
pharmacies, PBMs and health plans of course have strong incentives to drive generic use as high
as possible. So is this program designed to increase generic use above the already very high and rising level? If so, please explain what it adds to the strong incentives already in the system to promote generic use, other than spending, more bureaucracy, and government agents visiting doctors? Likewise, assume that a new drug is better for patients than a generic. Will your academic detailers go out and promote use of that new drug to replace use of generics?

Secretary Sebelius: The purpose of this activity is not to increase or decrease the use of generic medications or to promote one drug over another. This activity is intended to supply research findings to health care decision makers so that they can make informed decisions about what treatment options, including but not limited to medications, are best for their patients.

Mr. Rehberg: I'm concerned that government funded programs seeking to change "clinical behavior" inevitably take a "one size fits all" approach that ignores differences in patient needs, especially when one of the goals is cutting costs. This approach ignores, and will discourage, the emerging science of personalized medicine, which gives physicians new genetic and molecular tools to help them tailor treatment to the needs of the individual patient. In the health reform bill, we worked hard to make sure comparative effectiveness research recognizes this emerging science. Will this program take a similar approach, and include discussion of the genetic variations that have a potential to change a patient's response to treatment?

Secretary Sebelius: Individual patient characteristics and genomic information are an important part of health care decision making. This effort will address individual circumstances as well as the use of genomic testing in making treatment decisions.

Mr. Rehberg: I'm very concerned if this new AHRQ initiative is vulnerable to influence by health insurance companies, especially because one of its main goals is to use comparative effectiveness research results to cut costs, not just improve patient care. Can you describe for me what role health insurance companies or their affiliated organizations play in AHRQ's current CER stakeholder group, and whether these organizations are eligible to receive CER funds from AHRQ?

Secretary Sebelius: AHRQ traditionally involves stakeholders, including patients and their providers, in its programs to ensure that the information needs of participants in the health care system are effectively met. In its work, AHRQ places special emphasis on preventing undue influence from any sector in conducting its activities. In conducting research that studies the effectiveness of different medical options, AHRQ's main goal is to identify and describe the evidence underlying the effectiveness and safety of different health care interventions so that decision-makers can make informed decisions about the health care they provide and patients receive. AHRQ involves a broad group of stakeholders in its CER activities and stakeholder group, including health care plans, physicians, researchers, industry, employers, and patients and their caregivers but does not encourage or allow one view point to predominate or direct activities. Additionally, AHRQ funds CER contract and grant applications based on scientific and technical merit and rigorous peer review that similarly avoids undue influence from any sector.
INDEPENDENT PAYMENT ADVISORY BOARD

Mr. Rehberg: Madame Secretary, as you know the health reform law establishes a new Independent Payment Advisory Board to make recommendations to Congress for containing Medicare costs. If Congress does not act on these recommendations, they automatically take effect. Under the law, IPAB is prohibited from making recommendations that would "ration health care." This is a very important protection for America's seniors, especially because of the considerable power of this Board and the lack of mechanisms to ensure its accountability. What is your understanding of how IPAB will ensure its recommendations do not constitute rationing? How will this protect patient access to medically appropriate care?

Secretary Sebelius: I share your concerns; however, I believe that the Affordable Care Act includes a number of important mechanisms to ensure the accountability of the Independent Payment Advisory Board. As a State insurance commissioner for eight years, I worked every day to limit the extent to which private insurance companies could ration care based solely on costs. That is why it was so important that the Congress passed health reform legislation to eliminate the denial of coverage or payment for valuable health services. Arbitrary coverage limits reduce quality and shift costs. Low payments or lack of coverage can block access to important life-saving treatments. This situation is economically and morally wrong. The ACA recognizes this and Congress explicitly prohibits the Independent Payment Advisory Board (IPAB) from proposing recommendations that would "ration health care." ensures that the work of health reform will continue to benefit all Americans.

The statute also builds in numerous measures for review and transparency to ensure the Board's accountability. IPAB, by law, is required to consult with the Medicare Payment Advisory Commission (MedPAC), an independent Congressional Agency, and submit all draft proposals for review. IPAB is also required by law to submit all draft proposals to the Secretary of HHS for review and comment and the Secretary is required to submit the results of that review to Congress. The impact of the proposals must be reviewed and estimated by the Office of the Chief Actuary. The Board is also required to consult with the Medicaid and CHIP Payment and Access Commission. The statute establishes a separate Consumer Advisory Council to advise the Board on the impact of policies on consumers. Like MedPAC, the members of this Council are appointed by the Comptroller General of the United States. GAO is also required to report to Congress on the impact of any changes made as a result of IPAB recommendations.

Board members are appointed by the President with the advice and consent of the Senate and in consultation with the majority and minority leadership of both houses. Appointed members are to be selected based on nationally recommended qualifications for their expertise across a range of professions, with a requirement for broad geographic recommendations.

As you know, the Board will not begin to make recommendations until 2014 and the President has not yet begun to make the fifteen board appointments, which will be done with the advice and consent of the Senate. As such, the safeguards that will be put in place by the Board to ensure that their recommendations do not ration care are not yet developed. However, the law is clear and transparent and I have no doubt that any necessary safeguards will be instituted in a timely manner as the Board is developed.
Mr. Rehberg: In a recent column in the Washington Post, Ezra Klein suggested that the Independent Payment Advisory Board will "use a lot of the comparative effectiveness program's data when making its decisions." In the health reform law, we worked hard to include patient protections on how CER is used in Medicare so that it doesn't lead to policies that harm Medicare patients. If this Washington Post article is accurate, I am very concerned that the new IPAB board would effectively eviscerate all of these patient protections we worked so hard to include for Medicare beneficiaries. Is it accurate that IPAB's use of comparative effectiveness result is not subject to these protections? If so, what can we do to remedy this and ensure that CER results are not misused in ways that prevent seniors from gaining access to medically beneficial treatment options?

Secretary Sebelius: There are numerous beneficiary protections included in the Independent Payment Advisory Board provisions in the health reform legislation. The Board is explicitly prohibited from issuing any recommendation that would ration health care, raise Medicare beneficiary premiums, increase Medicare beneficiary cost-sharing, or otherwise restrict benefits or modify eligibility criteria. Research that studies the effectiveness of different medical options is one component of building a high-quality, value-oriented health system and it is about providing consumers with more choices, not less. It is not about government rationing. To improve the effectiveness of our health care system, we need to learn more about the causes of, and cures for, diseases, as well as the strengths and weaknesses of various treatment options. This is what this research can and should provide -- it is a tool for informed decision-making on how best to care for patients. I want to give patients and doctors objective information about which treatments work and which don't -- information that will improve the quality of care given in our country and inform the recommendations of the Board.

There are a number of provisions built into the new law to provide oversight for the Board's actions. Before making recommendations, the Board is required to share draft proposals with MedPAC and the Secretary of HHS. The ACA establishes a separate independent Consumer Advisory Council, with members appointed by the Comptroller General of the United States, to advise IPAB on the impact of policies on consumers. I want to assure you that any use of such research by the Board will be subject to all the beneficiary protections included in the Affordable Care Act.

Mr. Rehberg: A recent article in the New York Times reports that the Administration is considering speeding up the timetable for creations of the Independent Payment Advisory Board. Can you elaborate on this?

Secretary Sebelius: The Administration is committed to implementing the Affordable Care Act in a timely and expeditious manner, which includes the development of the Independent Payment Advisory Board. The law is clear that the first year the Board is required to develop and submit a proposal to Congress in 2014. However, much of the leg work of implementing the Board, including appointments, hiring of staff, and policy considerations must be complete before any work on these reports and recommendations can begin. Therefore, we are taking our work of implementing the legislation very seriously and building implementation plans that are both aggressive and attainable. I look forward to keeping the Congress abreast of our progress.

Mr. Rehberg: Under the health reform law, the Independent Payment Advisory Board is required, "to the extent feasible," to give priority to recommendations that improve the health care
delivery system and health outcomes, including by promoting integrated care, care coordination, prevention and wellness, and quality and efficiency improvement. It is not at all clear to me how this is feasible when the provision exempts large sectors of the health care system, including hospitals, that are essential to improving care delivery, integrating and coordinating care, and improving health care quality and efficiency. In addition, the financial benefits of improving quality and care be met when the IPAB recommendations must cut costs in a single year. Please explain how IPAB will meet its goals to cut spending on an annual basis with a focus on quality and outcomes, when it's so often the case that the budget scorekeepers simply won't give credit for savings related to quality and outcomes even over longer periods, much less over a single year? And if quality and outcomes improvements don't score, how will IPAB cut spending?

Secretary Sebelius: High-quality health care is critical to improving patient outcomes and containing rising costs. Yet, nearly 100,000 Americans lose their lives from preventable medical errors in hospitals and, on average Americans receive only 55 percent of recommended care. Experts believe that up to 30 percent of every health care dollar is wasted on inefficient and ineffective care.

Improving quality and reducing costs can be attainable at the same time if we can find ways to target the 30 percent of health care spending that is wasted. The Affordable Care Act anticipates that recommendations from the Independent Payment Advisory Board to promote integrated care, care coordination, prevention and wellness, and quality and efficiency improvement will assist in reducing this unnecessary waste in health care programs. I would also underscore that while IPAB is a critical component in the legislation’s effort to improve health care delivery systems and patient outcomes, there are many other changes within the ACA designed to support these efforts including expanded demonstration and pilot authorities and CMS’s Center for Medicare and Medicaid Innovations.
SURGICAL QUALITY METRICS

Mr. Bonner: The University of South Alabama Hospital in my district has a Level One trauma center, one of only three in the state of Alabama and one of only a few along the Gulf Coast. The chair of the surgery department there has been involved in looking at metrics for surgical quality improvement. He is concerned that the implementation of surgical quality rules, and the carrots and sticks that may go with them will not be accurate or effective if they do not take into account the multitude of preoperative and interoperative factors that are present in any surgical procedure.

Simply put: how do we adjust for the difference in expected outcomes from surgery between a healthy 25 year old patient and an 85 year old patient with serious health problems? Publication of complication rates at hospitals which take care of disproportionate share of the 85 year old man with health problems may lead the public to the mistaken conclusion that this hospital doesn't deliver good care.

Secretary Sebelius: CMS has adopted three types of surgical care quality measures in its hospital reporting programs: structural measures, process of care measures, and outcome measures. CMS did so in order to provide a more complete picture of the quality of care delivered at a particular hospital. Not all of these types of measures require adjustment for perioperative factors, or patient risk factors, in order to provide useful and accurate information to the public.

Structural measures assess the extent to which the practice environment is conducive to delivery of high quality care and better outcomes. Currently, we have adopted one structural measure for surgical care that we currently display on our consumer-oriented website for hospitals (Hospital Compare). The measure is whether hospitals performing cardiac surgery participate in a systematic clinical registry for cardiac surgery, and the hospital’s response to this question should not be contingent upon patient risk factors or perioperative factors.

Process of care measures assess the degree to which clinical guidelines and/or widely accepted clinical best practices are employed. Performance on these measures also in theory and principle should not systematically vary based on patient characteristics as the processes being measured should be occurring in most cases. However, there are some cases for which the process being measured is either unnecessary or contraindicated. Such cases are excluded from the population included in the measure. Doing so alleviates the need to statistically adjust for patient risk factors from a measure that theoretically should apply to all eligible cases. Currently, most of the surgical care measures that we have implemented on Hospital Compare are process of care measures.

We have also adopted and will begin to display outcome measures for surgical procedures on the Hospital Compare website in late 2010, and have expressed our intent to expand the number of outcome measures for reporting in the future through rulemaking. Outcome measures assess the state or health status of patients, i.e., death, survival, infection. The likelihood of outcomes does vary systematically with patient risk factors and co-morbidities. Therefore, risk adjustment for such factors will be employed for surgical outcome measures that we have adopted as well as for future outcome measures that we have proposed to adopt through rulemaking.
We have already successfully employed risk adjustment techniques for condition-specific outcome measures that are displayed on Hospital Compare, including the 30-day mortality and readmission measures for Acute Myocardial Infarction, Heart Failure and Pneumonia. In calculating these outcome measures, we take into account patient demographic characteristics (including age) and patient health problems (or comorbidities).

Mr. Bonner: Can you talk about whether the department is planning on examining the use of expected outcomes along with observed outcomes as it makes rules to implement programs for surgical quality improvement?

Secretary Sebelius: There are several statistical modeling methods for risk adjustment. One is the Logistic Regression that calculates the observed rate over the expected rate and another is the Hierarchical Modeling method that compares the predicted rate over the expected rate. CMS has considered the relative merits of both methods, and has adopted National Quality Forum (NQF)-endorsed outcome measures for public reporting that employ hierarchical modeling for risk adjustment in order to take into account hospital-specific effects in addition to patient case mix. CMS will continue to risk adjust current and future outcome measures it implements, including those pertaining to surgical procedures and complications, employing recommendations from our broadly representative Technical Expert Panels that guide measure development, and from the NQF.

AREA WAGE INDEX

Mr. Bonner: As you are aware from your service as governor of Kansas, CMS’ area wage index (AWI) can pose significant problems for hospitals in multi-state labor markets. Wage indices can vary significantly from city to city, especially where adjacent cities lie in bordering states. In areas like the Gulf Coast, where multiple states - and multiple statistical areas - are part of the same labor markets, hospitals finding themselves in low wage index cities face a very real disadvantage when competing with higher wage index cities.

Obviously, wage index disparities are not unique to Alabama or to the Gulf Coast. Over time, Congressional prerogative and bureaucratic expediency have combined to make a hash of an already confused patchwork of high and low wage indices.

Has HHS studied the budgetary impact of inequalities in the area wage index, including the effect such inequalities may have on nursing shortages? Has the department looked into alternatives to the current metrics which may provide for more consistent wage indices within labor markets, rather than exclusively within states? Thank you.

Secretary Sebelius: I am deeply committed to developing and implementing policies that advance health care quality and value, reduce unnecessary utilization, address geographic variation in provider reimbursement rates, and bend the cost-growth curve. A number of provisions in the Affordable Care Act address these issues, including a quality and value adjustment for physician payments; value-based purchasing for hospitals and other providers;
accountable care organizations that allow providers to share in savings from providing care that improves quality and lowers cost; and policies that address geographic payment differentials.

The Department will continue to take a number of steps to address these challenges. Recently, the Department issued a series of studies on revising the hospital wage index and on developing alternative geographic practice cost index payment locality structures under the physician fee schedule. And, section 3137 of the Affordable Care Act asks for a report on a plan to reform the hospital wage index system. This report should be ready by the end of 2011 and, hopefully, will provide us with more insight into how we proceed in addressing this issue.

In addition, I have committed to commissioning two studies on Medicare’s geographic payment adjustments for hospitals and physicians and geographic variations in the volume and intensity of Medicare services. The Department will seriously consider the results of these studies as part of our continuing effort to advance health care quality and value.

I also plan to convene a National Summit on Geographic Variation, Cost, Access, and Value in Health Care later this year to further examine these issues and consider ways to adjust our payment systems so they better account for geographic variation, while maintaining access and quality of care in all areas. While to date we have not done an analysis of the impact of area wage index inequities on nursing shortages specifically, we anticipate that research on Medicare’s geographic variation in reimbursement will be relevant to all health care providers.
VACCINE COST AND ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Mr. Cole: Madame Secretary, I understand that at the most recent meeting of the Advisory Committee on Immunization Practices (ACIP) in February, the Committee said that there would be no further additions to the pediatric schedule for infant vaccines - at least in the foreseeable future. Without a routine or permissive recommendation by ACIP, a childhood vaccine will not be covered by either a public program or private insurance, so even parents that want to give their infant a vaccine could be denied that opportunity. To what extent does the cost of a vaccine factor into a decision by ACIP to include or exclude a vaccination in their pediatric schedule?

Secretary Sebelius: Information on cost-effectiveness of vaccines is one of several factors considered by the ACIP when formulating vaccine policy recommendations. In addition to reviewing economic data on vaccines, the ACIP reviews a number of factors in this process, including: 1) morbidity and mortality associated with the disease in the general U.S. population and in specific risk groups; 2) available scientific literature (both published and unpublished) on the safety, efficacy, effectiveness, cost-effectiveness, and acceptability of the immunizing agent, with consideration of the relevant quality and quantity of published and unpublished data; 3) clinical trial results and usage information provided in the manufacturer’s labeling/package insert; 4) recommendations of other professional liaison organizations; and 5) the feasibility of incorporating the vaccine into existing domestic immunization programs. The ACIP adopted guidance for the presentation of cost-effectiveness and other types of economic analyses to ensure that economic data presented to the Committee and its Work Groups are uniform in presentation, understandable, and of the highest quality.

Mr. Cole: If the FDA subsequently approves a vaccine for use in infants that is found to be highly effective in preventing a deadly infectious disease, such as meningitis for example - would ACIP reconsider this decision?

Secretary Sebelius: If a new vaccine became available and was approved by FDA, ACIP would consider recommending the vaccine based on the scientific evidence available.

PEDIATRIC CANCER FUNDING

Mr. Cole: Madame Secretary, as you know, about 2,300 children die of cancer each year. Cancer is the number one killer of children more than asthma, cystic fibrosis, AIDS, and diabetes combined. Public Law 110-285, the Caroline Pryce Walker Conquer Childhood Cancer Act, was passed unanimously by the House and Senate. We all understand the fiscal constraints of your Department, so please understand that this statement and the following question comes with that knowledge and consideration. It's been said that we are judged by those we help who cannot help themselves. These children cannot take action on their own therefore we elected and appointed officials must take action. So there is the human element of this -- the prevention of the pain and suffering through identifying cures for cancer -- but there is also a fiscal benefit to such funding. The funding generated through the 2,300 lives saved each year - lives of children who turn into productive citizens.
In a recent letter to one of my colleagues from OMB Director Orszag, it is indicated that NIH will provide $215 million for the conditions and needs of children with cancer in FY 2010. However, in a document recently distributed by NCI, only $196.3 million will be provided for such research. Can you clarify how much funding will go specifically to pediatric cancer research and what you anticipate out year funding to be?

Secretary Sebelius: NIH has not set its tracking system on disease spending to be able to capture estimates for childhood cancers or pediatric cancer research funding across all of NIH. However, these estimates are available for research funded by NCI. The estimated funding level in Director Orszag’s letter reflects the NCI-projected FY 2010 funding level for pediatric research (approximately $215 million), which is a broader research category than childhood cancer alone, and includes research related to child health, childhood cancers, birth defects, multiple sclerosis, etc. In FY 2011, NCI expects to fund pediatric research at $223.7 million. NCI also projects funding in the category “childhood cancer research”, which is a subset of pediatric research and includes only childhood cancer research (such as childhood leukemia and neuroblastoma). The National Cancer Institute (NCI) estimates it will spend $196.3 million in FY 2010 and $202.7 million in FY 2011 on childhood cancer research. This is the funding level that was provided in the recent NCI document. The key difference between these two categories of research is pediatric research is a broader category that includes research related to child health in general, whereas childhood cancer specifically deals with cancers affecting children.

NCI uses this funding to support a comprehensive pediatric cancer research program that extends from basic biology research and preclinical testing to identifying new therapeutic targets and an extensive clinical trials program that determines whether the preclinical discoveries can be translated into clinical benefit. Pediatric research in the laboratory includes studying the genetic and other mechanisms related to tumor formation and metastasis. For example, NCI’s Childhood Cancer Therapeutically Applicable Research to Generate Effective Treatment (TARGET) Initiative applies high-throughput genomic analysis methods to identify novel therapeutic targets for childhood cancers. The Pediatric Preclinical Testing Program (PPTP), an NCI-supported research contract begun in 2005, generates preclinical data that informs decisions about prioritizing new agents and combinations of agents for study against specific types of childhood cancers. NCI supports several consortia of institutions to perform clinical trials of novel agents and treatments, thereby allowing preclinical discoveries to rapidly move to the clinic and be studied by experienced pediatric oncology investigators. The Children’s Oncology Group (COG) develops and coordinates cancer clinical trials available at over 200 U.S. and international institutions. The clinical trials conducted by COG, NCI, and other NCI-supported consortia play key roles in evaluating new treatment approaches.

Finally, an important feature of the NCI research program is its work addressing the special issues faced by childhood cancer survivors. Initiated in 1993, the NCI-funded Childhood Cancer Survivor Study (CCSS) is a collaboration of 27 institutions which seeks to increase knowledge of the late effects of childhood cancer treatment. With an original cohort of 20,000 childhood cancer survivors diagnosed between 1970 and 1986, the CCSS began recruiting an additional 14,000 individuals treated for cancer as children between 1987 and 1999 to allow for the evaluation of late effects of newer types of cancer treatment.
More than 12 million cancer survivors are alive in the United States, at least 270,000 of whom were originally diagnosed when they were under the age of 21. Although there has been some increase in the incidence of all forms of invasive pediatric cancer over the past 20 years, from 11.5 cases per 100,000 children in 1975 to 14.8 per 100,000 children in 2004, death rates have declined dramatically and five-year survival rates have increased for most childhood cancers during this same time. Advances in cancer treatment have meant that today, over 80 percent of children diagnosed with cancer are alive at least five years after diagnosis, compared to about 58 percent in the 1970s. These advances have averted an estimated 38,000 childhood cancer deaths in the U.S. between 1974 and 2006. This improvement in survival rates is due to significant advances in treatment, resulting in a cure or long-term remission for the majority of children with cancer.

It is important to note that the basic research on cancer mechanisms done by NCI as well as most of the other ICs at NIH also contributes heavily to the understanding of all cancer mechanisms including pediatric cancers. That research and the dollars spent on it are not reflected in the above mentioned programs that are specific to pediatric cancers and are designed to funnel basic research discoveries into specific studies and clinical trials in pediatric cancer.
WEDNESDAY, APRIL 28, 2010.

FY 2011 BUDGET OVERVIEW: NATIONAL INSTITUTES OF HEALTH

WITNESSES
FRANCIS S. COLLINS, M.D., PH.D., DIRECTOR, NATIONAL INSTITUTES OF HEALTH
ANTHONY S. FAUCI, M.D., DIRECTOR, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
THOMAS R. INSEL, M.D., DIRECTOR, NATIONAL INSTITUTE OF MENTAL HEALTH
GRiffin P. RODGERS, M.D., DIRECTOR, NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

CHAIRMAN OBEY OPENING STATEMENT

Mr. OBEY. Good morning, everybody.

Today we will hear from a variety of witnesses on the President's request for the National Institutes of Health. We will have as a principal witness Dr. Francis Collins, who has been here many times in his former role as the Director of the National Human Genome Research Institute at the National Institutes of Health (NIH). This is his first appearance before the Subcommittee in his new capacity as the Director of NIH.

Accompanying Dr. Collins is Dr. Tony Fauci, Director of the National Institute of Allergy and Infectious Diseases; Dr. Tom Insel, Director of the National Institute of Mental Health; and Dr. Griffin Rodgers, Director of the National Institute of Diabetes and Digestive and Kidney Diseases.

I think it is fair to say that supporting the work of NIH has been a priority of this Subcommittee, certainly for as long as I have been in the Congress, and I am pleased that the President has, in the context of a tight budget situation, still provided a request for a $1,000,000,000 increase proposed for NIH overall.

Depending upon how you measure it, NIH has either had a meaningful increase in spending over the past 30 years or it has had a spectacular increase in funding. NIH was spending $1,800,000,000 when I joined the Subcommittee in 1973. The current fiscal year budget provided NIH with $31,000,000,000, so that is 16 times what it was spending when I joined the Committee, which sounds awfully big except that it is not adjusted for inflation. When you adjust it for inflation, we have not quite doubled in real dollar terms funding for NIH over that period.

We have had, I think it is fair to say, a mixed bag with respect to success against various diseases. With some, childhood leukemia, we have had significant gains. We certainly have had gains in holding at bay, somewhat, AIDS in comparison to what we feared when the Subcommittee first started talking about it. And
yet there are other areas where very little progress has been made; for example, pancreatic cancer, esophageal cancer, and a variety of other maladies.

So today we want to hear from these witnesses about not only what they intend to do with their money, but what their observations are in terms of how we can develop a better track record in the future in attacking diseases that have not been the subject of much progress over the past two decades.

And I have to say one thing before I ask Mr. Tiahrt for his comments. I have always been rather disappointed that, in my many conversations with people in the medical field, with providers in the field, that the discussion, when it turns to health care, so often is focused simply on issues such as reimbursement rates, what are hospitals going to get by way of compensation, what are doctors going to get paid.

And that is all very legitimate, but I have personally been struck by the lack of comment or curiosity or, for that matter, the lack of visible political support for added medical research which, after all, lays the foundation for the product that the practitioners in the health care area have to offer their patients and their customers.

So I think while there are many activists who have, for years, been pushing for additional funding for National Institutes of Health, I think in some ways I have been disappointed by the lack of aggressive activism on the part of so many professionals in the field. And I am not quite sure what to do about that, but I know since Dr. Collins is a very smart fellow, he will have an answer to that and everything else.

The other thing I want to say, Doctor, I want to express my personal appreciation for the fact I think you have, by your public statements, made it quite clear that one does not have to believe—I am saying it backwards. You have made it quite clear that there is not necessarily any inconsistency between pursuit of science and the belief in religion. To me, I have never understood why people think that the two are at loggerheads; that has never been my conclusion either intellectually or emotionally. So I appreciate the role that you have played in driving that point home as well.

With that, let me simply turn to Mr. Tiahrt to see what comments he might have.

Mr. TIAHRT. Thank you, Mr. Chairman. It is always a mystery, what I am going to say, is it not?

I am very pleased to see you gentlemen here today. Thank you for coming; appreciate your time. Dr. Collins, I am enjoying the Language of Life. The first chapter caught my attention when you say we are not in Kansas anymore. Being from Kansas, you do not know how many times I have thought that here in the District of Columbia.

I think you do present genetics at a level that can be understood, and I think that is very important for our culture today. But certainly DNA research is proceeding at a very fast pace, and one of the concerns that I have is what we call the valley of death, the gap between our basic research and clinical development.

We seem to have this void in the middle where we cannot get it into action sometimes, and you are coming across very critical research, and we want to find mechanisms to get it into the clinic.
and get it into applying; I guess because I feel like basic research will not do us any good unless we get it in a practical application for those of us out here. And that is why we make the investment, so that we can get it into the clinics and into the cures.

I am pleased to see that there are initiatives that are relatively new in your budget request, particularly the Therapeutics for Rare and Neglected Diseases, or TRND. I think that is exactly the type of effort we need to focus NIH's resources so that we can get across this valley of death and start funding cures.

So I look forward to your testimony and I have some questions once we get through it.

Thank you, Mr. Chairman.

Mr. OBEY. Mr. Lewis.

Mr. Lewis. Thank you very much, Mr. Chairman. I will wait to ask questions after we have heard from the witnesses. I appreciate being recognized.

Mr. OBEY. All right. Dr. Collins, please proceed. Take as much time as you want, within reason. [Laughter.]

DR. COLLINS OPENING STATEMENT

Dr. COLLINS. Well, thank you, and good morning, Mr. Chairman and distinguished members of this Subcommittee. It is a great honor to appear before you for the first time in my role as the Director of the NIH and to present the fiscal year 2011 budget, but especially to discuss my vision for the future of biomedical research.

I would like for my written testimony to be included in the record. I am going to deviate from it quite a bit in my remarks this morning.

So I would like to thank each of you for your steadfast support of NIH's mission, which, as you can see—and I am going to show a few visuals on these screens—is a dual one: to support the discovery of fundamental knowledge about the nature and behavior of living systems, but to be sure that we are then applying that to extend healthy life and reduce the burdens of disability and premature illness and death.

I want to thank the Committee for the support in fiscal year 2010 of $31 billion, as well as the $10.4 billion that was provided through the American Recovery and Reinvestment Act. And I have been very grateful, over 15 years leading the Human Genome Project, for the support of this Committee. As you know, that project finished ahead of schedule and under budget, and was supported strongly by this Congress and by this Committee even at times when there were controversies about it.

But now, as steward of the entire portfolio of NIH, I believe that opportunities to turn discovery into health have never been greater. I am honored to have with me this morning three distinguished leaders from NIH that the Chairman has already introduced, Dr. Rodgers, Dr. Insel, and Dr. Fauci, and I am sure they will be happy to also engage you in the questions.

But I also want to introduce you to some other folks today, just a few of the millions of Americans who have been helped by NIH-funded research. And let us begin with Kate Robbins. So let us hear from Kate.
KATE ROBBINS. The message I got is make your plans, get your life in order, and enjoy the next few months; and I was enraged. [End of videotape.]

Dr. COLLINS. So eight years ago, at the age of 44, this non-smoking mother of two was diagnosed with lung cancer and given a diagnosis essentially of terminal disease. She had non-small cell lung cancer that had already metastasized to her brain. And it continued to spread, after surgery, radiation, and chemotherapy, to her liver, her pancreas. But she enrolled in a clinical trial of a new drug called Iressa, or gefitinib, which is a new genome-based drug for cancer. And after Kate started the drug, dramatic things happened: most of her metastases vanished.

As you can see in these CT scans of her liver before and after Iressa—this is before, six months later, and then today, seven and a half years later, those metastases shrunk and disappeared and have not returned. There is no sign of cancer in her liver, her lungs, her pancreas. Her brain metastases are small and manageable; and, as you saw in the video, she is doing extremely well.

So why does not Iressa work in all cases? Well, we understand that. The response depends on whether or not the tumor has a specific mutation in a gene called EGFR. And we now understand that, which demonstrates the potential of personalized medicine. This drug is a god-send for that subset of individuals with those mutations, but it is unlikely to work if that mutation is not present.

We need a lot more stories like Kate’s, so NIH-funded researchers are now busy with projects like the Cancer Genome Atlas, mapping genomic changes in many types of cancer, including, Mr. Chairman, pancreatic cancer, which I agree is one where we desperately need new solutions.

Next, I would like you to meet nine-year-old Corey Haas; his parents, Nancy and Ethan, shown up here in this photo. Corey was born with a disease which has quite a mouthful, Leber’s congenital amaurosis, and it is a cause of blindness; it gradually robs young people of their sight. It is caused by mutations in a gene called RPE65.

Now, by age seven Corey was legally blind; he needed a cane to get around, had to use a special computer screen. But that all changed in 2008, when Corey enrolled in a gene therapy trial at the University of Pennsylvania, which involved injecting normal copies of this RPE65 gene into his left eye. Researchers shot this video, then, of Corey navigating an obstacle course, and let me explain here. I am going to show you a video that is in the lower left here.

Basically, Corey is being asked to walk a maze pattern. There are arrows painted in the floor. In this image they have covered up his treated eye, so he is only able to navigate based upon the untreated eye; and you will see that he is very, very limited in his eyesight.

[Video shown.]

Unidentified SPEAKER. You do not see any lines on the floor that tell you which direction?

COREY HAAS. No. No, I do not.
Unidentified SPEAKER. Do you want a clue?
COREY HAAS. I cannot even see anything.
Unidentified SPEAKER. Okay.
[Video paused.]
Dr. COLLINS. Now see what happens when they repeated the trial, same day, but now covering up his untreated eye and allowing him to use the eye that has received the gene therapy to find his way around.
[Video resumed.]
Unidentified SPEAKER. Okay, perfect. All right. And you can start whenever you are ready.
Wow. Wow.
[Applause.]
[End of videotape.]
Dr. COLLINS. Pretty amazing, though Corey is probably even more amazed he can ride a bike now and read the chalkboard like any other kid.
Now finally meet Leslie Cook, a wonderful example of prevention-oriented research. Leslie smoked for 25 years, half of her life, a habit that put her at increased risk for heart attack, cancer, and many other diseases.
[Video shown.]
LESLIE COOK. I felt as though the drug nicotine was actually controlling me, I was not controlling it, and I just wanted control over my life again.
[End of videotape.]
Dr. COLLINS. So this high-powered real estate lawyer tried to kick the habit many times; she used the gum, the patch. You name it, she had tried it. Nothing worked. And then in 2006 she enrolled in a phase 2 clinical trial of an anti-nicotine vaccine called NicVAX. This vaccine actually stimulates the immune system to produce antibodies against nicotine. Those antibodies bind to the nicotine and keep it from entering the brain, therefore reducing the pleasure associated with smoking.
NicVAX apparently did the trick for Leslie; she has not smoked in three and a half years.
Now, hopefully her experience will soon be repeated on a much larger scale. A clinical trial of NicVAX involving about 1,000 smokers was recently launched. About $10 million in NIH Recovery Act funds are being used to support that effort, which is rooted in research-funded at NIH, and it is the first ever phase 3 trial of a smoking cessation vaccine.
So I would like to thank Leslie, Corey, and Kate for allowing me to share their stories. I think their experiences show that science is not a 100-yard dash, it is a marathon. Each of those built upon years of research getting to that clinical advance. But thanks to discoveries you have funded through NIH appropriations, we have covered a lot of ground in this marathon.
Let me tell you how NIH plans to meet that continuing challenge, because there is still a ways to go.
So one of my first actions upon being named NIH Director was to scan the landscape of biomedical research for areas that were ripe for major advances that could yield substantial benefits downstream, because this is a unique time. While the list of specific
projects could go on forever, I have identified five areas of exceptional opportunity I want to very briefly tell you about, and they are in a paper that you have at your place published in Science Magazine on January 1st.

The first of those opportunities is to use the high throughput technologies that have recently been invented to understand fundamental biology and how disease occurs. This includes genomics, nanotechnology, imaging approaches, computational biology, and a host of other new technologies that are truly powerful to understand the causes and the means to treat or prevent cancer, autism, infectious diseases, and a long list.

A second opportunity—and this ties very much into what Mr. Tiahrt was asking about—is the effort to take these basic science discoveries that are pouring out of research laboratories and accelerate the translation of this into new and better treatments. This is not an easy process, as the picture shows you; there can be a difficult passageway between basic research and drugs. We need to build a bridge—by the way, that is San Francisco, in case the first picture was not so clear—and we are doing that with programs like TRND, which stands for Therapeutics for Rare and Neglected Diseases.

And in the health care reform bill the cures Acceleration Network, which is a new provision that would give NIH additional flexibility to push this translational agenda even more robustly and in a more innovative way. And this includes cell therapy as well, the effort to use stem cells for therapeutics. If you noticed in this morning’s Washington Post, we have now approved another set of stem cell lines, bringing the total to 64 that are available for use by federally funded researchers.

The third opportunity here, shown by these various banners representing programs that NIH has supported particularly to try to get information out there about the public health, is to put science to work for the benefit of health care. We, after all, need evidence to support the transformation of the practice of medicine that we all agree is necessary. Some of that is comparative effectiveness research, personalized medicine, the study and the attempt to solve health disparities, the efforts to focus on behavioral medicine; and even on health care economics, to understand what are the factors that play into better outcomes at lower cost.

The fourth area, global health. Clearly we have a great opportunity now because science has moved forward rapidly in uncovering the nature of many pathogens that we previously did not understand that affect hundreds of millions of people in the developing world. We have the chance to push that agenda forward, building upon what NIH has done already in the past and focusing now not only on infectious diseases, but also on noncommunicable diseases like depression, which also become, in the developing world, major public health problems. It is the noncommunicable diseases that represent the most rapidly growing area of morbidity and mortality.

And, finally, and fifth, we need to reinvigorate and empower our biomedical research community, our most important resource. That means we need to focus on innovation, making sure that we are giving ideas that are a little wacky and out of the box a chance to
get supported. We need to be sure that we are supporting early-stage investigators, giving them the confidence that there is a place for them in our research community, even at times when budgets are tight. And we need to focus on training the next generation, and particularly reaching out to diverse communities that are not adequately represented right now in our workforce.

Those are the five themes that I have focused on. You also have at your place a new document that has just come out from NIH that talks more about these, and also the many advances that have occurred because of NIH research over the last few years.

So, to summarize, if our Nation is bold enough to act today upon these unprecedented opportunities in medical research, I think we will be amazed at what tomorrow can bring. In the world I envision just a few decades from now, the one-size-fits-all approach to medicine will be a thing of the past. We will use genetic information to personalize our health care. We will use stem cells to repair spinal cord injuries; bioengineered bones and cartilage to replace worn out joints; nanotechnology to deliver therapies with exquisite precision. We will preempt heart disease with minimally-invasive image-guided procedures and use an artificial pancreas or other new technologies to manage diabetes better.

As for infectious diseases, I look forward to having a universal vaccine with the power to protect against both seasonal and pandemic flu. I also hope, and that hope is based upon progress, for an AIDS vaccine and a malaria vaccine, which together would save millions of lives around the globe every year.

And I dream of a day where, in ways yet to be discovered, we will be able to prevent Alzheimer's disease, Parkinson's disease, and many others that rob us much too soon of family and friends.

Just imagine what that future could mean for our Nation, our economy, for all humankind. This is what keeps NIH in the research marathon and why we are asking you to go the distance with us. The fiscal year 2011 request for NIH from this Committee is $32 billion, an increase of $1 billion, or 3.2 percent above the fiscal year 2010 level. Those funds will enable the nationwide biomedical research community to pursue a whole number of substantial opportunities for major scientific and health advances.

So thank you, Mr. Chairman and members of the Subcommittee. I would be pleased to respond to any questions you may have.

[Written statement by Francis S. Collins, MD, PhD, follows:]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
NATIONAL INSTITUTES OF HEALTH

Fiscal Year 2011 Budget Request

Witness appearing before the
House Subcommittee on Labor – HHS – Education Appropriations

Francis S. Collins, M.D., Ph.D.
Director, National Institutes of Health

Accompanied by:

Anthony S. Fauci, M.D.
Director, National Institute of Allergy and Infections Diseases

Thomas R. Insel, M.D.
Director, National Institute of Mental Health

Griffin P Rodgers, M.D.
Director, National Institute of Diabetes and Digestive and Kidney Diseases

April 28, 2010
Good morning, Mr. Chairman and distinguished Members of the Subcommittee:

It is a great honor to appear before you today to present the Fiscal Year 2011 budget request for the National Institutes of Health (NIH), and to discuss my vision for the future of biomedical research.

First, I’d like to thank each of you for your steadfast support of NIH’s mission: discovering fundamental knowledge about living systems and then applying that knowledge to fight illness, reduce disability, and extend healthy life. In particular, I want to thank the committee for the FY 2010 budget level of $31 billion, and the $10.4 billion provided to NIH through the American Recovery and Reinvestment Act. I was very grateful for the committee’s interest and support over the course of my 15 years as Director of the National Human Genome Research Institute, most notably during our successful effort to sequence the human genome. Now, as steward of NIH’s entire research portfolio, I truly believe that the opportunities for us to work together to improve America’s health have never been greater.

One of my first actions upon being named NIH Director was to scan the vast landscape of biomedical research for areas ripe for major advances that could yield substantial benefits downstream. I found many of the most exciting opportunities could be grouped under five main themes: taking greater advantage of high-throughput technologies; accelerating translational science, that is, turning discovery into health; helping to reinvent health care; focusing more on global health; and reinvigorating the biomedical research community.

The Administration’s request of $32.1 billion for NIH’s biomedical research efforts in FY 2011 would help more researchers take greater advantage of these unprecedented opportunities, all with the aim of helping people live longer, healthier, more rewarding lives. We at NIH are fortunate to have a very solid foundation upon which to build, established by such extraordinary leaders as James Shannon, Nobel laureate Harold Varmus, Elias Zerhouni, and the late and much missed Ruth Kirschstein.

THE RESEARCH MARATHON

In his FY 2009 budget remarks, Dr. Zerhouni warned that our nation’s biomedical research effort is in a race that we cannot afford to lose. I wholeheartedly agree, and want to provide a few more insights about what that race involves.

Science is not a 100-yard dash. It is a marathon – a marathon run by a relay team that includes researchers, patients, industry experts, lawmakers, and the public.

Thanks to discoveries funded through NIH appropriations, we have covered a lot of ground in this marathon. Let us take a moment to look back at a few of the advances made possible by NIH-supported research, and then look ahead to some of our nation’s biggest health challenges and how NIH intends to meet them.
HOW FAR WE'VE COME

U.S. life expectancy has increased dramatically over the past century and still continues to improve, gaining about one year of longevity every six years since 1990. A baby born today can look forward to an average life span of 77.7 years, almost three decades longer than a baby born in 1900.

Not only are people living longer, they are staying active longer. From 1982 through 2005, the proportion of older people with chronic disabilities dropped by almost a third, from 27% to 19%.

Some of the most impressive gains have been made in the area of cardiovascular disease. In the mid-20th century, cardiovascular disease caused half of U.S. deaths, claiming the lives of many people still in their 50s or 60s. Today, the death rate for coronary heart disease is more than 60% lower -- and the death rate for stroke, 70% lower -- than in the World War II era.

What fueled these improvements? One major contributor has been the insights from the NIH-funded Framingham Heart Study, which began in the late 1940s and is still going strong. This population-based study, which changed the course of public health by defining the concept of disease risk factors, continues to break new ground with its recent move to add a genetic component to its analyses.

Other factors include NIH-supported research that led to minimally invasive techniques to prevent heart attacks and to highly effective drugs to lower cholesterol, control high blood pressure, and break up artery-clogging blood clots. Science also played a crucial role in formulating approaches to help people make lifestyle changes that promote cardiovascular health, such as eating less fat, exercising more, and quitting smoking.

Many chronic conditions have their roots in the aging process. One such disease, osteoporosis, can lead to life-threatening bone fractures among older people. NIH-funded research has led to new medications and management strategies for osteoporosis that have reduced the hospitalization rate for hip fractures by 16% since 1993. Science has also transformed the outlook for people with age-related macular degeneration, a major cause of vision loss among the elderly. Twenty years ago, little could be done to prevent or treat this disorder. Today, because of new treatments and procedures based on NIH research, 750,000 people who would have gone blind over the next five years will continue to have useful vision.

Biomedical research also has benefitted those at the other end of the age spectrum. NIH-funded research has given hearing to thousands of children who were born profoundly deaf. This hearing is made possible through a cochlear implant, an electronic device that mimics the function of cells in the inner ear. Since the Food and Drug Administration (FDA) approved cochlear implants for pediatric use in 2000, more than
25,000 children have received the devices, enabling many to develop normal language skills and succeed in mainstream classrooms.

Then, there are the infectious diseases—diseases that often know no boundaries when it comes to age, sex, or physical fitness. One of NIH’s greatest achievements over the past 30 years has been to lead the global research effort against the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) pandemic. With discovery building upon discovery, researchers first gained fundamental insights about how HIV works, and then went on to develop rapid HIV tests, identify a new class of HIV-fighting drugs, and, finally, figure out how to combine those drugs in life-saving ways in the clinic. As a result, HIV infection has changed from a virtual death sentence into a manageable, chronic disease. Today, HIV-infected people in their 20s who receive combination therapy may expect to live to age 70 or beyond.

HOW FAR WE HAVE TO GO

Although we have accomplished much, and as tempting as it may be for NIH to rest upon its laurels, we all know that biomedical research still has an enormous amount of ground to cover before discovery is turned into health for all Americans.

Consider the challenge posed by cancer. This disease still claims the lives of more than 500,000 Americans annually—about one every minute. But in 2007, for the first time in our nation’s history, the absolute number of cancer deaths in the U.S. went down. And, over the past 15 years, cancer death rates have dropped 11.4% among women and 19.2% among men, which translates into some 650,000 lives saved—more than the population of Washington, D.C. These are very encouraging milestones, but they are not nearly enough.

NIH-funded research has revolutionized how we think about cancer. A decade or two ago, cancer treatment was mostly reactive, diagnosis was based on the organ involved and treatment depended on broadly aimed therapies that often greatly diminished a patient’s quality of life. Today, basic research in cancer biology is moving treatment toward more effective and less toxic therapies tailored to the genetic profile of each patient’s cancer.

Among the early success stories in this area is the drug trastuzumab (Herceptin) for breast cancer. An NIH-sponsored clinical trial found that when breast cancer patients whose tumors were genetically matched to trastuzumab received the drug, along with standard chemotherapy, their risk of cancer recurrence fell 49%. That improvement is the best ever reported in post-surgical treatment of breast cancer. Studies also have found that the chemotherapy drugs gefitinib (Iressa) and erlotinib (Tarceva) work much better in the subset of lung cancer patients whose tumors have a certain genetic change.

To accelerate the development of more individualized strategies for more types of cancer, NIH has tapped into the promise of high-throughput technologies to launch The Cancer Genome Atlas (TCGA). Over the next few years, TCGA’s research team will
build comprehensive maps of the key genomic changes in 20 major types and subtypes of cancer. This information, which is being made rapidly available to the worldwide scientific community, will provide a powerful new tool for all those striving to develop better ways to diagnose, treat, and prevent cancer.

Already, TCGA has produced a comprehensive molecular classification system for ovarian cancer and glioblastoma, the most common form of brain cancer. The survey of glioblastoma recently revealed five new molecular subtypes of the disease. In addition, researchers found that responses to aggressive therapies for glioblastoma varied by subtype. The findings hold promise for matching the most appropriate therapies with brain cancer patients and may also lead to therapies directed at the molecular changes underlying each subtype, as has already happened for some types of breast cancer.

Diabetes is another disease that is inflicting much damage on U.S. health. More than 23 million Americans currently have diabetes — nearly 8% of the population. Another 57 million have blood sugar levels that indicate they are at serious risk of developing the disease, which is a major cause of kidney failure, stroke, heart disease, lower-limb amputations, and blindness.

For type 2 diabetes, prevention appears to be the name of the game. This form of the disease, which accounts for more than 90% of diabetes among adults, often can be averted or delayed by lifestyle factors. The NIH-funded Diabetes Prevention Program (DPP) trial showed that one of the most effective ways to lower the risk of type 2 diabetes is through regular exercise and modest weight loss. There is good reason to believe that such efforts may lead to a lifetime of health benefits. A recent follow-up study of DPP participants found the protective effects of weight loss and exercise persist for at least a decade. The United Health Group has recently announced a partnership with Walgreen’s and the YMCA to implement the results of this groundbreaking NIH-funded research on a broad scale.

More than one-third of adults in the U.S. are obese, according to the latest data from the National Health and Nutrition Examination Survey which is conducted by the Centers for Disease Control and Prevention (CDC). And there are signs that the next generation may face an even greater struggle. Over the past 30 years, obesity has more than doubled among U.S. children ages 2 through 5 and nearly tripled among young people over the age of 6. Those statistics translate into tens of millions of Americans who face an increased risk of type 2 diabetes, as well as cardiovascular disease, high blood pressure, certain cancers, osteoarthritis, and other serious health problems associated with excess body fat.

To address America’s growing problem with obesity, NIH has launched a variety of initiatives aimed at developing innovative approaches for weight control. One such effort, called the National Collaborative on Childhood Obesity Research, has pulled together experts from four NIH institutes, the CDC, and the Robert Wood Johnson Foundation. One example of their work is the Trial of Activity for Adolescent Girls, a national study to develop and test school- and community-based interventions to get
girls more involved in gym class, organized sports, or recreational activities. Another NIH program, called *We Can!,* provides families with practical tools for weight control at more than 1,000 community sites nationwide. How to get more people to lose weight is also among the questions being explored by OppNet, a new trans-NIH initiative for basic behavioral and social sciences research.

Meanwhile, other NIH-funded researchers are busy uncovering information about genes and environment that may pave the way for more personalized, targeted strategies for controlling weight and preventing diabetes. For example, in just the past few years, we have identified more than 30 genetic risk factors for type 2 diabetes.

A better understanding of genetic and environmental factors may also help solve a longstanding medical puzzle: the causes of autism. Children with autism spectrum disorders experience a range of problems with language and social interactions, sometimes accompanied by repetitive behaviors or narrow, obsessive interests. Recent studies funded by NIH have associated autism risk with several genes involved in the formation and maintenance of brain cells, but much more work is needed to follow up on these clues.

In FY 2011, NIH will support comprehensive and innovative approaches to piece together the complex factors that contribute to autism spectrum disorders. One ambitious effort will involve sequencing the complete genomes of 300 people with autism and their parents. Other researchers will examine a mother's exposure during pregnancy to identify possible environmental contributions. NIH hopes to use these insights to develop new molecular and behavioral therapies for such disorders, as well as to identify possible strategies for prevention.

Another brain disorder, depression, presents a different set of challenges. Although researchers have made significant progress in understanding the biology of depression, improving treatment, and lessening the social stigma associated with mental illnesses, suicide still claims the lives of twice as many Americans as homicide. And it does not end there -- untreated depression also increases the risk of heart disease and substance abuse.

How can medical research reduce depression's tragic toll? One way may be getting people into treatment more quickly. Researchers today are using functional magnetic resonance imaging and other innovative technologies to see how the brains of people with depression differ from those without the disorder. Rapid diagnosis is just part of the equation. Finding the right antidepressant drug for any particular patient currently is a lengthy, trial-and-error process that can take weeks before symptoms are relieved. NIH supports laboratory research aimed at developing quicker-acting antidepressants, as well as genetic studies that will help to match individuals with the drugs most likely to work for them.
In 2008, 143 soldiers died by suicide – the highest rate since the Army began keeping records three decades ago. To address this problem, NIH and the U.S. Army recently partnered to launch the largest study ever of suicide and mental health among military personnel. The Army Study to Assess Risk and Resilience in Service Members (Army STARRS) will identify risk factors that may inform efforts to develop more effective approaches to suicide prevention.

**TRANSFORMING DISCOVERY INTO HEALTH**

Whatever the disease, be it depression, diabetes, or something much rarer, NIH’s emphasis in FY 2011 and beyond will be on translating basic discoveries into new diagnostic and treatment advances in the clinic.

In the past, some have complained that NIH has been too slow to convert fundamental observations into better ways to diagnose, treat, and prevent disease. Although some of that criticism may have been deserved, most of the delay has stemmed from the lack of good ideas about how to traverse the long and winding road from molecular insight to therapeutic benefit.

That is now changing. For many disorders, there are new opportunities for NIH to shorten and straighten the pathway from discovery to health. This expectation is grounded in several recent developments: the dramatic acceleration of our basic understanding of hundreds of diseases; the establishment of NIH-supported centers that enable academic researchers to use such understanding to screen thousands of chemicals for potential drug candidates; and the emergence of public-private partnerships to aid the movement of drug candidates identified by academic researchers into the commercial development pipeline.

Let me give you one example of how NIH plans to implement this strategy: the Therapeutics for Rare and Neglected Diseases (TRND) program. This effort will bridge the wide gap in time and resources that often exists between basic research discoveries and the human testing of new drugs.

A rare disease is one that affects fewer than 200,000 Americans. However, if all 6,800 rare diseases are considered together, they afflict more than 25 million Americans. Private companies seldom pursue new therapies for these types of diseases because of the high cost of research and low likelihood of recovering their investments. Effective drugs exist for only about 200, or less than 3%, of rare diseases. Unlike rare diseases, neglected diseases may be quite common in some parts of the world, especially in developing countries. However, there also is a dire shortage of effective, affordable treatments for many of these major causes of death and disability.

Working in an open environment in which all of the world’s top experts on a disease can be involved, TRND will enable certain promising compounds to be taken through the preclinical development phase – a time-consuming, high-risk phase often referred to as “the valley of death” by pharmaceutical firms focused on the bottom line.
Besides speeding development of drugs for rare and neglected diseases, TRND will serve as a model for therapeutic development for common diseases, many of which are being resolved into smaller, molecularly distinct subtypes.

NIH will also take other steps to build a more integrated pipeline that connects all of the steps between identification of a potential therapeutic target by a basic researcher and the point when the FDA approves a therapeutic for clinical use. Among the tools at our disposal is the NIH Clinical and Translational Sciences Award program, which currently funds 46 centers and has awardees in 26 states and plans to add even more in FY 2011. This national network is pulling together interdisciplinary clinical research teams to work in unprecedented ways to develop and deliver tangible health benefits. We also need to take advantage of the nation’s largest research hospital, the Mark O. Hatfield Clinical Research Center, located on the NIH campus in Bethesda, Md. Just as they blazed a trail for safe and effective human gene therapy, NIH clinical researchers may be well positioned to move the ball forward for other pioneering approaches, such as those using human embryonic stem cells or induced pluripotent stem cells derived from skin cells.

To make the most of these new opportunities, the NIH and FDA recently forged a landmark partnership with the formation of a Joint Leadership Council. Members of this Leadership Council will work together to ensure that regulatory considerations form an integral component of biomedical research planning, and that the latest science is integrated into the regulatory review process. Such collaboration will advance the development of products to treat, diagnose and prevent disease, as well as enhance the safety, quality, and efficiency of clinical research and medical product approval.

BIOMEDICAL RESEARCH PROPELS U.S. ECONOMY

It is crucial to keep in mind that investing in NIH not only improves America’s health and strengthens our nation’s biomedical research potential, it empowers the entire U.S. economy. Consider the following statistics:

- A report issued by Families USA calculated that in 2007, every $1 in NIH funding resulted in an additional $2.11 in economic output in the U.S. ¹
- In FY 2007, a typical NIH grant supported the salaries of about 7 high-tech jobs in full or in part.²
- The 351,000 jobs resulting from NIH awards paid an average annual wage of more than $52,000 per annum and account for more than $18 billion in wages for FY 2007.³
- Long term, NIH funded R&D sparks U.S. economic innovation in the high-technology and high value-added pharmaceutical and biotechnology industries. For example, between 1982 and 2006, one-third of all drugs and nearly 60 percent of promising new molecular entities approved by the FDA cited either an NIH-funded publication or an NIH patent.⁴
- Gains in average U.S. life expectancy from 1970-2000 were worth an estimated $95 trillion.⁵
IMAGINE THE FUTURE

If our nation is bold enough to act today upon the many unprecedented opportunities now offered by biomedical research, we may be amazed at what tomorrow will bring.

In the world I envision just a few decades from now, we will use stem cells to repair spinal cord injuries; bioengineered tissues to replace worn-out joints; genetic information to tailor health outcomes with individualized prescriptions; and nanotechnology to deliver therapies with exquisite precision. I also dream of a day when, in ways yet to be discovered, we will be able to prevent Alzheimer’s, Parkinson’s, and other diseases that rob us much too soon of family and friends.

Just imagine what such a future would mean for our nation and all humankind. This is what keeps NIH in the research marathon, and why we ask you to go the distance with us.

Thank you Mr. Chairman. That concludes my formal remarks.

---

NIH: Steward of Medical and Behavioral Research for the Nation

“Science in pursuit of fundamental knowledge about the nature and behavior of living systems... and the application of that knowledge to extend healthy life and reduce the burdens of illness and disability.”
Kate's Story

- Diagnosed at age 44 with metastatic lung cancer
- Cancer spread after surgery, radiation, and chemotherapy
- Participated in a clinical trial testing Iressa™ (gefitinib), a new genome-based drug for cancer

The NEW ENGLAND JOURNAL of MEDICINE

Advancing Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib
Personalized Cancer Treatments

- Kate's metastases shrank; now undetectable in lungs, liver, pancreas
- Why doesn't Iressa work in all cases?
  - Response depends on specific mutation in *EGFR* gene
- Demonstrates the potential of personalized medicine

CT scans showing response of liver metastases to Iressa

<table>
<thead>
<tr>
<th>Onset</th>
<th>6 Months</th>
<th>Today</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.25.02</td>
<td>04.17.03</td>
<td>04.01.10</td>
</tr>
</tbody>
</table>
Corey's Story

Leber's congenital amaurosis is caused by a mutation in the RPE65 gene. Corey was legally blind by age 7. Gene therapy procedure was performed in one eye. Corey's eyesight is returning.

Using the treated eye

Using the untreated eye
Leslie’s Story

• Tried to stop smoking a number of times.
• Four years ago, she enrolled in a NicVAX Phase 2 clinical trial...
  - Stimulates production of antibodies to nicotine
  - Bound nicotine cannot enter brain, subverting rewarding effects
  - Leslie’s results: “To this day, I haven’t smoked a cigarette since. I don’t want one.”
NicVAX Phase III Trial

- Involves 1,000 smokers at 20 centers around the U.S.
- NIH Recovery Act funds ($10 million) are helping pay for the trial
  - Vaccine rooted in NIH-funded basic research
  - First-ever phase III trial of a smoking cessation vaccine

---

**CLINICAL TRIALS**

Safety and immunogenicity of a nicotine conjugate vaccine in current smokers

Dorothy K. Hatsukami, PhD, Stephen Rennard, MD, Douglas Jorenby, PhD, Michael Fiore, MD, MPH, Joseph Koopmeiners, Arjen de Vos, MD, PhD, Gary Horwitz, MD, and Paul R. Pestel, MD - Minneapolis, Minn, Omaha, Neb, Madison, Wis, and Rockville, Md
Opportunity 1: Using high throughput technologies to understand fundamental biology, and to uncover the causes of specific diseases.
Opportunity #2: Translating basic science discoveries into new and better treatments.
Opportunity #4: Encouraging a greater focus on global health

Depression
Leading cause of disability worldwide...

Disease Control Priorities Project

Zoonotic Diseases Lacking Adequate Control Measures:
Dengue, Leishmaniasis, and African Trypanosomiasis

World Health Organization
Opportunity #5: Reinvigorating and empowering the biomedical research community

Great projects outside the box
NIH... Turning Discovery Into Health
Mr. OBEY. Thank you.
Mr. Tiahrt.

COMPARATIVE EFFECTIVENESS RESEARCH

Mr. TIAHRT. Thank you, Mr. Chairman.
Just reading on personalized medicine in this new publication here. I think one of the concerns I have had with the comparative effectiveness money that we have invested is that the good side of comparative effectiveness is we see what works and we communicate it well to physicians and clinics and hospitals and treatment centers. The part that concerns me is that when we start placing a dollar value on comparative effectiveness, that at some point we start making decisions based on costs that start rationing some care, rationing some treatments.

And I think, during this health care debate that we have had over this past year and a half, that that has been part of the topic. Can you kind of give me some confidence that what we are doing at NIH now through comparative effectiveness research is not going to lead to rationing in the future.

Dr. COLLINS. So, Mr. Tiahrt, I understand the concern. I think when we look at the kinds of research that NIH has done in the past and are planning to do now, the goal really is here to identify interventions that may be more effective and others that are less so, because evidence has to be valuable in making decisions about how we are going to put together a health care system that actually works.

I might even ask my colleague, Dr. Rodgers, to tell you briefly about the Diabetes Prevention Program, the DPP, as an example of a comparative effectiveness research study that taught us something really important about how to prevent diabetes and which is now being implemented across the Country in a new and exciting way by United Healthcare.

So, Griff, do you want to say a word about the DPP?

Dr. RODGERS. Be very happy to.

The Diabetes Prevention Program was a landmark study that was started over 10 years ago involving the NIH, the Centers for Disease Control and Prevention (CDC), and multiple institutes within the NIH, to identify those patients who are at high risk of developing diabetes. In this country, at the moment, there are about 24 million Americans who suffer with diabetes, but there are 57 million Americans who are at high risk of developing diabetes based upon family history, racial and ethnic groups, the fact that they may be overweight or obese. And clearly we are understanding now that a lot of this has to do with the susceptibility genes for diabetes.

This intervention, which was a comparative effectiveness study, involved patients being treated with just general instructions, a so-called placebo group; a second group with a standard therapy for diabetes, Metformin; and a third group with an intensive lifestyle modification. In these over 3,000 patients that were studied, there was about a 58 percent reduction in the risk of patients who are at high risk for developing diabetes who underwent this intensive lifestyle modification over the period of time.
That study was published in 2002, but just last year a follow-up study to that DPP, called the Outcome Study, was published which shows that there is an ongoing effect, even as long as 10 years. Patients who were randomized in this intensive lifestyle still maintain the ability to prevent or delay the onset of diabetes.

Now, in a clinical research study, of course, we required one-on-one counseling with these individuals, but it was clear that in order for this to be effective, we had to figure out a way to make it more reasonable and cost-effective. So we turned to the YMCA to do a translational study to determine whether—because, of course, YMCAs exist in all communities. We have estimated that most individuals in the U.S. live within a five-mile radius of the YMCA, and we wondered whether, rather than doing this on a one-on-one basis, if we do it in a group basis, whether we can cut the cost. In fact, we did. The cost for implementing this intensive lifestyle was reduced from the thousands down to $300 with the same effect.

Mr. Tiahrt. Is that the dues at the YMCA?
Dr. Rodgers. I am sorry? Yes. That is right. I have to say that this study was so effective, our colleagues at CDC got involved, expanded beyond the Indiana center that we initially funded, and just two weeks ago United Healthcare have, for the first time, decided to provide coverage for the use of this intervention at Ys and similar places to all of its members. Initially in six cities around the Country, but in fiscal year 2011 they plan to roll this out nationwide.

Mr. Tiahrt. That is good, because diabetes is one of the leading causes for many things—amputation, blindness, heart disease.
Dr. Rodgers. Absolutely.

ADULT AND EMBRYONIC STEM CELLS

Mr. Tiahrt. One last question here, because my time is short. There are basically two kinds of stem cells—there is the adult and the embryonic—and you have come up with a third from skin cells that you can engineer. Can you tell me what the results have been as far as research? Which category has yielded the most results as far as getting cures available for people?

Dr. Collins. Well, we are very interested in the research on stem cells and, of course, that is a very much discussed topic. Adult stem cells, as they are called, have been around longer and certainly bone marrow transplants, for instance, depend upon the idea that there are stem cells in the bone marrow that can expand and repopulate when needed. So we have the greatest clinical experience because that kind of study has been around for quite a while.

Human embryonic stem cells have only been around for about 10 years, and because of the concerns about safety and also some limitations in terms of who had the authority to work with those cells, we are not yet in a position of really knowing what their therapeutic potential might be, although many people are quite excited about that potential based on animal studies. There is so far only one Food and Drug Administration (FDA) approved trial for human embryonic stem cells, and that is for spinal cord injury, and it is too soon, by far, to know how that is going to turn out.
The most recent type, as you mentioned, derive from skin cells, the so called induced pluripotent stem cells, or iPS cells, are even much newer on the scene. Only about three years ago Shinya Yamanaka came up with this amazing observation that with just four genes you could take a skin cell and convince it to be pluripotent.

The potential here is enormous, because that would mean these cells came from the individual, so they could potentially be used therapeutically without rejection by the immune system. But there are many concerns about safety, because pluripotent cells are also capable of growing when you do not want them to, and can even cause tumors. So we have to work that safety issue out very carefully before even beginning to propose a clinical trial. But I think there is a lot of excitement about getting there.

I have just recently initiated an Intramural iPS Cell Center at NIH to try to accelerate our study of these cells and the way in which they could be used in therapeutics.

Mr. TiaHrt. Thank you.

Mr. ObEy. Ms. Lee.

SICKLE CELL

Ms. Lee. Thank you very much, Mr. Chairman.

Let me first thank you all for being here again and just say how important we all recognize and know that your work is at NIH. Following up on the issue that we have discussed, I think most of you were here on the A1C diabetes public awareness campaign. I wanted to see, Dr. Rodgers, if you had any kind of results, feedback from what took place.

Just a bit of background. We learned—and I learned and we brought it to this Committee—and thank you for following up on this—that people who have the sickle cell trait, oftentimes the A1C test for diabetes gives or could give a false result, a false positive, false negative. So we developed a public awareness campaign to let physicians, labs, and what have you, and community clinics know that there are other tests.

So I just want to see how that public awareness campaign developed, what were the results, and also could you clarify the whole issue around sickle cell testing? Is sickle cell testing required at birth? I know it is no longer required when people apply for a marriage license, for what that is worth. So how do we make sure that people are aware that they have the trait or, well, the disease or prone or susceptible to the disease?

Dr. Rodgers. Thank you. Let me answer your second question first, and that is related to is it required to test for sickle cell disease. These are really done on a State-by-State basis, and it is my understanding that most States do now test at birth for the presence of the sickle cell protein. It can be done very easily, using blood samples to detect either sickle cell trait or sickle cell disease. When there are problems, the infant is called back and confirmatory tests are done. It is my understanding that most States currently do testing, but I would have to——

[The information follows:]
SICKLE CELL TESTING

Sickle cell (SC) disease testing is now universally required. Because of the testing used, “carrier status” is determined. While all states do report our carrier status to the responsible physician, where it goes from there (if anywhere) is highly variable, depending upon state and physician practice. In reality, it is likely a relatively small proportion of parents who are actually informed if their child is an SC carrier.

Ms. LEE. And how are adults reminded of that test result when they become adults? How do they know that? How does that follow the adult in terms of their medical records?

Dr. RODGERS. Right. Well, that is something that is certainly, with electronic health records and the ability to follow that as patients move from doctor to doctor and clinic to clinic would be very important. I would have to get information on how that is followed comprehensively. I am sort of aware of this from a limited number of experiences that I have, and I can certainly provide that information to you with our sister organization, the National Heart, Lung, and Blood Institute.

[The information follows:]

SICKLE CELL RESULTS

There is at present no system in place that ensures the orderly transition of health care information for an individual throughout his or her lifespan. Individuals diagnosed with sickle cell disease would ordinarily be aware of their diagnosis and in late adolescence the ongoing care of the child would be transferred from a pediatrician to either an internist or adult hematologist.

The maintenance of information on being a carrier of sickle cell disease is a responsibility shared by an individual, his or her family members, and the team of health care providers.

But back to your first question, and that relates to hemoglobin A1C. That is a very vital test that shows what the average level of blood sugar control is over the preceding three months. When we testified several years ago, you raised our attention to the fact that many patients are receiving this test done in the office and they may have sickle cell trait, and that is a confounding variable, and, as a result of that, we did develop this public awareness campaign, and in no small part due to that most of the tests that are done are now in compliance with the understanding that there is interference of the sickle cell and other genes that can cause a problem.

So essentially all of the commercially available testing for A1C is done using systems that can—that having an abnormal hemoglobin is no longer problematic.

Ms. LEE. Thank you very much.

Mr. Chairman, let me just say to the Committee that this was very important because so many people I know—family members, friends, people in especially communities of color—there were a lot of people who had false positives because of the fact that they had been tested with the wrong test, and did not even know they had the sickle cell trait. So this was a very important effort that started in this Committee, and I just wanted to thank you all for that.

And I am glad to hear now that they have changed the testing now is clear in what to do and look forward to your report back on the sickle cell trait, because I know a lot of people who I just talk to and say, look, do you have the sickle cell trait, and they say we do not know, and will ask their doctor to test them and, lo and behold, they have the trait, which, of course, means certain kinds
of medical tests would not be valid or they need to do certain things in terms of their health. But unless you follow from birth in the States that do do the testing and somehow people know as an adult they have the trait, they get in a lot of trouble. So we need to really figure out how to make sure that that happens, because most people I know, especially most African-Americans, do not ask their doctor to test them for the sickle cell trait.

Thank you.

Mr. OBEY. Mr. Lewis.

FISCAL YEAR 2011 FUNDING

Mr. LEWIS. Thank you very much, Mr. Chairman. Gentlemen, very much appreciate your presence here today. The Chairman has appropriately outlined the pattern of funding for NIH over time. There is a piece of that that concerns me. You know, beauty lies in the eyes of the genuflector, and with NIH funding we had a very significant increase in the 2009 fiscal year as a result of the stimulus package. I have some questions about that, but, most importantly, I am concerned that even though the President's budget has a $1,000,000,000 adjustment, if you take where we were in 2009 and that dollar amount, one could argue that there is an $8,000,000,000 reduction, if real value came from that stimulus funding.

So I would like to have some commentary regarding that and how you have budgeted to try to deal with that adjustment, if it remains as a part of our pattern, and very much be interested in knowing—maybe Dr. Fauci would like to respond to this piece of it.

There has been consistent adjustment also for Labor, Health and Human Services across the board, with a similar big adjustment in 2009. If I were looking at those adjustments and readjusting budgets, I would make sure that continuing funding flowing to NIH would have very high priority in those considerations. There is a broadly based nonpartisan support for research, applied research as well as the basic research. Lots of discussion that is healthy, pushing you to get more in the direction of the applied research, but, nonetheless, we need to preserve this nonpartisan environment in this Committee and otherwise.

So if you would start with that, Dr. Collins, I would appreciate it.

Dr. COLLINS. Mr. Lewis, I appreciate the question and I do appreciate the strong bipartisan support for medical research that has characterized the actions of this Subcommittee for many years. The diagram that you see on the screen there shows you what the total funding allocated for NIH has been over the course of the past decade, and, as you can see, after a period of flat funding from 2003 to 2008, with only modest increases, then, as shown in red, the Recovery Act dollars, $10.4 billion, were given to NIH, but obviously as a two-year enterprise, so roughly $5 billion each year.

[The information follows:]
NIH FY 2011 President's Budget Request
$32.2 Billion
Increase of $1B or 3.2% over FY 2010 non-ARRA dollars

ARRA Funding $5B for FY 2009, $5B for FY 2010
And the budget is here shown for fiscal year 2011, and I think you can see the delta there, and, in fact, this is the cliff that people are talking about, because effectively in fiscal year 2010, if you include the Recovery Act dollars, the total funding that NIH has had available is $36 billion. What is proposed in the President’s budget is $32 billion.

Now, let me say that given the very difficult economic times, the President’s support of science and the willingness to put forward a $1 billion increase for NIH is reflective of the Administration’s strong support for research and what it can do, and we are deeply grateful for that, because certainly it could have been justified, at a time of growing deficits, to be even more conservative here in terms of providing support for this.

So the $1 billion is certainly something we are delighted to see come forward, although it is a dollar figure which basically matches the inflationary index for biomedical research, just about 3.2 percent.

We were aware that this might be an outcome. What we have tried to do—although I would not tell you that we are going to be completely successful in reducing the consequences of this cliff—certainly some of the money funded by Recovery Act has been for one-time expenditures, special equipment needs, for instance, that universities across this Country have been clamoring for years during the flat funding; construction grants also to help those universities and institutes build up their physical plant or to do some renovations that are badly needed.

We have tried to fund special projects that we thought could get done in two years. The Cancer Genome Atlas, which went from a pilot phase into a full-bore assault on understanding cancer, and which, with that accelerated funding, will tell us in two years the basic landscape of cancer for the 20 most common cancers at the DNA level, a dramatic series of advances.

But we also funded a lot of innovative grants. We invited investigators out there to come forward with their best ideas, and they came forward in great numbers with exciting, innovative stuff. When I arrived at NIH in August, one of my first tasks in those first few weeks was to read a lot of these grants that came forward asking for support from the Recovery Act, and these were really exciting, innovative, many from investigators that had not previously come forward to NIH.

But science is, as I said in my opening statement, not a 100-yard dash, it is a marathon, and two-year cycles are really not the way that advances occur. So we are going to face a crunch in fiscal year 2011. We will be, I think, gracious to investigators who were funded during the Recovery Act for two years and who asked could they please have a no-cost extension for a third year. We will probably, with good justification, be willing to do that in order to try to smooth this out a bit.

But there is no question that if you measure what happens in terms of success rates, that is, what is the chance that an investigator who sends a grant in to NIH is actually going to get funded, that is going to be a tough number in fiscal year 2011. That number used to be, back in the course of the last 30 years, around 25
to 35 percent. That was the success rate for grantees. It has trickled down more recently to 20 percent.

Our predictions are that in fiscal year 2011, with this budget number, it will be more like 15 percent, one grant out of every.

Mr. Lewis. Dr. Collins, your response has taken up my time, but——

Dr. Collins. I am terribly sorry.

Mr. Lewis [continuing]. In the meantime, I would hope, as you see some of those vacuums or difficulties, that you and your people, Dr. Fauci, would keep very much in touch with this Committee so that we can try to be responsive in ways that will accelerate those opportunities.

Dr. Collins. Will do.

Mr. Obey. Ms. Roybal-Allard.

PANCREATIC CANCER

Ms. Roybal-Allard. First of all, let me thank you all for being here and for the really important work that you do. However, I have had some concerns with regards to NIH's lack of responsiveness to this Committee on two particular issues.

As you are aware, pancreatic cancer is the fourth most deadly type of cancer, with survival rates that have remained largely unchanged for the last 40 years. Yet, despite its lethal prognosis, only about 2 percent of the Federal cancer research budget continues to be devoted to pancreatic cancer. Recognizing the seriousness of pancreatic cancer, this Subcommittee requested, in fiscal year 2009, in the appropriations report, that the National Cancer Institute give a detailed account of what it would do to increase research and training on pancreatic cancer.

When that request was completely ignored, the Subcommittee, in fiscal year 2010, again made the request for a plan to address pancreatic cancer. The NCI once again ignored the request and has no plan, and we are being told now that there is going to be a meeting held in the future to address pancreatic cancer.

Since the Subcommittee has always chosen to respect the integrity of the scientific community by not directing funds or micro-managing NIH's activities, short of doing that, what does the Subcommittee have to do to get NIH to respect the requests of this Subcommittee and respond to an issue as important as pancreatic cancer?

Dr. Collins. Congresswoman, I was unaware, until this moment, of this lack of responsiveness to that specific request about pancreatic cancer, and I would promise to give it my personal attention. Pancreatic cancer is a particularly lethal and very devastating type of cancer about which, as you point out, progress has been rather limited.

We do have some, I think, exciting opportunities on the horizon, particularly trying to understand at the detailed molecular level what are the first steps that cause pancreatic cells to begin to grow into a cancer and what might we do in terms of developing early detection methods based upon that, because that is obviously much of the problem, is not detecting this disease until it is already far advanced; but, most importantly, to develop new treatments that
are targeted towards those specific pathways that seem to drive this cancer. Again, the Cancer Genome Atlas will provide that kind of information for our 20 most common cancers, and that includes pancreatic. But I am distressed that you feel that this Committee has not been answered in the requests you have made about this, and I will personally look into that. I will tell you that in the relatively near future we anticipate that a new Director of the National Cancer Institute will be named by the President, and I will be certain, if that happens, that this concern of yours is conveyed.

CLASS B DEALERS

Ms. ROYBAL-ALLARD. I would appreciate that. Thank you.

One other area of concern has been the use of Class B random source cats and dogs for NIH-funded research. We were pleased when NIH stopped purchasing dogs from Class B dealers for use in intramural research, but remain concerned that the practice still continues in some of the extramurally funded NIH research. So last year, once again, this Committee, in their report, asked NIH to submit a detailed plan for phasing out random source cats and dogs and extramurally-funded research. Again, NIH has ignored this Subcommittee's request and we have seen no plan.

So my question to you is how much progress has been made towards phasing out this practice and has NIH identified all current NIH-supported extramural projects using Class B dogs and cats? And, if so, how many? Also, does NIH have a plan that we have not seen for implementing a phase-out of the use of dealers by its grant recipients?

Dr. COLLINS. Congresswoman, again, I am sorry that this response has not been forthcoming in a timely fashion. I know it was due on April 1st. I can tell you that it is very close to being finalized; we wanted to be sure that we had answers to all of those questions. I can tell you the substance of the response will be that, yes, NIH is making a plan to phase out the use of Class B dealers for animals.

It is not possible to do that overnight because the needs for animals that currently have been coming from Class B dealers for cardiovascular research and transplant research would be injured rather badly if we did this in a precipitous way. But we will transition over the period of roughly three to four years into a circumstance where we no longer depend upon Class B dealers for animals, and we arrange to have the breeding Class A suppliers fill that need.

Again, that report should be coming forward to you very soon.

Ms. ROYBAL-ALLARD. Thank you. Appreciate that.

Mr. OBEY. Mr. Rehberg.

BREAST CANCER MAMMOGRAPHY GUIDELINES

Mr. REHBERG. Thank you, Mr. Chairman.

Welcome. I always feel like apologizing to somebody with your talent and credentials. And you have entered into the political realm of our world, so I guess my questions probably will be a little more political from the perspective of the comparative effectiveness research that we were talking about before.
While this organization is not necessarily under your purview, the U.S. Preventive Services Task Force, they have certainly created perhaps a firestorm within the breast cancer community, and I would like you to talk a little bit about your own concept of personalized medicine as it relates, then, to some of the comparative analysis that you are going to be doing within your research, because I will just use breast cancer as an example.

This was in the New York Times, an influential group, the one I referred to, provides guidance to doctors, insurance companies, and policy makers, and they have now made the recommendation that mammograms do not need to occur until 50, as opposed to 40; and that was wildly hailed as a step forward by the National Cancer Institute, National Breast Cancer Coalition, Breast Cancer Action, National Women’s Health Network welcomed the new guidelines, and, of course, the insurance companies will take that as, well, I guess we do not have to cover that until they are 50. Unfortunately, on the other side are the American Cancer Society and the American College of Radiology.

So a fight has been created that will probably rage on for quite some time. How are you working or how do you intend to keep those kinds of food fights out of NIH? Because it has the potential of creating a lot of politics for you in an arena that research and science should not have politics.

This is just one example, and it is the most recent example of something that is going to occur as a result of something similar to the comparative effectiveness research that is going on.

Dr. Collins. Well, Congressman, I appreciate the question and this certainly is an example where those recommendations from the USPSTF on mammography created quite a firestorm of controversy. Specifically, NIH is not in the business of establishing practice guidelines, for the most part, and in that instance the National Cancer Institute stayed out of the fray, basically. Our role is to provide the kind of data that might allow the establishment of guidelines that improve outcomes, and that is something that we are very determined to do.

When it comes to the mammography guidelines, I think you brought up the issue of personalized medicine. Perhaps the path forward here is for us to be more clear about how to utilize individualized information to make better predictions, because while there may be women who are not going to be benefitted by a mammogram in their 40s because they are at very low risk, there are others who are at higher risk for whom that is a highly appropriate procedure.

The Task Force recommendations touched on that, but we did not have enough data to actually be able to say how do you factor that in. That would be one of the things that NIH very much wants to work on.

**FUNDING FOR COMPARATIVE EFFECTIVENESS RESEARCH**

Mr. Rehberg. I feel very comfortable with your credentials. You are probably the right person at the helm of NIH at a time when we are spending a lot of money on this kind of comparative research. But the problem is—or not necessarily a problem—I do not want to create a problem—or I do not want to create an objective conclusion
for the various research? You are spending $400,000,000 on this kind of research, but if it does not come to a conclusion, all it does in this kind of a case is create more confusion in the minds of the patient, the poor 41-year-old woman who does not know what to do now.

And again I go back to this is an influential group that is now making a recommendation that provides guidance to doctors, insurance companies, and policy makers. So are you going to have $400,000,000 worth of confusion created at NIH similar to this, which is what this has done?

Dr. Collins. Well, we certainly do not want that outcome, Congressman, and, again, the mammography circumstance had data that fed into it from a variety of perspectives, much of it not supported by NIH.

If you look at our comparative effectiveness research portfolio, what you see are things like the Diabetes Prevention Program that Dr. Rodgers described. Now, there is an example where we learned by rigorous data analysis that in fact an intervention to prevent diabetes—which many people were not that convinced was going to work—worked spectacularly, and it worked better than the alternatives that are commonly used in practice, and that is now——

Mr. Rehberg. Okay, so you will stay out of this controversy and anything else that is controversial?

Dr. Collins. No. No, not at all. No, I am not trying to say that.

Mr. Rehberg. Well, then what would be your conclusion here?

Dr. Collins. My conclusion is that NIH’s role is to do research that generates rigorous evidence that can guide conclusions that are based upon data, and we will do everything we can to provide that kind of data to guide those organizations outside of us that are going to try to decide what is right for the individual as far as their health care.

Mr. Rehberg. So you are going to pick a fight.

Dr. Collins. We are going to try to——

Mr. Rehberg. Because you are going to provide data to both sides and then step back and watch them duke it out.

Dr. Collins. I think we believe that data that is based on evidence and reason is a good thing to add to any discussion, and we hope to be the providers of that.

Mr. Rehberg. Thank you, Mr. Chairman.

Mr. Obey. Ms. McCollum.

PRIVATE SECTOR INNOVATIONS FROM NIH INVESTMENTS

Ms. McCollum. Thank you, Mr. Chair.

I think what I heard clearly you said is that more research needed to be done so that people could make a better informed decision between doctor and patient, and that is your goal and your focus.

Dr. Collins. Well said.

Ms. McCollum. Thank you for that.

Mr. Chairman, members of the Committee, I see NIH as a public good. Like highways and clean waters, NIH is a benefit to our entire society. Those benefits are widespread, long lasting, and not always immediately profitable, where we see immediate return. That is why private business does not do and cannot often make the in-
vestments that NIH makes. So funding for the public good is one of the most important functions that the Federal Government has, and I think you gave us some excellent examples in the three patients that you provided, and I know you have hours and thousands, tens of thousands of success stories.

So the investment that this Committee is getting ready to make in the NIH are not only critical to the health of our citizens, but they also contribute to the growth of our economy.

Dr. Collins, I am going to take a little different track in some of the questions I am going to ask you and the panel here today. In your testimony, you state that every $1 of NIH funding directly results in more than $2 in economic output. The indirect and long-term benefits from NIH investments are greater, and I would like you to talk a little bit about that this morning.

So could you please tell us how investments in NIH lead to private sector innovation, both directly and indirectly? Where would the drug industry, the medical device sector, or any of the other major aspects of the U.S. health care sector be without the basic research that is supported by NIH?

Thank you.

Dr. Collins. Thank you for the question. And we do believe that by medical research investments at NIH are, besides being a wonderful stimulus of advances in health care, also a wonderful stimulus of the economy, and the evidence is very compelling for that.

Economists agree that American economic growth since World War II, more than half of that has been driven by science and technology. And if we are looking for an occasion to try to get our economy back on track, this sort of economic investment makes a lot of sense.

You quoted the direct effects of NIH investment, this more than twofold multiplier effect in one year. But if you look at the indirect effects in terms of our interactions with the private sector, if you look, for instance, at the development of new drugs, roughly 60 percent of new molecular entities that are put forward by pharmaceutical companies for FDA approval cite an NIH publication or an NIH patent as being fundamental to how that came forward.

And if you look at the way in which investments are being made by the pharmaceutical companies in research, again, much of that based upon the foundation that NIH provides, that is $56 billion of research investments done by the private sector exceeding what NIH is putting in at a little bit more than half of that.

The whole landscape, then, I think you can see is very much triggered by this. Let me give you an example of a company called Affymetrix in California, which is the main purveyor now of these DNA chips which have become a revolution in research and in clinical practice. They are the reasons now that people can actually get personalized medicine readouts, as I have done myself. This was started on an NIH grant, as a single investigator with a great idea;
and here we are now with a company that has capitalized in the billions.

I could give you many more examples. But I think your point is extremely well taken. People think of NIH—and we are glad about that—as the place where new cures for diseases are being sought, but it is also a place where our economy is getting one of the best kinds of stimulus it could.

Ms. McCOLLUM. Thank you, Mr. Chair. And I want to thank past members of this Committee for all the work they did in the genetic research that has led to the gene therapies that are out there now. If people were not willing on this Committee to invest in science, we would not only not have the cures, but we would find other countries getting far ahead of us in this technology and job creation field. So thank you, members.

Mr. OBEY. Thank you, members.

Mr. Cole.

PRIORITY SETTING FOR RESOURCE ALLOCATIONS

Mr. COLE. Thank you, Mr. Chairman.

Thank you for being here and thank you all very much for the work that you do; it is extraordinary.

A number of years ago our Congress passed the Caroline Price Walker Conquer Childhood Cancer Act and we authorized $150,000,000 a year for pediatric cancer research over a five-year period. We, as a Committee, never chose to fund that, to appropriate money for that purpose.

When you are confronted with a situation like that, where you have sort of congressional authorization on one hand, this Committee does not—because, frankly, I think it is very careful about trying not to interject itself into what are scientific decisions—how do you take something like that and balance it and make basic decisions? Or do you at all?

Dr. COLLINS. Well, it is a daily discussion that goes on amongst the NIH leadership about how to set priorities, Congressman, and it is not an easy task when we have so many opportunities and the resources are not sufficient to chase after all of them. A lot of this depends on scientific opportunity. Simply throwing money at a problem, even if it is a critical problem for public health, is not necessarily going to get you where you need to go; you need to see is there an idea here, is there a research project that could push the ball forward?

So we are always trying to both weigh public health needs, as well as scientific opportunities. We do not want to neglect rare diseases—and many pediatric cancers are rare—just because they do not affect that many people, because if it is your family where a child has been stricken with cancer, it does not matter a whole lot to you that that happens to be a rare disease.

With pediatric cancer, we have certainly adopted that as an area of great priority because of the terrible toll this takes on young people and their families. We have made great strides in many of these cancers that occur in children, but we have many others, particular solid tumors, for which we are not as successful as we would like to be.
The good news here is I think we have the tools—and this was sort of a couple of the themes that I talked about in my opening statement—both in terms of really laying out the landscape of why cancer occurs in children and accelerating the process of going from that understanding to a therapeutic; and that is moving forward at a pace that would not previously have been imaginable, and we are empowering academic investigators to take a larger role in the development of therapies, which, in the past, was largely left to the private sector. And for pediatric cancers that are rare, there is not much of an economic incentive to develop a new therapy if it is going to be risky. If academic investigators could de-risk the project, then it becomes more attractive.

The Cures Acceleration Network is another example of an authorized, but not yet appropriated, effort that I raised briefly in the opening statement that we are quite excited about because it would facilitate this process.

Mr. COLE. Well, quite often our colleagues count on this Committee to protect them from themselves, so this may be one of those instances, I do not know.

Let me ask you a follow-up question. I have gotten two different sets of responses—and they are not dramatically different—on how much money is actually devoted toward pediatric cancer care. From Director Worzog I think we had a communication that suggested it was something like $215,000,000; from the NIC we got an estimate like it was $195,000,000. Do we have any idea what the range, relatively, of dollars devoted in this effort is?

Dr. COLLINS. I do not have the numbers in front of me, Congressman; I can certainly provide them for the record. We do now have a better method of tracking how NIH is spending its dollars than we have had in the past, something that got unveiled about a year ago. So we are able to tell you, I think, accurate numbers based upon our entire portfolio.

[The information follows:]

NIH has not set its tracking system on disease spending to be able to capture estimates for childhood cancers or pediatric cancer research funding across all of NIH. However, these estimates are available for research funded by NCI. The estimated funding level in Director Orszag’s letter reflects the NCI-projected FY 2010 funding level for pediatric research (approximately $215 million), which is a broader research category than childhood cancer alone, and includes research related to child health, childhood cancers, birth defects, multiple sclerosis, etc. In FY 2011, NCI expects to fund pediatric research at $233.7 million. NCI also projects funding in the category “childhood cancer research”, which is a subset of pediatric research and includes only childhood cancer research (such as childhood leukemia and neuroblastoma). The National Cancer Institute (NCI) estimates it will spend $196.3 million in FY 2010 and $202.7 million in FY 2011 on childhood cancer research. This is the funding level that was provided in the recent NCI document. The key difference between these two categories of research is pediatric research is a broader category that includes research related to child health in general, whereas childhood cancer specifically deals with cancers affecting children.
NCI’s Pediatric Research and Childhood Cancer Funding, 2007–2010
(dollars in millions)

<table>
<thead>
<tr>
<th>Year</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010 (estimate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pediatric Research</td>
<td>243.2</td>
<td>235.4</td>
<td>240.8</td>
<td>215.0</td>
</tr>
<tr>
<td>Childhood Cancer</td>
<td>172.7</td>
<td>189.7</td>
<td>192.9</td>
<td>196.3</td>
</tr>
</tbody>
</table>

Mr. Cole. That would be very helpful. I would really appreciate that. And particularly if you could trend-line is over several years, if that was possible, so we could sort of see relatively where we are headed.

Finally on this topic—and you have answered this partly, but I just want to give you an opportunity to add anything else you would like to—where do you see us going in pediatric cancer research over the next five or ten years?

Dr. Collins. I think it is going to be a very exciting time. We will have the ability to identify what are the basic molecular drivers of a cancer that occurs by analyzing hundreds of these tumors and figuring out precisely what has gone wrong; what has made a good cell go bad and have it start growing in this fashion.

I should say, by the way, there is a wonderful new partnership between St. Jude’s and the Genome Center at Washington University in St. Louis involving $60 million of private philanthropic donations to make this go forward for pediatric cancers on hundreds of tumors.

We are going to, therefore, be able to say what are the targets for which we need magic bullets, and we should be able, in the next five or ten years, to transform our approach to pediatric cancer from the chemotherapies, which can be successful but which, as you know, are also quite toxic, into compounds that are much more directed, much more rational; more likely to be effective, less likely to be toxic.

Mr. Cole. Terrific. Thank you.

Thank you very much, Mr. Chairman.

Mr. Obey. Mrs. Lowey.

FOOD ALLERGIES

Mrs. Lowey. Thank you very much, Dr. Collins, Doctors all. I must say, having served on this Committee for many years, this is one of the most exciting hearings that we have, and I do wish we had hours, but we do not want to take you away from your important work, so let me just thank you for your service to the Country and to the people, and we look forward to continuing to increase the appropriations.

A few particular areas, first with food allergies. It is very frustrating, to those who suffer, that the only advice doctors can give now is do not eat certain foods. And as you probably remember, shockingly, it took me five years, five years to get legislation passed that mandated clear labels on food. But now at least allergy sufferers and celiac disease people call me and tell me how grateful they are that we have those labels on food.

So two questions. Allergies. I never had them until I got here to Washington. What progress are we making in understanding why the same amount of allergens has minimal impact on one person,
lethal to another? And we are any closer, Dr. Rodgers, to under-
standing why the number of children under the age of five who suf-
fer from peanut allergies has grown so much between 1997 and
2002? Every school has peanut tables; many schools do not allow
peanuts to be served. Perhaps you can respond.

Dr. Rodgers. We are going to redirect it.

Mrs. Lowey. Wrong directions. Dr. Fauci.

Dr. Rodgers. I would be happy to talk about celiac, but let me
turn to my colleague.

Dr. Fauci. Thank you for the question. It is obviously very——

Mrs. Lowey. How could I forget my good friend Dr. Fauci? I do
not know. Yes.

Dr. Fauci. It is very important, as you well know. Four percent
of the people in the United States of America suffer from food al-
lergy, peanut allergy being one of the most severe. Your question
about the differences in individuals are clearly related to genetic
predispositions. We do not know the exact genetic profile that
would pinpoint someone who has a propensity, but clearly these
are things that run in families, which strongly point to it being ge-
etic factors, which, as Dr. Collins mentioned in many of his re-
marks related to other diseases, the more we get a better handle
on the genomic basis of disease, the better opportunity we will have
to do one of the things that Francis mentioned, more personalized
medicine approach. And I think allergies and the response to aller-
gies and the desensitization to allergies are going to very, very
much fall into that category of personalized medicine.

The other question you asked is that why does it seem like we
have more peanut allergy now than we had before. Well, the honest
answer is we do not know. But we do feel that one of the issues
that may contribute to it is that, because of the greater sensitivity
in the community to the possibility of peanut allergy, more families
are withholding peanuts and peanut derivatives from children
early on in their lives, which, in our research projects now, we are
finding that that might actually, if a person is not allergic to pea-
nuts, have a paradoxical, deleterious effect, because some studies
are showing now that when you give children, at a very early age,
exposure to peanut, you naturally desensitize them to any allergy
they may have. There is a very interesting Israeli study that shows
that early exposures to peanuts actually wind up having a lesser
incidence of peanut allergy as the child gets older.

So there is a lot of active research going on. We are very excited
about it. We are getting new young investigators in the field, and
I hope in a year or so we will be able to give you even more encour-
ing information.

PEDIATRIC DIABETES

Mrs. Lowey. Thank you very much.

I was looking at you, Dr. Rodgers, because a group of children
came to my office just this week who suffer from diabetes, and it
is extraordinary to see the advances in treatment. Little children
are taking care of themselves. But we are not preventing diabetes
and we are not curing diabetes, and perhaps you can—I am not
talking about adult onset diabetes; I am talking about those that
are affecting our children. Perhaps you can comment on the research there and what progress are we making.

Dr. Rodgers. Thank you. We are actually making extraordinary progress on the treatments for kids with type 1 diabetes, the type that you are referring to. In fact, just to back up to one of the points that you made. What we are learning a lot about diabetes, actually type 1 diabetes, which is an autoimmune disease in which the body, for unclear reasons, turns against these insulin-producing islet cells in the pancreas, are actually giving us clues to patients with celiac disease. They share many features. So what we are learning in this particular disease may also have implications in a disease that perhaps affects about one percent of the U.S. population, that is, celiac disease.

In diabetes, we are trying to—this is a disease that affects individuals who have a particular genetic susceptibility, and within the last few years the number of genes that account for this susceptibility has greatly increased. Today there are over 40 susceptibility genes, which account for more than half of the predilection for developing the disease, so what that means is that we can identify, early on, which kids are likely to develop type 1 diabetes and when.

Now, it is thought that there are triggers associated with this, and understanding what the environmental triggers are is extremely important. We have almost, very recently, completed a study, a recruitment of about 7,800 infants who have this high type 1 diabetes propensity to follow them for a period of 15 years to understand what it is in the environment that is leading to the disease is it something that they eat, is it something in the environment, et cetera?

And this work is going on with other work that is funded by the NIH in specific areas, for example, the National Institute of Child Health and Human Development (NICHD) is funding a study comparing the effects of hydrolyzed infant formula to that of cow’s milk, because there are a number of people who believe potentially that cow’s milk may be that trigger. And that work is proceeding quite well.

The NIH, in association with the CDC, has also, for the first time, developed a surveillance program to look for diabetes in youth. This includes both type 1 and type 2. But, importantly, having CDC’s involvement, and because of their ability to do surveillance within States, we can better understand the clustering of type 1 diabetes that we are seeing. This may point to specific triggers in certain locales. And this is just in the surveillance. I can provide you more, because I see my time—

[The information follows:]

Pediatric Diabetes

If we find the trigger, we may be able to develop a vaccine or implement a change in diet that can prevent the disease. In addition to research to uncover the genetic and environmental components that contribute to the cause of type 1 diabetes, the NIH is pursuing research to prevent, treat, and one day cure type 1 diabetes. For example, Type 1 Diabetes TrialNet tests strategies for type 1 diabetes prevention and early treatment. TrialNet recently reported that the drug rituximab could preserve the function of the insulin-producing beta cells in people newly diagnosed with type 1 diabetes. Previous clinical trials have suggested that preserving patients’ remaining beta cell function can have dramatic, long-term health benefits. TrialNet has also launched a trial testing the ability of another agent, oral insulin, prevent
the disease in people who have high levels of insulin autoantibodies, a pre-clinical marker of the disease. TrialNet also has two other prevention trials that will launch soon or are under development.

An earlier, landmark NIH-supported clinical trial showed that improved control of blood sugar beginning as soon as possible after diagnosis can greatly improve the long-term prognosis of type 1 diabetes and result in reduced rates of life-threatening diabetes complications. This research has contributed to the fact that people with type 1 diabetes are living longer and healthier lives than ever before. However, blood sugar control is not always easy and even the most vigilant patients are at risk for sudden, acute episodes of dangerously low or high blood sugar levels. The NIH is deeply committed to helping patients achieve good blood sugar control and is taking two approaches to realize this goal: beta cell replacement and development of an artificial pancreas. With respect to beta cell replacement, the NIH supports the Beta Cell Biology Consortium (BCBC), which is studying ways to grow beta cells in the laboratory for transplantation into people and examining strategies to promote new beta cell formation in the pancreas. BCBC scientists are gaining key insights about beta cell biology and development, which is paving the way toward new cell-based therapies. The NIH also supports research toward the development of an "artificial pancreas"—a mechanical system that links glucose monitoring to insulin delivery—and has the potential to alleviate an enormous amount of patient burden.

Mrs. LOWEY. Thank you. I see that. But I look forward to it and thank you again, Dr. Collins.

Mr. OBEY. Mr. Moran.

ENVIRONMENTAL CAUSES OF ILLNESS

Mr. MORAN. Thanks very much, Mr. Chairman.

I want to follow up somewhat on the line of inquiry of Mrs. Lowey and Mr. Cole. First of all, NIH, of course, has done wonderful work. The whole Nation is justifiably proud of all you have done. In your opening remarks you cite the extension of life and the progress particularly in cardiovascular disease, the fact that older people with chronic disabilities is down markedly.

But much of the effort, at least in the past—now, I can sense kind of a shift here—has been on those called the dusk of life, and less emphasis on those at the dawn of life. That is why I was particularly impressed by a lot of the questions from the panel.

Something is happening among our children. This past generation, for example, the rate of asthma has tripled. Cancer is now, for the first time, other than accidents, the primary cause of childhood death. One in every six children is born with a developmental disability now; attention deficit disorder, dyslexia, but in many cases significant mental disability. One in 59 children is autistic. And we have talked about obesity, and it is just stunning that one in three children now, we estimate, will suffer from some form of diabetes, we understand.

There was a study commissioned by the Environmental Working Group that looked into umbilical cord blood, and they found that there were 232 industrial compounds in that umbilical cord blood. Many feel that what is happening with this most recent generation is a result of environmental factors; it is something we are breathing, we are eating or drinking. And it could well be the number of chemicals that we now depend upon for our food supply. Cow's milk, I read a number of studies that it may have a direct link to diabetes.

You have the National Institute of Environmental Health Sciences (NIEHS), and it is kind of a new thing. For a while it was sort of marginal in terms of focus.
Well, that is true, Doctor, you know that. You do not need to be defensive about it, but it really was not NIH’s focus.

But I think, as we see what is happening in this new generation of young people, these dramatic statistics point to environmental causes that we need to coordinate with our research. The endocrine disruptors is one. In the Potomac River here, that we are all familiar with, every single small mouth bass—and that is a principal fish species—every single one of them is intersexed. Something is wrong.

So I wonder—my first question really would be the extent to which we are integrating some of our findings with what the NIEHS is coming up with.

Dr. COLLINS. I appreciate the question, Congressman, and I agree that studying the environmental impact on diseases of children and of adults is a very high priority. We may be able to understand hereditary implications, but we are not going to change those anyway, so it would be much better if we understood how those interact with the environment.

And this has been one of the challenges, because a compound that in a certain concentration might be entirely safe for one person may actually be quite dangerous for another; and if we do not understand those differences, we have a very hard time identifying what in the environment we should pay attention to, because it all gets sort of blurred out by those individual differences.

With regard to children, the National Children’s Study, which is in its pilot phase of enrolling participants—and we are working hard to figure out how to do that in the most effective and cost-effective way—aims to follow 100,000 children preconception, all the way through pregnancy, and then until age 21. And a big part of that study is to collect the most sophisticated data we possibly can on environmental exposures, including in utero exposures, to try to see whether we can draw conclusions that so far have escaped us about what is causing these many different problems that we see in pediatrics.

That is the most ambitious enterprise that has yet been mounted. But, meanwhile, there are specific efforts in specific diseases to try to collect that kind of information, for autism, for instance. Certainly for pediatric cancers, if you see a cluster, what is going on there in terms of environment?

The difficulty we have oftentimes is we can measure the presence of many of these compounds, and we know that in larger concentrations they are not safe because animal studies have told us that. We often do not have the data to know what level would be safe, if any.

So our environment, which is full of the consequences of industrialization, may have things in it that, if we understood them better, we would want to get out of there, but the data is often insufficient to be confident that we know that answer; and what is the safe level is often the question for which there is not a clear response.

Mr. MORAN. Thank you.

Mr. OBEY. Mr. Kennedy.
MENTAL ILLNESS AMONG VETERANS

Mr. KENNEDY. Thank you, Mr. Chairman.
Welcome all of you. Thank you for your service to our Country in a very significant way in reducing the burden of illness for our people. One of the big burdens of illness for our people, and certainly an area where our budgetary dollars are so significant now, more than ever before—and if I could ask you all to comment on that with respect to the recent technology and the opportunities for that technology in the research that we have uncovered so far to make huge advances in this area as it relates to all of your institutes and every institute—is in neuroscience.
And particularly, talking about the burden of illness, my colleague, Mr. Moran, just mentioned autism and the prevalence of autism. Others of my colleagues have mentioned the burden of illness of Alzheimer's with the aging of America. And then, of course, you already have, as Dr. Insel knows, the huge burden of illness of mental illness in this Country, and addiction and substance abuse. And then on top of all of that you have a bow wave of needs coming down the line with our veterans population, and that is what I want to ask you about.
I know that there is greater coordination within the institutes on sharing relevant science amongst yourselves. When you are under a budget that Mr. Obey understands is part of the cap on discretionary funding increases, but Department of Defense and the VA are not, what I would like to know from you is to what extent can you coordinate your neuroscience research and—by the way, they have a big portfolio in areas that you also do research—that affect the veteran.
And I would like to know to what extent do you coordinate your work with perhaps medical research that is designed to help the veteran, because clearly the veteran is going to be—their challenges are going to also be the challenges of America with respect to all of these issues, because in finding out more about Traumatic Brain Injury (TBI) and Post Traumatic Stress Disorder (PTSD) and the complications of those, we are going to also find out the answers to many of these other issues.
And I even point out diabetes because not only do we know the correlation between depression and diabetes, but I know that there has just been a drug approved for type 2 diabetes that relates to neurotransmitters in the brain. And it is ironic because most people think it has to do with the pancreas. Now we know it has to do with the brain, just to show the interconnections in whole health.
So, Dr. Collins, if we could start with you.
Dr. COLLINS. Well, Congressman, you put your finger on a very important issue, and that is the need for us to collaborate across agencies to try to improve health in the area of neuroscience, and I think it is fair to say that that is a topic of great interest. Certainly the topics you mentioned—traumatic brain injury, PTSD, Alzheimer's—have all been areas in which we now have developed partnerships with the Department of Defense and with the Veterans Administration.
I am going to ask Dr. Insel, because he is intimately involved in several of those, to cite a few examples in answer to your question.

Mr. KENNEDY. And, Tom, if you could—by the way, I loved meeting Laura the other day. Anyway, I just want to say do you know if there is the same collaboration within VA and DOD that you have within NIH with respect to the various institutes, in terms of their neuroscience collaboration?

Dr. INSEL. Thanks for the question. I do not actually know what coordination goes on in terms of neuroscience between DOD and VA. It would be a great question to pose to each of them. I can tell you that for the collaboration with DOD, this is very tight and real, and it is a project that really came about because of the DOD's concern with the rising rate of suicide. As you know, there is a doubling of suicide amongst active duty soldiers. Last year, 160 suicides in the Army. That is actually more than the combat deaths in Iraq.

Mr. KENNEDY. Can I mention something, just if you could comment? Anahedalcytine. Do you know the drug that reduces inflammation in the capillaries, if given, in the brain, because it only goes to those areas where there is blood, so it covers the brain blood barrier? There is Defense Advanced Research Projects Agency (DARPA) research that shows that it can minimize or eliminate mild traumatic brain injury. Do you know about that research?

Dr. INSEL. We have a center that actually—it is a joint center between funded by the Veterans Administration and partly by DOD, but it is a joint center between the Intramural Program at NIH, National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Mental Health (NIMH) and the Uniformed Services University of the Health Services (USUHS), which is looking precisely at that issue.

I just met with the folks from USUHS about a week ago and heard a little bit about their excitement about this, that this is perhaps a great way for an acute treatment for TBI. And they are also very interested in being able to visualize the changes using new neuroimaging techniques which are just coming online.

So absolutely a very exciting area for science. It is not ready for prime time, but an area where it looks like we are getting some interesting advances.

NATIONAL CANCER INSTITUTE CLINICAL TRIALS

Mr. OBEY. Dr. Collins, as you know, the New York Times published an editorial about a week ago which raised serious questions about waste of time and money with respect to clinical trials, and the editorial indicated that 40 percent of the clinical trials sponsored by NCI are never completed, and it quoted the Institute of Medicine as being quite concerned about the entire situation. As you know, there is a doubling of suicide amongst active duty soldiers. Last year, 160 suicides in the Army. That is actually more than the combat deaths in Iraq.

Mr. KENNEDY. Can I mention something, just if you could comment? Anahedalcytine. Do you know the drug that reduces inflammation in the capillaries, if given, in the brain, because it only goes to those areas where there is blood, so it covers the brain blood barrier? There is Defense Advanced Research Projects Agency (DARPA) research that shows that it can minimize or eliminate mild traumatic brain injury. Do you know about that research?

Dr. INSEL. We have a center that actually—it is a joint center between funded by the Veterans Administration and partly by DOD, but it is a joint center between the Intramural Program at NIH, National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Mental Health (NIMH) and the Uniformed Services University of the Health Services (USUHS), which is looking precisely at that issue.

I just met with the folks from USUHS about a week ago and heard a little bit about their excitement about this, that this is perhaps a great way for an acute treatment for TBI. And they are also very interested in being able to visualize the changes using new neuroimaging techniques which are just coming online.

So absolutely a very exciting area for science. It is not ready for prime time, but an area where it looks like we are getting some interesting advances.
the conclusion that, as you have said, there are major difficulties in terms of not finishing trials that get started, in terms of trials that take very long to get on the ground after they have initially been designed. And they make a number of recommendations which NIH and NCI are going to now take very seriously.

One of the problems is that the networks are complicated in terms of multiple centers, and that is the nature of phase 3 trials, that they generally involve multiple centers. But there is so much bureaucracy involved in trying to get a trial started, some of that just being the paperwork, some of it being the human subjects effort, where every center has to have its own Institute Review Board (IRB) that reviews the protocol. We clearly need to move in the direction of more centralized IRBs.

It is clear that some of the clinical trials are not necessarily designed in a way that takes advantage of some of the newer discoveries about ways that you could optimize a trial by identifying those most likely to respond and, therefore, making a smaller, more tightly focused trial that would give you a result more quickly; and we need to think about that.

Some of this, though, I think relates to the fact that many of these were for rare diseases, and they simply were not able to enroll enough subjects to get enough power; and perhaps that was an unanticipated problem that should have been anticipated.

So clearly what needs to happen—and I think the IOM recommendations are actually very well put and will be a great starting point for NIH—is to worry more explicitly about efficiencies that could be achieved that are not being achieved. Maybe we do not need to have so many centers if they are only enrolling a few patients each; maybe we could do this more efficiently with a smaller number of centers with larger enrollments.

Maybe we need to prioritize what trials are really critical to do. And we need to come up with a better way to encourage participation by patients, because right now only 3 percent of adult patients with cancer participate in clinical trials, compared to the majority of pediatric patients; and we have to figure out why that is and why we have trials that we cannot manage to fill.

Mr. OBEY. Well, my concern is that one out of every four Americans is expected to die of cancer, so this is not a minor problem.

Dr. COLLINS. No.

Mr. OBEY. And people look at clinical trials as being the gold standard, and when we get a report like this, it raises really significant questions. I would ask that you keep in close touch with the Committee as you review those recommendations and concerns, because we are talking about not just a lot of lives, but a lot of money as well.

But what is the main reason why you think so many of those clinical trials do not finish?

Dr. COLLINS. I think many of them are for conditions where it has just been difficult to find enough patients with the precise conditions that had to be present to be able to enroll in the trial. They cannot find——

Mr. OBEY. Would not that tell us something about what is going on at the front end, before those trials are ever started? How should that process be changed?
Dr. COLLINS. I agree with you, it does tell you something about the inability to plan effectively about whether a trial is likely to be able to meet its enrollment criteria or not; and that is something that has to be looked at very carefully.

Imminently, we will see the appointment of a new Director of the National Cancer Institute. I guarantee you this will be a matter of the highest importance for that individual. And I think, as you have said, we have to get this right, because we are going to see, coming forward, in the next five or ten years, a very exciting list of new cancer therapeutics. But we will only know if they work if we have a clinical trials network that can test them quickly and efficiently. This has to be the highest priority.

Mr. OBEY. My time has expired.

Let me suggest we do a second round of about three minutes apiece.

Mr. Tiahrt.

BIODEFENSE RESEARCH

Mr. TIAHRT. Thank you, Mr. Chairman. This may have been asked by Dr. Fauci than you, Dr. Collins. Last year we ended up transferring $304,000,000 from the Bioshield Reserve Fund to the National Institute of Allergy and Infectious Diseases, and we justified that additional research was needed because, before we can purchase countermeasures for use in the event of a bioterrorism event.

Now, I was opposed to this; I think that it is better spent at the Biomed Advanced Research and Development Authority (BARDA)—in their advanced development program. But if these funds go to NIAID, will NIAID work with BARDA to ensure that the research is supported by those funds that address the issues that we are concerned about, and that is a bioterrorism event? And through these applications can you ensure that the funding will be spent on biodefense research?

Dr. FAUCI. Thank you for that question, Mr. Tiahrt. The answer is we work extraordinarily closely with BARDA. In fact, those very funds that ultimately came to us were spent in coordination with BARDA; they were allocated for the biodefense research and development. As you, I know, well know, we have an issue with regard to the far-end, downstream purchase of something to put into the strategic national stockpile, and what the NIH has been doing for decades, and does very well, is the fundamental basic research, concept development and preclinical development; and then there is a gap in the middle which many people refer to as the valley of death. Not a very good terminology, but it feels that way sometimes.

And that is really what we needed to shore up with the funds that were technically transfers from BioShield, but really went into the research and development in close coordination with BARDA.

So the answer to your question is yes, it will be.

Second question, is it used for biodefense? Absolutely yes.

CURES ACCELERATION NETWORK

Mr. TIAHRT. Okay. Thank you very much.
The valley of death, which we have referred to, I guess it was last authorization we put $500,000,000 in for the Cures Acceleration Network, or CAN, as we refer to it. Is CAN the best way to go about bridging this valley of death that we refer to, or are there other ideas that we should be considering?

Dr. Collins. Well, I think CAN is a very exciting idea. The Institute directors will all be gathering for a retreat all day tomorrow to talk about this, because this is an opportunity in a very flexible way to try to push forward new and exciting approaches to therapeutics.

The idea here is, as authorized, but not yet appropriated, is to provide large grants that include participation by public and private sector partners. It includes some flexible research authority to allow us, in a DARPA-like fashion, to move such projects forward rather quickly. And, if appropriated at a reasonable level, would allow multiple projects to go forward simultaneously with project managers that are authorized to both bring in resources when you need it and to kill projects that are failing, which is critical in this high-risk area as well.

The idea here is to develop a new paradigm for how we come up with new therapeutic ideas, partnering in a new way with the private sector, where academics are de-risking projects, which, as soon as they become commercial viable, can then be out-licensed, so the companies can take them and run with them. And I think, from my perspective as a physician who is anxious to see therapeutic successes come forward, this is a mechanism that we very much need and hope to be able to utilize.

Mr. Tiahrt. If I can just finish with a comment, Mr. Chairman. One of the things we saw in the DARPA program is that when we had new ideas that ended up not pursuing, failed, in other words, the people who were managing those programs got a black mark on their resume.

And I hope that when you are pursuing new ideas, that just because the idea does not work out does not mean the person failed; it may have been a very successful way of finding out not to waste more money. So please look at the individual and not put a black mark on their record just because they happen to be managing a program that is not what we want to invest more money in.

Dr. Collins. I agree with you, Congressman. Winston Churchill famously said that success is nothing more than going from failure to failure with undiminished enthusiasm. And one needs to keep that in mind. If we are not doing the kind of research that fails on a fairly regular basis, we are not pushing the envelope hard enough.

Mr. Obey. [Remarks made off microphone.]

Mr. Ryan. Thank you. I have been watching from my office, so do not feel like I have not been paying attention. [Laughter.]

Behavioral Research

Mr. Ryan. And I know not to ask about comparative effectiveness research. I know that ground has been covered.

Just briefly, I know Mr. Moran has talked about this, and I heard Congressman Kennedy talk about it a little bit, the issue of behavioral sciences, behavioral research. And last time you were
here I talked to you a little bit about mindfulness and some of the other approaches that I know NIH is looking into doing some research. Can you just kind of update me as far as is there anything that you have been doing over the last year that I should know about?

Dr. Collins. So, Congressman, we agree that this is a fruitful area for research. Clearly, the mind-body interaction plays a significant role in lots of illnesses, both in terms of their occurrence and their adaptation to those who are afflicted with them. Certainly, several of the institutes have significant portfolios in this area. I would think the National Center for Complementary and Alternative Medicine particularly comes to mind as a place that is devoted to trying to test out some of these what people might call unconventional therapies, but which clearly many people in the public are convinced are of value, and we need to develop the data to underscore what that is.

Already those kinds of studies, for instance, have shown some value of yoga in terms of helping people cope with chronic disease, and many others are being tested as well.

The National Heart, Lung and Blood Institute is also engaged in a number of these. We have a new program in basic behavioral and social science research called OPPNET, which we think also will provide some of the foundational information to help us understand the correlation between behavior and illness.

And I might ask my colleague, Dr. Insel, at NIMH, if he has other comments he would like to make about the mind-body connection because, of course, that is a topic of great interest in that area of medicine.

Dr. Insel. Well, I would say it is a topic of great interest across much of NIH in the same way as Mr. Kennedy mentioned the development of the neuroscience effort across institutes so that it is not balkanized in any way. We have a neuroscience blueprint effort across 16 institutes and centers who are now doing this, as Dr. Collins mentions, for behavioral and social science research as well.

So OPPNET is a new project; it is just getting off the ground at this point. It involves all of the institutes and centers at NIH and it will be a new forum, as well, for talking about these kinds of issues and their opportunities for taking those into a translational study of health.

Our own institute has been very interested in the work of people like Richie Davidson in Madison. We fund a center that he runs on the study of mindfulness, not only understanding what its health implications might be, but also looking at the brain and looking at physiology to understand the biology of this process as well as the psychology.

Mr. Ryan. Well, I appreciate that. I went out last year to see Richie's lab, and the work he is doing there is just amazing. And we are talking about adding 30 million people to the health care system, and I think this kind of individual responsibility, where we are actually teaching people how to manage their own levels of stress. We know what stress does to all of us in our daily lives, but over the long term that kind of high stress level leads to a lot of the problems that we are researching and spending a lot of money trying to figure out and then deal with and manage over time.
So I would just encourage you to continue to go down this road. I was at a conference a couple weeks ago at the University of Massachusetts Medical Center was sponsoring, and across the board recidivism, education, health care, prevention, right down the line. There were some cops that were there from Portland, Oregon, talking about being more aware in these kind of intense situations. There were a couple of colonels there. There were military folks talking about building up some resilience in your mind before you even go off to battle so that, when you come back, you are more resilient, you respond better, and over time I think it will prevent a lot of the PTSD that Congressman Kennedy was talking about.

So I just want to encourage you to go down this road. And whether it is health care or education, the idea that we can teach kids to focus—we always tell kids pay attention, but we never teach them how to pay attention. And this is a real way for us to teach kids how to pay attention, how to make better decisions, how to not get caught up in the moment and prevent problems.

So I just want to encourage you, because the science is there. It is there, and I think the more your seal of approval and your street cred is on some of these initiatives, the better off I think we are all going to be.

So I want to thank you for—the last point I wanted to make, too, in the field of education with social and emotional learning. I talked to the Secretary of Education about it when he was before this Committee. They have a metastudy that they did with 300,000 kids. There was an 11 percentile point increase with social and emotional learning, with some mindfulness involved in it as well. Eleven percentile point increase. You are teaching kids how to pay attention.

And we cannot just tell them to pay attention and not teach them how to pay attention; how to deal with their emotions and regulate. When you realize that your emotions are prohibiting your ability to concentrate, then we have to take step one. It does not matter how much money we throw—

And I hope our friends on the Republican side, who do not want us to keep throwing money at problems, will join with us in some of this and realize we are going to teach kids how to concentrate, how to focus, and how to reduce their level of stress and save the health care system a lot of money.

So I am glad I showed up, Mr. Chairman. Thank you.

Mr. Obey. Mr. Lewis.

COORDINATION OF RESEARCH

Mr. Lewis. Thank you, Mr. Chairman.

The gentleman’s concern about health cost and quality is one I share with you, and it has nothing to do with partisan politics. But let me say this. Years ago a couple of our members suffered from Parkinson’s, and that led some of us to organize in a nonpartisan way an environment where people who were doing research and treatment across the country came together, spent like a day and a half together.

The amazing thing to me at the bottom line was that they had never talked to each other in any significant level before, emphasizing that which has been said several ways here today, the need
to have voices within your institution pushing the kind of coordina-
tion that allows for us to tap many, many resources.

Years ago we specifically were interested in the proton therapy
process. At that time, NIH was not interested in the proton. I do
not know if it was based upon cost or what, but they were not in-
terested. So we took that issue to a hearing at the Energy and
Commerce Subcommittee of Appropriations, rather than this Sub-
committee; and, as a result of that, that subcommittee had about
a dozen members on it and ten of them had cancer in their family.
They were very interested and initial funding went forward.

Since that time, it has been suggested this might be a great item
for rationing because of relative cost for treatment, even though
initially we knew there were prospects for small tumors in the
brain, great success with prostate cancer; most recently, great suc-
cess with non-invasive breast cancer treatment. But above and be-

Well, that sort of coordination and communication could cause
NIH to help us very much tenor and hold back the tendency of
wanting to cut off avenues of research, as well as treatment, be-
cause of cost alone. So I would urge that to become a priority.

Mr. KENNEDY. I would hope maybe we could work together on
getting DOD and VA to really figure out how they are going to co-
ordinate like the NIH has on their neuroscience, because, really,
the biggest amount of additional science in brain research is going
to happen on TBI for the veteran, and that is going to accrue to
Parkinson's, it is going to accrue to epilepsy, it is going to accrue
to Alzheimer's and autism, and everything, because once you start
researching the brain—and the VA and DOD are going to be—
those veterans are going to be kicking down the door, as they did
overseas, to all of these diseases here at home.

Mr. LEWIS. Mr. Chairman, he is referring to a project that Mr.
Kennedy and I were going to begin to work on long-range relative
to the problems with veterans and specific problems like alcoholism
and drugs, et cetera, leading to homelessness. Unfortunately, Mr.
Kennedy has made a decision not to run for re-election.

Mr. KENNEDY. That is why I am leaving it all in your hands,
Jerry. [Laughter.]

Mr. LEWIS. Thank you, Mr. Chairman.

Mr. RYAN. Mr. Chairman, I would like to intervene. I would love
to help and make sure that this project continues.

Mr. OBEY. Mr. Kennedy.

TRAUMATIC BRAIN INJURY

Mr. KENNEDY. I want to go back to this anahedalcystine. From
what I understand, the DARPA showed that within the first 24
hours of a veteran suffering a concussion—and they can tell from
your rapid eye movement whether you have—and there are objec-
tive standards—whether you have suffered this—that that goes
right through the blood brain barrier because of the capillaries and
it can have long-term impacts in terms of the suffering of the con-
sequences of TBI. And it is sitting right now at the Surgeon Gen-
eral's Office of Review or whatever at I guess it is the Navy, because it is the Marine Corps.

This is something that cannot be sitting around; it has to get out there. We already have FDA approval for this. This would be off-label use of it. So I am just asking, with your basis of science at NIMH and coordination within your group, if you can offer research and support to whatever that surgeon general is going to have to review in terms of that DARPA research, please, as soon as possible, because this is going to help avoid a lot of that downward consequences as a result of TBI.

Dr. Insel. We are on it.

ELECTRONIC HEALTH RECORDS

Mr. Kennedy. And they show literally if you do not give it within the first 24 hours, you give it 72 hours later, the effectiveness diminishes dramatically.

To go to David Obey's question about the registries and clinical studies, tell us about how the new health bill and IT with the health bill offers us an opportunity, Dr. Collins, to have gene banks and registries of identify data to essentially do a lot of this that we are currently doing through clinical studies, but to really do it through the new health system.

Dr. Collins. Well, we desperately need better systems to do those kinds of large-scale research projects and, frankly, in this Country, we have been significantly impeded by the lack of electronic health records. It is very difficult to do thorough, accurate, efficient, cost-effective studies when everything is scribbled on bits of paper and it is very hard to sort out exactly what is in the medical record at all, if you can even find it. So having the opportunity to see our health care system evolve into an electronic framework is going to help enormously.

But there are a number of issues that we are engaged in here to make sure that we get the most out of this. There is whole term called meaningful use——

Mr. Kennedy. Are you consulting with those IT folks on this?

Dr. Collins. Yes, we are. Yes, we are. Obviously, one of the hopes is that that meaningful use will be defined for the standard medical record so that it is optimized for research questions to be posed. Obviously, this needs to be done, and shall be done, in a fashion that protects privacy and adheres to standards of informed consent, but I believe that those are pathways that can be negotiated. And we are really looking forward to the chance to greatly enlarge the ability to survey exactly what are the causes of illness by potentially having a much more robust system for doing so with the electronic record.

Mr. Obey. Mr. Cole.

BIOMEDICAL RESEARCH IN THE UNITED STATES

Mr. Cole. Thank you, Mr. Chairman.

Thank you, Dr. Collins. I want to ask you a series of questions just, frankly, will be easier if I just sort of laid it out, and then maybe you could educe me a little bit, since I am new to this Committee and certainly new to this topic, but very interested.
If you could, could you compare our national effort with other countries? Where would you rank us, obviously? Second, what percent of biomedical research done in the United States is actually done by NIH or something you fund? And, again, what percentage would that be nationally, if you know? And, finally, is there some realistic way—you implied in an earlier question that obviously you are at the foundation of a lot of very profitable research for people—that some of the money, some of the profits generated down the line in the private sector could, in some realistic way, flow back to you for the continuation and the augmentation of basic research? Not eliminating our role, but generating additional resources for you to do what you obviously do very well at NIH?

Dr. COLLINS. Those are great questions, Congressman, and I would be happy to quickly go through them.

As far as the national effort of the United States in biomedical research, I think it is fair to say we continue to lead the world, but that leadership is certainly being challenged substantially now by other countries—Europe, Japan, and increasingly China and India. And our trajectory in terms of the support and the numbers of individuals working in the field has tended to be fairly flat, while those are going up rapidly.

We were grateful to hear the President announce a year ago an intention to raise the U.S. investment in research and development to 3 percent of GDP, which would be a big shot in the arm, but no timetable has been set for that. The time is right, certainly, in terms of taking advantage of opportunity and of investigators who are ready to come forward with their best ideas and pursue them.

In terms of research that goes on in this Country, if it is research done in academia, that is, in our great universities and institutes all over the Country, and it is biomedical research, almost all of that is supported by the National Institutes of Health, with a healthy contribution also from philanthropy. Certainly, the private sector—I think I mentioned numbers a little bit ago—invests about $56 billion a year in biomedical research; NIH, at $31 billion is about 40 percent of the total, but in a good partnership.

And your third question about profits that might actually be able to feed back in some way to support the research that goes on at NIH is something we have thought about. In this new model, where we might have a partnership where academic investigators get more involved in the front-end of developing new therapeutics, that will result in some identification of intellectual property.

That intellectual property can then be licensed to a private company that is interested in taking it to the next step and all the way to FDA approval. And if a drug then actually gets approved and for which profits are made, some royalties stream back to the NIH would be highly appropriate, and most companies I have talked to are comfortable with that model as a good way to get the job done.

Mr. COLE. Thank you.

Thank you very much, Mr. Chairman.

Mr. OBEY. Mr. Ryan.

RECOVERY ACT INVESTMENTS

Mr. Ryan. Thank you, Mr. Chairman.
I just wanted to see if you can kind of outline—we put a lot of money into the Recovery Act, and I think you touched upon it a few times here. Can you just talk about, in your estimation, I know a lot of that money was needed to be spent years ago, and we were playing a lot of catch-up here in good measure to the leadership from Mr. Obey, but can you talk a little bit about how you feel the most impactful investments through the Recovery Act, where that went, what it is doing, and how we can—like you said, it is a marathon, not a sprint, and how we can continue to build on it over the years?

Dr. Collins. Well, because this was such a significant investment, the list of projects that were possible because of it is much longer than I can fit into this three minutes, but let me give you a couple of highlights of maybe signature initiatives—

Mr. Cole. I mean, things like we want to go out and there is a bid across the Country. Stimulus bill is not working, some people say. Well, all the metrics show otherwise. But if you could give us some tangible information on what would resonate with people, what they would grasp onto.

Dr. Collins. So Recovery Act dollars from NIH in fact went out to all 50 States, and we are in the process—quite clear we are creating or retaining 50,000 high-quality jobs in the biomedical research enterprise, which is a significant contribution.

In terms of science that this supports that is going to have a large impact on health, I have mentioned the Cancer Genome Atlas as a rapid acceleration in the ability to understand exactly at the molecular level what is going on in cancer. Similarly, with heart disease. We have the Framingham study, which has been going on for three generations, which now, because of these dollars, is possible to move into a phase of getting even more detailed information about the environmental and genetic risk factors for cardiovascular disease.

In the area of HIV/AIDS—and Dr. Fauci could tell you more details about this—this money has made it possible to tackle a couple of very novel and potentially very valuable ways to reduce the incidence of new cases of HIV/AIDS by identifying individuals who are infected and do not even know they are, and starting them on treatment which will reduce the likelihood that they can transmit the virus to others.

Autism. The effort now is funded by the Recovery Act to obtain the complete DNA sequence of 300 cases of autism and their parents to finally really understand what are the genetic contributions to a disease which clearly can run in families, so there must be something going on there.

All of those are things that we could not have done without Recovery Act dollars to provide that real opportunity to tackle things that are risky and expensive, but are potentially groundbreaking.

Mr. Ryan. I appreciate it. Kent State University, I was there a couple weeks ago. They got a significant amount of money from the stimulus bill from NIH, and I just want to say thank you, because there were a lot of folks there who were working in hiring people in Portage County, Ohio, because of what we did through the stimulus bill and what your work is. So I want to thank you for that as well. Thank you.
Dr. Collins. And I could have mentioned the pandemic flu effort, which also was greatly benefitted by the Recovery Act dollars.

Mr. Obey. Mr. Kennedy, you had one question?

HEALTH CARE REFORM AND RESEARCH

Mr. Kennedy. Yes.

Dr. Collins, you mentioned a new paradigm in terms of translational medicine perhaps working with the private sector. I would like to ask you, with this new health bill, the elimination of preexisting condition, the elimination of lifetime and annual caps puts a big onus on insurance companies now to come forward and develop models of care for different disease groups. How they put that together will ride on what the evidence-base is on how to best treat and care for groups. That is going to involve you talking to the President's assembled people who are going to roll this out, but also to insurers and, like is said, that public-private partnership as to how they best meet their obligations in the most efficacious way.

And, Tom, how do you think to do that, when it is not necessarily medical and clinical for autism, Alzheimer's, you know, cognitive disorders, but functional? And how do you have a reimbursement system that is not based on the old model? And what are you doing now to help instruct them so they are not just blocking—which they are doing now—and suing against the system? But how do you help them meet their obligations by showing them what the evidence-base is?

If you read this Sunday's New York Times about the veteran, we are not even getting it right in the DOD and VA, and we are supposed to have the best in cutting edge of treating cognitive disorders as a result of TBI and PTSD, and it is a disaster if you read or take anything from that New York Times cover story on returning warriors.

So I am wondering—hopefully, that is not the model, and I do not even know whether you guys are consulting with the VA or DOD.

Dr. Collins. We are. But I think your question is even broader in terms of the health care of the Nation, and how are we going to come up with systems that work in the new health care reform environment.

One of the things we are doing in that regard that might be worth mentioning is to try to work with HMOs that already have electronic medical record and are effectively well set up for experiments that we might be able to run in a research way to try to understand how you provide different kinds of incentives to providers to be able to improve outcomes. Because that is the big sort of missing piece in much of where we hope to go.

It is great to have all the data, and we generate a lot of that data to tell you what works and what does not. But how do you get it implemented and how do you implement it in a way where you have a health care system that actually responds to the right incentives instead of the wrong ones?

Mr. Kennedy. [Remarks made off microphone.] Are outcomes quality of life or outcomes blood pressure?

Dr. Collins. Oh, I would think quality of life and blood pressure, because they are connected.
Mr. KENNEDY. Yes, but HMOs do not measure—or insurance do not measure quality of life.

Dr. COLLINS. And you are right that we need better measures of whether quality of life is actually considered, and how would you define that in a rigorous way. Actually, we have a Common Fund Roadmap project on that, where patients actually are able to define, from their perspective, whether they are being benefitted by an intervention or not, which is often left out of the equation.

Mr. KENNEDY. Tom.

Dr. INSEL. If I may. I think you put your finger on what is going to be a very important challenge over the next couple of years. We are in a very interesting point in time for at least those with serious mental illness. We have the advent of parity for the first time as it rolls out—in spite of some suits, I think it is rolling out—and we have health care reform, which is going to have a tremendous impact for those with mental illness because of parity.

What has been such a struggle for us is so much of the cost and so much of the challenge for those with serious mental illness is outside of the health care system. They are incarcerated, they are homeless, or there are problems that play out in the school system, where we just do not see them in the health care system and we do not think about them through health care dollars.

And one of the challenges will be to figure out how do you throw that net so that all of those needs, as well as the needs of caretakers, get taken into account. We are in discussions with people and it has been a very interesting process, partly because of the parity in health care reform advances that we now are in discussions with payors, as well as everyone else, to think about what is the evidence that you need to make that extension? What would it take?

So I think you know about our Recovery After an Initial Schizophrenia Episode (RAISE) effort, which was really developed almost in the reverse; started with the payors and said what would you need for someone with an acute psychotic break to cover everything, to cover all the things that we know are necessary for recovery? And what kind of evidence could we provide to you that would make you come to the table and say this is a good buy for us, this is worth supporting?

And we are rolling this out; it is a large $25 million effort done with the Recovery Act funds, and we think this is actually going to be transformative for those people who end up being huge costs if we do not get it right on the front end.

Mr. KENNEDY. Thank you very much.

Mr. TIAHRT. Mr. Chairman, I ask unanimous consent to submit some questions for the record.

Mr. OBEY. Sure.

Mr. TIAHRT. Thank you.

Mr. OBEY. Let me ask just two questions. Do not worry, you are not missing much. [Laughter.]
NEW STEM CELL LINES

Mr. OBEY. First of all, would you explain the significance of the story that appeared in the Post this morning with respect to stem cell?

Dr. COLLINS. Yes, I would be happy to. As you know, President Obama, a little more than a year ago, issued an Executive Order indicating that stem cell lines—we are talking about human embryonic stem cell lines—that have been derived since August 2001—which is when the Bush Executive Order took effect—ought to now be considered for Federal funding if they met certain standards as far as the way in which those lines were developed in terms of the consent, especially, to be sure that that was ethical.

NIH was charged with putting together guidelines about how to do that review of stem cell lines, and those went into effect in July, and we have been receiving the information from many stem cell line developers since then and, as of today, there are 64 lines that have been approved.

Today’s news was about two particular lines that go by the names H7 and H9, which were derived a long time ago, more than 10 years ago, and were heavily utilized by researchers between 2001 and now, and for which there was a lot of data. Those lines had not been submitted to NIH for review until about two weeks ago; there were some complications in terms of finding all the documentation. The materials were submitted, we reviewed them rigorously, and yesterday I approved them as now being appropriate for support by Federal funding. Those two lines actually accounted for a substantial amount of the publications that have occurred in this field up until now.

So many people in the research community were hopeful for this outcome and I am glad to say we were able to get there with complete adherence to rigorous standards of consent, which were part of the Obama Executive Order.

DR. RUTH KIRSCHSTEIN TRAINING AWARDS

Mr. OBEY. Okay, one other long observation. As you know, Dr. Ruth Kirschstein visited this Subcommittee many, many times. She was a legendary scientist and administrator at the National Institutes of Health, and she died October 6th of 2009 after a public service career that spanned more than 50 years. Dr. Kirschstein worked on polio research, made history as the first woman to head an NIH institute, and later served as Deputy Director and Acting Director of NIH. She was a pioneer.

A significant part of her legacy is the way she served as a champion for the advancement of women and minorities in biomedical research. She was a strong advocate for research training, especially interdisciplinary pre-doctoral programs and programs to increase the number of minority biomedical scientists, physician scientists, and scientists trained in emerging or evolving areas.

In 2002, as a fitting tribute to her many years of exceptional service, particularly in the area of research training, Congress renamed the National Research Service Award Program in her honor. The Ruth Kirschstein National Research Service Award is an important tool to ensure we have a pipeline of future investigators
ready to take over as the current workforce continues to age and move toward retirement.

In 2001, NIH agreed to work towards increasing entry-level stipends under this program to $45,000 a year. Currently, NIH pays just under $38,000 a year despite their advanced degree in specialized technical skills that would allow them to earn considerably more in the open market.

I understand that the President’s budget proposes an increase of 6 percent in stipends under that program. How does that fit into your efforts to ensure a robust pipeline of young investigators? What is the current NIH policy for cost of living support in this program? And, more generally, how are we doing in attracting and keeping the next generation of biomedical researchers?

Dr. Collins. Well, Mr. Chairman. I appreciate your citation of Dr. Kirschstein and her role at NIH. It is impossible to overstate the remarkable impact that she had on the institution and on many of us personally, and she is greatly missed. We are having a symposium on May 17th, inviting many of the Ruth Kirschstein awardees to come back and talk about the science they have done in order to recognize the way in which her contribution has had a very specific personal effect on each of them, and we are expecting that to be a day of great celebration of her legacy.

In terms of what we are doing about training grants, yes, the President’s budget does propose a 6 percent increase, which I think is long overdue. If one looks at the stipends that have been proposed by NIH for such trainees, they have remained essentially flat for a long period of time, even as inflation has been eating away at the buying power. This has—I can tell you, because I recently met with the National Postdoctoral Association in Pennsylvania. This news of at least a proposed increase was a big morale booster for a group that has begun to worry about just how valued are they.

Being in that kind of training circumstance, you can imagine why that might feel a little uncertain. You are not yet independent. You have a Ph.D., so you know some stuff, but you are not making much money and you are not necessarily sure where you are going. And to get that kind of pat on the back, saying we value you and we think you are a bit underpaid—probably a lot underpaid, but we are going to try to do something about it—was well received.

How are we doing in terms of recruiting? I would say okay, but not great. And certainly when you look at the way other countries—for instance, China and India—are doing as far as bringing new talent into the scientific research community, they are surpassing us in terms of their reach and their ability to encourage people to find their careers in this path, and we are flagging a bit.

More particularly, I am concerned about the fact that our trainees do not represent the complexion or the diversity of our Country, and we need to work harder on the diversity issue and recruiting more disadvantaged individuals into this area, because we need the best and the brightest no matter what their background happened to be; and some of our programs have succeeded at that and some have not, and we are looking at a new set of ideas through a Pathfinder Award to try to improve that outreach to groups that are traditionally not represented in our workforce and should be.
So we have a lot of work to do here between the graduate students and the post-docs, the clinical investigators, the M.D. Ph.D.s who I met with this past Saturday, who are also concerned about their future but enormously energized about the scientific potential; and this is one of my personal priorities, to be sure that we are not passing up the chance to be filling our pipeline with this next generation.

And there are risks here, because they do hear their elders wringing their hands and complaining about the fact that it is hard to get a grant funded, and that one chance out of seven of having your grant actually receive funding may be a bit discouraging to some of the young people; and a few of them who met with me in Chicago talked about being on the brink of going off to do something else because of their uncertainty about whether there was a place for them. We have to work hard on that to be sure that they do see there is a place, even in difficult budget times, and hoping that, in the longer term, we might ultimately get to a point where we have stable, predictable kinds of trajectories for medical research instead of the feast and famine up and down experience, which has been pretty hard on everybody, but specifically on young trainees.

Mr. OBEY. One last question. There is a very sour mood in the Country about a lot of things these days, and when that occurs people tend to overlook some very important things that have occurred in society and in government through the years. I mentioned earlier that I have been on this Committee since, I do not remember, 1973 or 1974, one of those, and the way politics works, I guess, if you produce something that is physical and tangible, like a missile or a space vehicle, a shuttle, people can see visibly what they get for their tax dollars. But in a field like health care, there is not much that you can put your hands on to say, yes, this is what improvement in cancer research looks like. I mean, you cannot touch it. It is very different. And I think it is important that taxpayers understand that a lot of times, in lots of places, their tax dollars do some very good things.

The problem is also that you cannot see that in any one year. But if you step back and look at it over time, then you can see some major changes that have occurred.

What I would like you to do—and I do not expect you to do it now, but I would like you, at least for the record, to do this. If you take a look at what has happened because of NIH funding through the years, what are the ten biggest improvements, what are the ten most important steps forward? What are the ten ways in which the public’s health has been advanced because of what NIH and the researchers that it funds all around the Country have produced? If you can prepare that for the record, that would be useful.

Dr. COLLINS. I would appreciate the chance to do that.

[The information follows:]
TEN BEST SCIENCE ADVANCES

NIH Research and the Health of the Nation

In the first decade of the 21st century, life expectancy in the U.S. has continued to rise, standing now at an unprecedented 78 years for the total U.S. population. From 1986 to 2006 alone, life expectancy increased by 3 years.

Americans are not only living longer, they are healthier. Data from the National Long-term Care Survey shows that from 1982 to 2004, the age-standardized prevalence of reported chronic disability among American seniors (age 65 and older) dropped nearly 30 percent (28.3 percent)\(^1\). There are many factors that contribute to this decline in disability, but NIH research has played a key role. A major contribution comes from improvements in prevention and treatment of heart attacks and strokes, including control of cholesterol levels and hypertension with pharmaceuticals as well as improvements in materials and devices such as drug-eluting stents. Other specific advances include treatment of arthritis with pharmaceuticals and joint replacements, and improvements in technologies such as safe and effective outpatient cataract surgery.

Below are ten specific examples of health improvements over the last several decades that originate from the nation’s investments in NIH-funded research. Together with additional federal agencies and programs that ensure access to the best information and delivery of health care, these discoveries have transformed medical practice.

Heart Disease

The over 1,000,000 annual deaths from coronary heart disease seen 30-40 years ago have now been cut by more than half due to new drugs, procedures, and prevention programs developed through NIH research.

Thirty to forty years ago, there were approximately 1,000,000 deaths annually due to coronary heart disease. In 2006, that fell to 425,425 deaths. In the early nineties cardiac care was still relatively primitive. Bed rest was standard care for a heart attack. Bypass surgery was conservatively performed on only the youngest and healthiest. Heart failure was treated with 50 year old medications. Over the past several decades, there have been extraordinary advances in heart care, arising from NIH-funded research. In 2010, we have an array of new and more effective treatments such as use of clot-buster drug therapy during a heart attack to open up a blocked artery and use of angioplasty to open up blocked heart arteries that cause heart attacks. Bypass surgery and valve replacement surgery are now standard in 80 and 90 year olds, and “catheter ablation” treatment of a trial fibrillation and other heart rhythm problems is now standard and curative. In just 20

years time, thanks to investments in research, we have implantable defibrillators to keep the heart beat regular after a heart attack or in heart failure, new medications to prevent and treat heart failure, improved surgical treatments of congenital heart disease that result in survival well into adulthood, and safe and effective heart transplantation.

**HIV/AIDS**

In 1989 the diagnosis of HIV infection was a virtual death sentence; due to antiviral drugs developed by NIH, today an HIV positive 20 year old can be expected to reach the age of 70.

In 1989, HIV/AIDS was spreading rapidly throughout the world with no effective therapy available to treat the several hundred thousand infected people in the United States and the millions of infected people worldwide. By discovering how the human immunodeficiency virus destroys the body’s immune system, NIH-funded researchers could identify vulnerable targets for drug intervention in the virus replication cycle. This led to the rapid development of an increasing number of antiretroviral drugs that have transformed the lives of HIV-infected individuals. In 1989, if an HIV-infected individual was seen for the first time at any hospital in the USA or internationally, the therapeutic options were few and the diagnosis of HIV/AIDS was a virtual death sentence. If a person presented to his/her physician with advanced HIV disease, the survival was measured in months. Just one drug (AZT) was available, and this only modestly increased survival.

If a child was born of an HIV-infected mother in 1989, there was a 25 to 30% chance that the child would contract HIV from the mother at or around the time of birth. In the years from 1989 to 1996, NIH-funded investigators developed and proved the efficacy of a large number of antiretroviral drugs that began the era of highly effective therapy for HIV/AIDS, referred to as HAART (highly active antiretroviral therapy). Thanks to the Ryan White CARE Act, drugs have been available for low-income, uninsured and underinsured HIV-infected patients since 1991. Now in 2010, if a 20-year-old patient newly infected with HIV comes into a clinic and is treated with these drugs, it is projected that his/her average life span would be greater than 69 years. And if a child is born of an infected mother here in the USA in 2010, there is less than a 1% chance that this child will contract HIV from the mother. These advances were accomplished in large part by NIH-funded research, representing some of the most striking successes of domestic and global public health. In sum, in 1989 more than 28,000 people in the U.S. died of AIDS. That number continued to grow to its peak in 1995, when more than 50,000 people died. By 2007, the number had been dramatically reduced to 14,500 deaths.
Age-Related Macular Degeneration (AMD)

40 years ago there was little or nothing one could do to prevent or treat advanced AMD and blindness; because of new treatments and procedures based on NIH research, 750,000 Americans who would have gone blind over the next 5 years will instead continue to have useful vision.

AMD is the most common cause of blindness in the elderly. For decades there was little or nothing one could do to prevent or treat advanced AMD. Now, NIH has developed new nutritional supplements that are able to slow the development of advanced AMD by 25%. Despite this advance, over 750,000 Americans are destined to develop the abnormal blood vessels associated with advanced AMD in the next 5 years. Because of a series of remarkable discoveries, which led to new laser-based treatments, and most importantly to agents that, when injected into the eye, will reduce abnormal blood vessel growth and fluid leakage, today most of these 750,000 Americans will continue to have some useful vision, allowing them to better enjoy their later years. In addition, researchers recently identified important new genetic risk factor associated with the development of AMD, which give scientists a totally new approach to the treatment or prevention of advanced AMD and will likely to lead to new and even more effective ways to prevent and treat AMD in the coming years.

Cochlear Implants

Because of NIH supported research, profoundly deaf children that receive a cochlear implant within the first two years of life now have the same skills, opportunities, and potential as their normal-hearing classmates.

One or two of every 1000 children in the U.S. are born profoundly deaf, and those numbers have not changed for decades. What is changing – at an unprecedented pace – is the number of those children under 3 who receive cochlear implants, electronic devices that mimic the function of delicate cells of the inner ear. About 40% of such children now receive a cochlear implant, up about 25% from five years ago. In the past, most deaf children were not diagnosed until they were 2-3 years old. These children fell behind their peers in language, cognitive and social skills and, ultimately, in their ability to get and hold a job. Because of NIH supported research, deaf children who receive a cochlear implant at a young age develop language skills at a rate comparable to children with normal hearing. Improvements in speech processors and other related technologies now allow children with cochlear implants to succeed in mainstream classrooms. Today, profoundly deaf children now have the same skills, opportunities, and potential as their normal-hearing classmates after receiving a cochlear implant within the first two years of life.
Breast Cancer

Thirty five years ago, the five-year survival rate for women diagnosed with breast cancer was 75 percent; because of NIH-supported research, the five year survival rate has risen to over 90 percent.

Thirty five years ago, the annual mortality rate for women diagnosed with breast cancer was 33.2 per 100,000. Because of NIH-supported research, the five year survival rate has risen to over 90 percent. Breast-conserving surgery followed by local radiation therapy has replaced mastectomy as the preferred surgical treatment. New non-surgical therapies include combination chemotherapies, hormonal treatments, and new monoclonal antibody approaches.

A treatment option, matched to patients whose tumors express the receptor HER2, includes a monoclonal antibody, trastuzumab (Herceptin) that blocks growth signals to breast cancer cells. NIH-sponsored clinical trials demonstrated in 2005 that the addition of Herceptin to standard adjuvant chemotherapy for the 20-25 percent of women whose tumors express this receptor decreased the risk of breast cancer recurrence by 40 percent, the most dramatic improvement in the post-surgical adjuvant treatment of breast cancer ever described. Many of the genes that contribute to breast cancer risk, including BRCA1 and BRCA2, have now been identified and the results of such research are allowing life-saving screening for high risk individuals and early or preemptive treatments. And gene-based tests on the breast tumors of women with negative nodes now allow a large fraction of such women to forego chemotherapy, avoiding the toxicity of the treatment and saving the health care system approximately $100 million in 2009.

Colon Cancer

From 1974-1976, the five year survival for patients with colon cancer was 50 percent; in 2009, based on NIH-supported clinical trials, this same patient group has a five year survival rate of over 70 percent.

Mortality rates for colorectal cancer have declined in both men and women over the past 30-40 years, with a steeper decline since 2001. Twenty years ago, the five year survival for patients with colon cancer who had involved lymph nodes at the time of surgery was 40 percent. In 2009, based on NIH-supported clinical trials of surgery, chemotherapy combined with drugs, and targeted therapies such as Avastin, this same patient group has a five year survival rate of >70 percent. Twenty years ago, the median survival for patients with recurrent or metastatic colorectal cancer was <12 months. Based on a series of clinical trials conducted by the NIH, the median survival for these patients in 2009 was approximately 2 years. Progress in prevention is also encouraging -- two randomized controlled trials showed that taking aspirin daily for as little as three years reduces the development of colorectal polyps by 19 percent to 35 percent in individuals at high risk for cancer.
Cervical Cancer

Cervical cancer is the fifth most deadly cancer in women; due to groundbreaking NIH research, an FDA approved vaccine is now available which can prevent the development of cervical cancer.

Worldwide, cervical cancer is the fifth most deadly cancer in women. It affects about 16 per 100,000 women per year and kills about 9 per 100,000 per year. A few decades ago, NIH scientists established the link between human papillomavirus (HPV) and cervical cancer. This recognition set off a new quest: to develop a vaccine against a form of cancer that, at the time, claimed the lives of more than 5,000 American women each year. The researchers developed VLP (virus-like particle) technology that replicates the virus surface, boosting an immune response to the virus without accompanying viral genetic material being passed to the patient. FDA has now approved the first HPV-blocking vaccine to protect against cervical cancer. Approvals in Canada and Europe soon followed. Today, young women can be vaccinated to protect against the virus causing cervical cancer.

Type 1 Diabetes

Thirty to forty years ago, 30 percent of patients died within 25 years of a diagnosis of type 1 diabetes. Today, due to tight blood glucose control, heart disease and stroke in type 1 diabetics have been reduced by over 50 percent.

Thirty to forty years ago, 30 percent of patients died within 25 years of a diagnosis of type 1 diabetes. One in four diabetics developed kidney failure, and diabetic retinopathy was responsible for 20 percent of new cases of adult blindness. The concept of controlling blood glucose tightly to prevent diabetes-related eye disease, nerve damage, and kidney failure was untested. In 1989, enrollment of 1,441 subjects was completed in the landmark Diabetes Control and Complications Trial (DCCT). Four years later, the trial was stopped early because intensive control of blood glucose was shown to reduce eye, kidney, and nerve complications by 50 percent to 75 percent. Remarkably, 92 percent of the participants continue to be followed in an ongoing successor study. We see not only continued dramatic reductions in eye, kidney, and nerve complications, but also that heart disease and stroke are cut by over 50 percent. After 30 years of diabetes, less than 1 percent of the intensively-controlled participants have become blind, required kidney replacement, or had an amputation. Upon completion of the DCCT, intensive therapy rapidly became the standard of care nationwide. The DCCT also established a measure of glucose control as the basis for FDA approval of new diabetes therapies. As a result, the treatment options and opportunities to individualize therapy have grown and the number of drug classes for diabetes therapy has increased from two in 1998 to ten in 2009.
Hepatitis B

In the mid 1980s, hepatitis B infection caused untreatable and fatal illness. Because of intensive vaccination programs based on NIH research, the rate of acute hepatitis B has fallen by more than 80 percent—a feat considered to be one of the great achievements of 20th century medicine.

In the 1970s, the country was in the midst of an epidemic of hepatitis B that lasted well into the 1980s, with more than 280,000 new infections per year from 1984 through 1987. Twenty years ago, hepatitis B was still the leading cause of acute liver disease in the U.S., including cirrhosis and liver cancer. End-stage liver disease from hepatitis B was an untreatable and fatal illness. Because of research, we can now prevent, diagnose, and treat chronic hepatitis B infection. Safe and effective vaccines were developed and are now given to all newborns and children in the U.S. and many other countries. Because of intensive vaccination programs, the rate of acute hepatitis B has fallen by more than 80 percent. This dramatic reduction in hepatitis B infection—and in the resulting liver cirrhosis and cancer—is considered to be one of the great achievements of 20th century medicine.

Infant Health

In 1976, the infant mortality rate was 15.2 infant deaths per 1,000 live births. By 2006, that rate had fallen to 6.7 deaths per 1,000 live births with much of this progress due to NIH research in the areas of new neonatal care unit procedures and new drugs administered to women at risk for premature birth.

Forty years ago, the infant mortality rate was 15.2 infant deaths per 1,000 live births. By 2006, that rate had fallen to 6.7 deaths per 1,000 live births. Much of this progress is due to NIH research. Early studies informed the development of neonatal intensive care units, which enabled many premature infants to be kept alive, and NIH research showed how use of antenatal steroids could prevent respiratory distress syndrome and related conditions that would often lead to death within the first days of life for very frail infants. More recent NIH research continues to make inroads in preventing preterm birth and its complications. For example, in 2003, NIH supported scientists discovered that the drug 17-alpha hydroxyprogesterone caproate reduced the chances of giving birth prematurely by 34 percent in a large category of at-risk women—those pregnant with a single child who had previously given birth prematurely. More recently, physician-scientists funded by the NIH demonstrated that preterm infants born to women who received intravenous magnesium sulfate to delay labor were less likely to develop cerebral palsy. NIH research also helped infants who fail to receive enough oxygen at birth and are, thus, at greatly increased risk of death and disability: scientists found that lowering the infants' body temperatures to about 92 degrees Fahrenheit within the first 6 hours of life greatly reduced the chances of disability and death. Because preventing preterm birth remains a national health priority, NIH research will continue to develop interventions that not only ensure that a greater number of babies born too soon or too small survive, but that they will also be able to lead healthy and productive lives.
Mr. REY. What it really amounts to is—I mean, it is 35 years. It is a generation. And I think it is important people understand what has happened from one generation to another, what the taxpayer expenditures finally produce.

The other question I would have is you mentioned feast and famine. Some people might take that remark to suggest that that demonstrates that we made a mistake when we put the funding in that we did for the recovery package. So, again, I would like to know would it have been better had the Committee not provided that money over the last two years? Is it worth the discombobulation that you have because it is a two-year temporary shot in the arm? And you know what I am getting at.

Dr. COLLINS. I do.

Mr. REY. Is it worth it? Was it worth it? Was it a mistake? And is it worth the complication, I guess I would put it that way?

Dr. COLLINS. Well, Mr. Chairman, thank you for the opportunity to correct any misapprehension that might have arisen from my use of that particular phrase. It has been a wonderful investment in medical research. This $10 billion came at a time where there was a great pent-up demand and need, and a whole series of innovative ideas that were not possible to support; and they came forth in great numbers, and scientists supported by the Recovery Act are doing remarkable things right now, and we will see the consequence of those; not overnight, because science does not operate overnight, but in the long-run, as having been a very wise investment in advancing research.
It does create some stresses for the system when this comes forth in a two-year period and we cannot see sort of a more stable trajectory, and we are going to be experiencing those stresses, I fear, in fiscal year 2011, but it was worth every bit of it to get the research done that has been possible to support through the Recovery Act.

Mr. OBEY. Any other last questions?

ALZHEIMER’S FUNDING CARE VERSUS CURE

Mr. KENNEDY. On those questions that you would have Dr. Collins come back with, if there could be—we are spending a lot of money on the care of people with certain illnesses. I am thinking Alzheimer’s is one. Lots and lots of money is going to continue to go and it is going to go up.

However, if we put a fraction of the money that we are going to be putting into long-term care into researching the cure, or even researching delaying the onset of Alzheimer’s, how does that budgetarily pay for itself by averting costs averted from the actual dollars that we would otherwise be spending in the costly care of folks with these illnesses? If you could try to figure out a way how we put some metrics to that.

[The information follows:]
COST DIFFERENCE BETWEEN CARE VERSUS CURE FOR ALZHEIMER’S DISEASE

Alzheimer’s disease (AD) imposes enormous economic costs on the health care system. The Alzheimer’s Association estimates that in 2010, health care spending on persons over age 65 with AD or dementia totaled $172 billion plus $144 billion imputed to informal care provided mainly by families. Using data from the Health and Retirement Study, NIA-supported researchers are developing more sophisticated and reliable estimates of the costs imposed by AD, including the cost impact of AD on Medicare and Medicaid as well as the impact on private health insurance and out-of-pocket expenses.

In addition to vastly improving quality of life, curing, delaying, or preventing AD could potentially bring enormous economic benefits. The Lewin Group estimates that a major scientific breakthrough that substantially delayed onset of AD and slowed its progression could lead to annual Medicare savings of up to $51 billion in five years and up to $126 billion in fifteen years; corresponding annual Medicaid savings on nursing home care would be $10 billion and $23 billion, respectively. We would make two important points about these figures:

- The savings estimates cited above in the Lewin study are based on very optimistic assumptions about the new therapies. For many types of preventive medical services, expanded utilization leads to higher, not lower, medical spending overall – i.e., in order to avert one case of costly illness, it is usually necessary to provide preventive services to many patients. Accordingly, prospects for savings depend critically on the cost of the intervention and the successful targeting of the highest-risk groups.

- In addition, the Lewin study assumed that all Medicare spending for those with AD/dementia is due to AD/dementia without adjusting for age and other expensive chronic comorbidities including cardiovascular disease, cancer, renal disease, diabetes, etc.

In considering the net impact of an intervention on costs of illness, multiple factors must be considered. It is important to estimate whether or not a preventive service increases longevity, thus increasing federal spending because total Social Security outlays rise when people live longer; Medicare outlays could also rise because even if a preventive service lowers a beneficiary’s risk of one illness, a longer lifespan allows for more time to incur health care expenses. Also, if an intervention delays the onset of AD symptoms without increasing longevity, it might prolong the working lives of individuals or raise productivity.
Mr. Kennedy. And on Dr. Kirschstein, I too, David, want to just say what a pleasure it was working with her, and the fact that we were able to, with her help, put the network of basic behavioral research together, and encourage you to try to get med schools to incorporate behavioral education into their medical school curricula. I know that is a priority of yours. If you could keep the pressure going on our State boards to include that in their medical school curriculum.

Dr. Collins. Point well taken.

Mr. Obey. Thank you gentlemen. Thank you all.
ACCOMODATING THE FIVE THEMES IN THE FY 2011 BUDGET

Mr. Obey: The NIH budget overview and your testimony both describe five major themes or areas of scientific opportunity considered ripe for advances that could yield substantial benefits: genomics and other high-throughput technologies, translational science, activities that help enable health reforms, global health, and reinvigoration of the biomedical research community.

Please provide specifics as to how each of these themes is reflected in the fiscal year 2011 budget request, including any proposed redirection of resources and changes in policy.

Dr. Collins: The FY 2011 budget request includes resources to pursue aggressively the scientific opportunities articulated in the Director's Five Themes. Specifically, NIH will dedicate approximately $70 million to support innovative high throughput technologies associated with the *Genomics / High-Throughput Technologies* theme, including DNA sequencing, imaging, and computational biology; we will dedicate slightly under $90 million to expand activities in the *Translating Basic Research* theme. NIH will dedicate slightly under $90 million to research to improve the efficacy of health care and potentially lessen the cost associated with expanded access to health services within the context of the *Healthcare Reform* theme. Another $90 million is directed to ensuring the robustness of NIH training programs for the next generation of scientists as part of the *Reinvigorating the Biomedical Research Community* theme, as highlighted by a 6 percent increase for training stipends. Approximately $20 million will be directed to the *Focusing on Global Health* theme in order to support research to address the often-neglected diseases of low-income countries that contribute to staggering levels of morbidity and mortality.

INTRAMURAL RE-ALIGNMENT

Mr. Obey: Has NIH taken steps to re-align its intramural research program based on these themes, or are there plans to do so?

Dr. Collins: The NIH intramural research program (IRP) has been and will continue to be deeply involved in all 5 of Dr. Collins major themes. NIH hopes that the IRP will lead the way in developing new technology and programs that facilitate these goals. Some examples are given below:

1. High throughput approaches: The NIH IRP houses the NIH Chemical Genomics Center (NCGC) that has pioneered high throughput approaches to the discovery of new small molecules and small interfering RNAs to interrogate potential new therapeutic targets for a variety of diseases. This facility serves both the IRP and the whole community of non-NIH investigators.
2. Translational research: The NIH Clinical Center (CC) is the Nation's foremost clinical and translational research facility. It enables rapid transfer of laboratory discoveries on the NIH campus and elsewhere into early phase clinical trials. To facilitate this role for the CC, the NIH is undertaking the following: (1) The Scientific Management Review Board, at the request of the NIH Director, is in the process of recommending changes in the way the CC is funded to enhance its ability to support both extramural and intramural clinical research; (2) The Therapeutics for Rare and Neglected Diseases (TRND) program is utilizing the IRP and the CC to pilot new approaches to the diagnosis and treatment of these diseases; (3) The Undiagnosed Diseases Program at NIH is drawing patients from around the country who have complex disorders in need of diagnosis and new treatments; (4) The processes for scientific review and regulatory oversight of clinical research in the IRP are being re-engineered.

3. Health reforms: The IRP is pioneering new approaches to the harvesting of medical information for research purposes from electronic medical records. This program, called the Biomedical and Translational Information System (BTRIS) will accelerate the ability of physician-scientists to detect adverse reactions to therapies, to compare existing therapies, and to gain new insights into causes and treatments of disease, including the possibility of repurposing existing drugs. This information will reduce both research and patient care costs.

4. Global health: The IRP has traditionally been a major participant in Global Health efforts. A recipient inventory of the dozens of projects in the IRP related to Global Health can be found at (insert website). IRP contributions to global health include vaccine development such as recent Ebola and HPV vaccines, epidemiologic studies of cancer and infectious diseases, and the establishment of laboratories throughout the world to enable local research activities in areas endemic for specific diseases.

5. Re-invigoration of the research enterprise: The IRP is at the forefront of efforts to diversify and accelerate the training of the next generation of laboratory and clinical researchers. For example, the IRP is exploring the development of new programs to promote early career independent and strengthen interactions between the intramural and extramural programs.

FIVE THEMES

Mr. Obey: The NIH budget overview and your testimony both describe five major themes or areas of scientific opportunity considered ripe for advances that could yield substantial benefits: genomics and other high-throughput technologies, translational science, activities that help enable health reforms, global health, and reinvigoration of the biomedical research community.
Please describe plans for further development in each of these themes or areas in years after fiscal year 2011; and d) For each theme or area, please discuss anticipated results and impacts, and what milestones and benchmarks might be appropriate for measuring progress.

Dr. Collins: The five themes were chosen because each presents unprecedented opportunity and is a critical component for the development of a robust biomedical research enterprise. These will continue to be NIH’s major areas of focus well past FY 2011. The NIH ICs as well as the OD program offices and the Common Fund have all increased their investments in these five areas and will continue to invest in these areas as well as reap the benefits of this investment for a number of years.

Several specific examples of such ongoing investments in these areas and anticipated results, impacts, and benchmarks for measuring progress include the following.

**High-throughput technologies:** Cancer is a prime example of how high-throughput technologies promise new and improved treatments. Additional high-throughput technologies will enable assessment of gene expression and epigenomic regulatory alterations of gene transcription and translation within a given cancer. This will allow cancer diagnostics to evolve into a new paradigm, where classification is based on what molecular pathways are abnormal in the tumor. That classification will improve the ability to predict potential response to therapy, and there will be a substantial increase in new cancer drug targets. Based on these new targets, new promising compounds will be developed, often through partnerships, in both the public and private sectors. The majority of NCI-sponsored clinical trials will include complete genomic analysis of every tumor in order to match genomic findings with the appropriate drug combination. A key benchmark will be a significant increase in the number of novel compounds in Phase 1-3 clinical trials for cancer.

**Translational Science:** The National Heart Lung and Blood Institute provides informative examples of how NIH translates basic research findings into new and better treatments. The Bench to Bassinet (B2B) program is just getting underway, and in the future will create a critical mass of collaborative research across three interacting consortia. The Cardiovascular Development Consortium will probe the details of the transcriptional regulatory networks that govern cardiac development, using complementary animal models. The Pediatric Cardiac Genomics Consortium will recruit children into a common protocol to speed discovery of causative genes and evaluate the effects of genetic variation on short and long term outcomes in patients with congenital heart disease. These two Consortia will align with the third component of B2B, the Pediatric Heart Network, a multi-center clinical research enterprise. Ultimately, the results of B2B will be seen in the acceleration of the pace of fundamental discovery while simultaneously establishing a new paradigm for conducting translational research. One important benchmark for the success of these
Consortia will be the identification of new minimally invasive treatments for patients using image-guided interventions.

An important new effort in the area of translation science is the NIH Therapeutics for Rare and Neglected Diseases Program (TRND). TRND will build upon the successes of the NIH Chemical Genomics Center (NCGC). NCGC facilitates drug development from the basic research lab to the pre-clinical stage, which is when researchers begin to lay the groundwork for possible human testing of candidate drugs. Picking up where NCGC’s work leaves off, TRND will concentrate on the pre-clinical stage of drug development. TRND’s aim will be to move candidate drugs forward in the drug development pipeline until they meet Food and Drug Administration (FDA) requirements for an Investigational New Drug (IND) application. Once TRND generates enough data to support an IND application for a candidate drug, the drug would then be handed off to an experienced organization outside of NIH, such as a pharmaceutical company, for human testing and other aspects of clinical development. There may be situations in which TRND starts or remains involved in clinical studies. Like NCGC, TRND will pull together researchers with expertise in a broad and diverse range of scientific disciplines and disease areas.

Enabling Health Care Reform: Reinventing health care is thus an urgent national priority. NIH can make substantial contributions to this effort. Among projects that will be pursued are:

--- Comparative effectiveness research (CER). NIH continues to evaluate the outcomes of different medical treatment options. Examples include the Diabetes Prevention Program that demonstrated substantially better benefits of exercise and lifestyle changes over medication in preventing the onset of diabetes, and the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study that compared older, cheaper antipsychotic drugs with newer ones, demonstrating that the older drugs worked just as well and had a better side-effect profile. With support from the American Reinvestment and Recovery Act (ARRA), NIH is investing $400M in such studies in FY09 - FY10, and expects to continue high levels of support in the future.

--- Prevention and personalized medicine. Advances in pinpointing individual genetic and environmental risk factors for disease now make it possible to focus prevention strategies more effectively on those who need them most. For example, research to establish the utility of newly derived information about individual genetic risks associated with breast cancer, colon cancer, or prostate cancer, will help inform the timing of mammography, colonoscopy, or PSA screening. Some of these answers can be derived from retrospective analysis of legacy studies, but others will require prospective designs – including the possibility of initiating large scale cohort studies. Behavioral research focusing on how individual information about disease risk actually alters health behaviors and clinical outcomes will be a critical component of this program. A new NIH Basic Behavioral and Social Science Research Opportunity
Network (OppNet) has just been convened to explore the most effective ways to support this research.

-- Health disparities research. The health of racial and ethnic minorities, people living in poverty, and other disadvantaged groups in the United States is substantially worse than the health of the overall population. Using new and powerful tools to disaggregate environmental and genetic contributions, NIH will seek to pinpoint the causes of health disparities and point the way towards solutions.

-- Pharmacogenomics. Already there is compelling evidence of a correlation between genotype and drug response for more than a dozen drugs and that number is growing. But prospective studies will be needed for many of these applications, if FDA is to be convinced to require genotyping on the label, and insurance companies are to be convinced to reimburse for the cost of genotyping.

-- Health research economics. While the major justification for biomedical research will always be the relief of human suffering and the prolongation of life, further precision is needed in assessing the economic value of research initiatives, especially those that are large and expensive. Models that attempt to capture this cost-benefit balance in DALYs, QALYs, Value of Investment approaches, or other metrics are only partially successful in providing the kind of information that policymakers need. NIH could contribute usefully to this situation by initiating a grants program to encourage development and application of more rigorous models.

Global Health: Much of recent global health research has justifiably been focused on AIDS, tuberculosis, and malaria, given the enormous human toll from these common and life-threatening disorders. But it is also critical to go beyond the focus on the “big three” diseases to apply some of these same strategies to neglected tropical diseases (NTDs) of low income countries that contribute to staggering levels of morbidity and mortality. In collaboration with other sources of support such as the Bill and Melinda Gates Foundation, NIH is well positioned to play a major role in ramping up the discovery of novel targets in both pathogen and host, to facilitate advances in prevention, diagnostics, and therapeutics. Additional resources will be committed to respond to the growing challenge of chronic non-communicable diseases and injuries, which are now responsible for more than half of deaths in the developing world.

Reinvigorating the Biomedical Research Community: NIH will continue to develop innovative approaches to maintain a vibrant biomedical research community that evolves with changing conditions and is poised to exploit critical opportunities for growth and innovation. The NIH Office of the Director will continue to identify important areas of emerging scientific opportunities, rising public health challenges, and knowledge gaps that deserve special attention. NIH will continue to coordinate and oversee the planning, implementation, and evaluation of a series of trans-NIH programs supported by the NIH Common Fund. The Common Fund supports a number of new grant award mechanisms such as the Pioneer awards and the Transformative Research
Projects Initiative that provide funding for innovative research approaches. In the future, the Common Fund will remain a nimble source of funds for the NIH Director to develop new programs that address emerging challenges and opportunities.

FY 2010 STIPEND UNDER RUTH L. KIRSCHSTEIN NATIONAL RESEARCH SERVICE AWARD

Mr. Obey: What is the current NIH budget policy regarding stipends under the Ruth L. Kirschstein National Research Service Awards program in future years?

Dr. Collins: Enhanced training stipends are currently a key element of one of the NIH Director’s top five priorities, “Reinvigorating the Biomedical Research Community.” NIH is committed to improving research training stipend levels so that they reflect the extensive education and specialized skills that graduate students and newly trained investigators in the biomedical sciences bring to their vocation. The FY 2011 President’s Budget includes a 6% increase. This phased multi-year approach will seek to attain the stipend levels identified in 2001 in response to a report from the National Academy of Sciences -- $25,000 for pre-doctoral trainees and $45,000 for entry-level post-doctorate recipients.

RECRUITING AND TRAINING

Mr. Obey: What is your judgment regarding future needs for biomedical researchers?

Dr. Collins: Talented and dedicated scientists are the lifeblood of biomedical research. Today approximately 300,000 scientists and research personnel perform medical science at more than 3,100 universities, medical schools, hospitals and other research facilities located in all 50 States, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, and points abroad. The number of trainees supported by NIH formal research training programs is in fact only a fraction of the total number of individuals being trained for careers in biomedical research; a larger proportion are preparing for research careers by serving as research assistants on research projects supported by the NIH and other sources. The National Academies of Science has emphasized that the formal training program, although a small percentage of the overall training effort, sets the standard for quality and serve as an essential way to recruit talented individuals into the biomedical research careers. However, researcher training programs face many challenges. Stipends for graduate students have failed to keep up with inflation, a challenge recognized in the FY 2011 request with a 6% stipend increase versus FY 2010.

We also need to train and support a diverse biomedical research community of the best and brightest scientists, support and fund new investigators following their training, and attract and retain physician scientists, a need which will become more critical with increased emphasis on translational research to accelerate the translation of
basic science discoveries into new and improved diagnostic and treatment advances. Our success in increasing healthy life spans and preventing and treating disease -- especially given the demands of an aging population and health care reform -- depends upon a cadre of well-trained physician scientists.

Mr. Obey: Are we likely to be facing a shortage of well-trained and well-qualified principal investigators in future years, or should we be more concerned that there may be more researchers than can realistically be supported with likely public and private research funding?

Dr. Collins: Predicting the optimum size of the scientific workforce in the future is difficult and depends on many variables, including the overall research budgets of NIH, other Federal Agencies, and the for-profit and non-profit sectors. Estimates of future numbers have been derived by assessing the population of biomedical, behavioral, and clinical scientists currently employed at research universities and medical schools, biotechnology companies, the pharmaceutical industry, other large commercial biomedical research firms, small businesses engaged in biomedical research, and public and private research institutions; estimating the future growth of these enterprises, and the numbers of senior scientists leaving the workforce each year due to retirement. The studies conducted on a periodic basis by the National Academies of Science use these approaches and comprehensively consider the nation’s needs for biomedical researchers when making recommendations about the size and nature of the NIH research training and career development programs. The most recent report issued in 2005 indicated that there was reasonable balance between the supply and estimates of future demand. However, NIH believes it is time to develop better models about the optimum size and nature of the U.S. workforce for biomedical research. Scientific opportunities abound for well-trained basic and clinical scientists.

Mr. Obey: Should NIH and government generally be trying to encourage more students and graduates to enter this field?

Dr. Collins: The biomedical research enterprise depends on students and postdoctorates to provide a continuing and renewable supply of new, independent investigators. These individuals are the drivers of innovation, staffing labs that create new knowledge to answer critical, health-related research questions. Today there are unprecedented opportunities in biomedical research, including genomics and other high-throughput technologies, translational research, personalized medicine, nanotechnology, and stem cell therapy—to name but a few. As a nation, we must encourage the best and the brightest young minds to exploit these extraordinary opportunities and address the health needs of our citizens.
ATTRACTION AND RETENTION OF NEXT GENERATION

Mr. Obey: In addition to the Kirschstein NRSA fellowships, what other measures is NIH undertaking or planning in order to attract and retain the next generation of biomedical researchers?

Dr. Collins: The Ruth L. Kirschstein National Research Service Awards (NRSA) program serves to replenish the Nation’s corps of biomedical and behavioral research investigators. Through institutional awards and individual fellowships, NIH supports both basic and applied research training in biomedical and behavioral sciences, funding more than 17,000 Full-Time Training Positions (FTTPs) annually. The FY 2011 President’s Budget provides stipend increases of 6% versus FY 2010.

Over the last five years, NIH has developed a number of new programs and policies designed to minimize the length of research training and retain newly trained investigators in research. These programs include the Pathway to Independence Awards, to help postdoctorates transition to research independence, and the NIH Director’s New Innovator Awards, designed for creative new investigators.

NIH also has adopted policies to ensure a continuous flow of new, independent investigators by offering opportunities to previously unfunded applicants. Applications for traditional research grants (R01s) from new investigators are clustered at review to provide better comparisons across investigators at the same career stage. Institutes and centers also equalize the success rate for new investigators with the success rates for experienced investigators submitting applications for new projects (type 1). This ensures that approximately a quarter of all competing R01 awards involve new investigators. In addition, the NIH specifically identifies new investigators who are within 10 years of their terminal research degree or within 10 years of the completion of their medical residency. These individuals are called Early Stage Investigators (ESI) and current policy specifies that a majority of all new investigators will be ESIs. Recognizing that the path to independence can be interrupted by life events, the ten year ESI period can be extended to accommodate a career delay associated with illness, disability, family care responsibilities, military service and other factors. We believe these policies will help protect the supply of new investigators and will encourage universities to accelerate the advancement of biomedical scientists to independence.

DECREASE IN THE NUMBER OF COMPETING RPGs

Mr. Obey: Following are several questions about recent trends in Research Project Grants (RPGs), the basic mechanism NIH uses to support investigator-initiated research:

Under the budget request, the number of competing RPGs is estimated to decrease by 199 in fiscal year 2011, compared to the level expected to be supported with the FY
2010 regular appropriation (i.e., excluding Recovery Act funds) What is the reason for this decrease?

Dr. Collins: Support for RPGs remains a high priority in the FY 2011 Budget. The nominal 2 percent decrease in the estimated number of competing RPGs from FY 2010 is a result of several factors. A major one is the fact that there is a larger commitment base for prior multiyear grants in FY 2011 than in many past years, making fewer dollars available for new grants. In addition, NIH opted to provide an average cost increase of 2% for both competing and non-competing grants to help cover inflation, but which further reduced the pool of funds available for new grants. Furthermore, the FY 2011 Budget request for Buildings and Facilities (B&F) included an increase of approximately $26 million over the FY 2010 enacted level of $100 million to provide funds for specific projects related to building safety and regulatory compliance, as well as to implement facility repairs to help the NIH fulfill its continuing commitment to sustain its extensive infrastructure measured by overall Condition Index (CI). Finally, NIH is requesting a 5 percent in the Research Management & Support (RMS) mechanism to support more high-level, hands-on, and state-of-the-art skilled managers of scientific portfolios that mirror the growth in the complexity of science.

ESTIMATED COMPETING RPGS FOR FY 2010 AND FY 2011

Mr. Obey: The estimates provided with the fiscal year 2011 budget request indicate that the number of competing RPGs in fiscal year 2010 is now expected to be almost 600 fewer than the estimated last year when the fiscal year budget was submitted, even though Congress appropriated $250 million more than requested for NIH. Why has the estimated number of competing RPGs supported in fiscal year 2010 decreased so dramatically since last year?

Dr. Collins: The decrease in the number of projected competing RPGs between the FY 2010 column for the FY 2011 President’s Budget and the FY 2010 conference estimate is related to adjustments for FY 2009 Actual results. It reflects the net impact that ARRA had on the FY2009 Actuals and the impact of recalculating for competing RPGs as NIH continued to apply an average cost policy of 2% in FY 2010.

FY 2009 COMPETING RPG AVERAGE COST INCREASE

Mr. Obey: In fiscal year 2009, the number of competing RPGs supported with regular (non-Recovery Act) appropriations decreased by 626 compared to FY 2008. This decrease seems to be associated with a 13.1% increase in the average cost of competing grants, given 2% average cost increase policy. Why was there such a large increase in the average cost? Were there also other reasons for the decrease in the number of competing grants?
Dr. Collins: In FY 2009, the American Recovery & Reinvestment Act (ARRA) resulted in the blending of economic stimulus and science advancement goals of critical interest to both Congress and the Administration. Average cost projections for RPGs were calculated prior to NIH receipt of $10.4 billion from ARRA where the funds needed to be obligated before Sept 30, 2010. In order to meet the goals of ARRA to accelerate high-quality science that could be accomplished within two years, NIH leveraged the one-time ARRA resources to pay for meritorious research that was smaller in scope (i.e., shorter duration awards of two-years or less). Larger projects, which often need more than two years of support, were then overrepresented in the pool of awards funded by regular annual appropriated funds, skewing the competing RPG average cost statistic.

RESEARCH PROJECT GRANTS

Mr. Obey: Following are several questions about recent trends in Research Project Grants (RPGs), the basic mechanism NIH uses to support investigator-initiated research:

What actions does NIH take to manage the number and average cost of RPGs based on the figures reflected in the budget request, to avoid unanticipated decreases in the number of grants supported?

Dr. Collins: NIH takes several actions to manage the number and average cost of RPGs. Each year, a budget policy is developed and circulated to the Institutes and Centers by the Office of the Director. In addition, NIH publishes a yearly fiscal policy for grant awards. This policy is specifically designed to help stabilize the yearly variation in number of awards made by carefully determining equitable inflationary adjustments for existing non-competitive renewal awards. The annual average inflation increase has varied from zero in FY 2007 to 3 percent in FY 2009 and 2 percent in FY 2010. The FY 2010 policy can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-10-039.html

Mr. Obey: Please explain if this indicates a shift to lessened emphasis from investigator-initiated RPGs used to support basic biomedical research? Please explain what level of basic investigator-initiated RPGs does NIH feel is desirable, and why, to ensure a robust pipeline of future scientific discoveries are available to translate into improved health?

Dr. Collins: The one year estimated decrease in competing RPGs does not reflect a change in our commitment to investigator-initiated research or a lessened emphasis on the research project grant mechanism. The RPG mechanism is NIH’s primary mechanism for funding investigator-initiated biomedical research. These grants support investigators in a wide array of research programs across the entire medical research continuum, from basic scientific research at the molecular and cellular levels to translational research to develop treatments that are then tested in clinical trials. Most
grant applications originate with individual investigators who develop proposals for research in their area of interest. NIH experience suggests that an RPG success rate ranging between 20 and 30 percent is optimal for capturing highly meritorious research that is of interest to the researchers and is of high priority to NIH.

Mr. Obey: For each NIH institute and center, please briefly summarize three significant advances in scientific understanding or development of new therapies that have occurred over the past several years or are expected shortly that will have a tangible impact on health and that involved funding or other support through that institute or center. [Note: This request is in addition to the hearing for the record question for NIH to provide the top 10 biggest or most important advances that NIH funded in the past 30 years to advance public health.]

COMMON FUND

Dr. Collins: The information follows:

_Molecular Libraries and Imaging Program_

The Molecular Libraries and Imaging Program is supported by the Common Fund to develop specific chemicals that can be used either as probes to study biological processes or as new lead compounds for therapeutic development. The program has collected over 350,000 diverse small molecule compounds with many of the properties of successful drug candidates. These compounds are distributed to seven screening centers that test their biological activities in assays designed by academic researchers. Compounds found active in these assays are optimized for maximum biological performance by developing chemical analogs. To date, the program has produced 164 probes, including several that are lead candidates for therapies against critical diseases including cancer, neurological and psychiatric disorders (cognitive impairment, schizophrenia, Parkinson's disease, multiple sclerosis, Alzheimer's disease), and infectious diseases. All the data from these screens is rapidly released to the public through the PubChem database, which contains structures of over 26 million compounds and has over 60,000 daily users.

_Human Microbiome Project_

In FY 2008, the Common Fund launched the Human Microbiome Project to characterize the multitude of bacteria and viruses that live on and in us, including the many microbes necessary to maintain healthy digestive and immune systems. The program is creating a catalog of microbial genome sequences to enable researchers to associate specific health conditions with changes in certain microbes. To date, it has sequenced the genomes of over half of the planned 900 bacteria and made these publically available. To link changes in the microbiome with health status, the program is characterizing bacteria in samples from the mouth, nose, gut and skin of 300 healthy human volunteers using advanced, high-throughput technologies. To date, 286 people have been sampled once, 174 people have been sampled twice and 28 people have been sampled three times, which will allow the program to identify changes in the healthy
microbiome over time. In addition, the Human Microbiome Project is supporting 15 projects focused on associating changes in the microbiome with conditions that include obesity, cancer, acne, infant mortality, and Crohn’s disease. The results of the Human Microbiome Project will increase opportunities to improve human health through monitoring or manipulation of the human microbiome.

Epigenomics Program

The Epigenomics Program is intended to provide genome-wide maps of several epigenetic marks in a variety of cell types so that epigenomic changes may be correlated with diseases, conditions, and aging. The Epigenomics Program also provides support for discovery and technology development to advance the field of epigenomic analysis. Researchers funded through an initiative to generate human reference epigenome maps have completed almost 360 experiments. As of April 1, 2010 the Epigenomics Mapping Centers have mapped at least one epigenomic mark (DNA methylation or histone modification) for 28 distinct human cell/tissue types. These cell/tissue types include human embryonic stem cell types, induced pluripotent stem cell types, hematopoietic cell types, breast cell types, kidney, brain, lung, heart, and pancreatic islet cells. Using the Mapping Center definition of epigenome (global mapping of DNA methylation analysis and six histone marks) a total of six epigenomes have been mapped to date. Analysis of the data sets is well underway. These data sets deposited at the National Center for Biotechnology Information are being utilized by the scientific community. Over the past two weeks more than two thousand people have viewed Roadmap Epigenomics Program records and more than two hundred data downloads occurred. Investigators funded through this program have also successfully developed new technologies for epigenomic analysis that are being adopted throughout the research community.

FOGARTY INTERNATIONAL CENTER

Circumcision in HIV-Infected Men Does not Reduce Risk of HIV Infection in Female Partners

Recent clinical studies conducted in sub-Saharan Africa demonstrated that circumcision reduced risk of HIV infection in men by 50-60%. A study in Rakai, Uganda was the first randomized controlled trial to assess whether circumcision in HIV-infected men would reduce transmission of the virus to uninfected female sexual partners. Researchers found that circumcision of HIV-infected men did not reduce transmission of HIV to uninfected female partners over a 24 month study period. The results also suggested a higher risk of HIV transmission in couples who resumed intercourse before complete surgical healing from circumcision. As HIV prevention programs promoting male circumcision are scaled up in high disease burden areas, it is likely that HIV-infected men would also seek circumcision, in part, to mask HIV status and avoid HIV-related societal stigma. Given the findings of this study, the authors recommended that male circumcision should be offered in conjunction with HIV counseling services, condoms, and HIV prevention education for HIV-infected circumcised men and their
partners. Moreover, sexual intercourse should be resumed only after full healing of the wound after surgery.

Genomic Traits Predict Transmission of Viruses between Humans and Livestock
Many emerging infectious diseases that pose a threat to humans, such as SARS and West Nile Virus, are transmitted from animals. Researchers constructed and analyzed a database of genetic factors likely to affect the ability of a virus to infect another species. Surprisingly, researchers found that livestock viruses that replicated in the cytoplasm rather than the nucleus of the cell were more likely to infect humans. As evidenced by the rapid spread of infectious diseases in an increasingly globalized world, it is important to identify viruses that have the potential to cause pandemics. The finding that viral replication in the cytoplasm is the best predictor of animal to human transmission will assist scientists in future identification of viruses that have the potential to cause infectious disease epidemics or pandemics.

Fears of HIV/AIDS Stigma and Discrimination Discourage Women from Receiving Maternal Services in Kenya
In Sub-Saharan Africa, the intersecting epidemics of HIV/AIDS and maternal mortality have taken a terrible toll on young African women. Women comprise approximately 60% of adults living with HIV/AIDS in the region. Prior studies suggested that HIV/AIDS-related fears may adversely affect both use of facility-based delivery services and the quality of care provided on maternity units, but few have examined that link directly. In interviews by researchers, study participants reported that HIV-related fears, including HIV testing without consent, involuntary disclosure of HIV status, and HIV/AIDS stigma, are among the reasons that women avoid giving birth in health facilities. Importantly, women of unknown HIV status seemed to cause health workers considerable anxiety and were more likely to be targets of discrimination by healthcare workers than women who were HIV-positive. This study suggests that measures to counter stigma are important not only for HIV/AIDS diagnosis and treatment, but also for the improvement of maternal health and that greater outreach is needed to sensitize healthcare workers on issues related to patient consent and confidentiality.

NATIONAL CENTER FOR COMPLEMENTARY AND ALTERNATIVE MEDICINE

Ginkgo biloba Does Not Slow Cognitive Decline in Large Study of Older Adults
Although the herb Ginkgo biloba is widely marketed and used to improve cognitive health in aging adults, rigorous scientific evidence of its effect on long-term cognitive functioning has been lacking.

NIH-supported researchers rigorously analyzed Ginkgo biloba’s effects on memory. Results showed that ginkgo did not reduce dementia in Alzheimer’s patients or slow cognitive decline. The 2007 National Health Interview Survey found that over 11 percent of American adults who reported using natural products reported using ginkgo,
making it the seventh most used natural product among adults. Such results, which demonstrate no effect from ginkgo in reducing overall incidence of dementia or slowing cognitive decline, are important to share with the American public so they can make informed health care decisions.

**Physicians Use of Placebo Treatments for Patients**
Treating patients with placebos has a long, complicated, and often controversial history. Nonetheless, little is actually known about U.S. physicians’ current attitudes toward and use of placebo treatments. A recent survey found that about half of the physician respondents prescribed placebo treatments on a regular basis. Most (52%) said they think the practice is ethical. Among physicians who prescribed placebos, few said they used inert treatments such as saline injections or sugar pills; they were more likely to recommend over-the-counter analgesics (41%) or vitamins (38%). The survey provides insights into the complex relationship between placebo use and physicians’ traditional role in promoting positive expectations in their patients. Understanding the many dimensions of the placebo effect remains an extremely important topic for biomedical and behavioral research, and prescribing placebo treatments remains an appropriate topic for ethical and policy debates.

**Grape Seed Extract May Help Neurodegenerative Diseases**
A group of neurodegenerative conditions such as Alzheimer’s disease have been linked to the build-up of “misfolded” tau proteins in the brain. In an *in vitro* study investigators showed that grape seed polyphenol extract (GSPE) is capable of interfering with the generation of tau protein aggregates and of disassociating preformed aggregates, suggesting that GSPE may affect processes critical to the onset and progression of tau-associated neurodegeneration and cognitive dysfunction. This work followed an earlier study in which GSPE reduced Alzheimer’s-type neuropathology and cognitive decline in a mouse model of Alzheimer’s disease, and inhibited an Alzheimer’s-linked process called cerebral amyloid deposition. The study’s findings, together with indications that this GSPE is likely to be safe and well-tolerated in people, support further research and development of GSPE for the treatment or prevention of tau-associated neurodegenerative disorders such as Alzheimer’s disease.

NATIONAL CANCER INSTITUTE

**New Target Found for Common Childhood Cancer**
Rhabdomyosarcoma (RMS) is the most common type of sarcoma found in children. This aggressive cancer arises from skeletal muscle cells and can occur in many places in the body. Less than 30 percent of children with metastatic RMS survive more than five years. New evidence suggests that increased activity of FGFR4—a protein expressed during muscle development and highly expressed in RMS—may play a role in the growth and spread of RMS. Analysis of tissue from patients showed that high expression of the FGFR4 gene is associated with advanced-stage disease and poor patient survival. Depletion of wild-type FGFR4 in human RMS cells transplanted into
mice resulted in reduced tumor growth and fewer lung metastases. Experiments in mouse RMS cell lines showed that expression of these mutant genes resulted in activation of FGFR4 and downstream signaling pathways as well as increased tumor proliferation and metastatic potential. These results indicate that FGFR4 acts as an oncogene in RMS and provide a rational basis for targeting the FGFR4 pathway in patients with advanced-stage RMS, who currently have very poor long-term prognoses.

*Elucidating the Role of Antisense RNA Regulation in Cancer*
Antisense RNA, which is complementary to protein-encoding RNA, can play a role in regulating cellular processes. When expressed correctly, antisense RNA molecules can manage organization of the chromosomes and regulate gene expression; however, improper accumulation of antisense RNA can have harmful effects on the cell, such as the loss of growth control and tumor development. Recent studies indicate that a protein called H2A.Z and the RNA interference (RNAi) machinery (that degrades RNAs) have important roles in preventing the accumulation of antisense RNA. Cells that were genetically altered to remove H2A.Z exhibited a large increase in antisense RNA production. These experiments suggest that H2A.Z, together with the RNAi machinery, recognizes improper antisense RNA and facilitates its degradation before it can alter cellular processes. It is likely that aberrations in antisense RNA regulation contribute to cancer and other diseases. This knowledge expands our understanding of the cellular events that contribute to cancer initiation and progression and may help identify new therapeutic targets.

*The Cancer Genome Atlas Reports First Results of Comprehensive Study of Brain Tumors*
The Cancer Genome Atlas (TCGA) Research Network aims to catalogue and discover important cancer-causing genome changes through large-scale analyses and provide the data rapidly to the research community. Initial results of the comprehensive study of the most common and deadly brain tumor in adults, known as glioblastoma (GBM) provided new insights into the roles of three cancer-related genes—ERBB2, NF1, and TP53. The results also uncovered some of the focal points disrupted in three major cellular pathways and implicated them in the development of GBM. Determination of the patterns of deregulation of different major pathways in glioblastomas may be informative in guiding future therapeutic decisions. Together, these findings demonstrate the usefulness of the type of large-scale analysis carried out by TCGA for rapidly expanding our knowledge of the molecular basis of cancer.

NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES

*Effectively Recruiting Minorities into Clinical Research*
Although minority populations disproportionately bear the burden of many chronic illnesses and diseases, they are often under-represented in clinical research and traditional methods of engaging minority populations in clinical research have often proven ineffective. Using a Community Based Participatory Research (CBPR)
approach, academic researchers and community members collaborated to test the effectiveness of a range of strategies intended to recruit low-income minority persons in a diabetes prevention intervention. Results of this research suggested that recruitment approaches in which researchers partner with members of the targeted community are the most effective at recruiting and enrolling minority populations in clinical research (68% of enrollees). Identifying effective recruitment strategies is a huge initial step towards enrolling and retaining minorities in clinical research trials; determining whether the health practices or interventions under study are effective for members of minority groups; and reducing or eliminating health disparities.

The Role of Community Nutrition Programs in Reducing Obesity in Children from Medically Underserved Communities
The prevalence of overweight in children is high in the United States. Current estimates indicate that 17% of children and adolescents are obese, representing a threefold increase compared with two decades ago. This cross-sectional study of 2- to 12-year-olds living in medically underserved areas examined the proportion of children meeting the food group intake recommendations for fruits, vegetables, total grains, dairy, and meat/meat alternatives by age group and body weight status. Overall, the proportion of children meeting the food group intake recommendations was low with the exception of the meat group, which was met by 52% and 93% of the 2- to 5- and 6- to 12-year-old children, respectively. The data support the importance of community-level nutrition intervention programs to improve children’s diet quality in low-income, medically underserved areas and suggest that such interventions may help reduce the risk of obesity. The Community Health Center setting may be an appropriate venue for community-level intervention studies aimed at improving the dietary intake habits of children at high risk for childhood obesity.

Increasing the Capacity of Health Sciences to Address Health Disparities
In order to create a cohort of investigators who are engaged in health disparities research, scholarship, and practice, and to increase the amount of funding in the university that is invested in research focused on reducing health disparities, the San Diego EXPORT Center implemented 2 major initiatives: (1) the support of development of diverse junior faculty who are interested in health disparities research and (2) the funding of pilot research grants in health disparities. Ninety-five percent (18 of 19) URM junior faculty completed the faculty development program, and 83.3% (15 of 18) of the completers are advancing in their academic careers at the University of California San Diego (UCSD) and are teaching, working with populations at risk and/or conducting research in health disparities. EXPORT awarded 7 investigators a total of $429,186 to conduct pilot research, and 71.4% (5/7) have now obtained $4.7 million in independent extramural funding. The UC San Diego EXPORT Center has shown that both junior faculty development programs and pilot grant funding are ways in which universities may increase research capacity, strengthen infrastructure for health disparities research, and create a cohort of successful URM junior faculty who advance in their academic careers.
NATIONAL CENTER FOR RESEARCH RESOURCES

**Novel Therapy for Hepatitis C**

Chronic Hepatitis C virus (HCV) infection affects more than 170 million people worldwide who may subsequently develop liver cirrhosis or liver cancer. Chimpanzees are the only animals other than humans in which HCV meaningfully replicates, although HCV does not typically cause disease in chimpanzees. A novel treatment strategy relies on a drug directed against a host cell RNA, microRNA 122, which is needed for HCV to replicate. An oligonucleotide that interferes with microRNA 122 successfully blocked virus production in animals. This new class of drug that targets a cellular product needed for HCV replication (therefore, removing the potential for the development of drug resistance by the virus) showed excellent efficacy in chimpanzees. Further testing will be needed to assess safety in infected populations, and to potentially develop additional agonists with an acceptable efficacy/safety profile in humans.

**Method to Judge Effectiveness of HIV Vaccine Candidates Identified Through Use of a Monkey Model of AIDS**

The multi-decade effort to develop an HIV/AIDS vaccine has been hampered by the lack of a valid surrogate marker for effectiveness, which would help select hopeful vaccine candidates for testing in human clinical trials. Such markers would reduce costs and save time expended on human clinical trials. Scientists developed a mechanism-based method to predict vaccine effectiveness in a monkey AIDS model. The methods are based on counting "targets" (i.e., retrovirally infected cells that need to be killed by the host), and "effector cells" (i.e., relevant host immune cells that are available at the right time and the right place to kill the infected cells). Using this method, the location, timing, and magnitude of the immune responses from vaccination will enable pre-evaluations of HIV/AIDS vaccines tested in monkey models to predict whether an analogous approach is likely to be effective in humans.

**Molecular markers enhance the diagnosis and treatment of Non-Hodgkin’s Lymphoma**

There are many different forms of non-Hodgkin’s lymphoma, which is among the most common and deadly malignancies in adults. The many forms of lymphoma are very hard to distinguish using current clinical tests because the cancerous cells are virtually indistinguishable. This has a significant impact on diagnosis and treatment. The NCRR-supported Mass Spectrometry Resource for Biology and Medicine at Boston University has played a key role in developing a new approach to diagnosis and characterization of non-Hodgkin’s lymphoma using the molecular signatures of proteins that are produced by these cancerous cells. There are two important novel aspect of this strategy. First, information on protein markers is combined with gene expression data. This combination makes each approach significantly more powerful. Second, the protein signature of cancerous cells is compared not just with normal cells, but also normal cells that are rapidly growing and multiplying. This allows the researchers to distinguish the unique cancer signature from changes that occur when cells grow normally. Effective, reliable molecular "markers" of disease, particularly cancers, is an important goal of biomedical research. This study demonstrates the significantly
increased analytical power and molecular specificity of molecular markers that is possible through modern mass spectrometry and related techniques.

NATIONAL EYE INSTITUTE

Clinical trial network demonstrates comparative effectiveness of Lucentis for reversing some vision loss caused by diabetes
Diabetic retinopathy is a leading cause of blindness in the US. Fluid leaking from newly formed, but abnormal, blood vessels in the eye leads to retinal swelling and vision loss. For the past 25 years, diabetic retinopathy has been treated by using a laser to destroy abnormal blood vessels. Laser therapy slows progression of the disease, but new therapies are required to improve care and prevent further vision loss. Evidence has accumulated that abnormal blood vessel growth in diabetic retinopathy is caused by a protein, vascular endothelial growth factor (VEGF). This trial compared the effectiveness of laser therapy alone to laser therapy combined with Lucentis, a drug that prevents VEGF from stimulating abnormal blood vessel growth. Nearly 50 percent of patients who received the combination of Lucentis and laser treatment experienced substantial visual improvement after one year, compared with only 28 percent who received laser treatment alone. Lucentis is currently FDA-approved for treating age-related macular edema, which is also caused by leaky abnormal blood vessels. Although the use of Lucentis for diabetic retinopathy is currently off-label, the results of this trial are already changing clinical practice.

Clinical Trial of Gene Transfer Therapy for Congenital Eye Disease Finds Lasting Visual Improvement
In 2007, the National Eye Institute launched a phase 1 clinical trial to assess the safety of gene transfer in humans with a form of Leber congenital amaurosis (LCA). This is the first clinical trial to assess gene therapy in humans with eye disease. People with LCA are born with severe visual impairment or lose their vision in early childhood. The form of LCA being evaluated in this study results from mutations in the RPE65 gene which plays a critical role in the visual cycle, the set of biochemical reactions that convert light into an electrical signal to initiate vision. Mutations in the RPE65 gene disrupt the visual cycle resulting in LCA. Fortunately, the structure of the retina remains relatively intact into early adulthood, providing an opportunity to intervene therapeutically. In 2009 investigators published one year follow-up results of the three patients who received this investigational therapy. The patients, ranging in ages from 22-25, remained healthy and experienced no adverse events. Statistically significant increases in light sensitivity were found in the first three months of the trial in all patients and remained unchanged at one year. Gene transfer is particularly well-suited to the treatment of retinal degenerative diseases. Nearly 200 single gene defects have been implicated in these diseases. This clinical trial is an important step in treating LCA and in establishing proof-of-concept for gene transfer as a viable therapy for an entire family of eye diseases.
Elimination of Blinding Trachoma Unexpectedly Reduces Childhood Mortality

Trachoma is a leading cause of blindness in the developing world and affects an estimated 8 million people. Children are most susceptible to this infectious disease that is caused by exposure to *Chlamydia trachomatis*, a microorganism which spreads through contact with other infected people and through transmission by flies. An NIH-supported clinical trial demonstrated that six treatments of azithromycin for more than 90 percent of the population in two severely affected Ethiopian communities over a three year period eliminated trachoma. Additional analysis by these investigators showed that treating these villages with azithromycin also sharply reduced childhood mortality. This unexpected effect most likely occurred because the antibiotic was also active against undiagnosed respiratory infections, gastrointestinal diseases, malaria and other endemic diseases. The strategy of local elimination of trachoma in severely affected villages provides evidence that it is possible to eradicate the disease worldwide and significantly improve child health.

NATIONAL HUMAN GENOME RESEARCH INSTITUTE

Large-Scale Genetic Study on Lung Cancer Opens Door to Individualized Treatments

More than 150,000 people die of lung cancer each year in the United States. Lung adenocarcinoma, the most frequently diagnosed form of lung cancer, arises over the course of years from cumulative DNA changes, which are poorly understood. The Tumor Sequencing Project (TSP) consortium identified 26 genes that are frequently mutated in lung adenocarcinoma. In particular, over two-thirds of the tumors studied had at least one mutation affecting the mitogen-activated protein kinase (MAPK) pathway. This pathway likely has a crucial role in lung cancer, and now serves as an area of future study and development of therapeutics. Also, researchers found that tumors from smokers had a threefold increased mutation rate compared to tumors from patients who had never smoked. The discovery of additional genes and pathways involved in lung cancer will inevitably help pave the way for more individualized approaches for detecting and treating the nation's leading cause of cancer deaths. By utilizing the important subgroups identified by the study, doctors will be able to better characterize individual tumor types and suggest more effective, personalized therapies.

High throughput screening and medicinal chemistry used to identify lead compounds to treat trypanosomiasis

*Trypanosoma* is a group of parasites that infect and replicate inside a host. Spread by blood-sucking bugs, *T. cruzi* causes American trypanosomiasis, commonly called Chagas disease. About 16 million people are infected with the parasite, primarily in Latin America. The chronic form of Chagas disease can damage the heart, esophagus and peripheral nervous system. A related species, *T. bruceti*, which is transmitted by tsetse flies, causes African trypanosomiasis, or African sleeping sickness. If untreated, the parasite migrates to the central nervous system, causing seizures, mental disorders and, ultimately, death. NIH researchers designed an automated, high-throughput screen to search for and identify chemical compound that block a key group of enzymes that are essential to *Trypanosoma* survival and reproduction. Medicinal chemists further modified the structure of the chemical
compounds, resulting in 350 times more power to inhibit key *Trypanosoma* enzymes than the original compounds. In addition, the modified compounds demonstrated greater activity against live *T. brucei* parasites grown in the laboratory. This discovery provides an exciting starting point in the effort to create effective drugs for the devastating *Trypanosoma* infections and demonstrates how high throughput facilities can quickly translate scientific discoveries into potential therapies.

*Researchers Discover New Genetic Variants Associated with Increased Risk of Stroke*

Stroke is the third leading cause of death in the United States and causes serious long-term disabilities for many Americans. There are two major types of stroke. The most common kind, ischemic stroke, is caused by a blood clot that blocks a blood vessel in the brain. The second type, hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into or around the brain. Scientists identified a previously unknown connection between two genetic variants and an increased risk of stroke, providing strong evidence for the existence of specific genes that help explain the genetic component of stroke. The researchers discovered that two previously unsuspected common genetic variants or single-nucleotide polymorphisms (SNPs) were consistently associated with total stroke (all types) and ischemic stroke in white persons. The genetic variants were discovered by analyzing the genomes of individuals from the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) consortium. This extensive resource includes participants from the Framingham Heart Study, Atherosclerosis Risk in Communities study, Cardiovascular Health Study and Rotterdam Study. As we learn more about the role that an individual’s unique genetic makeup plays in their overall health, we will ultimately be able to tailor care to better diagnose, prevent, and treat conditions such as stroke.

**NATIONAL HEART LUNG AND BLOOD INSTITUTE**

*Researchers Identify New Treatment for Sickle Cell Disease (SCD)*

Individuals with SCD produce an abnormal form of hemoglobin that causes red blood cells to sickle, blocking circulation. Patients with milder cases of the diseases often have elevated levels of fetal hemoglobin (Hbf). Therefore, a major goal of SCD research is to develop therapies that raise Hbf levels. Researchers recently demonstrated that a small genetic change known to correlate with Hbf levels affects the function of the gene BCL11A, and that lower levels of BCL11A activity are associated with higher levels of Hbf. The investigators showed that artificially reducing levels of BCL11A activity in human red blood cells dramatically increased Hbf production, suggesting that blocking BCL11A in patients with SCD also might elevate Hbf and ameliorate symptoms. These findings advance the prospects for developing highly effective treatments for SCD via inhibition of BCL11A. SCD is responsible for substantial mortality and significant use of health care resources. The ability to eliminate symptoms and prevent complications would substantially improve the health of millions of people worldwide.
Comparative Effectiveness Study: New Surgery for Heart Failure Patients May Be Unnecessary

Heart failure is the inability of the heart to pump sufficient blood to provide proper nourishment to the body. It can develop when arteries feeding the heart tissue become blocked, as happens with a heart attack. In such cases, a healthy artery or vein from another part of the body can be used to route oxygen-rich blood around the blockage to the heart muscle, a procedure known as coronary artery bypass grafting (CABG). In many patients with heart failure, however, the heart expands like a balloon, further weakening it. Surgical ventricular reconstruction (SVR), a newer surgery that can be performed at the same time as CABG, was designed to eliminate the ballooned, scarred, and thinned area of heart. However, the health benefit of performing this additional surgical procedure during a CABG operation is not known. A comparative effectiveness trial was designed to determine whether CABG alone or CABG plus SVR is the better strategy for management of heart failure caused by obstructed coronary arteries. 1,000 heart failure patients from 96 medical centers in 23 countries were randomly assigned to undergo CABG alone (499 patients), or CABG plus SVR (501 patients). After 4 years of follow-up, researchers found no difference between the two groups in combined rates of death and heart-related hospitalizations. Moreover, no differences were observed in the ability to exercise or in symptoms such as chest pain. The study concluded that SVR offered no benefit over CABG alone in this population. Five million people suffer from heart failure in the United States. The finding that performing SVR in addition to CABG does not improve survival or reduce hospitalizations will help physicians decide how to treat heart failure patients.

New Research Holds Promise for Preventing High Blood Pressure

For years, scientists commonly thought that high uric acid levels (often associated with hypertension) were a result of hypertension rather than a cause. New research demonstrated that lowering blood uric acid levels with drug treatment can reduce blood pressure. In 30 adolescents with hypertension and high levels of blood uric acid, treatment with allopurinol, which lowers uric acid levels, was associated with decreased blood pressure. The results were dramatic—20 of the 30 adolescents attained normal blood pressure while taking allopurinol. Although the findings await confirmation in larger clinical trials, if high uric acid levels are determined to play a role in the etiology of hypertension, treatment with allopurinol may one day be used to delay, or even prevent, the development of hypertension.

NATIONAL INSTITUTE ON AGING

Extending Lifespan
Calorie restriction has been tested in laboratory animals and on a limited basis in humans and found to have a variety of positive effects on health and longevity. Despite these findings, calorie restriction may not be practical or safe for most people. Rapamycin, an inhibitor of the mTOR (mammalian target of rapamycin) pathway that helps to regulate cell growth and proliferation, is one of several compounds being studied for effects that might be similar to those of calorie restriction. Investigators
demonstrated lifespan extension when mice began receiving rapamycin in their chow at 270 or 600 days of age, when some age-associated changes have already begun. Although lifespan extension had been achieved in fly and worm models using pharmacological interventions, this is the first time a drug has been shown to extend lifespan in a mammal. Unfortunately, rapamycin has caused serious side effects in humans. Because of adverse side effects, rapamycin is not the ideal drug for extending the lifespan of humans. However, this research has more clearly identified the mTOR pathway as important across species for extending lifespan and may guide researchers to target different proteins in the same pathway in ways that do not cause harmful side effects.

*Brain Amyloid Deposits in Cognitively Normal People May Predict Alzheimer’s Disease (AD) Risk*

The progressive accumulation of beta-amyloid plaques is a hallmark of AD and is considered to be part of the degenerative process of the brain in this disorder. Although the amount of beta-amyloid in the brain is usually associated with the severity of the disease, researchers have long known that some individuals may have a considerable amount of beta-amyloid in their brains but remain cognitively unimpaired. Imaging techniques such as positron emission tomography (PET) used in conjunction with a new tracer compound called Pittsburgh compound B (PiB), which was developed by NIH investigators, allows scientists for the first time to visualize beta-amyloid in the brains of living individuals. Investigators used PiB PET imaging, magnetic resonance imaging, and standardized cognitive tests to explore the relationship between brain beta-amyloid and dementia risk in cognitively normal people. They found that higher amounts of the protein deposits in dementia-free people were associated with an increased risk of developing dementia over time and with loss of brain volume and subtle declines in cognitive abilities. These findings suggest that brain beta-amyloid may in fact be a preclinical sign of disease even among individuals who appear cognitively normal and represents an important step toward development of a comprehensive profile of AD in its earliest stages, before symptoms appear.

*Measurement of Biomarkers Shows Promise in Diagnosing Alzheimer’s Disease*

Alzheimer’s disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest tasks. Research suggests that the earliest AD pathology begins to develop in the brain long before clinical symptoms yield a diagnosis. Therefore, it is critical to detect signs of the disease at the earliest point possible in order to test interventions and, ultimately, treat the disease as early as possible. One of the most comprehensive efforts to date is the Alzheimer’s disease Neuroimaging Initiative (ADNI). In the first ADNI cerebrospinal fluid (CSF) biomarker study, NIH-supported researchers established a method and standard of testing levels of both tau and beta-amyloid proteins, known biomarkers for AD, in the CSF. Researchers correlated levels of these proteins in the CSF with changes in cognition over time and determined that changes in these two protein levels in the CSF may signal the onset of mild AD. This is a significant step forward in developing a test to help diagnose the initial stages of
Alzheimer’s disease earlier and more accurately so that treatment efforts may begin and potentially delay the development of more severe AD symptoms. This effort may open the door to the discovery of an entire panel of CSF biomarkers that will not only predict people at risk of developing AD, but also assess how the patient responds to therapies.

NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

**Activation of Aldehyde Dehydrogenase-2 Reduces Damage from Heart Attack**

Oxygen starvation to working heart muscle due to reduced or blocked blood flow (ischemia) causes a heart attack, which affects nearly one million people in the US every year and is the leading cause of death in developed countries. Prior exposure to certain chemicals such as ethanol and adenosine, and selective activation of protein kinase Cε (PKCε) has a protective effect and reduces the amount of damage during a heart attack. Previous studies demonstrated that exposure to alcohol activates PKCε. However, it was not known whether activation of PKCε or activation of other proteins was critical for the cardiac protection. Investigators found that a change in the enzyme aldehyde dehydrogenase 2 (ALDH2) caused cardiac protection and that PKCε activation increased ALDH2. The investigators demonstrated that protection by alcohol against heart damage during a heart attack is due to the activation of mitochondrial ALDH2 in response to PKCε activation. Therefore, agents that activate PKCε and/or ALDH2 might be beneficial in treating patients with heart attacks as well as patients that experience cardiac ischemia for other reasons, such as bypass surgery.

**Prevention of Risky Youth Behavior Associated With a Gene Polymorphism - A Test of the Interaction of Genes and Environment**

It is thought that both genes and environment influence the behavior of youth, including risky behaviors such as alcohol consumption, illicit drug use, and unprotected sexual intercourse. One genetic factor that affects the likelihood of initiation of risky behavior is a polymorphism in the gene that encodes the serotonin transporter (5HTT), which is known as the “short” variant. Individuals that have the “short” variant display more risky behaviors than individuals with the “long” variant of 5HTT. Investigators used a randomized prevention trial to test whether rural African American youth, possessing the short 5HTT, were less likely to engage in risky behaviors if they participated in a family-centered prevention program, SAAF (Strong African American Families Program). The researchers found that adolescents with the short variant of 5HTT who participated in the SAAF program were no more likely than control participants who possessed the long 5HTT, to engage in drinking, marijuana use, and sexual activity; and were half as likely to have engaged in these risky behaviors as their counterparts with the short 5HTT who did not participate in the family prevention program. This is the first study to test the interaction between genes and environment in a randomized prevention trial. It demonstrates that African American youth with a particular high-risk genotype benefited more from positive factors in their environments, such as enhanced parenting practices, than did youth with the low-risk, genotype. Parenting that includes high levels of control, vigilance, emotional support and racial socialization
helped young African Americans with the short SHTT avoid situations that promote risky behavior including affiliation with peers who are likely to engage in these behaviors, and to internalize parental norms for alcohol and drug use.

**Fetal Exposure to Ethanol Has Long-Term Effects on the Severity of Influenza Virus Infections**

Prenatal alcohol exposure is known to cause numerous birth defects including growth retardation, muscular and skeletal abnormalities, and intellectual and behavioral impairments. Fetal alcohol exposure also causes a variety of immune deficits both in human and animal models. To determine the long-term effects of fetal alcohol exposure on disease susceptibility and on the adult immune system, researchers exposed mice in utero and while nursing to ethanol, and then tested their response as adults to direct viral infection of the lungs. Fetal alcohol exposure resulted in serious long-term impairment of the adaptive immune response and these immune changes were associated with reduced body weight and increased survival times after influenza viral infection when compared to mice that were infected with virus but were not exposed to alcohol. Whether adult humans exposed to alcohol in utero have the same increased susceptibility to viral infections as observed in these mouse studies is not known; however, these results highlight the need for longitudinal clinical studies to assess the effects of in utero alcohol exposure on long-term immunity.

**NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES**

**Vaccine Regimen Shows Modest Reduction in Risk of HIV Transmission in Thailand**

The development of a safe and effective vaccine against the human immunodeficiency virus (HIV) is critical to controlling the pandemic worldwide. Traditionally, HIV vaccine studies have focused on a strategy that “primes” or initiates the immune system to respond to the virus followed by a “boost” at a later time period to strengthen the original response. This trial evaluated the administration of four priming injections with a recombinant whole virus vaccine, called ALVAC-HIV, followed by two booster injections of a separate recombinant vaccine that encodes the HIV surface protein gp120, called AIDSVAX B/E. The prime-boost vaccine regimen was found to be safe and 31 percent effective in preventing HIV infection. Patients were monitored for signs of HIV infection in the blood after a 6 month vaccination series and, subsequently, every six months thereafter for 3 years. Overall, 74 of 8,198 placebo recipients became infected with HIV compared with 51 of 8,197 participants who received the vaccine regimen. The well tolerated ALVAC-HIV prime and AIDSVAX B/E boost vaccine regimen may reduce the risk of HIV infection in a community-based population. Although the results show only a modest benefit, this finding represents a major step forward for HIV vaccine research, providing the first evidence that development of a safe and effective preventive HIV vaccine is possible.

**Rapid Characterization of the 2009 H1N1 Influenza Virus**

In April 2009, a new H1N1 influenza virus emerged in Mexico and the U.S. and quickly spread worldwide - the first influenza pandemic of the twenty-first century, as
declared by the World Health Organization. The NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS), established in 2007 to support the HHS Pandemic Influenza Plan, rapidly redirected funds and other resources to complement public health efforts in response to the emergence of the virus. Within two months investigators decoded the virus genome and found that it had genomic pieces from avian, human and swine flu viruses. Using a ferret model, investigators determined the new virus was more pathogenic than seasonal flu viruses, infecting cells deeper in the lungs than did seasonal viruses that typically stay in the nasal cavity. These researchers also analyzed human sera from different age groups to determine if pre-existing antibodies react to the new pandemic virus. Interestingly, they demonstrated that sera from older patients had the ability to bind and neutralize human H1N1 and 1918 viruses—suggesting that older people may have residual immunity to the new virus. This basic research supported by the NIAID CEIRS helped to rapidly analyze the genetics, pathogenicity, transmissibility, and antiviral susceptibility of a new emergent influenza virus. The CEIRS studies provided the Government the necessary information to begin implementing tools and strategies to control and lessen the impact of the pandemic.

*New Biomarkers of Kidney Transplantation Status Identified*

Immune-mediated graft rejection is one of the major barriers to the long-term success of organ transplantation. Currently, there is no way for doctors to detect very early stages of transplant rejection and tailor medications accordingly. Prevention and reversal of graft rejection requires potent immunosuppressive medications that are associated with a wide range of adverse effects and can increase susceptibility to serious infections and cancer. NIH-supported researchers found that biomarkers in the transplanted kidney or blood of kidney recipient patients may indicate whether the kidney is functioning well or if it will be rejected by the host. The researchers measured levels of microRNAs, small pieces of nucleic acids that regulate gene expression, in biopsies from healthy transplanted kidneys and in transplanted kidneys undergoing acute rejection. Patterns of microRNA expression were identified that distinguished healthy kidneys from those undergoing rejection or that were functioning poorly. MicroRNA patterns were similar between kidney biopsies and white blood cells from the same patient. Elevated levels of three specific microRNAs indicate that infiltrating immune cells are damaging the kidney by setting off inflammation. These results suggest that microRNA levels in a transplanted kidney or in the kidney recipient’s blood may be useful for diagnosing rejection and for predicting how well a transplanted kidney will function. These measurements might one day enable doctors to diagnose rejection and tailor immunosuppressive medications to the needs of individual patients without a kidney biopsy. In addition, this approach may prove applicable to other transplanted organs.
Identification and Treatment of Rare Pediatric Inflammatory Diseases

Neonatal-onset multisystem inflammatory disease (NOMID) is a rare, debilitating autoinflammatory disease. The first sign of the disease is a rash that develops within the first six weeks of life. However, the disease can also affect numerous other body systems, including the joints, eyes, and central nervous system. Other problems, including fever, meningitis, hearing loss, and mental retardation, can often follow and as many as 20 percent of children with NOMID do not survive to adulthood. While the mechanism of NOMID is not completely understood, research in recent years has revealed a particular genetic mutation in 60 percent of patients with the disease. The mutations lead to an imbalance of a chemical messenger, called interleukin-1 (IL-1), which is believed to drive the inflammation that causes the disease. This fact has suggested that anakinra, a drug best known for treating rheumatoid arthritis, might be effective in treating NOMID. Anakinra blocks the effects of IL-1 beta (IL-1β), and is used to stimulate or restore the ability of the immune system to fight disease and infection. Research published in 2006, found that anakinra treatment led to the disappearance of some NOMID symptoms within 3 days, and over the course of a few months, major organ functions were improved. In 2009, these results helped lead to the discovery of a new genetic autoinflammatory syndrome in children called DIRA (deficiency of the interleukin-1 receptor antagonist), as well as demonstrations of effective therapy for DIRA with anakinra. This new therapy will improve the lives of those young people suffering from these, and potentially many other, autoinflammatory diseases.

Surgical versus Nonsurgical Treatments for Three Common Causes of Low Back Pain

Low back disorders are common, costly, and often disabling. Back surgeries in Americans are one of the fastest growing areas of medical care, with hospital costs exceeding $21 billion per year. Before the 13-center Spine Patient Outcomes Research Trial (also known as “SPORT”), many people who had chronic low back pain were conflicted about whether to undergo surgery; some were not sure surgery was worth the risk, while others feared that delaying surgery might cause even more damage. In the past 4 years, SPORT demonstrated that, indeed, surgery is superior to nonoperative treatments for the 3 most common causes of severe low back pain: intervertebral disk herniation and lumbar spinal stenosis with or without degenerative spondylolisthesis (the slipping of vertebrae). However, people who have one of these conditions—and whose conditions are not worsening—are not subjecting themselves to further harm if they adopt a “wait-and-see” approach before committing to surgery. The benefits were particularly noteworthy for those patients with more severe disease and major neurologic deficit, whereas patients with minor complaints and without major neurologic deficit appeared to do comparably well with non-operative treatments. Likewise, SPORT findings are providing additional insight into which patients with herniated disks are likely to benefit most. Patients with a herniated upper lumbar disk
benefited significantly more than those who had lower lumbar herniations, while patients treated for middle lumbar herniations had intermediate benefits.

**An X-Chromosome Gene, IRAK1, Involved in Risk and Pathogenesis of Systemic Lupus Erythematosus**

Systemic lupus erythematosus (SLE), or lupus, is a devastating, multi-system autoimmune disease, characterized by autoantibody production and tissue damage. Although the cause of SLE is unknown, several lines of evidence support a complex interaction of multiple genes and environmental factors. The disease affects females more frequently than males, at a rate of almost nine to one. Despite the strong sex bias, little is known about whether genes on the X chromosome directly influence disease susceptibility. Interleukin-1 receptor associated kinase 1 (IRAK1), which is encoded by a gene on the human X chromosome, is a critical mediator in the immune system's ability to recognize and respond to pathogens in a non-specific manner. However, little was known about potential IRAK1 involvement in lupus. In a study involving over 10,000 individuals who had contracted SLE either as children or adults, investigators found five IRAK1 gene variants, which were more common in patients of multiple ethnic backgrounds, and three of the five overlapped in both childhood- and adult-onset lupus. To examine the biological relevance of IRAK1 in SLE, the investigators generated IRAK1-deficient mice by engineering a strain that is prone to developing the disease. In the absence of IRAK1, the animals lacked symptoms associated with lupus, including kidney abnormalities, autoantibody production, and activation of various types of immune cells. Collectively, these results provide compelling evidence that support IRAK1 as a disease gene in lupus, and its location on the human X chromosome as a possible explanation for female predominance of the disease. Identification and characterization of lupus-associated genetic markers should aid in the diagnosis of patients at risk, provide important insights into pathogenic mechanisms and contribute to the development of novel therapeutic interventions.

**NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING**

**Detecting Tumor Cells in Blood at Concentrations as Low as One Part per Billion**

Cells that spread, or metastasize, from a primary malignant tumor to distant organs are responsible for 90% of cancer-related deaths, a number that exceeds 500,000 every year in the U.S. alone. Circulating tumor cells (CTCs), which detach from the original tumor and enter the bloodstream, represent a direct link between the primary malignant tumor and its metastases. Although CTCs are present in low concentrations (parts per billion) in the blood, CTC analysis is being developed as an alternative to invasive biopsies as a source of tumor tissue for the detection, characterization and monitoring of many types of cancer. A team of scientists, engineers and clinicians has developed a microfluidic lab-on-chip device that can efficiently and reproducibly isolate CTCs at concentrations as low as one cell per billion from the blood of patients with metastatic cancers. The device consists of microfluidic channels and posts that have been coated with molecules that bind only to the CTCs. When a whole blood sample is run through the device, the CTCs are captured by the posts, while the background cells are carried
through the device by fluid flow. By coating the posts with molecules that have an affinity for different types of cells, the device can be adapted for use in a broad range of clinical settings. An attractive practical feature is that the chip has a simple design and sorts cells directly from whole blood in a single step without any need for sample pre-processing. These features make it conducive to point-of-care use and rapid integration into clinical practice. This new technology provides an early and preemptive diagnosis of disease, as well as the identification of new biomarkers to predict clinical outcomes using a simple blood-based test. In addition, the ability to capture and analyze CTCs in peripheral blood may be used in the development of therapeutic strategies that can be tailored to the individual patient and monitor an individual’s responses to cancer therapies.

Intelligent Prosthetic Leg Improves Locomotion for Individuals With Above-the-Knee Amputations
There are more than 300,000 above-the-knee amputees in the United States and 30,000 new amputations are conducted each year. One significant limitation of current lower-limb prosthetic technology is the inability to provide adequate power generation at the knee and ankle joints, which impairs the ability of the prosthesis to restore normal locomotive function during many activities. NIH-supported researchers developed a powered knee and ankle that is self-contained and can be used for both single and double amputees. Parameters such as friction, the type of activity (e.g. walking, standing, sitting and stair climbing), estimators of user intent, movement speed and type of terrain are all accounted for in a real-time control system that provides safe, natural, reliable, and effective control of the powered prosthesis this system. This allows for full user control in which the user implicitly communicates with the powered lower limb prosthesis. This represents the next generation of powered lower limb prostheses capable of implementing user intent in real-time. Vanderbilt University has been approached by three prosthetics companies interested in bringing this technology to market. This would immediately improve the quality of life for the thousands of wounded soldiers, as well as other individuals with leg amputations.

Hi-Tech Drug Delivery for Treating Myocardial Infarction and Other Inflammatory Diseases
Excessive inflammation, with chronic elevation of inflammatory cytokines and reactive oxygen species, is elicited following a myocardial infarction (MI), resulting in cardiac dysfunction. Many clinically approved small molecule inhibitors of inflammation have been identified, however, a safe vehicle to deliver these drugs, that have great potential for improving cardiac dysfunction following an MI, has been lacking. The development of a vehicle to deliver small molecule drugs within the myocardium with controlled and sustained release to slow or halt the progression of cardiac dysfunction following an MI is an area of great need and opportunity. Researchers have formulated polymer microspheres loaded with the inhibitor SB239063 which acts on p38, a mitogen-activated protein kinase that regulates the production of key inflammatory mediators. Studies in rats indicate that the microparticles: 1) were retained in the myocardium and reduced inflammatory signaling; 2) reduced fibrosis within the left ventricular wall; and
3) significantly improved cardiac function over time. All of these results were observed with just a single injection into the infarct zone of the rat left ventricle. This new microparticle holds great promise for controlling inflammation and reducing cardiac dysfunction following an MI, and could potentially be used to similarly treat many other inflammatory diseases.

EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

Genetic Risks of Autism Spectrum Disorders and Brain Cell Connections
Autism spectrum disorders (ASDs) are a complex range of neurodevelopmental disorders that last throughout a person’s life time. Even though ASDs appear genetically heritable, little progress has been made in identifying the genetic risk factors linked to ASDs. Part of the challenge is that there are many genes that seem to contribute to ASDs. In two separate studies, NIH-funded researchers identified common and rare genetic factors that affect the risk of ASDs. The results point to genes that are involved in forming and maintaining the connections between brain cells. These results support previous findings on the genetic contributions to ASDs and abnormal cortical connectivity in people with ASDs. These research results support earlier research that examined genetic contributions and abnormal brain connectivity in people with ASDs. In addition, these studies represent a successful application of the genome-wide association study (GWAS) approach to identify common genetic susceptibility alleles and are a significant step forward in a larger effort to understand the complex genetic architecture of ASDs.

Treating Even Mild Gestational Diabetes Reduces Birth Complications for Infants and Mother
Severe gestational diabetes (GDM) occurs when pregnant women develop diabetes during pregnancy, and affects up to 14 percent of pregnancies in the United States. Treating severe GDM is known to benefit mothers and infants. Although treatment is routinely prescribed for all women with gestational diabetes, there was no evidence that treating mild GDM benefited, or posed risks for, mothers and/or their infants. In clinical studies, researchers found that compared to their untreated counterparts, women treated for mild GDM had smaller, leaner babies less likely to be overweight or abnormally large, and less likely to experience shoulder dystocia, an emergency condition in which the baby’s shoulder becomes lodged inside the mother’s body during delivery. Treated mothers were also less likely to undergo cesarean delivery, to develop high blood pressure during pregnancy, or to develop preeclampsia, a life-threatening complication of pregnancy that can lead to maternal seizures and death. This study provides the first conclusive evidence that treating pregnant women who have even the mildest form of gestational diabetes can reduce the risk of common birth complications among infants, as well as certain health complications among mothers.
Researchers Develop DNA "Patch" for Canine Form of Muscular Dystrophy
Muscular dystrophies are a group of disorders causing muscle deterioration and weakness. Duchenne muscular dystrophy occurs almost exclusively in males, affecting 1 in every 3,500. Most boys with the condition lose the ability to walk by age 12, and death usually occurs by the early 20s, from heart and respiratory failure. Duchenne muscular dystrophy results from errors in the gene for dystrophin, a key component of muscles. The locations and kinds of the mutations occurring in the gene can vary. To study the disease, scientists use a dog model. The canine version of Duchenne muscular dystrophy occurs naturally in dogs, and affects the same gene that is affected in the human form of the disease. Using a novel genetic technology that covers up genetic errors, researchers funded in part by the NIH developed a successful treatment for dogs with the canine version of Duchenne muscular dystrophy. The technology, known as "exon skipping," uses tailor-made snippets of DNA-like molecules as molecular "patches." The patches, DNA-like molecules called morpholinos, are manufactured in a laboratory. Injections of the morpholino cocktail directly into the dogs' bloodstream curbed deterioration of the animals' skeletal muscles and improved muscle functioning. However, the treatment was unable to prevent deterioration of the animals' hearts. The researchers theorized that the muscles of the heart are less porous than the skeletal muscles, and did not absorb sufficient quantities of the morpholinos to curb the deterioration. These findings lay the foundation for developing therapies in humans by using a cocktail of morpholinos to patch most mutations that occur in the human form of the disorder. Additional research is needed to develop other means of delivering the morpholinos to the heart.

NATIONAL INSTITUTE ON DRUG ABUSE

Anti-Drug Vaccines—A Medication Innovation for Treating Drug Abuse and Addiction
Vaccination, which harnesses the body's own immune system to counter a broad range of disease agents, is being explored as an addiction treatment. Immunotherapy causes the body to generate antibodies that bind to specific drugs while they are still in the bloodstream, preventing their entry into the brain, thus blocking their pharmacological and behavioral effects. In FY09, NIDA awarded a $10 million grant to Nabi Biopharmaceuticals (Nabi) to conduct the first Phase 3 trial testing the efficacy of a nicotine vaccine (NicVax) against tobacco addiction, moving it closer to final FDA approval. Nabi entered an agreement with GlaxoSmithKline to receive an additional $40 million to exclusively in-license NicVAX on a worldwide basis and develop follow-on, next-generation nicotine vaccines, with the possibility of an additional $500 million depending on the outcome of the trial. Preliminary results of a cocaine vaccine are also promising. A proof of concept clinical trial has already occurred, this being the first immunotherapy tested against an illicit drug. Findings showed it to be effective in participants who achieved significant antibody levels in their blood, decreasing their cocaine use significantly during the period when their titers were up. Successful vaccines would represent a stunning breakthrough that could enhance the impact of existing therapies, particularly in the case of cocaine addiction, for which no
medications are currently available. Cessation programs for nicotine addiction would also benefit, since vaccines could assist in curbing the exceedingly high relapse rates among quit attempters.

**Studies Link Gene Cluster to Nicotine Addiction: Potential for New Therapeutic Development**

In the past few years NIDA-supported research has collected multiple and convergent evidence that polymorphisms in the nicotinic acetylcholine receptor subunits α5, α3, and β4 gene cluster are implicated in early initiation of smoking, the transition to nicotine dependence (ND), and two smoking related diseases: lung cancer (LC) and peripheral arterial disease (PAD). Previous research had focused on the α4 and β2 subunits, which were known to play a role in nicotine’s rewarding properties. A better understanding of how these genetic variants affect nicotinic receptor function and behavioral responses to nicotine will accelerate the development of new pharmacotherapies. Notably, the α5 is a particularly promising target because its relative low abundance in the brain may lead to medications with fewer side effects.

**The Impact of Chronic Cocaine on Epigenetic Factors**

Chronic use of an addictive drug, like cocaine, can cause long-lasting changes in the patterns of gene expression in selected brain areas, which may underlie or contribute to addiction. These changes are called “epigenetic” because they influence genetic traits without changing a gene’s DNA sequence.

A new study has identified an important mediator of cocaine’s epigenetic effects in the nucleus accumbens (a key area of the brain’s reward center). The finding sheds light on the long-term functional changes in the brain, brought about by chronic cocaine exposure. Researchers gave several doses of cocaine to young mice. Only animals exposed to chronic cocaine developed a strong preference for cocaine as adults. In addition, these animals showed a significant reduction in the expression of G9a, an enzyme that demethylates histones, effectively loosening up the packaging of genes along the DNA molecule, thus increasing the likelihood that particular genes will be expressed. Importantly, the authors were able to show that by artificially producing large amounts of G9a in the nucleus accumbens, they were able to compensate for cocaine’s effects and prevent the establishment of cocaine preference, effectively inhibiting the animal’s “craving” for cocaine. These results provide a more complete picture of the epigenetic processes affected by chronic cocaine and will not only help us identify additional pathways and mechanisms involved in the development of cocaine addiction, but potentially aid in the development of new therapeutic approaches.

**NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS**

**Autistic Children Hear Speech Differently**

One of the primary distinguishing features of autism spectrum disorder (ASD) is language impairment, particularly in the social and communicative use of language.
Several deficits in the higher processing of language have been identified previously; however, little is known about how the brain of autistic children translates sounds into meaningful information. Researchers presented non-speech (click) sounds and basic speech sounds (in this case a single syllable, /da/) to both children with normal development and children with ASD and then recorded the responses at the most basic level of the brain, called the brainstem. The researchers determined that both groups processed non-speech sounds the same; however, speech sounds were processed differently at the brainstem. Children with ASD did not show the same synchronization of brain activity as normal children, and they also were less able to translate speech signals when combined with background noise. This study is the first to identify deficits in the most basic levels of speech processing in children with ASD. The processing of speech information at the brainstem is easily recorded in a passive and non-invasive manner. These brainstem responses may eventually be used to identify specific deficits in speech processing to aid diagnosis of children with ASD and may also be used to measure the effectiveness of auditory training programs to assist children with ASD.

Restoration of Hearing by Generating Auditory Hair Cells in the Cochlea

Sensorineural hearing loss is a common form of hearing impairment which occurs when either sensory hair cells of the inner ear or auditory nerve cells are destroyed. Until recently, scientists believed that auditory hair cells in mammals could never be replaced if they were injured or destroyed. In a 2005 landmark study, NIDCD-supported scientists treated deafened guinea pig ears with a viral vector carrying the gene Atoh1. Eight weeks after treatment the researchers found new hair cells in the ears treated with the Atoh1 gene, and auditory testing confirmed that the generation of hair cells coincided with partial restoration of hearing. This is the first demonstration of the use of gene therapy to improve hearing in deafened animals. Following this discovery, another group of scientists successfully produced functional auditory hair cells in the cochlea of the newborn mouse inner ear using gene therapy with Atoh1. The gene was inserted along with green florescent protein (GFP) which is the molecule that makes a species of jellyfish glow. GFP is often used in research as a “marker” that a scientist can use to determine, in this case, the cells expressing the Atoh1 gene. Using this method, the researchers were able to trace how the inserted genetic material successfully led to hair cell production resulting in the appearance of more hair cells than are typically observed in the ears of early postnatal mice. Successful production of functional sensory hair cells in the inner ears of mice suggests that a new therapy to regain hearing may be possible for humans in the future.

Viewing Tinnitus in Action

Tinnitus is the perception of sound in the absence of sound (i.e. ringing, roaring, hissing, or clicking sounds in the ears). It is generally associated with hearing loss as a result of aging or noise exposure. Among individuals ages 65 and older in the United States, 12.3 percent of men and nearly 14 percent of women are affected by tinnitus. In addition, tinnitus is the number one cause of service-connected disability for American veterans returning from the wars in Iraq and Afghanistan. NIDCD-supported scientists
utilized a rat model of pharmacologically-induced tinnitus combined with brain imaging (microPET and MRI) techniques to identify brain regions in the rat that are affected during tinnitus.

Following experimental induction of tinnitus, the animals were then injected with a tracer chemical (fluorine-18 fluorodeoxyglucose, FDG) and their brains imaged using microPET and MRI both during tinnitus and under normal conditions. Two regions of the brain (inferior colliculus, IC, and temporal cortices, TCx) were identified to have increased activity during high dose, aspirin-induced tinnitus. These regions are consistent with those identified in humans experiencing either noise- or age-induced tinnitus.

This study is the first to demonstrate microPET and MRI techniques can identify brain regions involved in tinnitus. This technique may now be used to study other causes of tinnitus (such as noise) as well as to evaluate the efficacy of potential therapeutic treatments for tinnitus.

NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

Pediatric Clinicians Can Help Reduce Rates of Early Childhood Caries: Effects of a Practice Based Intervention

Early Childhood Caries (ECC) is a serious and preventable condition characterized by severe decay in the teeth of infants or young children. ECC disproportionately affects low-income and minority populations.

Not only can ECC be an expensive disease to treat properly, but manifestations of ECC may go beyond pain and infection. ECC has the potential to affect speech and communication, nutrition, productivity, and quality of life, even into adulthood. A multifaceted practice-based intervention was implemented treating 635 children vulnerable to ECC, comparing results with those from a similar nearby clinic providing usual care to 454 children. The intervention component provided communication skills training for pediatricians and pediatric nurses using patient-centered counseling, edited the electronic medical record to prompt counseling, and provided parents/caregivers with an educational brochure. Provider knowledge about ECC increased after the intervention training from 66% to 79% in terms of accurate knowledge about ECC and children at the intervention site had a 77% reduction in risk for developing ECC at follow up. The practice-based intervention increased provider knowledge and counseling, and significantly attenuated incidence of ECC. If validated by additional studies, similar interventions could have the potential to make a significant public health impact on reducing ECC among young children.

New Model Reveals Novel Molecular-Targeted Strategies for Oral Cancer Prevention and Treatment

Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer in the developed world, affecting nearly 45,000 patients each year in the US, and resulting
in around 11,000 deaths annually. There is an urgent need for new chemopreventive strategies and treatment options for HNSCC patients and emerging information on the deregulation of normal molecular mechanisms that results in the cancer’s progression provides the possibility of mechanisms-based therapeutic approaches for these aggressive oral malignancies. Scientists recently found that the drug rapamycin exerted a remarkable anticancer activity. It decreased the tumor burden of mice having early and advanced tumors, and even brought about the regression of recurrent squamous cell skin cancers. The scientists reported that the persistent activation of mTOR, the mammalian Target of Rapamycin, occurs frequently in HNSCC patients and that its inhibition by rapamycin causes cell death and regression of human oral cancer tumors implanted in mice. To test the involvement of mTOR in tumorigenesis, scientists developed a chemically induced mouse model of HNSCC and found that mTOR activation was an early event in tumorigenesis.

This carcinogenesis model demonstrates that the use of mTOR inhibitors may provide a novel molecular-targeted strategy for chemoprevention and treatment of not only head and neck but other oral squamous cell cancers.

**Bone Marrow Stromal Cells Help Fight Sepsis**

Sepsis is a serious medical condition that affects 18 million people per year worldwide, and is characterized by a generalized inflammatory state caused by bacterial infection. Widespread activation of inflammation and blood clotting pathways leads to multiple organ failure, collapse of the circulatory system (septic shock) and death. Bone marrow stromal cells (BMSCs, also known as mesenchymal stem cells) are potent modulators of immune responses. In this study in an animal model, BMSCs were administered before or shortly after inducing sepsis by puncturing the intestine in order to determine whether BMSCs injected into the circulation would have a beneficial effect in preventing or attenuating septic shock. Infusion of BMSCs significantly decreased sepsis-induced mortality and increased organ function. The effects appear to be mediated by the production of Prostaglandin E2 when BMSCs are activated during the early stages of sepsis. Prostaglandin E2 subsequently induces the recipient’s macrophages to produce substantially more IL-10, a factor that dampens the inflammatory response, which if left unabated, leads to death. This is the first determination of a mechanism by which BMSCs modulate the immune response in an animal model of sepsis. As many people die of sepsis annually as from heart attacks. A new treatment or preventative regimen is desperately needed. Since the animal model suggests that the BMSCs need not be isolated from the same individual as will receive them, it is possible that cells isolated from non-related donors could be prepared and stored for use in patients with high risk for sepsis.
Gut Microbes Protect Against Type 1 Diabetes in Mice

Type 1 diabetes is an autoimmune disease in which the body's own immune system attacks and destroys insulin-producing beta cells in the pancreas. Scientists do not know exactly what triggers the body's immune attack on beta cells in type 1 diabetes. During past decades, researchers saw clues in the observed increased incidence of type 1 diabetes in developed countries. The scientists suspected that changes in the environment, including the microbes that live in our bodies, may be influencing the disease. Research in mice has found that the trillions of bacteria and other microbes that live in the gut can blunt the immune system attack that causes type 1 diabetes. Receptors on certain immune cells recognize molecular patterns that mark the surface of microbes. These immune cells signal through a protein called MyD88 to launch an immune system response. When researchers disrupted the gene for MyD88 in a mouse model susceptible to type 1 diabetes, the mice no longer developed the disease.

The researchers then raised the mice in a germ-free environment. These same mice developed type 1 diabetes when raised in this type of environment, showing that the disease is not dependent solely on the MyD88 pathway. These experiments show that a complex interaction between the immune system and bacteria in the gut may help to lower the risk of developing type 1 diabetes. The widespread use of antibiotics and more aggressive cleanliness of modern society can alter the mix of microbes living in our body and an unintended consequence of this environmental change is an increased risk of autoimmune diseases like type 1 diabetes. The idea opens avenues for further exploration and hints at the possibility of developing bacteria-based interventions to preempt or treat autoimmune diseases.

Newly Identified Genetic Variations Account for Much of the Increased Burden of Kidney Disease among African Americans

As many as 26 million U.S. adults over the age of 20 are estimated to have some degree of impaired kidney function, and over a half million Americans were receiving life-sustaining kidney dialysis or were living with a kidney transplant at the end of 2006. The leading causes of kidney disease are diabetes and high blood pressure. African Americans bear an especially heavy burden of kidney disease, however, from any cause. In one form of kidney disease called focal segmental glomerulosclerosis (FSGS), the tiny filtering units of the kidneys—the glomeruli—are damaged and scarred. Most FSGS arises from unknown causes and is termed “idiopathic” FSGS. African Americans are approximately 5 times more likely to develop idiopathic FSGS compared to individuals of other racial backgrounds, and are 18 to 50 times more likely than whites to develop FSGS related to infection with HIV, the virus that causes AIDS.

In the fall of 2008, researchers announced that variations near a single genetic locus were strongly associated with some forms of kidney diseases that disproportionately affect African Americans. Researchers identified several variations in the region of the
MYH9 gene on chromosome 22 as major contributors to excess risk of non-diabetic kidney disease among African Americans. MYH9 risk variants account for nearly all of the increased risk for idiopathic FSGS and HIV-associated FSGS among African Americans compared to European Americans and a portion of the increased risk for kidney disease associated with high blood pressure. Future studies will focus on the pattern of MYH9 expression across tissues, investigation into the role played by MYH9 in kidney function, and how its functions might be disrupted in individuals carrying the risk variant.

Obesity Associated with Unique Mix of Intestinal Bacteria
Although microbes in the human body are estimated to outnumber human cells by ten to one, little is known about these bacteria because of the difficulty in isolating and culturing them in the laboratory.

Scientists are now gaining insight into these bacteria by studying the collective genomes of microbial communities, such as the “gut microbiota,” using new DNA sequencing technologies. A recent study compared the human gut microbiota of obese and lean adult twins and their mothers by analyzing fecal samples to determine whether host obesity, genetics, or environment is associated with the bacterial composition of the microbiota. Obesity was associated with significantly less bacterial diversity than leanness. Additional analysis revealed that family members have more similar microbiota than unrelated individuals. Surprisingly, the identical twins were not more similar in their gut microbes than fraternal twins, suggesting that composition of the gut microbiota is influenced more strongly by environmental factors than by an individual’s genes. This study does not demonstrate cause and effect—whether differences in human microbiota help cause obesity or leanness, or whether obesity or leanness leads to changes in gut microbes. However, earlier research showed that the composition of gut microbiota can influence weight gain in mice. This advance provides evidence of a link between obesity and the gut microbiome, including the identification of several hundred genes that represent biomarkers of unique gut bacterial activity in obese individuals. These biomarkers may lead to more personalized healthcare and potential probiotic interventions to prevent or treat obesity.

NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES

Transplacental Exposure to Airborne Polycyclic Aromatic Hydrocarbons and Childhood Asthma
Asthma is the most common chronic childhood disease and its risk may be strongly influenced by prenatal events. Low income communities experience some of the highest childhood asthma rates in the US and new preventive strategies are lacking due in part to the absence of predictive biomarkers.

Preliminary evidence suggests that transplacental exposure to polycyclic aromatic hydrocarbons (PAHs) derived largely from traffic-related air pollutants may be a risk factor for the early development of asthma-related symptoms in this cohort. This study
explored whether transplacental exposure to PAHs in humans induces epigenetic reprogramming involving aberrant DNA methylation of specific genes that might be mechanistically related to childhood asthma or airway inflammation. Methylation of a 5'-CpG island (CGI) in acyl-CoA synthetase long-chain family member 3 (ACSL3) was found to be positively and significantly associated with the level of maternal PAH exposure and with a parental report of asthma symptoms prior to age five. Researchers identified ACSL3 as a candidate biomarker/gene whose 5'-CGI methylation status appears to be related to transplacental PAH exposure and further associated with PAH-associated asthma. Thus, ACSL3 may be the first potential surrogate endpoint for environmentally related childhood asthma. A biomarker like ACSL3 would be very useful in assessing PAH exposure and as a clinically relevant predictor for asthma risk in children born to mothers exposed to air pollutants such as traffic-related combustion emissions.

Researchers Map the First Human Epigenome
Researchers developed a high-throughput method to determine the methylation status of every cytosine molecule in the genome and to layer the resulting epigenomic map onto the genome it regulates. The technique was then applied to human fibroblasts and human embryonic stem cells to determine if the epigenomes differed between differentiated cells that perform a specific job and cells that have the potential to become any cell type. The results showed that the fibroblasts had a high degree of expected CG-methylation, but the stem cells showed a surprising result. Their methylation pattern exhibited non-CG methylation, which previously had been considered a laboratory artifact. A comparison of the epigenomes of embryonic stem cells and fibroblasts shows a pattern of methylation unique to stem cells. The novel methylation pattern may help to explain how stem cells maintain their pluripotent state. These reference epigenomes provide a foundation for future studies exploring this key epigenetic modification in human disease and development.

Heterocyclic Aromatic Amine Pesticide Use and Human Cancer Risk
Imazethapyr, a heterocyclic aromatic amine, is an agricultural herbicide used to control weeds in corn, soybean, dry bean, alfalfa and other crops. Occupational aromatic amine exposure has long been recognized as a causative factor for bladder cancer, and several specific aromatic amine compounds have been implicated as human bladder carcinogens. Since information about the health effects resulting from exposure to imazethapyr is limited, cancer risks associated with exposure to this aromatic amine pesticide, particularly for bladder cancer, were investigated in the Agricultural Health Study. Significant excess risks of bladder and colon cancers were observed in the AHS among applicators exposed to imazethapyr. For bladder cancer, participants in the highest exposure category of imazethapyr had a 137% higher risk than nonexposed pesticide applicators. For colon cancer, detailed analysis by subsite revealed that imazethapyr use was significantly associated with a 173% increased risk of proximal cancers, but not with distal or rectal cancers. Interestingly, there is no evidence of mutagenicity or genotoxicity with exposure to imazethapyr in animal models. The
findings of this study provide new evidence for the possible role of imazethapyr and other heterocyclic aromatic amine compounds in the etiology of these cancers.

NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

**Scientists Create iPS Cells Without Using Viruses**
First identified in 2007, induced pluripotent stem cells, or iPS, have stimulated intense interest in the research and medical worlds. Created by re-programming ordinary skin cells, iPS cells appear to look and act like human embryonic stem cells, which can change into any of the body’s more than 200 cell types.

Now, the same researchers who created iPS cells have gone a step further by reprogramming skin cells to an embryonic-like state with a technique that avoids introducing potentially harmful genes. Instead of using a virus to deliver reprogramming genes into adult cells, James Thomson of the University of Wisconsin-Madison used a plasmid, a small ring of self-copying DNA that remains separate from the chromosomes in the cell’s control center, the nucleus. The new method removes a key safety concern from the use of iPS cells in research and potential treatments. As iPS cells become easier to make and safe to use, they could be an important technology on the road to personalized therapies. Patient-specific, customized cells made using the new iPS method could generate replacements for injured or diseased tissues and serve as powerful tools to study diseases and drugs in the laboratory.

**“Super Antibody” Attacks Wide Range of Flu Viruses**
Over the past century, three human influenza A pandemics have killed millions of people worldwide. The 2009 H1N1 influenza outbreak is a reminder that constantly changing viruses pose a serious and ongoing health threat. Previous pandemic viruses emerged, in part, when bird and human viruses mixed genes and gained new and deadly properties that allowed them to evade the human immune system. Researchers have made an important advance on this front by developing a research version of a “super antibody” that recognizes both seasonal and pandemic influenza viruses. Working with a European pharmaceutical company, Ian Wilson of the Scripps Research Institute in La Jolla, California, solved the structure of an antibody that attaches to several types of flu from both birds and humans. The researchers screened millions of antibodies to find one that has unique cross-flu properties and also used resources produced by the NIGMS-led Protein Structure Initiative (PSI) to prepare and analyze high-quality protein samples. The work is an important step toward the development of a durable and cross-protective universal influenza virus vaccine. Ultimately, such a flu vaccine could be given to a person just once to protect against most subtypes of influenza, including pandemic viruses.

**Researchers Develop Novel, Resistance-Free Antibiotic Molecules**
Bacterial resistance to antibiotics is one of medicine’s most urgent problems. An antibiotic drug treats infection by knocking out hundreds of strains of “sensitive” bacteria in the body. But left behind are many non-sensitive or resistant strains. With no
stops in place, the resistant microbes repopulate themselves and spread rapidly. To combat this problem, chemists made a molecule that locks onto a microbial enzyme, blocking the bacterium's ability to "talk" to its neighbors. In lab tests, the molecule completely prevented the development of resistance even after many generations of growth. The antibiotic molecules proved effective in lab tests against *Escherichia coli* O157:H7, which causes lethal food poisoning, and *Vibrio cholerae*, which causes cholera. Since other dangerous microbes use the same communication strategy, the approach may have broad applications against various infectious diseases.

NATIONAL INSTITUTE OF MENTAL HEALTH

**Clinical Trials Assessing the Efficacy of Antipsychotic Interventions**

Schizophrenia, which affects approximately 2.4 million Americans, is a chronic, severe, and disabling brain disorder characterized by hallucinations, delusions, and disordered thinking. Antipsychotic medications are effective in treating the symptoms of the disorder, but can be associated with serious side effects such as weight gain, muscle spasms, rigidity, and tremors. To provide much-needed information to guide the everyday treatment of people with schizophrenia, NIMH supported the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study, which compared the effectiveness and side effects of five medications — both new ("atypical") and older ("typical") antipsychotics. Overall, the study found that the medications were comparably effective but were associated with high rates of discontinuation due to intolerable side effects or failure to adequately control symptoms. One new medication, olanzapine, was slightly better than the other drugs but also was associated with significant weight-gain and metabolic changes. Surprisingly, the older, less expensive medication used in the study, perhenazine, generally performed as well as the newer medications. CATIE also provided information that will help doctors and individuals choose subsequent treatments if the first treatment option is discontinued. During the course of the CATIE study, almost three quarters of the patients switched from their first medication to a different medication. People who switched to clozapine from their first medication because it failed to manage symptoms adequately were twice as likely to continue treatment as patients who switched to other antipsychotic medications. The CATIE study has vital public health implications because it provides doctors and patients with information that will help them choose the most appropriate medication according to the patients' individual needs.

**The Complex Genetic Underpinnings of Mental Disorders**

Based on twin and family studies, we have long known that some mental disorders have a high degree of heritability, as great, as or greater than most other common medical disorders. In recent years, NIMH-supported researchers have discovered several genes that are associated with autism spectrum disorder (ASD), schizophrenia, and bipolar disorder. However, the genomic variants discovered to date can explain only a small fraction of the genetic risk. It is becoming clear that people with serious mental disorders are more likely to have rare variations, known as copy number variations (CNVs), than to share common variations, as is the case for diseases such as diabetes.
CNVs are variations within the genome that result from deletions or duplications of genomic segments, sometimes involving millions of bases of DNA. Although these large CNVs are 10 times more common in people with schizophrenia or autism, most of the known CNVs do not seem to be associated with any single neurodevelopmental disorder. Even within a single family, the same genetic lesion appears to be associated with different mental or developmental disorders. And even though there may be huge mutations, some CNVs by themselves have subtle effects unless there is a second insult such as a second mutation or an environmental influence. Another important area of focus is epigenomics—the mechanisms through which environmental and experiential influences interact with genes to control their function. For example, a rare CNV associated with ASD deletes the gene that codes for the oxytocin receptor. In many individuals with ASD who do not have this deletion, the gene is silenced by epigenomic modifications, essentially producing the same outcome as a gene deletion. Investigating rare genetic variation may hold promise for improved diagnosis, as well as more personalized prevention and treatment strategies for schizophrenia, ASD, and similar neurodevelopmental disorders.

**Flow of Potassium into Cells May Play a Role in Schizophrenia**

Evidence suggests that schizophrenia stems from complex interactions between multiple genes and environmental factors. Researchers have worked to uncover what precise cellular functions are affected by candidate genes in order to determine effective treatment approaches with fewer adverse side effects. A study on schizophrenia has implicated cellular machinery that maintains the flow of potassium in cells as having a significant role in the development of schizophrenia. Expression of a previously unknown form of a key potassium channel was found to be 2.5 fold higher than normal in the hippocampus and prefrontal cortex—brain regions essential to memory formation—of people with schizophrenia. Experiments suggest that selectively inhibiting the gene variant that encodes production of this particular form of potassium channel (known as KCNHA2) could help correct disorganized brain activity in schizophrenia—without risk of cardiac side effects associated with some existing antipsychotic medications.

**NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE**

*Gene silencing prevents neurodegenerative diseases in mice and promises new strategy for treating people*

In dominantly inherited disorders, a single defective gene from either parent produces a harmful protein that causes disease. Huntington’s disease, spinocerebellar ataxias, and an inherited type of amyotrophic lateral sclerosis (ALS) are among the dominantly inherited neurological disorders. All of these diseases are progressive and currently untreatable. RNAi is a widespread, but previously unrecognized, regulator of gene activity in plants, invertebrates, and mammals. The mechanism is based on the classic DNA matching code—a short RNA molecule matches up with a particular segment of DNA and silences activity of the specific gene. Scientists are unraveling how RNAi influences diverse processes from normal development to protection from viruses and
harnessing the phenomenon as a general tool for studying gene functions. RNAi also presents an appealing strategy for specifically silencing harmful genes in dominantly inherited disorders. Researchers have now shown that RNAi can slow neurodegeneration and improve performance on behavioral tests of movement ability in strains of mice that mimic dominantly inherited ALS, Huntington’s disease, and spinocerebellar ataxia. In each case, scientists designed a specific RNAi probe to silence the gene responsible for disease and delivered the agent by using a modified (and harmless) virus.

RNAi may be applicable to many dominantly inherited diseases, as well as non-inherited problems, such as brain tumors, that arise from improper activation of genes. NINDS is supporting continued basic and translational research to develop RNAi to the point where it is sufficiently safe and effective to warrant clinical trials in people.

Comparative effectiveness research provides evidence-based approach for treating childhood absence epilepsy
Childhood absence epilepsy is the most common form of epilepsy in kids, affecting an estimated 10 to 17 percent of new epilepsy cases among children each year. Absence seizures, resulting in a sudden loss of awareness for 10-30 seconds, can occur dozens to hundreds of times per day, and many affected children have cognitive deficits and long-term psychosocial difficulties. The three medications most commonly used as initial therapy for childhood absence epilepsy are ethosuximide, valproic acid, or lamotrigine, but a comprehensive comparison of their relative efficacy and profile of side effects has been lacking. Researchers have now compared the effectiveness of ethosuximide, valproic acid, and lamotrigine for the initial treatment of childhood absence epilepsy. Overall, they found that ethosuximide, one of the oldest available anti-seizure medications in the U.S., provided the best combination of seizure control and least adverse effects on children’s attentional abilities over a 16- to 20-week period of initial treatment. Decisions among available treatment options must take into account both comparative efficacy in reducing disease symptoms as well as relative tolerability in terms of adverse side effects. By establishing clinically important differences between the three most commonly used medications for the initial treatment of childhood absence epilepsy, this landmark study supports evidence-based recommendations to inform treatment decisions for this common childhood seizure disorder.

Scientists Restore Movement to Paralyzed Limbs through Artificial Brain-Muscle Connections
Previous efforts to compensate for paralysis after spinal cord injury (SCI) have used brain activity to control the movement of prosthetic limbs or other devices. An exciting alternative approach would enable patients to move their own limbs by using brain activity to drive functional electrical stimulation of paralyzed muscles. Investigators successfully used signals from individual neurons in the motor cortex of monkeys to drive voluntary movement of paralyzed muscles. As the monkeys modulated their neurons’ activity, electrical stimulation drove wrist movements that were used to direct the position of a cursor on a screen—as if the monkeys were being stimulated to control
a computer mouse. This research demonstrates, for the first time, that artificial connections between the brain and specific muscles can restore voluntary movement in paralyzed limbs and suggest a promising approach to developing assistive technology for SCI that would allow patients to move their own muscles.

NATIONAL INSTITUTE OF NURSING RESEARCH

Women’s Cytokine Levels Remain Higher Post Stress Event

Stress is both a pervasive and necessary component of life. There is well documented evidence of differences in the cardiovascular responses to acute psychological stress by gender; less is known regarding whether these differences extend to inflammatory processes and immune function. Researchers looked at biological indicators of immune and inflammatory responses, known as cytokines. Some of these markers included: interleukin-1beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). Blood samples from midlife men and women were repeatedly tested, including after the performance of a public speech task. Following the end of the stressor, all measured pro-inflammatory cytokines were elevated in men and women. However, immediately post-stress, men demonstrated a drop in cytokine production that was significantly lower than the stable levels measured in women. Further, post-menopausal women demonstrated greater subsequent increases in IL-6 and TNF-α production from baseline-to-post-task when compared to men. These data bolster existing evidence that stress causes the immune system to produce larger inflammatory responses. The results also demonstrate possible gender differences in stress-related cytokine activity, and suggest that post-menopausal women may be more susceptible to stress-related inflammatory responses. While stressors and the human response to stress are normal aspects of life, understanding the internal chemicals that moderate the immune and inflammatory effects of excess short term or continued stress can help prevent negative health consequences. Given the increased risk among women, especially after menopause, for development of inflammatory illnesses and conditions, further study of gender differences in stress-related production of pro-inflammatory cytokines could help illuminate pathways for therapeutic intervention and prevention.

Speed-of-Processing Cognitive Intervention Reduces Risk of Depressive Symptoms in Community-dwelling Elderly

Depressive symptoms in elderly persons have been consistently linked to increased risk for disease development and exacerbation of existing comorbidities. While pharmacological interventions have been demonstrated to be safe and effective in the treatment of depression, they come with an increased risk of medication interactions among populations, such as the elderly, who often take multiple medications for chronic health conditions. A group of researchers evaluated the effects of three cognitive training interventions for active, community-dwelling elderly persons on depressive symptoms. The training provided in the three treatment groups involved: 1) memory training focused on verbal strategies for remembering; 2) reasoning training focused on problem solving and executive function, and, 3) speed-of-processing training focused on visual search in a divided-attention format, respectively.
Participants in the speed-of-processing group were significantly less likely to experience clinically important increases in depressive symptoms at 1-year and 5-year post baseline. No differences were observed among the control, memory, or reasoning groups at either time period. While many studies of cognitive and behavioral interventions for depression have been undertaken in recent years, this is the first study to include the speed-of-processing intervention. These results indicate that the speed-of-processing intervention provides a plausible, readily available and non-pharmacological intervention to reduce the risk of depressive symptoms in community-dwelling elderly.

Serotonin Transporter Gene Polymorphisms are Associated with Increased Risk for Post-stroke Depression

Post-stroke depression (PSD) is thought to affect approximately 33% of stroke survivors. While the precise etiology of PSD is unknown, it is likely multifactorial, and may be linked, like other mental illnesses, to polymorphisms of the serotonin transporter gene (or, ‘SERT’). Variations in the SERT gene have been widely used as possible risk factors for psychiatric illness. A team of researchers sought to determine whether variations of the serotonin transporter gene (specifically, the 5-HTTLPR, STin2 VNTR, and rs25331 polymorphisms) are associated with post-stroke depression (PSD) in stroke survivors. Stroke survivors with a specific 5-HTTLPR variation had 3-fold higher odds of having post-stroke depression. Participants with variations in STin2 had 4-fold higher odds of PSD. These results indicate that the 5-HTTLPR and the STin2 VNTR polymorphisms of the serotonin transporter gene are significantly associated with PSD in stroke survivors. These findings provide further evidence of a role of SERT polymorphisms in mediating resilience to biopsychosocial stress and represent the first study to characterize an association of SERT polymorphisms with increased risk for PSD. These findings are a critical first step toward identifying those at risk for developing PSD and the development of possible preventive therapeutics.

NATIONAL LIBRARY OF MEDICINE

Newborn Screening Coding and Terminology Guide

Newborn screening is an important part of public health because it can detect rare disorders in babies who may look healthy at birth. When certain disorders are detected right away, serious health problems can be prevented with rapid intervention. Because the disorders are so rare, wide variations among states in the ways tests are conducted and results recorded make it difficult to aggregate data and conduct quality assurance needed to improve testing and treatment methods. NLM worked with many other agencies to organize standard definitions and codes for more than 100 newborn screening conditions and the tests used to detect them. The NLM Newborn Screening Coding and Terminology Guide is a new Web site that indicates the preferred standard terminologies and codes for all the conditions and tests. The new Web site is a translator, to help deal with current complexity and help states move toward the use of common terminology and coding standards. The NLM Newborn Screening Coding and Terminology Guide will support quality health care for children by harmonizing standard coding, terminology and electronic messaging methods in newborn screening.
Interoperable electronic messaging can help ensure that pediatricians get the information they need to interpret newborn screening results and act quickly to save lives.

**Implementation of the ClinicalTrials.gov Results Database**

The ClinicalTrials.gov registry and results database provides the public with summary information about interventional and observational clinical research studies and, since September 2008, summary results data. The site provides descriptions of over 84,000 recruiting and completed studies, of which 1,200 studies have results information posted. In September 2008, NLM launched the ClinicalTrials.gov results database to provide researchers, health care professionals, and members of the public, with access to basic data resulting from completed clinical studies. In September 2009, NLM implemented the requirements for sponsors to report adverse event information as specified by FDAAA 801. The results database is seamlessly integrated into the ClinicalTrials.gov site, allowing users to search for information about clinical research studies and their results, if available, with a single set of search and navigation tools. The ClinicalTrials.gov results database represents a first-of-its-kind, publicly accessible source of summary clinical study results, whether published or not. Systematic posting of basic results data for certain publicly and privately funded clinical research studies will not only help mitigate the problem of selective reporting of “positive” study results, but will also contribute toward fulfilling the ethical responsibility to those who volunteered to participate in research.

**Health Information Exchange, Biosurveillance Efforts, and Emergency Room Crowding During the Spring 2009 H1N1 Outbreak in New York City**

Novel H1N1 influenza spread rapidly around the world in spring 2009, widely-affecting the New York region, and resulting in a crowding crisis due to record numbers of emergency room visits. Biosurveillance efforts by public health agencies can lead to earlier detection, potentially forestalling spread of outbreaks and leading to better situational awareness by frontline medical staff and public health workers as they respond to a crisis. This research explored the use of health information exchange networks, which enable secure flow of clinical data among unaffiliated providers across regions, as a tool for automated biosurveillance reporting in real-life emergency. This study in preparedness tested whether health information exchanges can reliably replace inefficient manual biosurveillance reporting, with the potential to be implemented nationally. Because reporting was automated and imposed no additional burden on hospitals during the crisis, the daily response rate was 100%. Based on retrospective analysis of a single measure, emergency department visit rates, this preliminary study suggests the potential is great for more robust data across multiple health information exchanges to be leveraged in the future and for new biosurveillance information to be provided in real time. Health information exchanges have great potential for providing real-time biosurveillance information to public health agencies and healthcare organizations, to support their situational awareness and ability to react to crises more swiftly. Coordination with existing health information exchanges may assist public health officials and hospitals with data monitoring during future outbreaks.
AMERICAN RECOVERY AND REINVESTMENT ACT

Mr. Obey: Please describe how NIH planned to make use of each major category of funding provided in the American Recovery and Reinvestment Act, and the progress to date in implementing those plans.

Dr. Collins:
1. NIH's plans for the ARRA funding included:

- **Scientific Research.** The NIH Recovery Act Implementation provided $8.2 billion for scientific research. A plan for these funds was developed to benefit three main activities:
  a. Specific areas of health research that will exploit new technologies or are likely to yield significant outcomes, as well as will cultivate a stronger biomedical research infrastructure;
  b. Meritorious research programs that previously could not be supported by NIH's base appropriation, to accelerate the pace of ongoing research; and
  c. New investments in programs that offer potentially transformative approaches to address major challenges in biomedical research.

- **Shared Instrumentation.** The NIH Recovery Act Implementation provided $300 million to facilitate "state-of-the-art" research using advanced technologies to enable better images, diagnostics, data analysis, and new discovery tools, as follows:
  a. Shared Instrumentation Grants (approximately $140 million) support groups of three or more NIH-supported investigators at public and non-profit domestic institutions for the purchase of commercially available instruments costing from $100,000 to $500,000, including confocal and electron microscopes, biomedical imagers, mass spectrometers, DNA sequencers, biosensors, cell sorters, X-ray diffraction systems, and NMR spectrometers, among others.
  b. High-End Instrumentation Grants (approximately $160 million) support groups of three or more NIH-supported investigators at public and non-profit domestic institutions for the purchase of a single major item of biomedical research equipment costing from $600,000 to $8,000,000, such as structural and functional imaging systems, macromolecular NMR spectrometers, high-resolution mass spectrometers, cryoelectron microscopes, and supercomputers.

- **Extramural Construction.** The NIH Recovery Act Implementation provided $1 billion to facilitate and enhance biomedical and behavioral research by supporting the design and construction of non-Federal basic and clinical research facilities, as follows:
a. Extramural Research Facilities Improvement Program (approximately $800 million) provides grants to public and nonprofit private entities to expand, remodel, renovate, or alter existing research facilities or construct new research facilities for biomedical and behavioral research.

b. Core Facility Renovation, Repair, and Improvement Program (approximately $200 million) provides grants to public and nonprofit private entities to renovate, repair, or improve core facilities (i.e. a centralized shared resource that provides access to instruments or technologies or services, as well as expert consultation to investigators).

- **Comparative Effectiveness Research (CER).** The NIH Recovery Act Implementation provided $400 million to compare different interventions and strategies to prevent, diagnose, treat, and monitor health conditions. The ARRA funds allowed NIH to expand its portfolio of landmark CER to fund additional comparisons within ongoing clinical trials, support new CER projects, and bolster CER infrastructure and training.

- **Building and Facilities.** The NIH Recovery Act Implementation provided $500 million to make contract awards on projects that will enhance NIH’s ability to conduct biomedical research, to include the following specific projects:

  a. The John Edward Porter Neuroscience Research Center Phase II Project ($175.7 million) will complete the consolidation of most of the NIH neuroscience research community into one facility. The Center will support bench-to-bedside research by basic and clinical neuroscientists, engineers, mathematicians, and computer scientists under one roof.

  b. The Building 10 F Wing funding ($160.3 million) will renovate one of the NIH’s Clinical Research hospital’s oldest wings dating back to 1955 which is no longer able to support biomedical research and training. The conversion of the F Wing (Phases A for Anatomical Pathology and B1-B2, Floors 6-13) from hospital to laboratory space will support translational research for nine of the twelve Institutes and Centers.

  c. The Build-Out of Building 3 ($21 million) will transform an unused, vacant building into useable space to provide offices for Scientific Directors and their administrative staff.

  d. Conversion of Building 7 ($6.2 million) at the Rocky Mountain Laboratories in Hamilton, Montana will convert unused, former mechanical space to laboratories providing critical additional space for National Institute of Allergy and Infection Diseases (NIAID) research program.

  e. The West Utility Tunnel ($22.3 million) increases the size and capacity of chilled water and steam distribution systems available to support future renovations in the F and Distal-Wings of building 10. This
project is very close award. It will be awarded as a task on a competitively awarded IDIQ contract.

f. Renovation of Building 4 ($11.3 million) replaces obsolete laboratories and improves aging building systems on the first and second floor to ensure compliance with current codes and accreditation requirements. This project is very close to award. It will be a competitively awarded contract.

g. Building 12 Continuous Power and Upgrade to NIH Data Center ($8 million) Phase 3 completes the project to ensure liability of the NIH Data Center supporting critical, enterprise-wide applications. This project is very close to award. It will be a competitively awarded contract.

h. Other R&I Projects ($95.2 million) are focused to improve the reliability and condition of several other NIH facilities.

2. What is the progress, to date, in implementing the ARRA categories:

- **Scientific Research.** NIH is making excellent progress and is on target in meeting the goals of this plan. NIH has awarded over 12,000 grants to research institutions in all 50 States, supporting innovative projects to address major challenges in biomedical research, accelerate critical breakthroughs and support applied research on cutting-edge technologies. The funds, for example, are allowing NIH to expand the Cancer Genome Atlas, collecting more than 20,000 tissue samples to sequence the DNA of more than 20 types of cancer and provide the potential to better treat this destructive disease. NIH also awarded more than 50 autism research grants, the result of the largest funding opportunity for research on autism spectrum disorders to date. The remaining funds will be obligated by September 30, 2010 as described in the implementation plan.

- **Shared Instrumentation (SI).** NIH is making excellent progress and is on target in meeting the goals of this plan. NIH has awarded several grants. To include 29 cell sorters; 17 computers, 8 crystallography units; 40 DNA and protein sequencers; and 17 electron microscopes. The remaining funds will be obligated by September 30, 2010 as described in the implementation plan.

- **Extramural Construction (EC).** NIH is making outstanding progress and is on target in meeting the goals of this plan. NIH has awarded over 142 extramural construction grants to various non-Federal institutes improving basic and clinical research facilities as well as animal facilities to meet the needs of biomedical and/or behavioral research. The remaining funds will be obligated by September 30, 2010 as described in the implementation plan.

- **Comparative Effectiveness Research (CER).** NIH is making progress and is on target in meeting the goals of this plan. NIH has awarded 166 projects totaling $342 million. The balance of funding will target methodology development, training, and three research gap areas: Upper Endoscopy in
Gastro-Esophageal Reflux Disease (GERD); Eradication Methods for Meticillin Resistant Staphylococcus Aureus (Staph); Dementia Detection and Management Strategies. The remaining funds will be obligated by September 30, 2010 as described in the implementation plan.

- **Building and Facilities (B&F).** NIH is making progress and is on target in meeting revised goals. B&F will obligate a total of $500 million for these awards; $49.7 million of which was obligated in FY 2009 and the remaining $450.3 million is being obligated in FY 2010. Of the 15 original Building and Facilities ARRA projects, five projects – PNRCII, Building 10 F Wing, Building 3, RML Building 7, and the Electrical Vaults (under Other R&I), require awarding via newly competitive contracts. One project — the RML Installation of a Dedicated Electrical Feeder — was executed through collaboration with the local utility. Three projects in Building 10-The Tube Nest Condensate Line Repair, The Cell Processing Deficiency Corrections, and The Anatomical Pathology HVAC Repair- were awarded as task orders to existing contracts that had previously been awarded to participants in the 8(a) small disadvantaged business program (FAR 19). Existing competitive contracts can be used to implement the remaining projects.

**ARRA AND ITS SIGNIFICANT IMPACTS**

Mr. Obey: What would you consider among the most significant investments made with the Recovery Act funds, and what impact on health can be expected from each?

Dr. Collins: With the generous $10.4 billion in ARRA funds, NIH has made over 12,000 awards for exciting projects that will address virtually every disease, medical condition and critical challenge in biomedical research. These are all significant investments. Specific projects that are worth highlighting are several of the ARRA signature projects. Signature projects are major initiatives, developed by the Institutes and Centers, in areas of research where there are unprecedented opportunities to make significant biomedical progress. In addition, the following signature projects were so compelling, they were selected by the Office of the Director for co-funding to ensure that these important opportunities were met with the most vigorous and comprehensive response possible.

**Acceleration of The Cancer Genome Atlas Project**: This joint NCI/NHGRI signature project will accelerate The Cancer Genome Atlas Project (TCGA) to enable full examination of tumor genomes to discover new causative mutations in cancers. The pilot project has already demonstrated that knowledge of these mutations can be exploited for rapid translation in the clinic. ARRA funds will be used to rapidly move from the pilot phase of TCGA to identify all of the relevant genomic alterations in 20-25 tumor types by the end of FY 2014.
Evaluating the Safety of Engineered Nanomaterials: Engineered nanomaterials represent a significant breakthrough in material design and development for medicine, industry, and consumer products. This signature project will provide much needed data in the areas of toxicity profiles for nanomaterials, biochemical/molecular characterization of toxic effects in model systems, biomarkers for nanomaterials exposure, identification of susceptibility issues for nanomaterials health effects, and intervention strategies for prevention of public health episodes due to environmental nanomaterial exposures. The result will be the accelerated development of safe nanomaterial-based medical interventions.

DNA Sequencing of Well-Phenotyped Population Cohorts for the Identification of Disease-causing Genetic Variants and Understanding of Biological Pathways: Although genome-wide association studies (GWAS) have been successful in identifying high frequency genetic variants that are associated with numerous common complex traits and diseases, they are incapable of identifying specific disease-causing genetic variants, especially those of lower frequency and potentially larger effects. Finding those variants will require large-scale DNA sequencing of thousands of individuals from well-phenotyped populations. With recent technological advances, the feasibility of such a project is now within reach. Through this signature project the well-phenotyped NHLBI cohorts will be sequenced in order to identify actual disease-causing genetic variants of low frequency that may have large effects on the development of important common diseases including myocardial infarction, stroke, diabetes, obesity, hypertension, chronic pulmonary disease, and anemia.

Enhancing Electronic Health Records: This initiative will support basic and applied research in biomedical informatics to develop real-time decision aids and data visualization capabilities within electronic health records to help physicians, public health officers and researchers make complex diagnostic and treatment decisions. The goals of the project are to develop tools to allow physicians to see a high-level portrait of a patient’s total condition; to draw in appropriate data from a variety of sources to aid in a clinical decision; to visualize the effects of interventions on the patient; and to perform real-time health research by mining data in large repositories housed at multiple sites.

Genome-wide Association Studies and Replication of Studies in Minority Populations: The purpose of this signature project is to expand the use of genome-wide association to understudied diseases and phenotypes within the NIDDK mission to identify associated loci and genes. Genome-wide association studies (GWAS) have been undertaken in type 1 diabetes, type 2 diabetes, inflammatory bowel disease, obesity, and kidney disease but, in general, these studies have concentrated on available European populations. Studies to replicate key GWAS findings are necessary, as is extending these findings to other ethnic groups that comprise the U.S. population. Highest priority will be given to studies in minority populations or studies that are addressing diseases or phenotypes that have not been the subject of previous GWAS.
Integration of Pharmacogenomics with Electronic Health Records (EHR): This signature project focuses on the critical relationship between genotype and the response of individuals to a particular drug in a real-world setting, with the goals of improved patient care, reduced errors and safe and effective use of medications. Recent progress in several areas sets the stage for the realistic implementation of personalized medicine: 1) the discovery and validation of many significant genetic predictors of drug responses; 2) the widespread implementation of electronic health records; and 3) advances in bioinformatics and clinical decision-making algorithms. As a result, there are unprecedented opportunities to invest in system-wide demonstration projects for applying genomic information to personalized health care.

Framework Programs for Global Health: This signature project responds to the huge and growing demand on U.S. college campuses (including in the IDeA states) to prepare students to address global health issues. This program will be funded through administrative supplements to approximately 26 U.S. awardees. The goal is to significantly increase the process of building the multidisciplinary teams, curriculum and infrastructure needed to address global health research at U.S. universities.

TRANSLATIONAL RESEARCH

Mr. Obey: One of the themes emphasized in your testimony and the budget request is translating research results into new therapies available to treat patients. Please provide an inventory of the principal efforts already underway at NIH and proposed for fiscal year 2011 to advance this objective, including estimated funding levels for fiscal years 2009, 2010 and 2011?

Dr. Collins: In the broadest sense, translational research advances scientific discoveries arising from laboratory, clinical, or population studies into clinical applications to improve healthcare and public health. The translational continuum spans basic science discovery; preclinical testing; all phases of clinical investigation; dissemination of new technologies, therapeutics and information; and finally adoption as standards of care. “Translating Basic Science into New and Better Treatments” represents one of the Five Themes I have developed as NIH Director which I emphasized in the NIH FY 2011 President’s Budget request. A number of major initiatives underway at NIH are directly associated with this Theme and are summarized below.

- A national consortium of medical research institutions, funded through the Clinical and Translational Science Awards (CTSAs), is transforming clinical and translational research across the nation. This unique network of organizations is working together to accelerate laboratory discoveries into treatments for patients, to engage communities in clinical research and to train clinical and translational researchers. Currently, the consortium comprises 46 medical research institutions in 23 states. When fully implemented by 2012, 60
institutions will be linked together to advance the discipline of clinical and translational science.

- An important new effort in the area of translation science is the NIH Therapeutics for Rare and Neglected Diseases Program (TRND). TRND will build upon the successes of the similarly structured NIH Chemical Genomics Center (NCGC). NCGC facilitates drug development from the basic research lab to the pre-clinical stage, which is when researchers begin to lay the groundwork for possible human testing of candidate drugs. Picking up where NCGC's work leaves off, TRND will concentrate its efforts on the pre-clinical stage of drug development. TRND's aim will be to move candidate drugs forward in the drug development pipeline until they meet Food and Drug Administration (FDA) requirements for an Investigational New Drug (IND) application. Once TRND generates enough data to support an IND application for a candidate drug, the drug would then be handed off to an experienced organization outside of NIH, such as a pharmaceutical company, for human testing and other aspects of clinical development.

- Cancer Therapy Evaluation Program (CTEP) is responsible for coordinating the largest, publicly funded oncology clinical trials organization in the world, with over 900 active trials enrolling annually 30,000 study participants, nearly 400 grants and cooperative agreements, and about 100 investigational new drugs (INDs). CTEP has been able to effectively team with different companies to develop multiple targeted therapies in phase 1-2 trials. These combinations hold the promise for both more effective and less toxic treatments for many cancers. Thanks to CTEP's Cooperative Group program, active treatments found in phase 2 studies can be moved rapidly into definitive phase 3 trials.

- Basic and applied research programs sponsored by the National Institute of General Medical Sciences (NIGMS) and others are working toward a better understanding of how compounds bind and cause effects, thereby providing tools that will increase the efficiency of drug design. Research in pharmacogenomics and the NIGMS Pharmacogenomics Research Network (PGRN) sheds light on who will benefit from and who will experience adverse events as a result of treatment, improving the ability to design trials showing safety and efficacy of medications and allowing more personalized treatments to be made available.

- Enabled by high-throughput screening tools, combined with a growing assortment of in vitro assays and computational methods, the Tox21 partnership -- comprising the National Toxicology Program, the NIH Chemical Genomics Center, and the U.S. Environmental Protection Agency -- seeks to identify new mechanisms of chemical activity in cells, to prioritize the backlog of untested chemicals for more extensive evaluations, and to develop better predictive models of human response to toxicants. Tox21 scientists are now working to
identify and map toxicity pathways and the ways chemicals interact with the biochemical processes involved in cell function, communication, and the ability to adapt to environmental changes.

- The Molecular Libraries Roadmap offers public sector biomedical researchers access to the large-scale screening capacity necessary to identify small molecules that can be optimized as chemical probes to study the functions of genes, cells, and biochemical pathways. These projects facilitate the development of new drugs, by providing early stage chemical compounds that enable researchers in the public and private sectors to validate new drug targets, which could then move into the drug-development pipeline. This is particularly true for rare diseases, which may not be attractive for development by the private sector.

- The NIH Rapid Access to Interventional Development (RAID) program makes available, on a competitive basis, certain critical resources needed for the development of new therapeutic agents. This program uses resources of NCI’s Developmental Therapeutics Program and the National Heart Lung and Blood Institute’s (NHLBI) Gene Therapy Resource Program. Services available include: production, bulk supply, GMP manufacturing, formulation, development of an assay suitable for pharmacokinetic testing, and animal toxicology. Assistance is also provided in the regulatory process, through access to independent product development planning expertise.

- Research Centers in Minority Institutions (RCMI) Translational Research Network provides opportunities for multi-site clinical and translational research among minority and other collaborating institutions throughout the nation. Investigators at these institutions are focused on cancer, diabetes, renal disease, infant mortality, HIV/AIDS, and cardiovascular diseases—diseases that disproportionately affect minority populations.

- With regard to the commercialization of NIH technologies, the Office of Technology Transfer is highly efficient and effective at identifying and disseminating access to NIH inventions. Their facilitation of roughly 400 new inventions reports per year, 300-400 new patent applications per year, about 250 new licenses of NIH technologies per year, and receipt of royalties of about $90M per year demonstrates the effectiveness of an approach which seeks to emphasize non-exclusive licensing to entities capable of making NIH inventions viable to improve the public health.

There are also a number of programs underway at individual Institutes and Centers. Representative examples are described below.

- The Office of Translational Research of the National Institute of Environmental Health Sciences (NIEHS) strives to convert environmental health research into
information, resources, or tools that can be used by public health and medical professionals and by the public to improve overall health and well-being, especially in vulnerable populations.

- The National Institute of Neurological Disorders and Stroke (NINDS) Office of Translational Research aims to facilitate the preclinical discovery and development of new therapeutic interventions for neurological disorders by: 1) supporting preclinical development from discovery candidate therapeutics through Investigational New Drug (IND) and Investigational Device Exemption (IDE) applications to the FDA; 2) supporting the design, implementation, and management of research infrastructure activities that apply advanced research technologies to problems in neuroscience and neurology; and 3) supporting translational research projects and networks.

- The National Institute of Mental Health (NIMH) Division of Developmental Translational Research supports integrative, multi-disciplinary research on: 1) neurobehavioral mechanisms responsible for the development of psychopathology; 2) trajectories of risk/illness based on the combined and interactive influences of genetics, brain development, environment, and experience; and 3) design and testing of innovative and personalized preventive and treatment interventions.

- The National Institute of Allergy and Infectious Diseases (NIAID) Respiratory Pathogens Translational Research Services Program comprises three components: the Bacterial Respiratory Pathogens Research Unit, the Viral Respiratory Pathogens Research Unit, and the Bacterial Respiratory Pathogens Reference Laboratory. These components provide four types of services to facilitate the development of treatments targeting specific pathogens: a biological research repository, *in vitro* testing, *in vivo* testing, and clinical trial units.

- The National Institute on Aging (NIA) Translational Initiative is a multi-component translational initiative to facilitate early drug discovery and drug development research by academic scientists and small biotechnology companies for treating and preventing Alzheimer's disease, mild cognitive impairment, and age-related cognitive decline. This initiative provides small grants for early, exploratory drug discovery efforts and larger cooperative grants for various stages of preclinical drug development, in which new compounds are tested for safety and efficacy in test tube and animal studies before being tested in humans. The grants are awarded to investigators who have identified new compounds that need to be refined and characterized in relevant animal models in order to receive FDA’s Investigational New Drug (IND) approval.
Estimated funding levels for NIH Translational Research are:

<table>
<thead>
<tr>
<th>Year</th>
<th>Funding Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2009</td>
<td>$6.229 billion</td>
</tr>
<tr>
<td>FY 2010</td>
<td>$6.357 billion</td>
</tr>
<tr>
<td>FY 2011</td>
<td>$6.517 billion</td>
</tr>
</tbody>
</table>

**CURES ACCELERATION NETWORK**

Mr. Obey: The recently enacted health reform legislation authorizes a new program to advance the objective of translating research into treatments called the “Cures Acceleration Network.” In your professional judgment, what are the advantages and disadvantages of this newly authorized program compared to other programs and mechanisms currently in use at NIH for translational research?

Dr. Collins: The “Cures Acceleration Network” (CAN) is intended to advance the development of “high need cures” by reducing and overcoming the barriers between research discoveries and new treatments in areas that the private sector is unlikely to pursue. The program will smooth the pathway for developing new drugs, biologics, and devices and focus on addressing problems in the so-called “valley of death” phase of the therapeutic pipeline, which is a period between basic and clinical research where potentially promising candidates are identified and tested for potential first-in-man clinical trials. The valley of death represents a particularly challenging research development phase in which companies are becoming increasingly reluctant to invest. CAN will help minimize some of the financial risks to others associated with this phase of development and provide a pathway for private sector investment in the later stage development of promising compounds.

The legislation establishing CAN provides NIH with a number of new authorities and flexible funding mechanisms. For example, NIH is now authorized to use up to 20% of the funds using the Flexible Research Authorities mechanism, as is currently utilized by DARPA. These authorities also enable the program to move quickly to integrate, direct and make course corrections to projects as needed. For the first time, NIH grantees will be able to use funds for technical assistance to meet FDA regulatory requirements, and NIH will ensure that funded activities are coordinated with FDA approval requirements. The Flexible Research Authorities mechanism, as is currently utilized by DARPA, and in a manner not currently permissible under traditional grant and contract mechanisms, enable the program to move quickly and make course corrections to projects as needed.

If Congress appropriates new funds for the program, individual awards of up to $15 million can be made to support the development of novel compounds as well as abandoned products that might be revised or repurposed. CAN will allow NIH to pay for so-called “failed compounds” and explore, using high-throughput and other technologies, whether they can be repurposed for other preventative, diagnostic, and therapeutic applications. CAN will partner with FDA, industry, patient advocacy, and
other non-profit entities in the coordinated and accelerated pursuit of new diagnostics, therapies, and cures. The program will identify, fund, and work collaboratively with individual subject matter experts, creating teams as necessary on a project-by-project basis. In this way, NIH will be able to direct the project, set and monitor specific milestones, and stay substantially involved both scientifically and administratively. NIH will be able to fund exactly what is needed to clear the precise scientific and developmental hurdles presented by each case.

The CAN program also offers the opportunity to carry out systematic process engineering on the drug development pipeline. Unlike private sector companies, which generally conduct development programs in isolation and treat process improvements as proprietary information, CAN will publish both positive and negative results to demonstrate what can be done and to remove technical hurdles for all parties in the field.

CAN will build on other programs and mechanisms currently in use at the NIH for translational research, leverage existing NIH resources and programs, and incentivize collaborations between sectors, including intramural and extramural programs. The current NIH infrastructure and resources provides efficiencies of scale. For instance, access to state-of-the-art technologies and resources will facilitate the conduct of the studies necessary to identify a target, find a lead compound and optimize it, and meet regulatory requirements for taking the compound into clinical trials. These programs include the NIH Molecular Libraries Screening Center Network and Probe Production Center which aim to enhance chemical biology efforts through high throughput screening to obtain small molecule probes effective at modulating a given biological process or disease state; NIH Chemical Genomics Center, which consists of a robotic, high-throughput screening system and a library of more than 350,000 compounds for use in basic discoveries and as probes of cellular pathways. Certain molecules with potential therapeutic properties that emerge from NCGC screening process can be fed into the Therapeutics for Rare and Neglected Diseases (TRND) drug development pipeline; the TRND program is a drug development pipeline for producing new treatments for rare and neglected diseases; and the Clinical and Translational Science Award (CTSA) Institutions which have established infrastructure and trained personnel for performing clinical investigations.

NIH recognizes that along with the many opportunities provided by CAN, there are challenges. CAN may have successes but also failures if the safety and efficacy data generated by CAN projects still do not meet the standards or regulatory criteria necessary for marketing approval. It will be important for NIH to assess and manage the risks of the program.
HEALTH REFORM LEGISLATION AND NIH

Mr. Obey: What are the major provisions of the recently enacted health reform legislation that affect the activities of NIH? What changes in NIH operations and activities do you anticipate as a result?

Dr. Collins: Section 10409 of the Patient Protection and Affordability Act (PPACA) establishes the Cures Acceleration Network (CAN) within the NIH Office of the Director to bridge the “valley of death” in medical product development. See Mr. Obey Question above “CURES ACCELERATION NETWORK” above.

NATIONAL CHILDREN’S STUDY

Mr. Obey: Please provide an update on the National Children’s Study, including the status of the comprehensive review now underway, major schedule milestones, and cost estimates for fiscal years 2010 and 2011.

Dr. Collins: The National Children’s Study (NCS) is a large multi-year research study with the goal to examine the relationships among the environment (as broadly defined), genetics, growth, development, and health of 100,000 children from before birth through age 21 years. Several components collectively constitute the NCS. The current pilot phase is the Vanguard Study, to be followed by a larger Main Study. The NCS is actively implementing the Vanguard phase to determine the feasibility, acceptability, and cost of such aspects as recruitment, sample and information collection and storage, and visit assessments.

Although the unique nature of the NCS is what makes it so valuable, it also means that prior studies may not be useful organizational models. Thus, we have adopted an empirical approach to the further development of the study; we will design the Main Study based on information collected and analyzed during the Vanguard phase and minimize reliance on other sources. For instance, the pilot recruitment in the Vanguard locations made it clear that the initial assumptions regarding recruitment strategy and efficiency were overly optimistic. Thus, the Vanguard Study is currently implementing three additional recruitment strategies to determine the feasibility, acceptability, and cost of each. We expect to develop sufficient empirical data to develop a comprehensive recruitment strategy that allows customized recruitment for specific areas and populations and an efficient and cost-effective, field-tested strategy for the Main Study.

In addition to these new recruitment strategies, formative research sub-studies are occurring in parallel to develop feasibility, resource, and cost estimates for the Main Study with as much precision as possible. All aspects of study operations including logistics, supplies, communications, data transfer, and sample storage are being analyzed and evaluated. We are in contact with, and regularly track, the efforts of other
large ongoing longitudinal studies, which though they differ from the NCS in many ways, might provide lessons and practices that could be applicable to the NCS.

The NCS planning process assumes essentially flat budgeting for FY 2010 and FY 2011. The FY 2010 NCS appropriation is $193,880,000. The FY 2011 planned budget is $194,400,000.

Major Schedule Milestones:

November/December 2009 - The NCS developed three alternate recruitment strategies in addition to the household based strategy used in the original study design. Requests for Letters of Interest (LOI) to implement the new strategies were sent to the 36 Study Centers currently under contract.

January 2010 – The NCS convened a review panel to evaluate the LOI responses on feasibility, scientific rigor, and feasibility. An additional 30 study centers were selected, and the centers were notified of the selection.

July/August 2010 - The new recruitment strategies will begin in the expanded Vanguard Study Centers and continue for one year.

July/August 2011 – The NCS will commence analysis of expanded Vanguard Study results and develop the Main Study Protocol.

September/November 2011 – A scientific panel review will review the expanded Vanguard Study results and the Main Study Protocol.

January 2012 – The NCS plans to commence the Main Study after final decisions are reached on issues of feasibility, acceptability, and cost.

H1N1

Mr. Obey: Please describe the role that NIH played in preparing for a possible H1N1 influenza pandemic.

Dr. Collins: Pandemic preparedness has been and continues to be an important component of the National Institutes of Health (NIH) influenza research program. Led by the National Institute of Allergy and Infectious Diseases (NIAID), NIH-supported influenza research includes basic research as well as applied and clinical research focused on the development of vaccines, diagnostics, and therapeutics against influenza. Research activities on seasonal and pandemic influenza are integrated; increased understanding and preparedness for one inherently furthers understanding and preparedness for the other.
A comprehensive research infrastructure and ongoing preparedness efforts enabled the Institute to respond both rapidly and effectively to the 2009 H1N1 pandemic. NIAID rapidly initiated and continues to conduct a series of clinical trials across the United States to test the safety and immunogenicity of the 2009 H1N1 influenza vaccine. These trials have generated critical information for the nationwide and worldwide immunization campaigns against 2009 H1N1 influenza. For example, the studies have shown that a single standard 15 μg-dose of the vaccine is safe and effective in inducing an immune response that would be predictive of protection in adults, the elderly, pregnant women, and older children. As with the seasonal influenza vaccine, two doses of the vaccine were necessary to induce a robust immune response in children aged six months to nine years. The vaccine also is being tested in HIV-positive individuals and people with asthma. NIAID also is supporting research to develop new and improved influenza vaccines. These efforts include optimizing delivery methods, improving manufacturing procedures and expression systems, and identifying new antigenic combinations. Efforts also include research toward the ultimate goal of developing a “universal” influenza vaccine that would protect against all influenza subtypes, obviating the need for annual updating.

NIAID also conducted and supported basic research on the newly emerged 2009 H1N1 influenza. For example, investigators at the NIAID Centers of Excellence in Influenza Research and Surveillance (CEIRS) helped to rapidly analyze the genetics, pathogenicity, transmissibility, and antiviral susceptibility of 2009 H1N1 influenza viruses. In addition, NIAID-supported investigators studied the ability of existing antiviral drugs to combat several pandemic H1N1 influenza virus strains, including in children. NIAID also supported research on rapid diagnostics for H1N1 influenza.

AUTISM STRATEGIC PLANNING

Mr. Obey: The Combating Autism Act of 2006 requires the Interagency Autism Coordinating Committee (IACC) to develop a strategic plan for autism research and to update it each year. Has that been done? What progress has been made in implementing the plan?

Dr. Collins: The IACC released its first strategic plan, the 2009 IACC Strategic Plan for Autism Spectrum Disorder (ASD) Research, in January 2009, and an update in January 2010. The Plan advises the Secretary of Health and Human Services on needs and priorities for ASD biomedical and services research. It is organized around seven critically important questions for people with ASD and their families regarding diagnosis; the biology of autism; risk factors; treatments and interventions; services and supports; issues faced by adolescents, adults, and older adults with ASD; infrastructure; and surveillance. Each chapter in the Plan includes a brief discussion of what is currently known and what is needed prior to listing research objectives that address biomedical aspects of ASD as well as services research. The 2009 Plan incorporated extensive input from the public and the scientific community to identify over 30 objectives for research. With additional public and scientific input, the revised Plan
adds 32 new research objectives and contains an entirely new chapter on infrastructure needed to support ASD research.

The new objectives cover topics such as health disparities in early diagnosis; characterization of children with reported regression; and the biology and treatment of co-occurring conditions, such as epilepsy and gastrointestinal disorders. The additional chapter on infrastructure development includes objectives aimed at enhancing the ASD research workforce; data sharing; surveillance programs; biological specimen repositories; and communication and implementation of research findings. In addition, the updated Plan more fully addresses the needs of the people with ASD across the spectrum, from young children to adults, and places new emphasis on both non-verbal and cognitively-impaired people with ASD.

The release of the 2009 Plan coincided with the passage of the American Recovery and Reinvestment Act of 2009 (Recovery Act or ARRA). In 2009, NIH was able to use the IACC Strategic Plan to guide investment of approximately $64 million of Recovery Act funds in new research on ASD. With this addition, NIH funding for ASD research reached its highest level yet in 2009 at a total of $196 million. (For a full listing of funded projects, please refer to the NIH RePORT website.) NIH projects funded under the Recovery Act in 2009 addressed each major objective of the Plan, including research on rapid screening tools; risk factors for ASD; biomarkers for early diagnosis; genetics and environmental epigenomics of ASD; potential behavioral and drug interventions; adult services; telehealth; and how autism manifests in the second half of life. In 2010, NIH will continue to address priorities identified in the IACC Strategic Plan to advance treatments and research to benefit people with ASD and their families. For more information about the IACC and its Strategic Plan please see: www.iacc.hhs.gov.

OFFICE OF SCIENCE EDUCATION

Mr. Obey: With respect to the NIH Office of Science Education—-Please describe the types and levels of outreach and support that the Office of Science Education provides to schools and educators across the country.

Dr. Collins: The NIH Office of Science Education directs a number of programs for K-12 teachers and students nationwide. The OSE website, http://science.education.nih.gov, is the main access point for these resources. Specific programs are:

NIH Curriculum Supplements
Since 1997, OSE has partnered with NIH Institutes and Centers to develop, distribute, and support 17 NIH Curriculum Supplements (seven for high school, nine for middle school, and one for grades 1 and 2) that bring cutting edge biomedical research into the classroom: http://science.education.nih.gov/supplements. Topics covered include cancer, scientific inquiry, sleep, metabolism, oral health, and bioethics.
To date they have been distributed to over 92,000 educators nationwide upon their request, http://science.education.nih.gov/map. While the vast majority of these 380,000 total supplements have gone directly to classroom teachers, the materials are also being utilized in home schools, colleges, universities, afterschool programs, law enforcement activities, and health-care facilities. OSE partners with dozens of educators, school districts, universities, and education- and health-related organizations to promote the lessons and support the teachers who use them. To better facilitate their use under No Child Left Behind, each set of lessons is aligned to individual state education standards for English, science, mathematics, and health.

LifeWorks
OSE maintains an interactive database of 150 (and growing) careers in the health and medical science: http://science.education.nih.gov/LifeWorks. These web pages were visited more than 220,000 times in the last month, April 2010. Students can explore the breadth and diversity of occupations and use a career finder to identify specific jobs related to their unique interests. Lifework also contains information on college and career planning for grades 8 through 12. Many of the careers descriptions include written interviews with individuals working in the profession. A recent addition to the website is 3-minute video interviews of unique careers such as biochemist, forensic science technician, and recreational therapist. The videos are also posted on NIH’s YouTube channel.

NIH Educational Resources Database
The OSE homepage features a database of 1,500+ NIH educational resources for K-12 teachers and students: http://science.education.nih.gov. Examples include pamphlets on cancer, PowerPoint presentations on the mechanisms of drugs in the brain, and web-based games on sleep. To meet the needs of teachers, these resources are organized by topic, grade level, and format. The resources come from across NIH and are carefully selected for their relevance to elementary and secondary education. In the last month, April 2010, these resources were visited 80,500 times.

Women Are Scientists Career Videos
In partnership with the NIH Office of Research on Women’s Health, OSE produced a series of five 30-minute videos (DVDs) that feature women in specific fields of medical research: http://science.education.nih.gov/womenare. The videos show women as pathologists, surgeons, researchers, and dental researchers. A fifth video highlights women scientists with disabilities. Over 21,000 videos have been sent to teachers nationwide upon their request. The videos are posted on the OSE and NIH YouTube websites.

Scientists in Science Education – the NIH Science Education Nation
Recently, OSE developed a web-based resource for scientists across the countries who are interested in improving K-12 science education: http://science.education.nih.gov/NIHSciEdNation. The site includes an overview of today’s K-12 education system and how it could benefit from scientist input. Details on
how to develop meaningful scientist-educator partnerships and specific examples of ways to help are provided. This site is being received enthusiastically by professional science societies as an important outreach guide for their members. OSE is continuing to promote the new site and has been asked to present it at the annual meeting of the Council of Engineering and Scientific Society Executives this July in Pittsburgh. A key goal of the NIH Science Education Nation website is to promote and support participation in National Lab Day effort promoted by President Obama.

Mr. Obey: Please indicate the budget and staffing level (in FTEs) for the Office in each of fiscal years 2007 through 2009 and the estimates for fiscal years 2010 and 2011.

Dr. Collins:

<table>
<thead>
<tr>
<th>Year</th>
<th>Budget</th>
<th>FTEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2007</td>
<td>3,852,000</td>
<td>9</td>
</tr>
<tr>
<td>FY2008</td>
<td>3,942,000</td>
<td>9</td>
</tr>
<tr>
<td>FY2009</td>
<td>3,981,000</td>
<td>9</td>
</tr>
<tr>
<td>FY2010</td>
<td>4,039,000</td>
<td>9</td>
</tr>
<tr>
<td>FY2011</td>
<td>4,169,000</td>
<td>9</td>
</tr>
</tbody>
</table>

RESEARCH MANAGEMENT AND SUPPORT INCREASE

Mr. Obey: One of the largest percentage increases in the NIH fiscal year 2011 request is for the Research Management and Support mechanism. Why the relatively large proposed increase for this area? How would the increased funds be used and what results can be expected?

Dr. Collins: We have requested $1.525 billion for the Research Management and Support (RMS) budget, an increase of $72.6 million or five percent over the FY 2010 RMS budget. This increase will support many functions, including scientific oversight and management by NIH staff in the review, award, and performance monitoring of extramural awards (research grants, training awards, and research and development contracts), administrative and technical support for Congressionally mandated review groups and advisory councils and bodies; and special interest organizations; monitoring of advances emerging from basic science laboratories to determine possible clinical applications for treatment and prevention.

The increasing complexity of contemporary scientific research involves highly sophisticated and newly emerging technologies that integrate genetic and other information (medical chemistry, toxicology, clinical and behavioral study data, medical histories, and population based studies) from a variety of sources. State-of-the-art skilled managers of scientific portfolios are essential to manage these resources and to ensure that the maximal scientific value of the investment is realized. In addition, translational research and the advancing of these scientific discoveries arising from the
laboratory into clinical applications will require managers with expertise in every phase of the translational continuum. The need for this level of expertise contributes to larger payroll expenditure. Additional staff will provide NIH with sufficient capacity to manage its research portfolios, and to improve stewardship of all funds. In addition, the increase will enable NIH to expand information technology infrastructure in support of scientific staff, support services for our prevention programs, and education initiatives.

OPPORTUNITIES TO ACHIEVE EFFICIENCIES

Mr. Obey: Please describe opportunities and plans to achieve better economy and efficiency by consolidating procurement and management activities across multiple institutes and centers. In particular: To what extent does NIH currently consolidate purchasing and/or management in areas such as equipment purchases, development and management of IT, and contracts for other services?

Dr. Collins: It is NIH’s practice to consolidate purchasing and use all contract capabilities available to us to achieve both cost and time savings wherever possible. This is demonstrated by the following:

- In FY 2009, the NIH Office of Acquisition Logistics and Management (OALM), in partnership with the NIH Office of Intramural Research, implemented a Consolidated Scientific Equipment pilot program to consolidate our purchases of various types of scientific equipment using American Reinvestment and Recovery Act (ARRA) funding. As a result, in FY 2009 the NIH achieved a cost savings of $3.6M or 16% of our total FY09 ARRA Scientific Equipment Acquisitions.

- The consolidation of commodities through the use of strategic sourcing contract vehicles. These vehicles are established to leverage the Federal Government’s buying power with industry.

- The NIH Supply Center is aggressively initiating contracts for strategic sourcing of NIH supply products, by leveraging Departmental capabilities, GSA commodities contracts, the Defense Logistics Agency (DLA), as well as trans-NIH contracts. Recently, contracts have been negotiated for Office Supplies, Paper products, Gas Cylinders and Medical Surgical supplies. Personnel at the center are now initiating a contract for Laboratory supplies, and over 250 products are now sourced through DLA using its vast economies of scale for buying commodities.

- The NIH also consolidates the acquisition of administrative services. We have awarded a long-term administrative services contract which provides a range of administrative capabilities to all of NIH through multiple contract awardees. NIH recently awarded a technical services contract, whereby the NIH community can obtain technical services at very competitive prices.

- The NIH Information Technology Acquisition and Assessment Center (NITAAC) manages three Government-Wide Acquisition Contracts (GWACs). These contracts are used by many Federal agencies, in addition
to the NIH research institutes and centers. We are currently utilizing reverse auctioning procedures to obtain maximum cost savings and efficiencies.

- In 2005, NIH consolidated Offices of Acquisition from 18 to 10 in an effort to better utilize staff and share other resources. This consolidation created organizational efficiencies, while preserving those efficiencies that are evident in a decentralized model of having Contracting Offices in close proximity to the Research and Development (R&D) laboratories and extramural offices. Such efficiencies in a decentralized model foster communication, knowledge and partnership between contracting and program staffs. It enables the contracting staff to gain expertise with their program’s requirements.

SAVINGS AND EFFICIENCIES TO BE ACHIEVED

Mr. Obey: What plans do you have to increase such consolidation and what savings and efficiencies do you believe can be achieved? If there are no such plans, do you believe that consolidation would not achieve greater efficiency or economy, or are there other reasons that consolidation is not being pursued?

Dr. Collins: The NIH will continue to aggressively pursue savings via extensions of the above strategies such as:

- Expansion of the NIH Consolidated Scientific Equipment pilot program. As a result of the overwhelming success of the consolidated pilot program initiated in FY 2009, we have expanded our consolidation strategy of scientific equipment in FY10. Each institute and center has been asked to identify FY 2010 equipment requirements, and though it is too early to quantify the cost and time savings, we anticipate the savings will be significant NIH-wide.
- Expansion of NIH wide services through consolidated services contracts. Examples include ongoing efforts in the public communications and information sphere as well as consolidated conference services.
- The NIH Supply Center efforts to award umbrella contracts for commodities and further competition through reverse-auctioning. This will result in lower priced commodities available to the NIH community.
- It is our plan to significantly increase education and outreach throughout the Department and Federal Government, so that awareness of the NITAAC GWACs is increased throughout the Federal Government. As a result, we anticipate that the benefits of leveraging our GWACs to fulfill information technology product and services requirements will result in increased efficiencies.
- As a result of a “spend analysis” and a study of the NIH Supply Center Warehouse operation, an aggressive education and outreach campaign has begun which reaches out to customers to determine requirements, then if
demand dictates, the items are bought into stock at the Center. This has proven beneficial and many stale items, no longer being procured have been removed from stock and new products with higher demand are now being carried. The Supply Center procures in volume resulting in reduced costs for products.

CENTRALIZED FUNDING FOR NLM/NCBI

Mr. Obey: The fiscal year 2011 budget request proposes to centralize funding in the National Library of Medicine for support of public access to research results and the National Center for Biotechnology Information, and includes base adjustments to institute and center funding for fiscal years 2009 and 2010 to reflect this proposed shift. Why does NIH prefer this approach, rather than continued use of its management fund authority to support these assets and activities from the budgets of individual institutes and centers based on their utilization? Doesn’t the current approach more accurately allocate costs to the appropriate activities, if not please explain why it does not?

Dr. Collins: The NIH Director and the NCBI Resource Board, which consists of eight NIH IC Directors, have consistently recommended that NCBI’s funding needs be built into its base budget. Their recommendation is based upon recognition that NCBI’s workload is heavily affected by trans-NIH initiatives such as public access and the growing proportion of genomics-related research in NIH’s extramural funding. Only through a stable, appropriated base budget can NCBI anticipate new scientific developments in order to have the necessary lead time to create the databases and tools for these new sources of data. Furthermore, the NCBI Resource Board is considering how to better link the NCBI resource requirements to IC funding priorities.

HARD FUNDS CONTROL

Mr. Obey: The NIH leadership has committed to upgrade its financial computer system to provide “hard funds control”, in order to prevent violation of financial management laws (including rules governing reprogramming of funds). Please provided the phased timetable for this upgrade with semi-annual milestones?

Dr. Collins: NIH is committed to implementing reprogramming hard funds control in FY 2013 since it would be most cost effective to do so with the implementation of Oracle v. 12.FSIO. A number of actions are currently underway to assure an optimal installation of this software and these are listed above under "Upgrade NIH Financial Systems". However, until hard funds control for reprogramming is established, actions are being taken to facilitate adherence to the Congressional reprogramming requirements. These include the development of clear NIH-wide budget policies, the development and implementation of an enhanced NIH-wide reporting capability that will allow tracking of obligations by submechanism against authorized levels, and an examination and refinement of extramural policies to
allow implementation of reprogramming requirements while minimizing potential program impact.

NIH BUILDINGS AND FACILITIES

Mr. Obey: What is the estimated dollar value of the backlog of buildings and facilities maintenance and improvement requirements projected for fiscal years 2010 and 2011?

Dr. Collins: The estimated backlog of maintenance and repairs (BMAR) for fiscal year 2010 is $1.313 billion; at the end of fiscal year 2011 it is estimated to be $1.260 billion. The decrease is associated both with current projects underway and with projects expected to start in FY2011.

Mr. Obey: What would be the desirable or appropriate backlog for NIH, given the size, complexity and age of its physical plant?

Dr. Collins: NIH’s goal is to achieve a condition index (CI) of at least a 90 for every building in our portfolio. CI is based on the ratio of the total Backlog of Maintenance and Repair (BMAR) to total portfolio Plant Replacement Value (PRV). With a current PRV of $5.15B, the desired backlog of maintenance and repair for NIH is $515M or below.

Mr. Obey: What is the plan to achieve the desirable state for NIH buildings and facilities?

Dr. Collins: In 2002, NIH (as well as all DHHS Operating Divisions) adopted a facility assessment protocol called the Condition Index, which used by many public and private organizations to determine the condition of their real property inventory and create a plan for correcting deficiencies. The Condition Index, which scores a building’s health on a scale of 0 to 100 (with 100 being a perfect score) is a useful tool in both forecasting annual budgetary requirements and in prioritizing available funds during the execution year. NIH’s stated goal is to achieve a Condition Index of 90 or greater for each facility. Currently, of 280 NIH owned buildings, 123 have a Condition Index of 90 or greater.

THIRD PARTY COLLECTIONS

Mr. Obey: NIH has the authority to seek reimbursement from insurance companies for the cost of clinical services provided to insured patients who receive care at the NIH Clinical Center.

To what extent has NIH used this authority to seek third-party reimbursement for Clinical Center care, or plans to do so in the future? If the authority is not being fully used, why not? Doesn’t failure to achieve maximum third party collections have the
effect of subsidizing insurers and reducing resources available for research? Explain if NIH believes recent health changes will impact any earlier analysis?

Dr. Collins: The NIH Clinical Center has not sought third-party reimbursement from its patients, for a variety of reasons discussed further below. However, it is a concept that has been repeatedly examined as environmental and technological factors evolve.

The most important factor of note is that the NIH Clinical Center’s mission and statutory authority is to conduct research, not to provide health services. Research costs are not reimbursable by insurers. The most recent comprehensive NIH Clinical Center third-party reimbursement feasibility study, conducted in 2005, estimated the net achievable annual income from implementation of third party billing at ~$10M annually. The proposal was rejected as the risks listed below were determined by the previous NIH Director, with input from the NIH Advisory Board for Clinical Research, to outweigh the financial benefit.

Relationship with patients: Currently the NIH Clinical Center has a partnership relationship with patients who volunteer to participate in clinical studies. Past surveys of physician investigators have revealed concern that relationships with patients would change to consumer-provider affiliations, altering the nature of the research mission at the NIH Clinical Center. In the 2005 study, 23% of patients indicated they would not continue to participate in research if their insurance were billed. However, this may have changed with the health care reform legislation since there is no longer a life time cap on reimbursement and a patient cannot be denied coverage based on previous diagnosis.

Competition with outside providers: Introducing a business model of third party collection will place the NIH Clinical Center in competition with academic medical centers and referring physicians, possibly negatively impacting the patient referral stream, especially the referral of local patients who represent about half of the NIH Clinical Center patient population.

Complexity and cost of billing at the NIH Clinical Center: As a national hospital, with patients admitted from every state, the NIH Clinical Center would have to manage scores of insurance companies from across the country, not just the local providers as is the situation with other hospitals. This would add substantially to the administrative workload to meet the requirements of each payer.

Additionally, since every NIH Clinical Center patient participates in a clinical protocol involving participation in complex research processes, the majority of services provided are not considered health services or standard of care. Identification of health services (standard of care) versus research services is a manual process, for which no automated commercial products are currently available. As such, the NIH Clinical Center would need a team to institute a system to separate these costs.
Finally, the implementation of billing services would affect the Clinical Center’s status as a HIPAA-exempt organization, resulting in significant additional expense to become HIPAA-compliant.

- **Clinical investigator retention.** The clinical investigators who work at the NIH Clinical Center come often for a fraction of the salary they would receive at academic medical centers, because of the scientific opportunities relatively free of administrative hassle. Implementation of a third-party payer system will impose a new administrative burden on these clinical scientists and, based on a survey of our clinical scientists, many say they would leave because the cultural change would be significant and the advantages for staying at NIH will be compromised.

**THIRD PARTY COLLECTIONS**

Mr. Obey: Dr. Collins, NIH has the authority to seek reimbursement from insurance companies for the cost of clinical services provided to insured patients who receive care at the NIH Clinical Center.

Please explain how NIH has or plans to examine ways in which third party collections authority has been used by other Federal organizations, such as the Department of Defense, the Department of Veterans’ Affairs, or the Indian Health Service?

Dr. Collins: As part of a comprehensive feasibility study conducted in 2005, an examination of third party collections at other federal agencies was performed to frame the billing and collection of third party reimbursement revenues in the context of federal authorities. Interviews were conducted with federal organizations that collect revenues designed to elicit insights on infrastructure, processes, tools, culture and other components required to maintain collections within a federal agency. The federal agencies interviewed included amongst others the Department of Veterans Affairs, Food and Drug Administration, Indian Health Service, and the Air Force Medical Command.

There are several key differences between the NIH Clinical Center and these Federal organizations that must be addressed when considering third party collections.

**Mission:** Patient care at other Federal organizations is focused on standard medical care for treatment of illness and disease. In contrast, at the NIH Clinical Center, the focus is on clinical research and standard patient care for treatment of illness and disease is coincidental. At the VA and DoD, patients seek established therapeutic treatment of known diseases whereas at the NIH Clinical Center only patients enrolled in research protocols are admitted and participate within the parameters of the protocol on a journey of discovery of new innovative treatments for diseases, both known and previously undiagnosed.
Economies of scale: The patient population at the NIH is small compared to our Federal counterparts. We are one, 234-bed hospital; the VA and IHS have a network of hospitals and clinics. An example of the differences in scale: the VA expects to see over 6,000,000 patients in 2011, which is exponentially larger than the NIH Clinical Center population of approximately 7,000 inpatient admissions (~60,000 patient days) and 100,000 outpatient visits. The projected net cost recovery is $10M, after taking into account the impacts of infrastructure to support third party collections. Potential revenue estimates have to be weighed against the negative impact to patient recruitment and staff retention from billing. When all factors were considered, NIH decided that the negative impacts to the Institution’s mission and culture were greater than the potential financial benefits.

Billing eligibility: Only IHS is able to recover costs for Medicare/Medicaid covered individuals; this represents approximately 15-20% of our patient population. If the NIH were to bill patients, it would be important to obtain specific legislative authority to enable recovery of costs from CMS.

SCIENTIFIC MANAGEMENT REVIEW BOARD

Mr. Obey: The NIH Reform Act of 2006 requires establishment of a Scientific Management Review Board to advise the NIH Director. Please provide an update on the activity of this Board, including the anticipated schedule for issuing its first recommendations.

Dr. Collins: As of the end of May 2010, the Scientific Management Review Board (SMRB) has met in full session four times. In addition, three working groups have been formed and have met numerous times.

The Working Group on Deliberating Organizational Change and Effectiveness has prepared a draft report outlining a process for considering organizational change at NIH, the principles that should guide the consideration of change, and the underpinning attributes of the process. The Working Group on Substance Use, Abuse and Addiction has been considering whether organizational change within NIH could further optimize research into substance use, abuse and addiction. The Working Group on the NIH Intramural Research Program and Clinical Center has been exploring whether organizational changes are needed to improve the fiscal sustainability and utilization of the NIH Clinical Center. The working groups have conducted systematic analyses of their respective issues, received extensive briefings from internal and external experts and stakeholders, and examined a broad range of possible options to address each issue.

At the Board’s next meeting May 18-19, 2010, the SMRB will consider the draft report on organization change and explore public and stakeholder perspectives on the deliberations of the Working Group on Substance Use, Abuse and Addiction, and the Working Group on the NIH Intramural Research Program and Clinical Center. A fifth SMRB meeting will be scheduled in the summer of 2010 to consider recommendations.
for a reorganization strategy for the agency to optimize NIH conducted or supported research on substance use, abuse and addiction and a new vision, budget model and governance structure to support utilization and fiscal sustainability of the NIH Clinical Center.

CONFLICT OF INTEREST REGULATIONS

Mr. Obey: Section 219 of the fiscal year 2010 appropriations legislation for the Department of Health and Human Services requires amended regulations to be issued by May 1, 2010 governing financial conflicts of interest among extramural researchers receiving support from NIH. Have such regulations been issued? If not, when will they be issued and what is the reason for the delay?

Dr. Collins: As the first step in the rulemaking process, NIH published an Advanced Notice of Proposed Rulemaking (ANPRM) on May 8, 2009 for public comment. The ANPRM asked for input in six broad areas related to how institutions manage conflicts of interest and whether the regulations should be amended to strengthen NIH oversight. The public comment period closed July 7, 2009. The many comments we received from universities, members of the public, scientific research organizations, and patient advocacy groups were carefully analyzed. The findings and recommendations of recent reports issued by the Department of Health and Human Services Office of Inspector General (DHHS OIG), the Institute of Medicine, and professional associations were also reviewed.

NIH has drafted a Notice of Proposed Rulemaking (NPRM) that outlines proposed changes throughout the regulation with a focus on three broad areas, disclosures by investigators; information that must be submitted to NIH; and information that is to be made public. The NPRM was published in the Federal Register on May 18 for a 60-day public comment period. After the comment period ends, the comments will be analyzed and final regulations drafted. We are proposing that the final regulations will be ready for HHS and OMB review in September 2010, and that the final regulation will be published the following month.

OUTSTANDING CACRS

Mr. Obey: Please provide a table listing all reports requested from NIH by the House Appropriations Committee that have not yet been provided, showing the date by which they were requested and the expected completion date.

Dr. Collins: At this time all outstanding CACRs have been submitted to the Department for review. The Department is working to ensure that future CACRs are submitted in an appropriate and timely manner. The table follows:
<table>
<thead>
<tr>
<th>IC</th>
<th>Requestor</th>
<th>Report Name</th>
<th>Due to Committee</th>
<th>Target Submission Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NIMH-NIA</td>
<td>Geriatric Mental Health, p. 108</td>
<td>10/1/2009 Sep-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>OD/ODISSR</td>
<td>Basic Behavioral Research, p. 166</td>
<td>3/1/2009 Sep-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OD</td>
<td>Clinical and Translational Science Awards (CTSA) clinical research, p. 107</td>
<td>8/1/2009 annually Aug-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NINDS</td>
<td>Parkinson's Disease, Udall Clin prog, p. 147</td>
<td>6/1/2009 Aug-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NINDS</td>
<td>Peripheral Neuropathies, p. 147</td>
<td>3/1/2009 Jul-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NHLBI</td>
<td>Lymphatic Disease</td>
<td>3/1/2009 Aug-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NCI</td>
<td>Cancer Information Service Partnership Program (CIP), p. 108</td>
<td>2/1/2010 Jul-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OD</td>
<td>Discretionary Funds (3rd Quarter), p. 129</td>
<td>Quarterly Sep-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OD</td>
<td>Discretionary Funds (4th Quarter), p. 129</td>
<td>Quarterly Nov-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NIAMS</td>
<td>Musculoskeletal Conditions, p. 124</td>
<td>9/30/2010 Oct-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NCI</td>
<td>Pancreatic Cancer, p. 110</td>
<td>60 days of occurrence TBD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NCI</td>
<td>Pediatric Cancer, p. 110</td>
<td>6/1/2010 Aug-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OD/NCMHD</td>
<td>Translating NIH Research to Address Racial and Ethnic Health Disparities</td>
<td>TBD TBD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ANTIMICROBIAL RESEARCH

Mr. Honda: Although I support your efforts to focus on obesity, HIV, and rare
diseases, multiple and extreme drug resistant staph, tuberculosis, gonorrhea, and syphilis
are all on the rise — in some cases there are alarmingly high rates of infections and we
are only one drug away from being powerless against these extremely common
bacteria/microorganisms. Still, research and development on new antibiotics to treat
these and other infections and diseases lags alarmingly behind the reality of these
infections.

What is NIH doing to focus research on better understanding and new treatments
for antibacterial and antimicrobial therapies?

Dr. Collins: The National Institute of Allergy and Infectious Diseases (NIAID),
the lead Institute of the National Institutes of Health (NIH) for research on infectious
diseases, conducts and supports basic research to identify new antimicrobial targets and
translational research to apply this information to the development of therapeutics; to
advance the development of new and improved diagnostic tools for infections; and to
create safe and effective vaccines to control infectious diseases and thereby limit the
need for antimicrobial drugs. This includes efforts to advance our knowledge of
microbial genetics and genomics that can bolster our understanding of antimicrobial
resistance, reveal vulnerable areas in a microbe’s genome that could be potential drug
targets, and aid in the development of better diagnostic tests. NIAID funds research and
development of diverse products through a variety of mechanisms, including grants and
contracts to academic laboratories and to small and large companies. NIAID also is
conducting studies to inform the rational use of existing antimicrobial drugs or
alternative therapies to help limit the development of antimicrobial resistance. As part
of the federal government’s comprehensive efforts to combat the problem of
antimicrobial resistance, NIAID oversees a major effort built upon a foundation of
basic research to understand the biology of microbial pathogens, the interactions
between these pathogens and their human hosts, and the biological mechanisms by
which pathogens develop resistance to antimicrobial drugs.

To complement these collaborative research efforts, NIAID developed an
innovative program that provides a broad array of pre-clinical and clinical research
resources and services to researchers in academia and industry designed to facilitate the
movement of a product from bench to bedside. By providing these critical services to
the research community, NIAID can help to bridge gaps in the product development
pipeline and lower the financial risks incurred by industry to develop novel
antimicrobials.

Mr. Honda: How much of NIH resources as a percentage of your total budget is
devoted to this type of research?
Dr. Collins: NIAID funding for antimicrobial research in FY 2009 was $750M, or 15% of the total NIAID budget of $4.703B. The total for antimicrobial research includes basic research as well as applied research for drugs, diagnostics, and vaccines for a range of microbes, including drug-resistant bacteria and viruses such as HIV.

ENDOCRINE DISRUPTERS

Mr. Honda: Endocrine disrupting chemicals are found in plastics, pesticides, flame retardants, flooring, and many other items that make up our modern environment. They have been linked to mutations, decreased fertility, cancers, menstrual problems, behavioral changes, early puberty, impaired immune functions, and a range of other problems. In addition, tap water, as well as treated and raw sewage water released into our oceans and waterways, frequently contain relatively high levels of chemicals and hormones humans excrete every day.

How is NIH working with EPA to better study and understand the effects of these chemicals on our health?

Dr. Collins: The National Institute of Environmental Health Sciences (NIEHS) and the National Toxicology Program (NTP) have been active partners with the Environmental Protection Agency (EPA) in supporting research to understand health effects of exposure to endocrine disrupting chemicals. NTP scientists have provided important information to EPA throughout the development of EPA’s Endocrine Disruptor Screening Program. The Interagency Coordinating Committee for the Validation of Alternative Methods (ICCVAM), with NTP support, reviewed endocrine disruption screening test methods, recommended standards for assay validation, and is currently conducting an international validation study of one of the receptor-based assay methods, while also consulting on the study protocol for a second method.

The NTP High-Throughput Screening Program, in partnership with EPA and the National Human Genome Research Institute’s (NHGRI’s) NIH Chemical Genomics Center, is working on the Tox21 program, a new approach to toxicological testing. This approach consists of using in vitro assays targeting the key pathways, molecular events, or processes linked to disease or injury, including endocrine pathways, and incorporating them into a framework of research and testing using more traditional methods. The researchers are using quantitative high throughput screening assays to test a large number of chemicals, among which are a number of endocrine disrupting chemicals. The resulting data are being deposited into publicly accessible relational databases. Analyses of these results will set the stage for a new framework for toxicity testing.

Finally, the NTP, through an interagency agreement with EPA, is supporting research to determine how well the outcomes from exposures to combinations of endocrine disrupting chemicals are predicted based on our current assumptions of how these chemicals may interact. This research program currently focuses on a single class of commonly used chemicals in plastics and cosmetics called phthalates but may soon
expand to evaluate different classes of chemicals that appear to target similar biological processes.

DIVERSITY IN BIOMEDICAL RESEARCH

Mr. Honda: The chronic underrepresentation of minorities and women in the sciences is a well known and undisputed fact. Diversity in grant review panels, among researchers, and in the leadership of the various institutes is critically important to bring new perspectives to biomedical research.

What are you doing to improve diversity on NIH review panels and to encourage individuals from underrepresented minorities and women to enter and stay in biomedical research?

Dr. Collins: NIH is committed to ensuring the diversity of peer review panels. At the end of 2009, 27 percent of peer reviewers were members of ethnic minority groups and 33 percent were women. According to NIH policy NIH advisory councils are to be ethnically diverse and geographically balanced. In keeping with this policy, every nomination slate and advisory committee roster is carefully reviewed to ensure their diversity. If slates lack ethnic representation, NIH staff is responsible for managing peer review panels and advisory councils are required to outline plans for rectifying the problem. These efforts are tracked centrally by the Office of the Director, NIH.

NIH also is committed to encouraging underrepresented minorities and women to enter careers in biomedical research. NIH has developed a number of policies, programs, and initiatives to promote careers in science among minorities and women. These include:

- NIH policy encourages diversity in all institutional research training, fellowship, career development, and research education project awards. The policy is included in funding opportunities for these programs and is part of the peer review considerations for all institutional training programs.
- The Research Supplements to Promote Diversity in Health-Related Research program encourages investigators with active grants to provide mentoring and learning experiences in research to individuals from diverse backgrounds.
- The NIH Director's ARRA-Funded Pathfinder Award to Promote Diversity in the Scientific Workforce encourages exceptionally creative scientists to develop innovative approaches for promoting diversity in the biomedical workforce.
- The Research on Causal Factors and Interventions that Promote and Support the Careers of Women in Biomedical and Behavioral Science and Engineering grant program examines factors that contribute to women entering and staying in the biomedical workforce.
• The amount of paid parental leave for Ruth L. Kirschstein National Research Service Awards trainees has been doubled to sixty calendar days or eight work weeks.
• The NIH reentry supplement program, which provides opportunities for fully trained researchers to reenter careers in science after a hiatus due to family or other responsibilities, has been expanded to include postdoctoral researchers (http://grants.nih.gov/grants/guide/pa-files/PA-08-191.html).
• To enable more parents with young children and others to attend scientific conferences, NIH now requires applicants for NIH Conference Grants (R13/U13) to describe a plan for identifying family care resources so that conference attendees with child care needs or other types of family support needs can make the necessary arrangements.

DIVERSITY NIH STAFF

Mr. Honda: Are you making any internal administrative efforts to diversify NIH staff?

Dr. Collins: Promoting and increasing diversity of the NIH workforce, and particularly tenured and tenure track scientists in NIH's intramural research programs, is a priority for the agency. In particular, the NIH is placing special emphasis on recruiting minority scientists to increase the applicant pool of candidates for tenure and tenure track positions. NIH has developed a plan to enhance diversity and promote the inclusion of under-represented scientists within these ranks. Elements of this plan include:

• Reaching a diverse pool of applicants by notifying the diversity specialists at Association of American Medical Colleges accredited medical schools, and program directors at NIGMS Minority Opportunities in Research Programs of all tenured and tenure track vacancies and soliciting their assistance in reaching prospective applicants.
• Reaching a diverse pool of applicants by conducting targeted outreach to individuals as well as organizations known to have diverse individuals with the requisite skills.
• Preparing NCMHD loan repayment recipients to compete for NIH tenured and tenure track positions by providing the Disparities Research Education Advancing our Mission intramural postdoctoral training program.
• Conducting focus groups to learn about any barriers that may inhibit the employment and retention of diverse groups, and develop strategies to remove any identified barriers.

In addition, for the entire NIH workforce, not just the intramural research programs, there is strategy to recruit and retain Hispanic employees. Elements include:
• Targeting outreach to University of Texas, Texas A&M, University, University of New Mexico and University of Puerto Rico.
• NIH institutes participating in conferences which target Hispanic audiences
• NIH conducting focus groups to learn more about the workforce’s perceptions of the reasons for the limited numbers of Hispanics in the workforce.

Similarly, for all positions at NIH, there is a plan to recruit individuals with targeted disabilities. Elements include:

• The Disability Program Manager providing training sessions on special hiring authorities, reasonable accommodations and the Americans with Disabilities Act Amendments to educate managers and supervisors
BIODEFENSE RESEARCH

Mr. Tiahrt: Please provide a list of each grant funded by the $304,000,000 that was transferred from the BioShield Special Reserve Fund to the National Institute of Allergy and Infectious Diseases in fiscal year 2010. In your response, please include the title of the grant, when it was initially funded, the amount to be provided in fiscal year 2010 and the specific countermeasure the advanced biodefense research NIAID is funding is intended to address. For funds that have yet to be awarded, how does NIAID intend to ensure that the research addresses the specific biodefense needs identified by the Biomedical Advanced Research and Development Authority?

Dr. Collins: In the Consolidated Appropriations Act of 2010 (P.L. 111-117), $304 million was transferred from the Project BioShield Special Reserve Fund (SRF) to the NIAID, the lead Institute of NIH for biodefense research, primarily as an offset for other budget authority. The total combined appropriation for NIAID in FY 2010 is over $4.8 billion, of which NIAID estimates it will spend nearly $1.7 billion, including the transferred funds, for research on biodefense and other emerging infectious diseases. For example, one of the new activities to be supported in FY 2010 are projects solicited under a Broad Agency Announcement (BAA) entitled, “Development of Technologies to Facilitate the Use of, and Response to, Biodefense Vaccines.”

Other new activities to be supported in FY 2010 include research and development of broad spectrum antibiotics and filovirus vaccines.

A description of NIAID’s plans for the nearly $1.7 billion in funding for biodefense and emerging infectious diseases research can be found in the FY 2010 NIAID budget justification: http://www.niaid.nih.gov/about/whoWeAre/budget/Documents/fy2010cj.pdf. The $304 million in transferred funds has been included in, and is making a substantial contribution to, the overall biodefense and emerging infectious diseases program for NIAID in FY 2010.

NIAID’s biodefense research is guided by the Institute’s Biodefense Research Agendas and its Strategic Plan for Biodefense Research, which align with the Department of Health and Human Services (HHS) Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Implementation Plan. In coordination with BARDA, NIAID aligns its funding strategies for biodefense research with the research priorities set out in these plans. NIAID anticipates that candidate products successfully developed through its Biodefense and Emerging Infectious Diseases Research Program will transition to BARDA for late-stage advanced product development and future acquisition under Project BioShield.
BIODEFENSE RESEARCH

Mr. Bonner: Director Collins, it is my understanding that National Institute for Allergy and Infectious Diseases serves as the source of basic biodefense research and development where BARDA provides funding for advanced R&D. Is this correct?

Dr. Collins: Yes, with regard to biodefense, NIAID supports basic and applied research and early product development. The Biomedical Advanced Research and Development Authority (BARDA) supports advanced product development and eventual procurement.

Mr. Bonner: I also understand that a not insignificant amount of the funding provided following the Anthrax attacks and in subsequent appropriations cycles has either been provided directly to NIH for medical countermeasures against biological attack or epidemic concerns such as H1N1 or transferred from within BARDA for the same reason. Can you provide the subcommittee with the exact amount of funds either directly appropriated or transferred from BARDA for biodefense and medical countermeasure since the anthrax attacks?

Dr. Collins: NIAID represents over 90% of NIH’s biodefense research effort. Within its annual appropriation since the anthrax attacks, NIAID has allocated the following amounts for biodefense and emerging and infectious diseases research and development of medical countermeasures:

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2003</td>
<td>$1.162B</td>
</tr>
<tr>
<td>FY 2004</td>
<td>$1.600B</td>
</tr>
<tr>
<td>FY 2005</td>
<td>$1.658B</td>
</tr>
<tr>
<td>FY 2006</td>
<td>$1.632B</td>
</tr>
<tr>
<td>FY 2007</td>
<td>$1.596B</td>
</tr>
<tr>
<td>FY 2008</td>
<td>$1.602B</td>
</tr>
<tr>
<td>FY 2009</td>
<td>$1.641B</td>
</tr>
<tr>
<td>FY 2010 (est.)</td>
<td>$1.679B</td>
</tr>
</tbody>
</table>

In addition to these funds, BARDA developed interagency agreements (IAAs) with NIAID for it to continue certain biodefense research and development activities that NIAID had initiated. In these IAAs, BARDA provided NIAID the following amounts:

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2007</td>
<td>$98.8M</td>
</tr>
<tr>
<td>FY 2008</td>
<td>$58.1M</td>
</tr>
<tr>
<td>FY 2009</td>
<td>$25.8M</td>
</tr>
</tbody>
</table>

Lastly, the following amounts have been appropriated to the NIH Office of the Director for research and development of medical countermeasures for radiological/nuclear and chemical threats:
Mr. Bonner: There is some concern that this funding has not only been used on the development of medical countermeasures but also to fill the funding gaps of NIH elsewhere to the detriment of our national preparedness. Can you provide this subcommittee a better understanding here today and then much more specifically in a follow up: 1) how that funding has been spent?

Dr. Collins: Through its Biodefense and Emerging Infectious Diseases research program, NIAID has supported and will continue to support a comprehensive and robust portfolio of basic and applied research in order to facilitate the milestone-driven development of vaccines, therapeutics, and diagnostics for NIAID Category A, B, and C Priority Pathogens. This research has included investigator-initiated basic research, Small Business Innovation Research (SBIR) grants, and solicited grants and contracts for applied research and early product development for a variety of countermeasures against NIAID priority pathogens, including the microbes that cause anthrax, smallpox, botulism, and the viral hemorrhagic fevers. Recently, NIAID began focusing on new efforts for the development of broad-spectrum platforms and technologies for next-generation therapeutic agents directed toward biodefense threats and agents of public health concern.

Within its Biodefense and Emerging Infectious Diseases research program, NIAID has built and maintains a comprehensive infrastructure to respond rapidly to newly emerging microbial threats such as extensively drug-resistant tuberculosis and the novel 2009 H1N1 influenza. For example, NIAID has built a national network of Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases (RCEs), which support research focused on countering threats from bioterror agents and emerging infectious diseases and provide core facilities for NIAID biodefense researchers in the region. The network of RCEs is complemented by the NIAID National and Regional Bioccontainment Laboratories, which also will be available and prepared to assist national, state, and local public health efforts in the event of a bioterrorism or infectious disease emergency. In addition, NIAID provides a broad array of pre-clinical and clinical research resources and services to researchers in academia and industry designed to facilitate the movement of candidate medical countermeasures through early development.

NIAID anticipates that candidate products successfully developed through its biodefense and emerging infectious diseases research program will transition to BARDA for late-stage advanced product development and future acquisition under Project BioShield.
With regard to funds provided by BARDA to NIAID through interagency agreements in FY 2007 through FY 2009, NIAID has used these funds to support a variety of development activities for medical countermeasures for biological threats, including pandemic influenza, nuclear/radiological threats, and chemical threats.

Mr. Bonner: What progress has been made in the basic development of countermeasures?

Dr. Collins: NIAID supports a comprehensive and robust portfolio of basic and applied research in order to facilitate the milestone-driven development of medical countermeasures—vaccines, therapeutics, and diagnostics—for NIAID Category A, B, and C Priority Pathogens. Examples of these candidate medical countermeasures include:

- **Smallpox therapeutics**: NIAID has supported and continues to support the development of the antiviral drug, ST-246. A Phase II/III clinical trial was recently completed.
- **Smallpox vaccine**: NIAID supported the development of Modified vaccine Ankara (MVA) vaccine, which was recently transitioned to BARDA. NIAID supported Phase III clinical trials.
- **Anthrax vaccine**: NIAID supported the development of recombinant protective antigen (rPA) vaccine, which has now been transitioned to BARDA. NIAID is supporting vaccine enhancement activities for Anthrax Vaccine Adsorbed (AVA).
- **Botulinum monoclonal antibodies**: NIAID is supporting the development of therapeutic antibodies that are entering Phase I clinical testing.
- **Plague antibiotics**: NIAID supported the development of a plague nonhuman primate model which allowed the completion of studies of three licensed antibiotics. Data on the antibiotic ciprofloxacin for treatment of plague has been submitted to the Food and Drug Administration.
- **Ebola/Marburg viruses**: NIAID is supporting the development of vaccine candidates and therapeutics against Ebola and Marburg viruses.

Mr. Bonner: If funds been redistributed to other areas of research?

Dr. Collins: NIAID has not redistributed appropriated funds from its allocation for biodefense and emerging infectious diseases to other areas of research. Nor has NIAID redistributed funds transferred from BARDA through interagency agreements for biodefense research and development activities to other areas of research.

Mr. Bonner: What means has NIH used to prioritize and award funds for biodefense and medical countermeasure research?

Dr. Collins: NIAID's biodefense research is guided by the priorities set out in its Biodefense Research Agendas and its Strategic Plan for Biodefense Research. NIAID also coordinates with the Department of Health and Human Services (HHS) Public
Health Emergency Medical Countermeasures Enterprise (PHEMCE), which includes partners with BARDA, CDC, FDA, and the Departments of Defense, Homeland Security, and Veterans Affairs.

EPSCOR

Mr. Bonner: Director Collins, Alabama is blessed to be home to the University of Alabama Birmingham, a first class medical school and research university. UAB’s expertise in a broad variety of medical research areas makes it a center for innovation and it also means UAB has access to millions of dollars annually in NIH grants.

This is great, except that it means Alabama’s other universities cannot take advantage of another potentially promising program, the Experimental Program to Stimulate Competitive Research, or EPSCOR. EPSCOR grants from NIH would allow UAB and other Alabama universities like the University of South Alabama in Mobile to work together to do the innovative and groundbreaking medical research everyone on this subcommittee wants to see pursued.

- The EPSCOR program at NIH is subject to a limit which denies funding to states which receive above a certain amount of overall NIH funding. UAB’s NIH grants put Alabama over that limit.

- EPSCOR programs at other agencies, like the Department of Defense, the Department of Energy, the National Science Foundation, and others, do not use similar limits in awarding their grants.

Why does the NIH impose this limit, when other agencies do not?

Dr. Collins: Both the NIH Institutional Development Award (IDeA) Program and the NSF Experimental Program to Stimulate Competitive Research (EPSCOR) determine eligibility based on funding received by each state respectively. IDeA eligibility is based on a five-year average of NIH funding. States are eligible for the IDeA Program if the average NIH support is less than $120 million or the application success rate is less than 20 percent. NSF EPSCOR bases its eligibility on a three-year average of NSF support. States are eligible if their funding level is less than 0.75 percent of the total NSF funding. Alabama meets the EPSCOR eligibility criteria at NSF but its level of NIH support exceeds the NIH criteria for participating in the IDeA Program. Other federal agencies with EPSCOR or EPSCOR-like programs base eligibility either on the NSF eligible list or have their own eligibility criteria.
PEDIATRIC CANCER

Mr. Cole: Director Collins, as you know, about 2,300 children die of cancer each year. Cancer is the number one killer of children than asthma, cystic fibrosis, AIDS, and diabetes combined. Public Law 110-285, the Caroline Pryce Walker Conquer Childhood Cancer Act, was passed unanimously by the House and Senate. We all understand fiscal constraints, so please understand that this statement and the following questions come with that knowledge and consideration. It's been said that we are judged by those we help who cannot help themselves. These children cannot take action on their own therefore we elected and appointed officials must take action. So there is the human element of this-the prevention of the pain and suffering through identifying cures for cancer- but there is also a very real fiscal benefit to such funding. The funding generated through the 2,300 lives saved each year, lives of children who turn into productive citizens.

The Caroline Pryce Walker Conquer Childhood Cancer Act, authorized $150 million over five years to increase funding for pediatric cancer trials to address pediatric cancer research.

Would you please inform me if you take into consideration this law when planning future funding for cancer research?

Dr. Collins: The Caroline Pryce Walker Conquer Childhood Cancer Act sent a strong message from the Congress that all that can be done to help children and families who are affected by pediatric cancer must be done. We at the NIH fully agree with this message and are working aggressively to incorporate the spirit of the law into our future plans. We are fully committed to meeting and exceeding the directives in the Act through a robust research effort led by the National Cancer Institute (NCI). The NCI has identified pediatric cancer as one of its highest priorities and has developed an ambitious research strategy designed to bring the most promising new technologies and ideas to the efforts of developing effective therapies and other interventions to help children with cancer, including research on the special issues associated with surviving childhood cancer.

Mr. Cole: Further, in a recent letter (attached to brief) to one of my colleagues from OMB Director Orszag, it is indicated that NIH will provide $215 million for the conditions and needs of children with cancer in FY10. However, in a document recently distributed by NCI, only $196.3 million will be provided for such research.

Can you provide me with some clarity as to how much funding will actually go to pediatric cancer research this year and what you anticipate out-year funding for that research to be?

Dr. Collins: NIH has not set its tracking system on disease spending to be able to capture estimates for childhood cancers or pediatric cancer research funding across all of NIH. However, these estimates are available for research funded by NCI. The
estimated funding level in Director Orszag’s letter reflects the NCI-projected FY 2010 funding level for pediatric research (approximately $215 million), which is a broader research category than childhood cancer alone, and includes research related to child health, childhood cancers, birth defects, multiple sclerosis, etc. In FY 2011, NCI expects to fund pediatric research at $223.7 million. NCI also projects funding in the category “childhood cancer research”, which is a subset of pediatric research and includes only childhood cancer research (such as childhood leukemia and neuroblastoma). The National Cancer Institute (NCI) estimates it will spend $196.3 million in FY 2010 and $202.7 million in FY 2011 on childhood cancer research. This is the funding level that was provided in the recent NCI document. The key difference between these two categories of research is pediatric research is a broader category that includes research related to child health in general, whereas childhood cancer specifically deals with cancers affecting children.

### NCI’s Pediatric Research and Childhood Cancer Funding, 2007 – 2010 (dollars in millions)

<table>
<thead>
<tr>
<th>Year</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010 (estimate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pediatric Research</td>
<td>243.2</td>
<td>235.4</td>
<td>240.8</td>
<td>215.0</td>
</tr>
<tr>
<td>Childhood Cancer</td>
<td>172.7</td>
<td>189.7</td>
<td>192.9</td>
<td>196.3</td>
</tr>
</tbody>
</table>

**IOM Cancer Study**

Mr. Cole: We know that research undertaken through clinical trials has been instrumental in the advancement of treating and preventing cancer. The Federal Government had the foresight to create the Clinical Trials Cooperative Group (background info on the group is below) in the 1950s and is now considered a primary method for identifying and curing pediatric cancer and early-stage cancers in adults.

On April 15, 2010 the Institute of Medicine (IOM) issued a report, “A National Cancer Clinical Trial for the 21st Century,” that states “...many stakeholders have expressed concerns that the program is falling short of its potential to conduct the timely, large-scale, innovative clinical trials needed to improve patient care.” The report identifies the cooperative group clinical trials are an essential component of a robust cancer research program. And the report makes recommendations to improve efficiency of the trials process. Among those findings the report indicates that there is severe inadequacy of NCI funding to support clinical trials.

Given these findings do you agree that this is a good opportunity to begin to appropriately support trials, starting with pediatric trials and using the authorized funds under the Conquer Childhood Cancer Act to increase the current per case reimbursement rates from $2000 to say $5000?
In addition, the IOM report contained a short history called the "Overview of Creation of Children's Oncology Group" by Dr. Sharon Murphy (page 149). In it she describes the challenges of bringing the several sectors of research, government, and industry together to successfully coordinate pediatric cancer research. One sentence stands out:

"This process of working with industry was inherently challenging, because the pharmaceutical industry had relatively little interest in developing and licensing drugs for childhood cancers because of the small market."

I raise this point because the sentence illustrates the task we in Congress have to ensure that proper attention is paid to those who cannot advocate for themselves, in this case it is the children afflicted with cancer and their families. The Conquer Childhood Cancer act was Congress' acknowledgement that there is a disparity between adult cancer research and childhood cancer research.

Dr. Collins: Recognizing the changing understanding of the biology of cancer and the critical need to incorporate this into clinical trials, the NCI requested that the Institute of Medicine (IOM) assess the current state of cancer clinical trials review the NCI Cooperative Group Clinical Trials Program and provide recommendations for improvement. The IOM report, entitled, "A National Cancer Clinical Trial for the 21st Century," recognized the work of NCI's Operational Efficiency Working Group and noted that this group's recommendations had similar goals to those described in the IOM report.

Specifically, the IOM report validated the importance of the Cooperative Group Clinical Trials program as an essential component of a robust cancer research program. This is especially true in the childhood cancer setting, as the pediatric clinical trials program supported by NCI is optimally placed to prioritize the most compelling research questions for clinical evaluation in children with cancer and then to conduct these clinical trials in a clinically and scientifically sound manner. NCI is increasing per case reimbursement rates from $2000 to $5000 for Cooperative Group phase 2 studies, and additional funding beyond the standard $2000 is being provided for selected phase 3 trials based on their complexity.

Mr. Cole: I would like to hear your thoughts about, and your Institute's commitment to the long term funding for pediatric cancer research.

Dr. Collins: NIH is committed to the wise investment of funds in opportunities that will lead to a reduction in the cancer death rate for children. We share your hope for a future in which no parent will endure the grief of losing a child to cancer. The National Cancer Institute (NCI), which leads our pediatric cancer research effort, supports a comprehensive pediatric cancer research program that extends from basic biology research and preclinical testing to identifying new therapeutic targets, as well as an extensive clinical trials program. Pediatric research in the laboratory includes studying the genetic and other mechanisms related to tumor formation and metastasis.
For example, NCI’s Childhood Cancer Therapeutically Applicable Research to Generate Effective Treatment (TARGET) Initiative applies high-throughput genomic analysis methods to identify novel therapeutic targets for childhood cancers. The Pediatric Preclinical Testing Program (PPTP), an NCI-supported research contract begun in 2005, generates preclinical data that informs decisions about prioritizing new agents and combinations of agents for study against specific types of childhood cancers. NCI supports several consortia of institutions to perform clinical trials of novel agents and treatments, thereby allowing preclinical discoveries to rapidly move to the clinic and be studied by experienced pediatric oncology investigators. The Children’s Oncology Group (COG) develops and coordinates cancer clinical trials available at over 200 U.S. and international institutions. The clinical trials conducted by COG, NCI, and other NCI-supported consortia play key roles in evaluating new treatment approaches.

An important feature of the NCI research program is its work addressing the special issues faced by childhood cancer survivors. Initiated in 1993, the NCI-funded Childhood Cancer Survivor Study (CCSS) is a collaboration of 27 institutions which seeks to increase knowledge of the late effects of childhood cancer treatment. With an original cohort of 20,000 childhood cancer survivors diagnosed between 1970 and 1986, the CCSS began recruiting an additional 14,000 individuals treated for cancer as children between 1987 and 1999 to allow for the evaluation of late effects of newer types of cancer treatment.

More than 12 million cancer survivors are alive in the United States, at least 270,000 of who were originally diagnosed when they were under the age of 21. Although there has been some increase in the incidence of all forms of invasive pediatric cancer over the past 20 years, from 11.5 cases per 100,000 children in 1975 to 14.8 per 100,000 children in 2004, death rates have declined dramatically and five-year survival rates have increased for most childhood cancers during this same time. Advances in cancer treatment have meant that today, over 80 percent of children diagnosed with cancer are alive at least five years after diagnosis, compared to about 58 percent in the 1970s. These advances have averted an estimated 38,000 childhood cancer deaths in the U.S. between 1974 and 2006. This improvement in survival rates can be attributed to the large proportion of patients participating in clinical trials and to significant advances in treatment, resulting in a cure or long-term remission for the majority of children with cancer.

It is important to note that the basic research on cancer mechanisms done by NCI, as well as most of the other Institutes and Centers at NIH, also contributes heavily to the understanding of all cancer mechanisms including pediatric cancers. That research and the dollars spent on basic cancer mechanisms are not reflected in the above mentioned programs that are specific to pediatric cancers. However, the importance of broad research on molecular mechanisms of cancer cannot be overstated as they inevitably funnel seminal basic research discoveries into specific studies and clinical trials in pediatric as well as other cancers.
# WITNESSES

<table>
<thead>
<tr>
<th>Witness</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collins, F. S</td>
<td>279</td>
</tr>
<tr>
<td>Duncan, Hon. Arne</td>
<td>59</td>
</tr>
<tr>
<td>Fauci, A. S</td>
<td>279</td>
</tr>
<tr>
<td>Insel, T. R</td>
<td>279</td>
</tr>
<tr>
<td>Rodgers, G. P</td>
<td>279</td>
</tr>
<tr>
<td>Sebelius, Hon. Kathleen</td>
<td>145</td>
</tr>
<tr>
<td>Solis, Hon. Hilda</td>
<td>1</td>
</tr>
</tbody>
</table>
## Index

### Department of Labor

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman's Opening Remarks</td>
<td>1</td>
</tr>
<tr>
<td>Secretary's Opening Statement</td>
<td>1–6</td>
</tr>
<tr>
<td>Secretary's Written Statement</td>
<td>7–23</td>
</tr>
<tr>
<td>Green Jobs</td>
<td>24/38</td>
</tr>
<tr>
<td>G–20 Summit</td>
<td>25</td>
</tr>
<tr>
<td>Bureau of International Labor Affairs</td>
<td>27</td>
</tr>
<tr>
<td>OSHA Ergonomics Regulation</td>
<td>27</td>
</tr>
<tr>
<td>Worker Protection</td>
<td>28</td>
</tr>
<tr>
<td>OSHA Staffing</td>
<td>29</td>
</tr>
<tr>
<td>Racial Disparities in Unemployment</td>
<td>29</td>
</tr>
<tr>
<td>Ex-Offender Grants</td>
<td>30</td>
</tr>
<tr>
<td>Ratio of Job Seekers to Jobs</td>
<td>31</td>
</tr>
<tr>
<td>Number of Federal Employees</td>
<td>31</td>
</tr>
<tr>
<td>Foreign Government Subsidized Employment</td>
<td>31</td>
</tr>
<tr>
<td>DOL Budget Request</td>
<td>32</td>
</tr>
<tr>
<td>Addressing Chronically Unemployed</td>
<td>32</td>
</tr>
<tr>
<td>Job Sectors Facing Contraction</td>
<td>34</td>
</tr>
<tr>
<td>Rebounding Job Sectors</td>
<td>34</td>
</tr>
<tr>
<td>Job Sector Contractors</td>
<td>34</td>
</tr>
<tr>
<td>Shortages in Traditional Energy Industry</td>
<td>37</td>
</tr>
<tr>
<td>Continuing Education</td>
<td>37</td>
</tr>
<tr>
<td>Employee Readiness To Enter Job Market</td>
<td>39</td>
</tr>
<tr>
<td>Extension of Retirement Age</td>
<td>40</td>
</tr>
<tr>
<td>Protecting Migrant Farm Worker Children</td>
<td>42</td>
</tr>
<tr>
<td>Exposure of Children to Hazardous Materials</td>
<td>43</td>
</tr>
<tr>
<td>Leveraging Stimulus Funding</td>
<td>44</td>
</tr>
<tr>
<td>Reemployment of Highly-Skilled Workforce</td>
<td>44</td>
</tr>
<tr>
<td>Training for High-Growth Industries</td>
<td>45</td>
</tr>
<tr>
<td>Improving Job Loss Picture</td>
<td>46</td>
</tr>
<tr>
<td>Conclusion</td>
<td>47</td>
</tr>
<tr>
<td>Questions of Record</td>
<td>48–58</td>
</tr>
</tbody>
</table>

### Department of Education

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman's Opening Remarks</td>
<td>59</td>
</tr>
<tr>
<td>Secretary's Opening Statement</td>
<td>59–66</td>
</tr>
<tr>
<td>Secretary's Written Statement</td>
<td>67–75</td>
</tr>
<tr>
<td>Pell Grant Programs Costs</td>
<td>76</td>
</tr>
<tr>
<td>Rising Tuitions and Cost to Students</td>
<td>76</td>
</tr>
<tr>
<td>Financing Pell Grants and Direct Lending Proposal</td>
<td>77</td>
</tr>
<tr>
<td>Direct Lending Proposal-Terminating Lender Subsidies</td>
<td>77</td>
</tr>
<tr>
<td>21st Century Community Learning Centers</td>
<td>78</td>
</tr>
<tr>
<td>Topic</td>
<td>Page</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Impact of Economy on After-School Programs</td>
<td>78</td>
</tr>
<tr>
<td>After-School Programs</td>
<td>78</td>
</tr>
<tr>
<td>Competitive Grant Programs and Rural Districts</td>
<td>80</td>
</tr>
<tr>
<td>Turning Around Low-Performance Schools</td>
<td>80</td>
</tr>
<tr>
<td>School Improvement Intervention Models</td>
<td>81</td>
</tr>
<tr>
<td>Helping Struggling Populations</td>
<td>81</td>
</tr>
<tr>
<td>Charter Schools in Rhode Island</td>
<td>82</td>
</tr>
<tr>
<td>Adult Literacy</td>
<td>82</td>
</tr>
<tr>
<td>Pell Grants and College Tuition</td>
<td>82</td>
</tr>
<tr>
<td>Adult Literacy and Training</td>
<td>83</td>
</tr>
<tr>
<td>Student Loan Interest Rates</td>
<td>84</td>
</tr>
<tr>
<td>Even Start Program—Family and Adult Literacy</td>
<td>84</td>
</tr>
<tr>
<td>Teacher Support and Chronic Low-Achieving Schools</td>
<td>85</td>
</tr>
<tr>
<td>Holding Schools, Districts and States Accountable</td>
<td>86</td>
</tr>
<tr>
<td>Funding for Low-Achieving Schools</td>
<td>86</td>
</tr>
<tr>
<td>Support for Teachers</td>
<td>86</td>
</tr>
<tr>
<td>Increased Resources, Shared Responsibility</td>
<td>87</td>
</tr>
<tr>
<td>Programs Flat-Lined in FY 2011 Budget</td>
<td>87</td>
</tr>
<tr>
<td>Indian Education</td>
<td>88</td>
</tr>
<tr>
<td>Increased Funding in Consolidations</td>
<td>88</td>
</tr>
<tr>
<td>Graduation Rates of NCAA Athletes</td>
<td>89</td>
</tr>
<tr>
<td>Real Estate Market Impact on School Funding</td>
<td>89</td>
</tr>
<tr>
<td>Education Funding as Investment in Nation</td>
<td>90</td>
</tr>
<tr>
<td>Disparities in CCAA Graduation Rates</td>
<td>90</td>
</tr>
<tr>
<td>National Education Policy Discussions</td>
<td>91</td>
</tr>
<tr>
<td>Formula-Driven Stimulus Bill Funding</td>
<td>91</td>
</tr>
<tr>
<td>Helping Schools Not in Formula Calculations</td>
<td>91</td>
</tr>
<tr>
<td>State Fiscal Stabilization Funds</td>
<td>92</td>
</tr>
<tr>
<td>Tax Credit for Privately Schooled Students</td>
<td>92</td>
</tr>
<tr>
<td>Fiscal Constraints on National School Districts</td>
<td>92</td>
</tr>
<tr>
<td>Federal vs. Local Share in Education Funding</td>
<td>93</td>
</tr>
<tr>
<td>Addressing Low Graduation Rates of NCAA Athletes</td>
<td>94</td>
</tr>
<tr>
<td>Native American and Alaska Native Students Education</td>
<td>94</td>
</tr>
<tr>
<td>Common Course Standards</td>
<td>95</td>
</tr>
<tr>
<td>Texas Proposed Textbook Changes</td>
<td>95</td>
</tr>
<tr>
<td>48 States Working Toward Common Standards</td>
<td>95</td>
</tr>
<tr>
<td>ESEA Reauthorization</td>
<td>96</td>
</tr>
<tr>
<td>Shepherd Program—Poverty and Human Capability</td>
<td>96</td>
</tr>
<tr>
<td>Effective Teachers and Leaders Funding</td>
<td>96</td>
</tr>
<tr>
<td>Educational Opportunity Equity Commission</td>
<td>97</td>
</tr>
<tr>
<td>Ensuring Educational Equity</td>
<td>97</td>
</tr>
<tr>
<td>Teacher and Principal Equity</td>
<td>98</td>
</tr>
<tr>
<td>Schools as a Reflection of Community</td>
<td>98</td>
</tr>
<tr>
<td>Promise Neighborhoods</td>
<td>99</td>
</tr>
<tr>
<td>Shift Toward Competitive Programs and Consolidations</td>
<td>99</td>
</tr>
<tr>
<td>Educational Technology State Grant Programs</td>
<td>99</td>
</tr>
<tr>
<td>Income-Based Repayment of Student Loans</td>
<td>100</td>
</tr>
<tr>
<td>TRIO, Gear-Up, HEP and Camp Program Requests</td>
<td>100</td>
</tr>
<tr>
<td>College Access and Completion Funds</td>
<td>101</td>
</tr>
<tr>
<td>Social and Emotional Learning Programs</td>
<td>101</td>
</tr>
<tr>
<td>Social, Emotional Development and Decision Making Ability</td>
<td>101</td>
</tr>
<tr>
<td>Teaching Students To Understand Emotions</td>
<td>102</td>
</tr>
<tr>
<td>Early college Enrollment and Dual Enrollment Programs</td>
<td>103</td>
</tr>
<tr>
<td>College Pathways</td>
<td>103</td>
</tr>
<tr>
<td>Pell Grant and Early College Programs</td>
<td>103</td>
</tr>
<tr>
<td>Topic</td>
<td>Page</td>
</tr>
<tr>
<td>------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Disproportionality in Special Education</td>
<td>103</td>
</tr>
<tr>
<td>Early Learning Challenge Fund</td>
<td>103</td>
</tr>
<tr>
<td>Even Start</td>
<td>104</td>
</tr>
<tr>
<td>Education Jobs Saved by Recovery Act</td>
<td>105</td>
</tr>
<tr>
<td>Education Jobs Bill</td>
<td>105</td>
</tr>
<tr>
<td>Title 1, ESEA Funds for High-Poverty Schools</td>
<td>106</td>
</tr>
<tr>
<td>School Improvement Grants</td>
<td>106</td>
</tr>
<tr>
<td>Title 1 Funding</td>
<td>106</td>
</tr>
<tr>
<td>Addressing Inequality in Education</td>
<td>107</td>
</tr>
<tr>
<td>Race to the Top Application Process</td>
<td>107</td>
</tr>
<tr>
<td>Focusing Increased Resources on Inequality</td>
<td>108</td>
</tr>
<tr>
<td>History and Civics Education</td>
<td>108</td>
</tr>
<tr>
<td>Budget Increased To Promote Well-Rounded Education</td>
<td>109</td>
</tr>
<tr>
<td>Civil Rights</td>
<td>109</td>
</tr>
<tr>
<td>Proposal for Direct Lending for Student Loans</td>
<td>109</td>
</tr>
<tr>
<td>Proposal To Increase Pell Grant Funding</td>
<td>110</td>
</tr>
<tr>
<td>Student Loan Reform</td>
<td>110</td>
</tr>
<tr>
<td>Individuals With Disabilities—Grant to States</td>
<td>111</td>
</tr>
<tr>
<td>Teachers Recruitment and Retention</td>
<td>111</td>
</tr>
<tr>
<td>Teachers Incentive Fund</td>
<td>112</td>
</tr>
<tr>
<td>Promise Neighborhoods</td>
<td>112</td>
</tr>
<tr>
<td>Move Toward More Consolidation and Competitive Programs</td>
<td>113</td>
</tr>
<tr>
<td>Dropout Rate and College Completion</td>
<td>113</td>
</tr>
<tr>
<td>Focus on Achievement Gaps</td>
<td>114</td>
</tr>
<tr>
<td>Assessment of No Child Left Behind</td>
<td>114</td>
</tr>
<tr>
<td>Focus on Growth, Gain; Reward Success, Excellence</td>
<td>114</td>
</tr>
<tr>
<td>Flexibility and Accountability</td>
<td>114</td>
</tr>
<tr>
<td>Proposal To Move to Student Loan Direct Lending</td>
<td>115</td>
</tr>
<tr>
<td>Robotics Competitions</td>
<td>116</td>
</tr>
<tr>
<td>Incentives and Public-Private Partnerships</td>
<td>116</td>
</tr>
<tr>
<td>Partnering of School Districts To Share Services</td>
<td>117</td>
</tr>
<tr>
<td>Pell Grants</td>
<td>117</td>
</tr>
<tr>
<td>Savings From Direct Lending</td>
<td>117</td>
</tr>
<tr>
<td>IG Audit of Reading First</td>
<td>117</td>
</tr>
<tr>
<td>Eliminating Conflict of Interest in Competitive Awards</td>
<td>118</td>
</tr>
<tr>
<td>Actions To Prevent Conflicts of Interest</td>
<td>118</td>
</tr>
<tr>
<td>Origins of U.S. Deficit</td>
<td>119</td>
</tr>
<tr>
<td>Chairman’s Closing Remarks</td>
<td>119</td>
</tr>
<tr>
<td>Questions for the Record</td>
<td>120–143</td>
</tr>
<tr>
<td>Department of Health and Human Services</td>
<td></td>
</tr>
<tr>
<td>Chairman’s Opening Remarks</td>
<td>145</td>
</tr>
<tr>
<td>Witnesses Opening Statements</td>
<td>147–149</td>
</tr>
<tr>
<td>Witnesses Written Statements</td>
<td>150–161</td>
</tr>
<tr>
<td>Health Care Reform</td>
<td>162</td>
</tr>
<tr>
<td>Cost of Insurance Premiums</td>
<td>162</td>
</tr>
<tr>
<td>Individual Mandates</td>
<td>168</td>
</tr>
<tr>
<td>Medical Loss Ratio</td>
<td>168</td>
</tr>
<tr>
<td>State Insurance Commissioners</td>
<td>169</td>
</tr>
<tr>
<td>Single-Payer System</td>
<td>170</td>
</tr>
<tr>
<td>Medical Error Rates</td>
<td>171</td>
</tr>
<tr>
<td>Medical Advantage</td>
<td>171</td>
</tr>
<tr>
<td>Diversity in Health Professionals</td>
<td>172</td>
</tr>
<tr>
<td>High Risk Pools</td>
<td>175</td>
</tr>
<tr>
<td>Section</td>
<td>Page</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>279</td>
</tr>
<tr>
<td>Chairman’s Opening Statement</td>
<td>279</td>
</tr>
<tr>
<td>Witnesses Opening Statement</td>
<td>281–285</td>
</tr>
<tr>
<td>Witnesses Written Statement</td>
<td>286–308</td>
</tr>
<tr>
<td>Comparative Effectiveness Research</td>
<td>309</td>
</tr>
<tr>
<td>Adult and Embryonic Stem Cells</td>
<td>310</td>
</tr>
<tr>
<td>Sickle Cell</td>
<td>311</td>
</tr>
<tr>
<td>FY 2011 Funding</td>
<td>313</td>
</tr>
<tr>
<td>Pancreatic Cancer</td>
<td>316</td>
</tr>
<tr>
<td>Class B Dealers</td>
<td>317</td>
</tr>
<tr>
<td>Breast Cancer Mammography Guidelines</td>
<td>317</td>
</tr>
<tr>
<td>Funding for Comparative Effectiveness Research</td>
<td>318</td>
</tr>
<tr>
<td>Private Sector Innovations From NIH Investments</td>
<td>319</td>
</tr>
<tr>
<td>Priority Setting for Resource Allocations</td>
<td>321</td>
</tr>
<tr>
<td>Pediatric Cancer Research</td>
<td>322</td>
</tr>
<tr>
<td>Food Allergies</td>
<td>323</td>
</tr>
<tr>
<td>Pediatric Diabetes</td>
<td>324</td>
</tr>
<tr>
<td>Environmental Causes of Illness</td>
<td>326</td>
</tr>
<tr>
<td>Mental Illness Among Veterans</td>
<td>328</td>
</tr>
<tr>
<td>National Cancer Institute Clinical Trials</td>
<td>329</td>
</tr>
<tr>
<td>Biodefense Research</td>
<td>331</td>
</tr>
<tr>
<td>Behavioral Research</td>
<td>332</td>
</tr>
<tr>
<td>Coordination of Research</td>
<td>334</td>
</tr>
<tr>
<td>Traumatic Brain Injury</td>
<td>335</td>
</tr>
<tr>
<td>Electronic Health Records</td>
<td>336</td>
</tr>
<tr>
<td>Biomedical Research in the United States</td>
<td>336</td>
</tr>
<tr>
<td>Recovery Act Investments</td>
<td>337</td>
</tr>
<tr>
<td>Health Care Reform</td>
<td>339</td>
</tr>
<tr>
<td>Health Care Reform and Research</td>
<td>339</td>
</tr>
<tr>
<td>Prohibition on Lobbying With Federal Funds</td>
<td>176</td>
</tr>
<tr>
<td>Prevention and Wellness Funding</td>
<td>177</td>
</tr>
<tr>
<td>Reducing Caesarean Births</td>
<td>178</td>
</tr>
<tr>
<td>Increasing Birthing Centers</td>
<td>178</td>
</tr>
<tr>
<td>FMAP Formula</td>
<td>179</td>
</tr>
<tr>
<td>Health Care Fraud</td>
<td>179</td>
</tr>
<tr>
<td>Medicare Reimbursement</td>
<td>180</td>
</tr>
<tr>
<td>Hospital Acquired Infections</td>
<td>181</td>
</tr>
<tr>
<td>Medicare Reimbursements Rates</td>
<td>182</td>
</tr>
<tr>
<td>Health Insurance Costs</td>
<td>184</td>
</tr>
<tr>
<td>Prevention and Public Health Fund</td>
<td>185</td>
</tr>
<tr>
<td>Prevention and Mindfulness</td>
<td>185</td>
</tr>
<tr>
<td>Primary Care Physician Shortage</td>
<td>186</td>
</tr>
<tr>
<td>Health Reform Compliance and Enforcement</td>
<td>187</td>
</tr>
<tr>
<td>Prevention Issues</td>
<td>188</td>
</tr>
<tr>
<td>Health Care Reform</td>
<td>190</td>
</tr>
<tr>
<td>Unfunded Programs in Health Reform</td>
<td>192</td>
</tr>
<tr>
<td>Underage Drinking</td>
<td>194</td>
</tr>
<tr>
<td>Section 317 Vaccination Program</td>
<td>195</td>
</tr>
<tr>
<td>Projected Coverage Rates</td>
<td>195</td>
</tr>
<tr>
<td>Physician-Owned Hospitals</td>
<td>196</td>
</tr>
<tr>
<td>Children’s Health Task Force</td>
<td>196</td>
</tr>
<tr>
<td>Forum Health Bankruptcy</td>
<td>197</td>
</tr>
<tr>
<td>Food Safety</td>
<td>198</td>
</tr>
<tr>
<td>Questions for the Record</td>
<td>200–277</td>
</tr>
<tr>
<td>Section</td>
<td>Page</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>New Stem Cell Lines</td>
<td>341</td>
</tr>
<tr>
<td>Dr. Ruth Kirschstein Training Award</td>
<td>341</td>
</tr>
<tr>
<td>Ten Most Important Advancements</td>
<td>343-349</td>
</tr>
<tr>
<td>Recovery Act Funds</td>
<td>350</td>
</tr>
<tr>
<td>Alzheimer's Funding Care Versus Cure</td>
<td>351-352</td>
</tr>
<tr>
<td>Questions for the Record</td>
<td>354-437</td>
</tr>
</tbody>
</table>